[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpA7xV_SaqxFfOAxwAO8c89a5-v9bB0gy4yfkTUmZMa8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"Seoul National University Hospital",[4],1869,false,230,85,6602367,93,1175,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Coronary Artery Disease",41,{"name":18,"count":19},"Hepatocellular Carcinoma",39,{"name":21,"count":22},"Healthy",25,{"name":24,"count":25},"Breast Cancer",23,{"name":27,"count":28},"Anesthesia",17,{"name":30,"count":28},"Anesthesia, General",{"name":32,"count":33},"Schizophrenia",16,{"name":35,"count":33},"Pancreatic Cancer",[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05773222","Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient","2022-03-04","Apixaban",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05567536","Long Term Follow-up of Comparison of Clopidogrel vs. Aspirin Monotherapy After Drug-eluting Stent Implantation","2022-10-01","Antiplatelet Agents",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04503148","Anesthesia and Cancer Study: Renal Cell Carcinoma","2022-12-22","Propofol",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07154784","Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis","2023-07-19","Fecal microbiota transplantation",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03900637","PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate","2023-10-31","Leuprorelin acetate",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05801068","Perioperative Management of Factor Xa Inhibitors","2024-05-15","Factor Xa Inhibitor",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05529940","NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","2024-12","Folfirinox",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04997941","Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients","2024-12-31","Tamoxifen Oral Product",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT06400771","Safety of DNP007 in Healthy Subjects","DNP007",{"nctId":82,"briefTitle":83,"date":75,"intervention":84},"NCT05631769","HOST - DAPT Duration According the Bleeding Risk","Dual antiplatelet agent duration",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,137,196,236,273,300,325,343,361,392,420,443,471,496,524,598,639,681,721,778,809,836,859,886,904,928,946,975,1022,1059,1110,1147,1181,1205,1231,1257,1283,1305,1323,1341,1359,1384,1406,1430,1453,1476,1501,1526,1544,1568,1593,1611,1633,1801,1897,1992,2027,2363,2469,2572,2632,2688,2718,2755,2784,2805,2823,2847,2875,2893,2915,2940,2963,2991,3009,3027,3052,3075,3099,3120,3138,3167,3185,3209,3228,3256,3274,3292,3319,3344,3362,3385,3410,3436,3492,3538,3587,3638,3677,3716,3762,3794,3821,3856,3885,3916,3949,3983,4005,4039,4074,4102,4139,4163,4181,4205,4223,4246,4264,4287,4311,4329,4351,4369,4392,4410,4433,4451,4473,4500,4518,4536,4562,4580,4603,4621,4639,4665,4683,4707,4731,4754,4777,4795,4818,4836,4861,4879,4897,4921,4944,4966,4984,5007,5031,5049,5075,5099,5117,5142,5160,5182,5207,5231,5257,5275,5301,5324,5342,5368,5386,5408,5436,5454,5482,5500,5518,5536,5554,5579,5597,5619,5642,5665,5683,5701,5725,5749,5767,5785,5811,5829,5847,5865,5894,5912,5936,5954,5972,5990,6014,6032,6058,6076,6099,6124,6146,6164,6189,6212,6230,6248,6272,6290,6308,6332,6356,6384,6408,6426,6449,6467,6493,6514,6537,6561,6579,6603,6627,6645,6663,6681,6705,6727,6751,6769,6787,6805,6829,6847,6865,6887,6905,6928,6952,6975,6996,7019,7037,7055,7073,7100,7118,7136,7160,7178,7196,7221,7244,7269,7287,7305,7328,7346,7364,7388,7412,7430,7448,7471,7489,7512,7536,7554,7580,7598,7621,7645,7663,7685,7707,7732,7750,7771,7792,7845,7889,7925,7947,7980,8009,8045,8074,8105,8127,8149,8180,8204,8231,8254,8272,8290,8308,8326,8344,8369,8387,8410,8428,8452,8475,8499,8522,8544,8567,8585,8609,8630,8651,8673,8691,8715,8733,8759,8783,8801,8824,8842,8867,8891,8918,8936,8954,8979,9001,9024,9046,9064,9089,9107,9130,9157,9182,9204,9228,9252,9270,9288,9316,9334,9352,9374,9428,9472,9510,9550,9582,9604,9626,9648,9685,9715,9740,9762,9798,9833,9860,9885,9907,9929,9951,9983,10008,10039,10061,10086,10115,10137,10159,10182,10205,10229,10253,10277,10300,10322,10345,10363,10381,10404,10428,10452,10473,10491,10509,10527,10545,10566,10589,10613,10637,10661,10679,10705,10732,10750,10773,10797,10819,10837,10855,10879,10905,10926,10944,10969,10987,11010,11028,11046,11068,11092,11115,11138,11156,11181,11199,11220,11243,11261,11285,11309,11327,11345,11363,11387,11412,11437,11455,11473,11499,11521,11539,11557,11575,11600,11626,11650,11671,11692,11714,11738,11760,11784,11802,11820,11838,11860,11882,11900,11923,11945,11970,11992,12015,12037,12058,12080,12101,12119,12142,12160,12183,12207,12232,12253,12275,12304,12329,12368,12400,12423,12448,12469,12487,12505,12523,12548,12566,12584,12602,12623,12645,12670,12694,12712,12734,12752,12774,12792,12814,12832,12857,12875,12893,12918,12936,12958,12981,12999,13025,13048,13071,13092,13116,13137,13160,13181,13205,13226,13250,13268,13289,13310,13333,13354,13375,13393,13411,13432,13456,13478,13496,13529,13550,13574,13601,13625,13646,13717,13786,13846,13892,13944,13990,14041,14078,14111,14152,14188,14223,14252,14285,14328,14370,14396,14432,14470,14505,14537,14563,14592,14619,14641,14667,14695,14717,14750,14772,14808,14838,14860,14890,14922,14949,14971,14995,15023,15052,15082,15112,15145,15176,15198,15228,15250,15279,15304,15326,15350,15374,15396,15423,15441,15465,15489,15514,15532,15554,15572,15597,15620,15638,15660,15682,15700,15723,15747,15771,15789,15812,15835,15853,15874,15892,15917,15939,15961,15982,16006,16024,16042,16060,16083,16108,16131,16149,16171,16194,16219,16247,16265,16283,16301,16319,16343,16368,16386,16404,16422,16446,16469,16487,16513,16531,16549,16571,16593,16611,16633,16656,16681,16699,16725,16743,16761,16779,16802,16827,16845,16863,16888,16906,16929,16955,16973,16991,17012,17035,17053,17074,17096,17118,17143,17161,17183,17210,17236,17260,17278,17301,17319,17342,17366,17384,17407,17425,17448,17466,17484,17502,17523,17546,17571,17589,17607,17625,17646,17668,17686,17707,17731,17753,17771,17793,17819,17837,17855,17879,17897,17921,17939,17965,17983,18001,18019,18044,18062,18084,18106,18129,18147,18169,18187,18212,18233,18256,18274,18292,18318,18340,18363,18386,18408,18433,18455,18476,18501,18519,18541,18565,18587],{"intervention":94,"totalTrials":95,"cells":96},"Crystalloid solutions",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":122},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":121,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT07410988","Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications","NOT_YET_RECRUITING",[90],"2029-03-31","2029-05-31","2026-06-01",1292,[118],"Cardiac Surgery",[120,94],"Volulyte®",1,{"trials":123,"activeCount":121,"soonestReadout":129},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT06710353","The Effect of Preoperative Albumin Administration on Postoperative Acute Kidney Injury in Pediatric Patients With Hypoalbuminemia Undergoing Cardiac Surgery","RECRUITING",[91],"2027-12-31","2025-01-09",190,[133,134],"Acute Kidney Injury","Pediatric Cardiac Surgery",[136,94],"Albumin solution",{"intervention":138,"totalTrials":139,"cells":140},"Prednisolone",4,{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":194},{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":99},[],{"trials":150,"activeCount":121,"soonestReadout":129},[151,163,174,185],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":161},"NCT01908972","The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma","COMPLETED",[90],"2015-05","2013-06",34,[160],"Hemangioma",[138,162],"Propranolol",{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT02695797","Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody","UNKNOWN",[90],"2016-12","2015-09",40,[172],"Epilepsy, Unspecified, Intractable",[138],{"nctId":175,"briefTitle":176,"status":166,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT02618057","Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia",[90],"2020-12","2016-06",80,[182],"Mycoplasma Pneumoniae Pneumonia",[138,184],"Levofloxacin",{"nctId":186,"briefTitle":187,"status":111,"phases":188,"primaryCompletion":129,"completion":129,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT07227428","Comparison of Glucocorticoid Tapering Schedules in Rheumatoid Arthritis",[90],"2025-12-01",206,[192],"Rheumatoid Arthritis (RA)",[138,138,138],{"trials":195,"activeCount":99},[],{"intervention":197,"totalTrials":95,"cells":198},"Febuxostat",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":234},{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[203],{"nctId":204,"briefTitle":205,"status":154,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT05575297","A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy Subjects",[87],"2022-05-03","2022-05-09","2021-12-20",12,[212],"Drug Interaction",[214,215,197],"Methotrexate Sodium","Rifampicin Sodium",{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":121,"soonestReadout":226},[222],{"nctId":223,"briefTitle":224,"status":127,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":233},"NCT06622603","the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More",[90],"2027-02-19","2027-08-19","2025-09-10",59,[231,232],"Gout","Uric Acid",[197],{"trials":235,"activeCount":99},[],{"intervention":237,"totalTrials":95,"cells":238},"Lidocaine",{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":271},{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":99},[],{"trials":248,"activeCount":121,"soonestReadout":253},[249,259],{"nctId":250,"briefTitle":251,"status":127,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":180,"conditions":255,"interventions":257},"NCT06710405","The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (\u003C 7 Years Old) Undergoing Thoracoscopic Surgery",[90],"2026-12-31","2024-12-09",[256],"Pain Management After Surgery",[237,258],"Saline",{"nctId":260,"briefTitle":261,"status":166,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":269},"NCT02205502","Lidocaine as Local Anesthetics in Children Under Ketamine Sedation",[90],"2018-10","2013-12",58,[267,268,27],"Conscious Sedation Failure During Procedure","Analgesia",[237,270],"Normal saline",{"trials":272,"activeCount":99},[],{"intervention":274,"totalTrials":121,"cells":275},"Fentanyl-Morphine",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":298},{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":121,"soonestReadout":290},[286],{"nctId":287,"briefTitle":288,"status":111,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":296},"NCT06570343","Analgesic Efficacy of Intrathecal Fentanyl-Morphine Combination Versus Morphine Alone for Intraoperative Pain During Elective Cesarean Delivery",[90],"2025-09-20","2025-12-25","2024-09-20",186,[295],"Intraoperative Pain",[274,297],"Morphine",{"trials":299,"activeCount":99},[],{"intervention":301,"totalTrials":121,"cells":302},"Remifentanil (Limited) - Target Controlled Infusion system",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":323},{"trials":304,"activeCount":99},[],{"trials":306,"activeCount":99},[],{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":121,"soonestReadout":189},[313],{"nctId":314,"briefTitle":315,"status":111,"phases":316,"primaryCompletion":189,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT01003028","Reduction of Remifentanil-related Complications",[90],"2026-12-01","2024-11-01",160,[27],[301,322],"Remifentanil (Control) - Target Controlled Infusion system",{"trials":324,"activeCount":99},[],{"intervention":322,"totalTrials":121,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":341},{"trials":328,"activeCount":99},[],{"trials":330,"activeCount":99},[],{"trials":332,"activeCount":99},[],{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":121,"soonestReadout":189},[337],{"nctId":314,"briefTitle":315,"status":111,"phases":338,"primaryCompletion":189,"completion":317,"start":318,"enrollment":319,"conditions":339,"interventions":340},[90],[27],[301,322],{"trials":342,"activeCount":99},[],{"intervention":120,"totalTrials":121,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":359},{"trials":346,"activeCount":99},[],{"trials":348,"activeCount":99},[],{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":121,"soonestReadout":113},[355],{"nctId":109,"briefTitle":110,"status":111,"phases":356,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":357,"interventions":358},[90],[118],[120,94],{"trials":360,"activeCount":99},[],{"intervention":362,"totalTrials":121,"cells":363},"Antiplatelet Drug",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":390},{"trials":365,"activeCount":99},[],{"trials":367,"activeCount":99},[],{"trials":369,"activeCount":99},[],{"trials":371,"activeCount":99},[],{"trials":373,"activeCount":121,"soonestReadout":378},[374],{"nctId":375,"briefTitle":376,"status":127,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":388},"NCT05995600","Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE",[90],"2029-03","2024-02-20",200,[382,383,384,385,386,387],"Antiphospholipid Syndrome","Ischemic Stroke","Transient Ischemic Attack","Cerebrovascular Disease","Cardiovascular Diseases","Major Bleed",[362,389],"Warfarin",{"trials":391,"activeCount":99},[],{"intervention":393,"totalTrials":121,"cells":394},"Phenoxybenzamine",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":418},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":121,"soonestReadout":409},[405],{"nctId":406,"briefTitle":407,"status":127,"phases":408,"primaryCompletion":409,"completion":129,"start":410,"enrollment":411,"conditions":412,"interventions":417},"NCT05702944","The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma",[90],"2027-08-31","2023-01-18",24,[413,414,415,416],"Pheochromocytoma","Paraganglioma","Adrenalectomy; Status","Adrenergics Causing Adverse Effects in Therapeutic Use",[393],{"trials":419,"activeCount":99},[],{"intervention":84,"totalTrials":121,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":441},{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":121,"soonestReadout":75},[432],{"nctId":82,"briefTitle":83,"status":433,"phases":434,"primaryCompletion":75,"completion":129,"start":435,"enrollment":436,"conditions":437,"interventions":440},"ACTIVE_NOT_RECRUITING",[90],"2020-07-24",4900,[15,438,439],"Acute Myocardial Infarction","Stable Angina",[84],{"trials":442,"activeCount":99},[],{"intervention":444,"totalTrials":121,"cells":445},"Acetaminophen\u002FIbuprofen",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":469},{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":121,"soonestReadout":460},[456],{"nctId":457,"briefTitle":458,"status":127,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":467},"NCT06479122","Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen\u002FIbuprofen After Cesarean Section",[90],"2026-06-25","2026-08-25","2024-10-09",84,[465,466],"Cesarean Section","Postoperative Pain",[468,444,468,444],"Acetaminophen",{"trials":470,"activeCount":99},[],{"intervention":472,"totalTrials":121,"cells":473},"Clopidogrel treatment group",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":494},{"trials":475,"activeCount":99},[],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":121,"soonestReadout":488},[484],{"nctId":485,"briefTitle":486,"status":127,"phases":487,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":493},"NCT05845489","Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)",[90],"2028-12-31","2031-12-31","2023-03-22",11086,[15],[472],{"trials":495,"activeCount":99},[],{"intervention":497,"totalTrials":121,"cells":498},"EPHEDrine Hydrochloride 5 mg\u002Fml",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":522},{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":99},[],{"trials":508,"activeCount":121,"soonestReadout":513},[509],{"nctId":510,"briefTitle":511,"status":111,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":521},"NCT06257316","Appropriate Dosage of Vasopressor in Neonates and Infants",[90],"2027-02-28","2028-02-28","2024-02-15",132,[518,519,520],"Hypotension","Neonatal Hypotension","Intraoperative Complications",[497],{"trials":523,"activeCount":99},[],{"intervention":258,"totalTrials":525,"cells":526},6,{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":542,"PHASE4":555,"NA":561},{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":99},[],{"trials":532,"activeCount":99},[533],{"nctId":534,"briefTitle":535,"status":166,"phases":536,"primaryCompletion":537,"completion":537,"start":538,"enrollment":170,"conditions":539,"interventions":541},"NCT02985060","Mild Hypothermia After Endovascular Treatment in Acute Ischemic Stroke",[88],"2017-11","2016-11",[383,540],"Thrombolytic Therapy",[258],{"trials":543,"activeCount":99},[544],{"nctId":545,"briefTitle":546,"status":154,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT02596269","Nefopam\u002FFentanyl Postoperative Intravenous Patient-Controlled-Analgesia",[88,89],"2013-09","2012-10",73,[552],"Laparotomy",[554,258],"Nefopam",{"trials":556,"activeCount":121,"soonestReadout":253},[557],{"nctId":250,"briefTitle":251,"status":127,"phases":558,"primaryCompletion":253,"completion":253,"start":254,"enrollment":180,"conditions":559,"interventions":560},[90],[256],[237,258],{"trials":562,"activeCount":99},[563,574,587],{"nctId":564,"briefTitle":565,"status":154,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT03132701","The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children",[91],"2017-12-12","2017-06-08",66,[571],"Emergence Delirium",[573,258],"Magnesium",{"nctId":575,"briefTitle":576,"status":154,"phases":577,"primaryCompletion":578,"completion":578,"start":579,"enrollment":463,"conditions":580,"interventions":584},"NCT02100293","Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium",[91],"2014-12","2013-10",[581,582,583],"Observation of Neuromuscular Block","Intubation Condition","Surgical Condition",[585,586],"magnesium sulfate 30 mg\u002Fkg","saline",{"nctId":588,"briefTitle":589,"status":154,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT05366777","Intravenous Acetaminophen\u002FIbuprofen Fixed-dose Combination on Postoperative Opioid Consumption",[91],"2023-07-14","2023-10-15","2022-10-03",96,[466],[597,258],"acetaminophen\u002Fibuprofen fixed-dose combination",{"intervention":297,"totalTrials":599,"cells":600},3,{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":626},{"trials":602,"activeCount":99},[],{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":121,"soonestReadout":290},[611,615],{"nctId":287,"briefTitle":288,"status":111,"phases":612,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":613,"interventions":614},[90],[295],[274,297],{"nctId":616,"briefTitle":617,"status":154,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT00783016","Effect of Pain Control on the Diagnosis of Acute Appendicitis on the Diagnostic Accuracy of General Surgeon",[90],"2011-02","2011-05","2008-10",234,[624],"Appendicitis",[297],{"trials":627,"activeCount":99},[628],{"nctId":629,"briefTitle":630,"status":154,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":180,"conditions":635,"interventions":636},"NCT04824274","TAP Block With Intrathecal Fentanyl vs. Intrathecal Morphine in Cesarean Delivery",[91],"2022-02-18","2022-02-20","2021-04-12",[465],[637,638],"fentanyl","morphine",{"intervention":389,"totalTrials":599,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":667},{"trials":642,"activeCount":99},[],{"trials":644,"activeCount":99},[],{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":121,"soonestReadout":378},[651,655],{"nctId":375,"briefTitle":376,"status":127,"phases":652,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":653,"interventions":654},[90],[382,383,384,385,386,387],[362,389],{"nctId":656,"briefTitle":657,"status":658,"phases":659,"primaryCompletion":169,"completion":179,"start":660,"enrollment":99,"conditions":661,"interventions":664},"NCT01668901","Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease","WITHDRAWN",[90],"2012-09",[662,663],"Atrial Fibrillation","Chronic Kidney Disease",[665,666],"warfarin","Aspirin",{"trials":668,"activeCount":99},[669],{"nctId":670,"briefTitle":671,"status":166,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT01986192","Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study",[91],"2015-02","2015-11","2013-11",72,[678],"Ileofemoral Deep Vein Thrombosis",[680,389],"rivaroxaban",{"intervention":468,"totalTrials":599,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":709},{"trials":684,"activeCount":99},[],{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":121,"soonestReadout":460},[693,697],{"nctId":457,"briefTitle":458,"status":127,"phases":694,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":695,"interventions":696},[90],[465,466],[468,444,468,444],{"nctId":698,"briefTitle":699,"status":154,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":210,"conditions":704,"interventions":706},"NCT02180334","The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones",[90],"2014-11","2015-04","2014-07",[705],"Diabetes Mellitus, Type 2",[707,708,468],"Mosapride citrate","Linagliptin",{"trials":710,"activeCount":99},[711],{"nctId":712,"briefTitle":713,"status":154,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":463,"conditions":718,"interventions":720},"NCT03644147","Additive Effect of Intravenous Acetaminophen on Postoperative Pain Control",[91],"2021-01-06","2021-01-07","2018-08-27",[466,719],"Gynecologic Disease",[468],{"intervention":722,"totalTrials":139,"cells":723},"Rifampicin",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":746,"PHASE3":757,"PHASE4":774,"NA":776},{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[728,738],{"nctId":729,"briefTitle":730,"status":154,"phases":731,"primaryCompletion":702,"completion":702,"start":732,"enrollment":411,"conditions":733,"interventions":734},"NCT02328443","Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI",[87],"2014-01",[21],[735,736,737],"Midazolam","itraconazole","rifampicin",{"nctId":739,"briefTitle":740,"status":154,"phases":741,"primaryCompletion":548,"completion":548,"start":742,"enrollment":33,"conditions":743,"interventions":744},"NCT01760642","Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity",[87],"2012-12",[21],[735,745,722],"Ketoconazole",{"trials":747,"activeCount":99},[748],{"nctId":749,"briefTitle":750,"status":154,"phases":751,"primaryCompletion":752,"completion":752,"start":753,"enrollment":95,"conditions":754,"interventions":756},"NCT01932268","A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin",[88],"2011-12","2011-01",[663,755],"Tuberculosis",[722],{"trials":758,"activeCount":121,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":111,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT04485156","Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)",[89],"2025-08","2026-12","2020-09",926,[768],"Tuberculosis, Pulmonary",[770,771,772,773,722],"High-dose rifampicin","Isoniazid","Pyrazinamide","Ethambutol",{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"intervention":772,"totalTrials":95,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":799,"PHASE4":805,"NA":807},{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[786],{"nctId":787,"briefTitle":788,"status":154,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT02619994","Treatment Shortening of MDR-TB Using Existing and New Drugs",[88],"2021-06","2016-01",214,[794],"Tuberculosis, Multidrug-Resistant",[796,797,184,772,798],"Linezolid","Delamanid","Locally-used WHO-approved MDR-TB regimen in Korea",{"trials":800,"activeCount":121,"soonestReadout":763},[801],{"nctId":760,"briefTitle":761,"status":111,"phases":802,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":803,"interventions":804},[89],[768],[770,771,772,773,722],{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":99},[],{"intervention":773,"totalTrials":95,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":826,"PHASE4":832,"NA":834},{"trials":812,"activeCount":99},[],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[817],{"nctId":818,"briefTitle":819,"status":166,"phases":820,"primaryCompletion":821,"completion":179,"start":732,"enrollment":822,"conditions":823,"interventions":825},"NCT01994460","Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis",[88],"2015-12",429,[824],"Pulmonary Tuberculosis Without Resistance to Rifampicin",[796,773],{"trials":827,"activeCount":121,"soonestReadout":763},[828],{"nctId":760,"briefTitle":761,"status":111,"phases":829,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":830,"interventions":831},[89],[768],[770,771,772,773,722],{"trials":833,"activeCount":99},[],{"trials":835,"activeCount":99},[],{"intervention":56,"totalTrials":121,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":855,"NA":857},{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":121,"soonestReadout":55},[846],{"nctId":53,"briefTitle":54,"status":847,"phases":848,"primaryCompletion":55,"completion":849,"start":55,"enrollment":850,"conditions":851,"interventions":854},"ENROLLING_BY_INVITATION",[88,89],"2027-06-30",30,[852,853],"Ulcerative Colitis","Fecal Microbiota Transplantation",[56],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"intervention":860,"totalTrials":121,"cells":861},"mFOLFIRINOX-FOLFIRI intensified chemotherapy",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":882,"NA":884},{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":121,"soonestReadout":874},[870],{"nctId":871,"briefTitle":872,"status":127,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":880},"NCT05534087","Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)",[89],"2028-09-30","2030-09-30","2022-12-15",236,[879],"Colon Cancer",[860,881],"FOLFOX or CAPOX adjuvant chemotherapy",{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[],{"intervention":881,"totalTrials":121,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":900,"NA":902},{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":121,"soonestReadout":874},[896],{"nctId":871,"briefTitle":872,"status":127,"phases":897,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":898,"interventions":899},[89],[879],[860,881],{"trials":901,"activeCount":99},[],{"trials":903,"activeCount":99},[],{"intervention":71,"totalTrials":121,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":924,"NA":926},{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":121,"soonestReadout":70},[914],{"nctId":68,"briefTitle":69,"status":127,"phases":915,"primaryCompletion":70,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":923},[89],"2027-12","2023-04-01",609,[920,921,922],"Resectable Pancreatic Cancer","Neoadjuvant Chemotherapy","Effects of Chemotherapy",[71],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":99},[],{"intervention":770,"totalTrials":121,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":942,"NA":944},{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":121,"soonestReadout":763},[938],{"nctId":760,"briefTitle":761,"status":111,"phases":939,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":940,"interventions":941},[89],[768],[770,771,772,773,722],{"trials":943,"activeCount":99},[],{"trials":945,"activeCount":99},[],{"intervention":771,"totalTrials":95,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":960,"NA":962},{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":121,"soonestReadout":763},[956],{"nctId":760,"briefTitle":761,"status":111,"phases":957,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":958,"interventions":959},[89],[768],[770,771,772,773,722],{"trials":961,"activeCount":99},[],{"trials":963,"activeCount":99},[964],{"nctId":965,"briefTitle":966,"status":154,"phases":967,"primaryCompletion":968,"completion":969,"start":970,"enrollment":33,"conditions":971,"interventions":974},"NCT03665402","A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status",[91],"2018-12-31","2019-03-31","2018-05-13",[755,972,973],"Drug-Induced Liver Injury","Adverse Drug Event",[771],{"intervention":976,"totalTrials":599,"cells":977},"Olaparib",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":95,"soonestReadout":1000},[984,996,1006],{"nctId":985,"briefTitle":986,"status":166,"phases":987,"primaryCompletion":75,"completion":75,"start":988,"enrollment":989,"conditions":990,"interventions":993},"NCT04298021","DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer",[88],"2020-06-25",74,[991,992],"Bile Duct Cancer","Chemotherapy Effect",[994,995,976],"AZD6738","Durvalumab",{"nctId":997,"briefTitle":998,"status":433,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1005},"NCT03594396","Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer",[87,88],"2025-12-31","2018-06-29",54,[1004],"Breast Neoplasms",[976,995],{"nctId":1007,"briefTitle":1008,"status":127,"phases":1009,"primaryCompletion":1000,"completion":1000,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT05536128","Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4\u002F6 Inhibitor",[88],"2022-12-31",64,[1013],"Advanced Breast Cancer",[976,1015],"Fulvestrant",{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"intervention":1023,"totalTrials":95,"cells":1024},"SNUH-CD19-CAR-T",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1040,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":121,"soonestReadout":1033},[1029],{"nctId":1030,"briefTitle":1031,"status":127,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1039},"NCT05210907","Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia",[87],"2025-09-30","2026-08-31","2022-02-15",5,[1038],"B-cell Acute Lymphoblastic Leukemia",[1023],{"trials":1041,"activeCount":121,"soonestReadout":488},[1042],{"nctId":1043,"briefTitle":1044,"status":127,"phases":1045,"primaryCompletion":488,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1052},"NCT06247501","Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation",[88],"2029-12-31","2024-01-19",50,[1050,1051],"Very High Risk Acute Lymphoblastic Leukemia","CD19 CAR-T Therapy",[1023],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"intervention":995,"totalTrials":1036,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[],{"trials":1066,"activeCount":121,"soonestReadout":1000},[1067,1074,1087,1091,1095],{"nctId":1068,"briefTitle":1069,"status":166,"phases":1070,"primaryCompletion":75,"completion":1000,"start":988,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT04298008","AZD6738 Plus Durvalumab in Biliary Tract Cancer",[88],26,[991,992],[994,995],{"nctId":1075,"briefTitle":1076,"status":166,"phases":1077,"primaryCompletion":1078,"completion":75,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT03046862","Durvalumab(MEDI4736)\u002FTremelimumab in Combination With Gemcitabine\u002FCisplatin in Chemotherapy-naïve Biliary Tract Cancer",[88],"2020-05-30","2017-02-25",31,[1082],"Biliary Tract Neoplasms",[995,1084,1085,1086],"Tremelimumab","Gemcitabine","Cisplatin",{"nctId":985,"briefTitle":986,"status":166,"phases":1088,"primaryCompletion":75,"completion":75,"start":988,"enrollment":989,"conditions":1089,"interventions":1090},[88],[991,992],[994,995,976],{"nctId":997,"briefTitle":998,"status":433,"phases":1092,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1093,"interventions":1094},[87,88],[1004],[976,995],{"nctId":1096,"briefTitle":1097,"status":154,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":411,"conditions":1102,"interventions":1103},"NCT04124991","Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC",[87,88],"2022-07-06","2022-07-28","2020-06-12",[18],[995],{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"intervention":1111,"totalTrials":95,"cells":1112},"Tislelizumab",{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":121,"soonestReadout":1123},[1119,1130],{"nctId":1120,"briefTitle":1121,"status":433,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1128},"NCT05253118","Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)",[88],"2026-12-28","2022-08-18",28,[1127],"DLBCL",[1111,1129],"Pemetrexed",{"nctId":1131,"briefTitle":1132,"status":166,"phases":1133,"primaryCompletion":1134,"completion":75,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT04727996","Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer",[88],"2023-07-31","2020-11-01",43,[1138],"Advanced Biliary Tract Cancer",[1140,1111],"Sitravatinib",{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":99},[],{"intervention":1148,"totalTrials":95,"cells":1149},"Bortezomib",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":121,"soonestReadout":129},[1156,1165],{"nctId":1157,"briefTitle":1158,"status":127,"phases":1159,"primaryCompletion":129,"completion":488,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1164},"NCT05599880","The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed\u002FRefractory Immune Thrombocytopenia",[88],"2023-07-07",29,[1163],"Relapsed\u002FRefractory Immune Thrombocytopenia",[1148],{"nctId":1166,"briefTitle":1167,"status":166,"phases":1168,"primaryCompletion":178,"completion":178,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1174},"NCT03335098","Study of VTD in Waldenstrom's Macroglobulinemia",[88],"2016-11-21",15,[1172,1173],"Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[1148],{"trials":1176,"activeCount":99},[],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"intervention":1182,"totalTrials":121,"cells":1183},"NEBULA",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":121,"soonestReadout":1194},[1190],{"nctId":1191,"briefTitle":1192,"status":111,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":115,"enrollment":1196,"conditions":1197,"interventions":1198},"NCT07464210","Nemtabrutinib, Bortezomib, and Rituximab for WM",[88],"2029-08-01","2030-08-01",19,[1172],[1182],{"trials":1200,"activeCount":99},[],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"intervention":1206,"totalTrials":121,"cells":1207},"Golcadomide + Poseltinib + Rituximab",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":121,"soonestReadout":1218},[1214],{"nctId":1215,"briefTitle":1216,"status":111,"phases":1217,"primaryCompletion":1218,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT07269639","Golcadomide, Poseltinib, and Rituximab for Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[87,88],"2027-12-01","2028-09-01","2026-01-01",20,[1223],"Large B-Cell Lymphoma (LBCL)",[1206],{"trials":1226,"activeCount":99},[],{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":99},[],{"intervention":1232,"totalTrials":121,"cells":1233},"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":121,"soonestReadout":1244},[1240],{"nctId":1241,"briefTitle":1242,"status":111,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1220,"enrollment":1246,"conditions":1247,"interventions":1250},"NCT07273396","Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer",[87,88],"2030-04-30","2030-08-31",53,[1248,1249],"Ovarian Neoplasms","Peritoneal Neoplasms",[1232],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"intervention":1258,"totalTrials":121,"cells":1259},"Glofitamab, Poseltinib, Lenalidomide",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":121,"soonestReadout":1270},[1266],{"nctId":1267,"briefTitle":1268,"status":433,"phases":1269,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1276},"NCT05335018","GPL in Patients with Relapsed\u002Frefractory Diffuse Large B Cell Lymphoma",[88],"2025-11-30","2026-11-30","2022-05-30",76,[1275],"Relapsed\u002Frefractory Diffuse Large B Cell Lymphoma",[1258],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[],{"intervention":61,"totalTrials":121,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":121,"soonestReadout":60},[1291],{"nctId":58,"briefTitle":59,"status":433,"phases":1292,"primaryCompletion":60,"completion":488,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1296},[88],"2019-11-08",122,[24],[61,1297,1298],"Letrozole","MammaPrint",{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"trials":1304,"activeCount":99},[],{"intervention":1297,"totalTrials":121,"cells":1306},{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1308,"activeCount":99},[],{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":121,"soonestReadout":60},[1313],{"nctId":58,"briefTitle":59,"status":433,"phases":1314,"primaryCompletion":60,"completion":488,"start":1293,"enrollment":1294,"conditions":1315,"interventions":1316},[88],[24],[61,1297,1298],{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"trials":1322,"activeCount":99},[],{"intervention":1298,"totalTrials":121,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":99},[],{"trials":1330,"activeCount":121,"soonestReadout":60},[1331],{"nctId":58,"briefTitle":59,"status":433,"phases":1332,"primaryCompletion":60,"completion":488,"start":1293,"enrollment":1294,"conditions":1333,"interventions":1334},[88],[24],[61,1297,1298],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[],{"trials":1340,"activeCount":99},[],{"intervention":1129,"totalTrials":121,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":99},[],{"trials":1346,"activeCount":99},[],{"trials":1348,"activeCount":121,"soonestReadout":1123},[1349],{"nctId":1120,"briefTitle":1121,"status":433,"phases":1350,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":1125,"conditions":1351,"interventions":1352},[88],[1127],[1111,1129],{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"intervention":1360,"totalTrials":121,"cells":1361},"betahistine",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1363,"activeCount":99},[],{"trials":1365,"activeCount":99},[],{"trials":1367,"activeCount":121,"soonestReadout":1372},[1368],{"nctId":1369,"briefTitle":1370,"status":127,"phases":1371,"primaryCompletion":1372,"completion":1000,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT06001593","Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation",[87,88],"2025-11","2023-09-18",120,[1376],"Meniere's Disease",[1360],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"intervention":76,"totalTrials":121,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":121,"soonestReadout":75},[1392],{"nctId":73,"briefTitle":74,"status":433,"phases":1393,"primaryCompletion":75,"completion":488,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1399},[88],"2021-10-21",238,[1397,1398],"Premenopausal Breast Cancer","Hormone Receptor-positive Breast Cancer",[76],{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"intervention":1407,"totalTrials":121,"cells":1408},"Naltrexone",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1410,"activeCount":99},[],{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":121,"soonestReadout":513},[1415],{"nctId":1416,"briefTitle":1417,"status":111,"phases":1418,"primaryCompletion":513,"completion":1419,"start":115,"enrollment":1420,"conditions":1421,"interventions":1423},"NCT06622239","Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury",[88],"2027-05-31",150,[1422],"Nonsuicidal Self-Injury",[1407],{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"intervention":1431,"totalTrials":121,"cells":1432},"Talazoparib Oral",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":121,"soonestReadout":1419},[1439],{"nctId":1440,"briefTitle":1441,"status":127,"phases":1442,"primaryCompletion":1419,"completion":1419,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1446},"NCT04892693","Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency",[88],"2021-05-25",70,[1013],[1431],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"intervention":1454,"totalTrials":121,"cells":1455},"Letermovir",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1457,"activeCount":99},[],{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":121,"soonestReadout":129},[1462],{"nctId":1463,"briefTitle":1464,"status":127,"phases":1465,"primaryCompletion":129,"completion":488,"start":1466,"enrollment":170,"conditions":1467,"interventions":1469},"NCT06920251","Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy",[88],"2025-09-11",[1468],"Relapsed Refractory Multiple Myeloma (RRMM)",[1454],{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":99},[],{"intervention":1477,"totalTrials":121,"cells":1478},"Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":121,"soonestReadout":1489},[1485],{"nctId":1486,"briefTitle":1487,"status":127,"phases":1488,"primaryCompletion":1489,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1494},"NCT06794294","Effects of Allogenic Umbilical Cord-Derived Mesenchymal Stem Cells on Patients With Rotator Cuff Disease",[87,88],"2027-01","2025-01-17",21,[1493],"Rotator Cuff Disease",[1477],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"intervention":1502,"totalTrials":121,"cells":1503},"Maribavir",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":121,"soonestReadout":1514},[1510],{"nctId":1511,"briefTitle":1512,"status":127,"phases":1513,"primaryCompletion":1514,"completion":1515,"start":1516,"enrollment":1221,"conditions":1517,"interventions":1519},"NCT07014319","Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies",[88],"2027-10-31","2028-01-31","2025-11-03",[1518],"Cytomegalovirus (CMV)",[1502],{"trials":1521,"activeCount":99},[],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"intervention":1015,"totalTrials":121,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":121,"soonestReadout":1000},[1534],{"nctId":1007,"briefTitle":1008,"status":127,"phases":1535,"primaryCompletion":1000,"completion":1000,"start":1010,"enrollment":1011,"conditions":1536,"interventions":1537},[88],[1013],[976,1015],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[],{"intervention":1545,"totalTrials":121,"cells":1546},"decitabine plus venetoclax",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":121,"soonestReadout":409},[1553],{"nctId":1554,"briefTitle":1555,"status":127,"phases":1556,"primaryCompletion":409,"completion":1557,"start":1558,"enrollment":1125,"conditions":1559,"interventions":1561},"NCT06712121","Venetoclax and Decitabine in R\u002FR T-ALL",[88],"2028-08-31","2025-01-30",[1560],"T Lymphoblastic Leukemia\u002FLymphoma",[1545],{"trials":1563,"activeCount":99},[],{"trials":1565,"activeCount":99},[],{"trials":1567,"activeCount":99},[],{"intervention":1569,"totalTrials":121,"cells":1570},"Eribulin Mesylate + Samfenet",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":121,"soonestReadout":1581},[1577],{"nctId":1578,"briefTitle":1579,"status":127,"phases":1580,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},"NCT05530057","Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer",[88],"2028-06-30","2020-02-18",180,[1013],[1569,1586],"Eribulin Mesylate",{"trials":1588,"activeCount":99},[],{"trials":1590,"activeCount":99},[],{"trials":1592,"activeCount":99},[],{"intervention":1586,"totalTrials":121,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":121,"soonestReadout":1581},[1601],{"nctId":1578,"briefTitle":1579,"status":127,"phases":1602,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":1603,"interventions":1604},[88],[1013],[1569,1586],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[],{"intervention":80,"totalTrials":121,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1631},{"trials":1614,"activeCount":99},[],{"trials":1616,"activeCount":121,"soonestReadout":75},[1617],{"nctId":78,"briefTitle":79,"status":127,"phases":1618,"primaryCompletion":75,"completion":75,"start":1619,"enrollment":210,"conditions":1620,"interventions":1624},[87],"2024-06-10",[1621,1622,1623],"Liver Transplant Rejection","Liver Transplant; Complications","Steatohepatitis, Nonalcoholic",[80],{"trials":1626,"activeCount":99},[],{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":99},[],{"intervention":51,"totalTrials":1170,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":599,"soonestReadout":50},[1647,1658,1669,1678,1687,1695,1704,1716,1728,1737,1748,1758,1767,1778,1789],{"nctId":1648,"briefTitle":1649,"status":154,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1002,"conditions":1653,"interventions":1655},"NCT05397886","Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation",[91],"2023-04-25","2022-08-02",[1654],"Recovery",[1656,1657,51],"Remimazolam Besylate","Flumazenil",{"nctId":1659,"briefTitle":1660,"status":154,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT02932722","Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)",[91],"2018-02-07","2017-02-22",51,[1666],"Myocardial Infarction",[51,1668],"Sevoflurane",{"nctId":48,"briefTitle":49,"status":433,"phases":1670,"primaryCompletion":50,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},[91],"2025-12-22","2020-09-22",562,[1675],"Renal Cell Carcinoma",[51,1677],"Inhaled General Anesthetics",{"nctId":1679,"briefTitle":1680,"status":658,"phases":1681,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":99,"conditions":1684,"interventions":1685},"NCT05375747","Remimazolam Versus Propopol Based Total Intravenous Anesthesia for Breast Surgery",[91],"2023-01-09","2022-06-13",[518],[1686,51],"Remimazolam",{"nctId":1688,"briefTitle":1689,"status":154,"phases":1690,"primaryCompletion":1691,"completion":1691,"start":1652,"enrollment":569,"conditions":1692,"interventions":1693},"NCT05435911","Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol",[91],"2022-12-21",[1654],[1694,1657,51],"REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]",{"nctId":1696,"briefTitle":1697,"status":433,"phases":1698,"primaryCompletion":1699,"completion":1699,"start":1582,"enrollment":1700,"conditions":1701,"interventions":1703},"NCT04259398","Anesthesia and Cancer Study: Colon Cancer",[91],"2028-05-03",797,[1702,27],"Cancer of Colon",[51,1668],{"nctId":1705,"briefTitle":1706,"status":154,"phases":1707,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1713},"NCT05423951","Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in OPCAB Patients",[91],"2023-11-08","2022-07-26",106,[1712],"Hemodynamic Instability",[1694,51,1714,1715],"Rocuronium","Sufentanil",{"nctId":1717,"briefTitle":1718,"status":154,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1726},"NCT04474600","Anesthesia and Acute Kidney Injury After Nephrectomy",[91],"2024-02-06","2024-03-06","2020-07-20",324,[1725],"Nephrectomy",[51,1727],"Desflurane",{"nctId":1729,"briefTitle":1730,"status":111,"phases":1731,"primaryCompletion":129,"completion":129,"start":1220,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT07265050","Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery",[91],204,[1734],"Emergence Agitation",[1736,51],"Remimazolam with Flumazenil",{"nctId":1738,"briefTitle":1739,"status":154,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1747},"NCT03132688","A Study on Safety and Efficacy of Propofol in Small Children Under 2 Years of Age",[],"2017-04-22","2017-04-20",100,[1745,1746],"Heart Rate Low","Anesthesia; Functional",[51],{"nctId":1749,"briefTitle":1750,"status":154,"phases":1751,"primaryCompletion":578,"completion":578,"start":703,"enrollment":1752,"conditions":1753,"interventions":1755},"NCT02191371","Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation",[91],104,[1754],"Mechanical Ventilation Complication",[1756,1757],"propofol","desflurane",{"nctId":1759,"briefTitle":1760,"status":154,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1444,"conditions":1764,"interventions":1766},"NCT04520503","Relationship Between Pre-induction Electroencephalogram Pattern of Adult Patients and Their Sensitivity to Propofol",[],"2022-02-28","2020-09-09",[1765],"Propofol Overdose of Undetermined Intent",[51],{"nctId":1768,"briefTitle":1769,"status":154,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":701,"enrollment":1772,"conditions":1773,"interventions":1777},"NCT02252445","Propofol and Sevoflurane for Catheter-Related Bladder Discomfort",[91],"2015-01",82,[1774,1775,27,1776],"Catheter Site Discomfort","Complications","Urinary Bladder Neoplasms",[51,1668],{"nctId":1779,"briefTitle":1780,"status":166,"phases":1781,"primaryCompletion":1782,"completion":1783,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1788},"NCT04239794","The Influence of Type of Anesthesia on Postoperative Pain",[91],"2023-12-19","2024-01-31","2020-02-20",468,[1787,27],"Colo-rectal Cancer",[51,1668],{"nctId":1790,"briefTitle":1791,"status":154,"phases":1792,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1799},"NCT03152981","Analysis of Change of Optic Nerve Sheath Diameter in Robot Assisted Laparoscopic Radical Prostatectomy",[91],"2017-12-30","2017-06-03",60,[1797,1798],"Optic Nerve Sheath Diameter","Robot Assisted Laparoscopic Radical Prostatectomy",[1727,1756,1800],"remifentanil",{"intervention":1800,"totalTrials":1802,"cells":1803},8,{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[1810],{"nctId":1811,"briefTitle":1812,"status":1813,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":210,"conditions":1817,"interventions":1820},"NCT01713127","Remifentanil in Ventilated Preterm Infants","TERMINATED",[87,88],"2013-02","2012-08",[1818,1819],"Preterm Infants","Mechanical Ventilator Care",[1800],{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":599,"soonestReadout":1875},[1827,1839,1850,1859,1871,1882,1893],{"nctId":1828,"briefTitle":1829,"status":433,"phases":1830,"primaryCompletion":1831,"completion":1832,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1837},"NCT04364945","Association Between Anesthetic Drugs for General Anesthesia and Postoperative Intelligence\u002Fbehavioral Assessment Results in Children",[91],"2028-05-30","2028-12-30","2020-06-17",400,[1836],"Anesthesia and Neurotoxicity",[1838,1800,1668],"dexmedetomidine",{"nctId":1840,"briefTitle":1841,"status":154,"phases":1842,"primaryCompletion":1843,"start":1844,"enrollment":1048,"conditions":1845,"interventions":1849},"NCT01489137","The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation",[91],"2012-02","2011-11",[1846,1847,1848],"Brain Tumor","AVM","ICH",[1800],{"nctId":1851,"briefTitle":1852,"status":154,"phases":1853,"primaryCompletion":1854,"completion":742,"start":1844,"enrollment":180,"conditions":1855,"interventions":1857},"NCT01542099","The EC50 of Remifentanil Blunting Hemodynamic Response to Double Lumen Tube Intubation",[91],"2012-04",[1856],"Hemodynamic Responses During Tracheal Intubation",[1858,1858],"Remifentanil",{"nctId":1860,"briefTitle":1861,"status":658,"phases":1862,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":1865,"interventions":1867},"NCT03763305","Comparison of Skin Sympathetic Nerve Activity According to Different Anesthetics",[91],"2023-12-31","2023-01-01",[1866],"SKNA According to Different Anesthetics",[1868,1858,1668,1727,1869,1870],"Propofol continuous","Propofol bolus","Fentanyl",{"nctId":1872,"briefTitle":1873,"status":111,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT06260046","Effect of Sufentanil on the Postoperative Pain",[91],"2025-01-15","2027-01-15","2024-03-01",48,[1880],"Postoperative Pain, Acute",[1715,1858],{"nctId":1883,"briefTitle":1884,"status":127,"phases":1885,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1889,"conditions":1890,"interventions":1892},"NCT06091904","Effects of Sufentanil on the Intraoperative Hemodynamics",[91],"2025-11-01","2026-11-01","2023-11-24",92,[1891],"Intraoperative Hypotension",[1715,1858],{"nctId":1790,"briefTitle":1791,"status":154,"phases":1894,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":1795,"conditions":1895,"interventions":1896},[91],[1797,1798],[1727,1756,1800],{"intervention":1668,"totalTrials":210,"cells":1898},{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1905,"PHASE4":1907,"NA":1928},{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[1909,1918],{"nctId":1910,"briefTitle":1911,"status":154,"phases":1912,"primaryCompletion":675,"completion":264,"start":742,"enrollment":1444,"conditions":1913,"interventions":1916},"NCT01886664","Comparison of PRS According to Inhalation Agent During LDLT",[90],[1914,1915],"Liver Transplantation","Postreperfusion Syndrome",[1917,1727],"sevoflurane",{"nctId":1919,"briefTitle":1920,"status":154,"phases":1921,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":676,"conditions":1924,"interventions":1927},"NCT03209193","Effect of Anesthetics on Microcirculation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery",[90],"2019-11-07","2017-07-04",[1925,1926],"Microcirculation","Anesthetic Complication Spinal",[1668,1727],{"trials":1929,"activeCount":95,"soonestReadout":1699},[1930,1934,1938,1942,1949,1953,1961,1973,1984,1988],{"nctId":1828,"briefTitle":1829,"status":433,"phases":1931,"primaryCompletion":1831,"completion":1832,"start":1833,"enrollment":1834,"conditions":1932,"interventions":1933},[91],[1836],[1838,1800,1668],{"nctId":1659,"briefTitle":1660,"status":154,"phases":1935,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":1936,"interventions":1937},[91],[1666],[51,1668],{"nctId":1696,"briefTitle":1697,"status":433,"phases":1939,"primaryCompletion":1699,"completion":1699,"start":1582,"enrollment":1700,"conditions":1940,"interventions":1941},[91],[1702,27],[51,1668],{"nctId":1943,"briefTitle":1944,"status":154,"phases":1945,"primaryCompletion":675,"completion":675,"start":742,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT01899248","The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)",[],52,[30],[1668,1727],{"nctId":1860,"briefTitle":1861,"status":658,"phases":1950,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":1951,"interventions":1952},[91],[1866],[1868,1858,1668,1727,1869,1870],{"nctId":1954,"briefTitle":1955,"status":154,"phases":1956,"primaryCompletion":703,"completion":703,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1960},"NCT02096224","Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort",[91],"2014-05",108,[1774,1775,27,1776],[1668,1727],{"nctId":1962,"briefTitle":1963,"status":166,"phases":1964,"primaryCompletion":1965,"completion":1966,"start":1967,"enrollment":1968,"conditions":1969,"interventions":1972},"NCT02510586","Sevoflurane and Hyperperfusion Syndrome",[91],"2018-08","2018-09","2015-08",152,[1970,1971],"Hyperperfusion Syndrome","Moyamoya Disease",[1668],{"nctId":1974,"briefTitle":1975,"status":154,"phases":1976,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":380,"conditions":1980,"interventions":1982},"NCT02470442","Desflurane in Children With Laryngeal Mask Airway",[91],"2016-02","2016-03","2015-06",[1981],"Desflurane Anesthesia",[1983,1668],"Sevoflurane\u002FDesflurane",{"nctId":1768,"briefTitle":1769,"status":154,"phases":1985,"primaryCompletion":1771,"completion":1771,"start":701,"enrollment":1772,"conditions":1986,"interventions":1987},[91],[1774,1775,27,1776],[51,1668],{"nctId":1779,"briefTitle":1780,"status":166,"phases":1989,"primaryCompletion":1782,"completion":1783,"start":1784,"enrollment":1785,"conditions":1990,"interventions":1991},[91],[1787,27],[51,1668],{"intervention":1715,"totalTrials":139,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":95,"soonestReadout":1875},[2006,2010,2014,2018],{"nctId":1872,"briefTitle":1873,"status":111,"phases":2007,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":2008,"interventions":2009},[91],[1880],[1715,1858],{"nctId":1705,"briefTitle":1706,"status":154,"phases":2011,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1710,"conditions":2012,"interventions":2013},[91],[1712],[1694,51,1714,1715],{"nctId":1883,"briefTitle":1884,"status":127,"phases":2015,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1889,"conditions":2016,"interventions":2017},[91],[1891],[1715,1858],{"nctId":2019,"briefTitle":2020,"status":166,"phases":2021,"primaryCompletion":2022,"completion":2022,"start":2023,"enrollment":170,"conditions":2024,"interventions":2026},"NCT05672212","Goal-directed Analgesia Using ANI During General Anesthesia in Children With Moyamoya Disease",[91],"2025-01-04","2023-01-04",[2025],"Pain",[1715],{"intervention":270,"totalTrials":1080,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2084,"PHASE4":2122,"NA":2201},{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[2035,2048,2060,2073],{"nctId":2036,"briefTitle":2037,"status":154,"phases":2038,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":411,"conditions":2042,"interventions":2044},"NCT02298023","Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)",[88],"2016-07-19","2018-04-10","2014-09",[2043],"Rotator Cuff Tear",[2045,2046,2047],"allogenic adipose stem cell","fibrin glue\u002Fnormal saline","normal saline",{"nctId":2049,"briefTitle":2050,"status":166,"phases":2051,"primaryCompletion":2052,"completion":2052,"start":1967,"enrollment":2053,"conditions":2054,"interventions":2058},"NCT02597257","Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain",[88],"2016-07",44,[2055,2056,2057],"Postherpetic Neuralgia","Diabetic Polyneuropathy","Peripheral Neuropathy",[2059,270],"Lidocaine HCl",{"nctId":2061,"briefTitle":2062,"status":154,"phases":2063,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":850,"conditions":2067,"interventions":2069},"NCT03449082","Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)",[88],"2019-07-16","2021-03-08","2018-03-15",[2068],"Lateral Epicondylitis",[2070,2071,2072,270],"High concentration of Allo-ASC","Low concentration of Allo-ASC","Fibrin glue",{"nctId":2074,"briefTitle":2075,"status":166,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":1011,"conditions":2080,"interventions":2082},"NCT05005715","Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery",[88],"2022-08-29","2023-08-29","2021-08-30",[2081],"Non-functioning Pituitary Adenoma",[2083,2047],"Dexmedetomidine",{"trials":2085,"activeCount":99},[2086,2097,2106],{"nctId":2087,"briefTitle":2088,"status":154,"phases":2089,"primaryCompletion":1863,"completion":2090,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2095},"NCT03547791","Effects of ACS in Twin With LPB: Study Protocol for a RCT",[88,89],"2024-07-26","2018-05-05",848,[2094],"Twin Pregnancy, Antepartum Condition or Complication",[2096,270],"Betamethason Sodium Phosphate",{"nctId":2098,"briefTitle":2099,"status":154,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":742,"enrollment":1048,"conditions":2102,"interventions":2104},"NCT01715597","Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma",[89],"2017-10",[2103],"Uterine Leiomyoma",[2105,270],"ascorbic acid",{"nctId":2107,"briefTitle":2108,"status":166,"phases":2109,"primaryCompletion":2110,"completion":75,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2119},"NCT04201561","High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy",[89],"2023-04-30","2019-12-24",68,[2114,2115,2116,2117,2118],"Chemotherapy-induced Peripheral Neuropathy","Recurrent Ovarian Carcinoma","Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[2120,270,2121],"sodium selenite pentahydrate","Chemotherapy",{"trials":2123,"activeCount":99},[2124,2136,2146,2157,2167,2177,2188,2192],{"nctId":2125,"briefTitle":2126,"status":154,"phases":2127,"primaryCompletion":2128,"completion":2129,"start":2130,"enrollment":2131,"conditions":2132,"interventions":2134},"NCT03074968","Effect of Benzydamine Hydrochloride to Postoperative Sore Throat in Pediatric Patients",[90],"2018-03-13","2018-04-05","2017-03-08",142,[2133],"Intubation Complication",[2135,270],"Benzydamine Hydrochloride",{"nctId":2137,"briefTitle":2138,"status":1813,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":411,"conditions":2142,"interventions":2145},"NCT03253224","Magnesium and Postoperative Pain",[90],"2018-03-29","2017-09-10",[2143,2144,2083],"Arthritis Knee","Magnesium Sulfate",[2144,270],{"nctId":2147,"briefTitle":2148,"status":154,"phases":2149,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":2153,"conditions":2154,"interventions":2155},"NCT01001403","Effect of Nafamostat on Postreperfusion Syndrome (PRS)",[90],"2010-03","2010-04","2009-03",62,[1914,1915],[2156,270],"Nafamostat",{"nctId":2158,"briefTitle":2159,"status":154,"phases":2160,"primaryCompletion":2161,"completion":179,"start":169,"enrollment":676,"conditions":2162,"interventions":2163},"NCT02802683","Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery",[90],"2016-05",[518],[2164,2165,2166,2047],"Bupivacaine","Levobupivacaine","Phenylephrine",{"nctId":2168,"briefTitle":2169,"status":154,"phases":2170,"primaryCompletion":2171,"completion":2172,"start":157,"enrollment":28,"conditions":2173,"interventions":2175},"NCT01860196","Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy",[90],"2017-03","2017-06",[2174],"Adult Cerebral Palsy",[2176,270],"Meditoxin",{"nctId":2178,"briefTitle":2179,"status":166,"phases":2180,"primaryCompletion":2181,"completion":1135,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2186},"NCT04401735","Effects and Safety of Epidural PDRN vs. Placebo",[90],"2020-05-31","2019-11-01",45,[2185],"Spinal Stenosis Lumbar",[2187,270],"Polydeoxyribonucleotides",{"nctId":260,"briefTitle":261,"status":166,"phases":2189,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":2190,"interventions":2191},[90],[267,268,27],[237,270],{"nctId":2193,"briefTitle":2194,"status":166,"phases":2195,"primaryCompletion":2196,"completion":1863,"start":2197,"enrollment":1011,"conditions":2198,"interventions":2200},"NCT05553678","The Effect of MDZ on Movement During UIA Clipping",[90],"2023-09-30","2022-09-29",[2199],"Intraoperative Movement",[735,270],{"trials":2202,"activeCount":121,"soonestReadout":2326},[2203,2212,2225,2236,2247,2255,2263,2271,2280,2290,2300,2312,2322,2333,2343,2352],{"nctId":2204,"briefTitle":2205,"status":166,"phases":2206,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":319,"conditions":2209,"interventions":2211},"NCT04484922","Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery",[91],"2023-05-31","2020-08-25",[2210],"Congenital Heart Disease",[2083,270],{"nctId":2213,"briefTitle":2214,"status":154,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2053,"conditions":2219,"interventions":2223},"NCT04873531","Feasibility of Neostigmine for Intraoperative Neuromonitoring in Thyroid Surgery",[91],"2021-08-23","2021-08-31","2021-05-10",[2220,2221,2222],"Thyroid Diseases","Surgical Injury","Nerve Monitoring",[2224,270],"Neostigmine",{"nctId":2226,"briefTitle":2227,"status":154,"phases":2228,"primaryCompletion":2229,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2234},"NCT04450355","Effects of Continuous Infusion of Intravenous Nefopam on Postoperative Pain and Opioid Consumption After VATS",[91],"2021-08-09","2021-11-10","2020-07-30",90,[466],[2235,270],"Nefopam 80mg\u002Fday",{"nctId":2237,"briefTitle":2238,"status":658,"phases":2239,"primaryCompletion":2240,"completion":2241,"start":2242,"enrollment":99,"conditions":2243,"interventions":2245},"NCT01801878","Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts",[91],"2021-10-30","2021-12-30","2020-12-01",[1004,2244],"Skin Abnormalities",[2246,270],"Adipose SVF cell",{"nctId":2248,"briefTitle":2249,"status":154,"phases":2250,"primaryCompletion":1965,"completion":1965,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2254},"NCT02888275","Dexmedetomidine in Pediatric Cardiac Surgery",[91],"2016-10",144,[133],[2083,2047],{"nctId":2256,"briefTitle":2257,"status":658,"phases":2258,"primaryCompletion":1978,"completion":1978,"start":1957,"enrollment":99,"conditions":2259,"interventions":2261},"NCT02315235","The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy",[91],[2260],"Diabetic Neuropathy",[270,2262],"stem-cell",{"nctId":2264,"briefTitle":2265,"status":154,"phases":2266,"primaryCompletion":742,"completion":1815,"start":2267,"enrollment":1743,"conditions":2268,"interventions":2270},"NCT01650961","The Effect of Palonosetron on the QTc Interval During Perioperative Period",[91],"2012-07",[30,2269],"Palonosetron",[2269,270],{"nctId":2272,"briefTitle":2273,"status":166,"phases":2274,"primaryCompletion":702,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2279},"NCT02203123","Ratio of Inferior Vena Cava and Aorta Diameter in Dehydrated Children",[91],"2014-03",226,[2278],"Dehydration",[2047],{"nctId":2281,"briefTitle":2282,"status":166,"phases":2283,"primaryCompletion":1863,"completion":1863,"start":2284,"enrollment":1795,"conditions":2285,"interventions":2288},"NCT03882060","Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients",[91],"2019-04-08",[1971,2286,2287],"Pediatrics","Cerebrovascular Disorders",[2289,270],"erythropoietin",{"nctId":2291,"briefTitle":2292,"status":154,"phases":2293,"primaryCompletion":2294,"completion":2294,"start":157,"enrollment":2295,"conditions":2296,"interventions":2298},"NCT02139241","The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery",[91],"2014-10",114,[2297,518],"Coronary Artery Bypass Graft Triple Vessel",[2299,270],"Ramosetron",{"nctId":2301,"briefTitle":2302,"status":166,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT04564521","Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.",[91],"2024-06-30","2024-12-30","2020-09-28",36,[2309],"Retinoblastoma",[2311,270],"Nitroglycerin",{"nctId":2313,"briefTitle":2314,"status":154,"phases":2315,"primaryCompletion":702,"completion":702,"start":701,"enrollment":1889,"conditions":2316,"interventions":2317},"NCT02856087","The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study",[91],[2025],[2318,2319,2320,2321],"High dose Remifentanil","Naloxone","Low dose remifentanil","Normal Saline",{"nctId":2323,"briefTitle":2324,"status":111,"phases":2325,"primaryCompletion":2326,"completion":2327,"start":115,"enrollment":2328,"conditions":2329,"interventions":2331},"NCT07550803","Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery",[91],"2027-06-01","2027-07-01",102,[2330],"Sleep Disturbance",[2332,2321],"Dexamethasone",{"nctId":2334,"briefTitle":2335,"status":154,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":380,"conditions":2339,"interventions":2342},"NCT05443061","Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children",[91],"2025-03-24","2022-09-08",[2340,2341],"Arterial Line","Ischemia",[2311,270],{"nctId":2344,"briefTitle":2345,"status":154,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2351},"NCT03849183","Subcutaneous Nitroglycerin for Pediatric Radial Artery Cannulation",[91],"2019-07-22","2019-03-20",116,[2340],[2311,270],{"nctId":2353,"briefTitle":2354,"status":166,"phases":2355,"primaryCompletion":1010,"completion":1010,"start":2356,"enrollment":2357,"conditions":2358,"interventions":2361},"NCT05386953","Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation",[],"2022-04-01",1440,[2359,1622,2360],"End Stage Liver DIsease","Liver Cirrhosis",[270,2362],"Balanced crystalloid solution",{"intervention":2083,"totalTrials":210,"cells":2364},{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2375,"PHASE4":2377,"NA":2425},{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[],{"trials":2370,"activeCount":99},[2371],{"nctId":2074,"briefTitle":2075,"status":166,"phases":2372,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":1011,"conditions":2373,"interventions":2374},[88],[2081],[2083,2047],{"trials":2376,"activeCount":99},[],{"trials":2378,"activeCount":99},[2379,2390,2398,2406,2415],{"nctId":2380,"briefTitle":2381,"status":166,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":2349,"conditions":2386,"interventions":2388},"NCT01578161","The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia",[90],"2013-01","2013-04","2012-01",[2387],"Psychomotor Agitation",[2083,2389],"0.9% Normal Saline",{"nctId":2391,"briefTitle":2392,"status":166,"phases":2393,"primaryCompletion":752,"completion":1843,"start":2394,"enrollment":22,"conditions":2395,"interventions":2397},"NCT01374737","ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children",[90],"2011-06",[2396],"Agitation",[2083],{"nctId":2399,"briefTitle":2400,"status":154,"phases":2401,"primaryCompletion":1843,"completion":1843,"start":2394,"enrollment":2402,"conditions":2403,"interventions":2405},"NCT01373021","The Effect of Dexmedetomidine on Postoperative Analgesia",[90],95,[2404],"Colon Cancer, Rectal Cancer",[1870,2083],{"nctId":2407,"briefTitle":2408,"status":154,"phases":2409,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":1752,"conditions":2412,"interventions":2414},"NCT05447507","Comparison of Remimazolam and Dexmedetomidine for Intraoperative Sedation",[90],"2022-10-26","2022-07-08",[2413],"Orthopedic Disorder",[1686,2083],{"nctId":2416,"briefTitle":2417,"status":154,"phases":2418,"primaryCompletion":2419,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2424},"NCT01404689","Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP",[90],"2012-03","2011-08",110,[2423],"Undergoing ERCP for Diagnostic or Therapeutic Purposes",[2083],{"trials":2426,"activeCount":121,"soonestReadout":1831},[2427,2431,2435,2439,2449,2460],{"nctId":1828,"briefTitle":1829,"status":433,"phases":2428,"primaryCompletion":1831,"completion":1832,"start":1833,"enrollment":1834,"conditions":2429,"interventions":2430},[91],[1836],[1838,1800,1668],{"nctId":2204,"briefTitle":2205,"status":166,"phases":2432,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":319,"conditions":2433,"interventions":2434},[91],[2210],[2083,270],{"nctId":2248,"briefTitle":2249,"status":154,"phases":2436,"primaryCompletion":1965,"completion":1965,"start":2251,"enrollment":2252,"conditions":2437,"interventions":2438},[91],[133],[2083,2047],{"nctId":2440,"briefTitle":2441,"status":154,"phases":2442,"primaryCompletion":2443,"completion":821,"start":2444,"enrollment":2421,"conditions":2445,"interventions":2447},"NCT02157818","A Comparison of Sedative Drugs for Conscious Sedation During Ultrasound Guided Transbronchial Needle Aspiration",[91],"2015-07","2014-06",[2446],"Endobronchial Ultrasound Guided Transbronchial Needle Aspiration",[2448,2083],"midazolam",{"nctId":2450,"briefTitle":2451,"status":154,"phases":2452,"primaryCompletion":2305,"completion":2453,"start":2454,"enrollment":2455,"conditions":2456,"interventions":2458},"NCT04871308","Dexmedetomidine and Myocardial Protection",[91],"2025-01-07","2021-07-07",224,[118,2457],"Cardiopulmonary Bypass",[2083,2459],"Control",{"nctId":2461,"briefTitle":2462,"status":166,"phases":2463,"primaryCompletion":2464,"completion":2465,"start":2466,"enrollment":1795,"conditions":2467,"interventions":2468},"NCT04700514","Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure - Preliminary Study",[91],"2025-01-20","2025-02-20","2021-02-05",[2309],[2083],{"intervention":2299,"totalTrials":2470,"cells":2471},10,{"EARLY_PHASE1":2472,"PHASE1":2482,"PHASE2":2484,"PHASE3":2493,"PHASE4":2517,"NA":2545},{"trials":2473,"activeCount":99},[2474],{"nctId":2475,"briefTitle":2476,"status":166,"phases":2477,"primaryCompletion":263,"start":2478,"enrollment":1743,"conditions":2479,"interventions":2481},"NCT02869984","Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome",[86],"2016-08",[2480],"Anterior Resection Syndrome",[2299],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[2486],{"nctId":2487,"briefTitle":2488,"status":154,"phases":2489,"primaryCompletion":2294,"completion":2294,"start":2384,"enrollment":594,"conditions":2490,"interventions":2492},"NCT01806948","Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting",[88],[2491],"Postoperative Nausea and Vomiting",[2299],{"trials":2494,"activeCount":99},[2495,2506],{"nctId":2496,"briefTitle":2497,"status":154,"phases":2498,"primaryCompletion":619,"start":2499,"enrollment":2500,"conditions":2501,"interventions":2503},"NCT00971399","Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting",[89],"2009-09",172,[2502],"Radiotherapy Induced Nausea and Vomiting",[2504,2505],"ramosetron","ondansetron",{"nctId":2507,"briefTitle":2508,"status":166,"phases":2509,"primaryCompletion":2510,"completion":318,"start":2511,"enrollment":2512,"conditions":2513,"interventions":2515},"NCT06166615","The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence",[88,89],"2024-05-30","2023-12-15",148,[2514],"Fecal Incontinence",[2299,2516],"Psyllium",{"trials":2518,"activeCount":99},[2519,2528,2536],{"nctId":2520,"briefTitle":2521,"status":154,"phases":2522,"primaryCompletion":2523,"completion":2150,"start":2499,"enrollment":2524,"conditions":2525,"interventions":2527},"NCT01102491","Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty",[90],"2010-02",153,[2526],"Osteoarthritis, Knee",[2299],{"nctId":2529,"briefTitle":2530,"status":1813,"phases":2531,"primaryCompletion":673,"completion":673,"start":752,"enrollment":2532,"conditions":2533,"interventions":2535},"NCT01637545","Evaluation of Safety and Efficacy of Nasea(R)\u002FRamosetron Inj. in Patients Undergoing Facial Bone Fracture Operations",[90],49,[2534],"Facial Bones Fracture",[2299],{"nctId":2537,"briefTitle":2538,"status":166,"phases":2539,"primaryCompletion":1762,"completion":1762,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2544},"NCT04297293","Ramosetron OD Tablet and Postdischarge Nausea and Vomiting",[90],"2020-05-12",138,[2543],"Day Surgery",[2299],{"trials":2546,"activeCount":121,"soonestReadout":2565},[2547,2557,2561],{"nctId":2548,"briefTitle":2549,"status":166,"phases":2550,"primaryCompletion":742,"completion":2551,"start":1816,"enrollment":1743,"conditions":2552,"interventions":2556},"NCT01669213","Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension",[91],"2013-08",[518,2553,2554,2555],"Shivering","Nausea and Vomiting","Vasopressor",[2504,2505,2505],{"nctId":2291,"briefTitle":2292,"status":154,"phases":2558,"primaryCompletion":2294,"completion":2294,"start":157,"enrollment":2295,"conditions":2559,"interventions":2560},[91],[2297,518],[2299,270],{"nctId":2562,"briefTitle":2563,"status":127,"phases":2564,"primaryCompletion":2565,"completion":2566,"start":2567,"enrollment":2568,"conditions":2569,"interventions":2571},"NCT05577845","5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)",[91],"2025-12","2032-12","2023-03-27",212,[2570],"LARS - Low Anterior Resection Syndrome",[2299],{"intervention":2332,"totalTrials":1036,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":99},[],{"trials":2579,"activeCount":99},[2580,2589,2600],{"nctId":2581,"briefTitle":2582,"status":166,"phases":2583,"primaryCompletion":2584,"completion":2584,"start":2251,"enrollment":850,"conditions":2585,"interventions":2587},"NCT02966522","Thalidomide\u002FDexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis",[88],"2019-09",[2586],"Cardiac Amyloidosis",[2588,2332],"Thalidomide",{"nctId":2590,"briefTitle":2591,"status":658,"phases":2592,"primaryCompletion":2593,"completion":874,"start":2593,"enrollment":99,"conditions":2594,"interventions":2598},"NCT06437054","Verification of the Efficacy\u002FSafety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss",[87,88],"2026-12-15",[2595,2596,2597],"Hearing Loss, Sensorineural","Hearing Loss, Sudden","Intratympanic Injection",[2332,2599],"Hyaluronic acid",{"nctId":2601,"briefTitle":2602,"status":154,"phases":2603,"primaryCompletion":2604,"completion":2605,"start":2606,"enrollment":1170,"conditions":2607,"interventions":2611},"NCT04766853","Verification of the Efficacy\u002Fsafety of the Intratympanic Drug Delivery for Hearing Loss",[87,88],"2023-04-18","2024-07-19","2021-07-22",[2596,2608,2609,2610],"Hearing Loss, Ototoxic","Hearing Loss, Noise-Induced","Meniere Disease",[2332,2599],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":121,"soonestReadout":2326},[2618,2628],{"nctId":2619,"briefTitle":2620,"status":166,"phases":2621,"primaryCompletion":673,"completion":2622,"start":2294,"enrollment":2623,"conditions":2624,"interventions":2626},"NCT02252419","Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat",[91],"2015-03",242,[2625],"Pharyngitis",[2332,2627],"Paracetamol",{"nctId":2323,"briefTitle":2324,"status":111,"phases":2629,"primaryCompletion":2326,"completion":2327,"start":115,"enrollment":2328,"conditions":2630,"interventions":2631},[91],[2330],[2332,2321],{"intervention":2633,"totalTrials":139,"cells":2634},"Sugammadex",{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2641,"PHASE4":2643,"NA":2655},{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[],{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[2645],{"nctId":2646,"briefTitle":2647,"status":154,"phases":2648,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":2651,"conditions":2652,"interventions":2654},"NCT05354466","Perioperative Respiratory Adverse events_sugammadex",[90],"2024-09-04","2022-06-27",174,[2653],"Respiratory Complication",[2633,2224],{"trials":2656,"activeCount":121,"soonestReadout":409},[2657,2668,2678],{"nctId":2658,"briefTitle":2659,"status":127,"phases":2660,"primaryCompletion":409,"completion":2661,"start":2662,"enrollment":850,"conditions":2663,"interventions":2667},"NCT05993390","Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients",[91],"2028-04-30","2024-01-11",[2664,2665,2666],"Neuromuscular Blockade","Critical Illness","Neurologic Findings",[2633,2224],{"nctId":2669,"briefTitle":2670,"status":166,"phases":2671,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":1946,"conditions":2675,"interventions":2677},"NCT05760560","Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex",[],"2023-08-31","2024-08-31","2023-03-15",[2676],"Postoperative Residual Curarization",[2633],{"nctId":2679,"briefTitle":2680,"status":154,"phases":2681,"primaryCompletion":2682,"completion":2683,"start":2684,"enrollment":550,"conditions":2685,"interventions":2687},"NCT05724550","Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children",[91],"2024-06-07","2024-06-08","2023-02-22",[2686],"Neuromuscular Block, Residual",[2633,2224],{"intervention":2224,"totalTrials":139,"cells":2689},{"EARLY_PHASE1":2690,"PHASE1":2692,"PHASE2":2694,"PHASE3":2696,"PHASE4":2698,"NA":2704},{"trials":2691,"activeCount":99},[],{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":99},[2700],{"nctId":2646,"briefTitle":2647,"status":154,"phases":2701,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":2651,"conditions":2702,"interventions":2703},[90],[2653],[2633,2224],{"trials":2705,"activeCount":121,"soonestReadout":409},[2706,2710,2714],{"nctId":2658,"briefTitle":2659,"status":127,"phases":2707,"primaryCompletion":409,"completion":2661,"start":2662,"enrollment":850,"conditions":2708,"interventions":2709},[91],[2664,2665,2666],[2633,2224],{"nctId":2213,"briefTitle":2214,"status":154,"phases":2711,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2053,"conditions":2712,"interventions":2713},[91],[2220,2221,2222],[2224,270],{"nctId":2679,"briefTitle":2680,"status":154,"phases":2715,"primaryCompletion":2682,"completion":2683,"start":2684,"enrollment":550,"conditions":2716,"interventions":2717},[91],[2686],[2633,2224],{"intervention":2719,"totalTrials":599,"cells":2720},"Rivaroxaban",{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2727,"PHASE4":2729,"NA":2741},{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[2731],{"nctId":2732,"briefTitle":2733,"status":154,"phases":2734,"primaryCompletion":168,"completion":168,"start":579,"enrollment":2735,"conditions":2736,"interventions":2740},"NCT01989845","Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer",[90],127,[2719,2737,2738,2739],"Cancer-associated Thrombosis","Recurrence","Bleeding",[2719],{"trials":2742,"activeCount":121,"soonestReadout":2751},[2743,2747],{"nctId":670,"briefTitle":671,"status":166,"phases":2744,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":2745,"interventions":2746},[91],[678],[680,389],{"nctId":2748,"briefTitle":2749,"status":127,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":1834,"conditions":2753,"interventions":2754},"NCT06216769","Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation",[91],"2030-12-31","2024-02-01",[662],[2719],{"intervention":136,"totalTrials":95,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[],{"trials":2766,"activeCount":99},[],{"trials":2768,"activeCount":121,"soonestReadout":129},[2769,2780],{"nctId":2770,"briefTitle":2771,"status":166,"phases":2772,"primaryCompletion":2773,"completion":2774,"start":2775,"enrollment":2307,"conditions":2776,"interventions":2779},"NCT06111261","Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance",[91],"2025-07-15","2025-08-15","2023-11-15",[2739,2777,2778],"Massive Hemorrhage","Massive Transfusion Protocol",[136,2362],{"nctId":125,"briefTitle":126,"status":127,"phases":2781,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":2782,"interventions":2783},[91],[133,134],[136,94],{"intervention":66,"totalTrials":121,"cells":2785},{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":121,"soonestReadout":65},[2798],{"nctId":63,"briefTitle":64,"status":433,"phases":2799,"primaryCompletion":65,"completion":1000,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2804},[91],"2020-08-04",2500,[662,2803],"Anticoagulant-induced Bleeding",[66],{"intervention":1677,"totalTrials":121,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2813,"PHASE4":2815,"NA":2817},{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":121,"soonestReadout":50},[2819],{"nctId":48,"briefTitle":49,"status":433,"phases":2820,"primaryCompletion":50,"completion":1671,"start":1672,"enrollment":1673,"conditions":2821,"interventions":2822},[91],[1675],[51,1677],{"intervention":2824,"totalTrials":121,"cells":2825},"Ipilimumab plus Nivolumab",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2827,"activeCount":99},[],{"trials":2829,"activeCount":99},[],{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":121,"soonestReadout":2842},[2838],{"nctId":2839,"briefTitle":2840,"status":111,"phases":2841,"primaryCompletion":2842,"completion":2843,"start":189,"enrollment":2500,"conditions":2844,"interventions":2846},"NCT07233668","Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab\u002FNivolumab in mRCC",[91],"2028-10-01","2029-02-01",[2845],"Metastatic Renal Cell Carcinoma ( mRCC)",[2824],{"intervention":2848,"totalTrials":121,"cells":2849},"Statins and\u002For Ezetimibe",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[],{"trials":2859,"activeCount":99},[],{"trials":2861,"activeCount":121,"soonestReadout":2866},[2862],{"nctId":2863,"briefTitle":2864,"status":127,"phases":2865,"primaryCompletion":2866,"completion":2866,"start":2867,"enrollment":2868,"conditions":2869,"interventions":2873},"NCT06649240","Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke",[91],"2030-09","2024-10-04",4016,[383,2870,2871,2872,386],"Small Vessel Cerebrovascular Disease","Cholesterol, LDL","Secondary Prevention",[2848,2874],"PCSK9 inhibitor",{"intervention":2874,"totalTrials":121,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":121,"soonestReadout":2866},[2889],{"nctId":2863,"briefTitle":2864,"status":127,"phases":2890,"primaryCompletion":2866,"completion":2866,"start":2867,"enrollment":2868,"conditions":2891,"interventions":2892},[91],[383,2870,2871,2872,386],[2848,2874],{"intervention":2894,"totalTrials":121,"cells":2895},"FoundationOne CDx",{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2900,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2897,"activeCount":99},[],{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[],{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":121,"soonestReadout":1000},[2908],{"nctId":2909,"briefTitle":2910,"status":847,"phases":2911,"primaryCompletion":1000,"completion":1000,"start":2912,"enrollment":380,"conditions":2913,"interventions":2914},"NCT04098640","Molecular Profiling in Young (\u003C50 Years of Age) Patients With Metastatic Breast Cancer",[91],"2019-09-23",[24],[2894],{"intervention":2916,"totalTrials":121,"cells":2917},"Optimal medical treatment",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[],{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":121,"soonestReadout":2661},[2930],{"nctId":2931,"briefTitle":2932,"status":127,"phases":2933,"primaryCompletion":2661,"completion":2934,"start":2935,"enrollment":2936,"conditions":2937,"interventions":2939},"NCT06930092","RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy",[91],"2029-04-30","2025-08-03",158,[2938],"Ischemic Cardiomyopathy",[2916],{"intervention":2941,"totalTrials":121,"cells":2942},"Gene mutation test",{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"trials":2948,"activeCount":99},[],{"trials":2950,"activeCount":99},[],{"trials":2952,"activeCount":99},[],{"trials":2954,"activeCount":121,"soonestReadout":253},[2955],{"nctId":2956,"briefTitle":2957,"status":433,"phases":2958,"primaryCompletion":253,"completion":129,"start":2959,"enrollment":380,"conditions":2960,"interventions":2962},"NCT04592393","Pancreas Cancer Surveillance Using an Abbreviated MRI",[91],"2020-10-28",[2961],"Pancreas Cancer",[2941],{"intervention":2964,"totalTrials":121,"cells":2965},"Guideline-directed Optimal Medical treatment",{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2972,"PHASE4":2974,"NA":2976},{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":121,"soonestReadout":2982},[2978],{"nctId":2979,"briefTitle":2980,"status":111,"phases":2981,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2988},"NCT07577518","Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome",[91],"2030-04-27","2034-03-10","2026-04-27",2301,[2987],"Chronic Coronary Syndrome",[2964,2989,2990],"Carvedilol Sustained-Release","Carvedilol Immediate-Release",{"intervention":2989,"totalTrials":121,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":121,"soonestReadout":2982},[3005],{"nctId":2979,"briefTitle":2980,"status":111,"phases":3006,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":3007,"interventions":3008},[91],[2987],[2964,2989,2990],{"intervention":2990,"totalTrials":121,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3012,"activeCount":99},[],{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":121,"soonestReadout":2982},[3023],{"nctId":2979,"briefTitle":2980,"status":111,"phases":3024,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":3025,"interventions":3026},[91],[2987],[2964,2989,2990],{"intervention":3028,"totalTrials":121,"cells":3029},"stromal vascular fraction",{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3036,"PHASE4":3038,"NA":3040},{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"trials":3035,"activeCount":99},[],{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":121,"soonestReadout":2565},[3042],{"nctId":3043,"briefTitle":3044,"status":111,"phases":3045,"primaryCompletion":2565,"completion":3046,"start":3047,"enrollment":33,"conditions":3048,"interventions":3051},"NCT07094958","Efficacy of Stromal Vascular Fraction on Acne Scar Correction",[91],"2026-07","2025-07",[3049,3050],"Acne Scars","Acne Scars - Atrophic",[3028],{"intervention":3053,"totalTrials":121,"cells":3054},"RAAP",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3061,"PHASE4":3063,"NA":3065},{"trials":3056,"activeCount":99},[],{"trials":3058,"activeCount":99},[],{"trials":3060,"activeCount":99},[],{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":121,"soonestReadout":2751},[3067],{"nctId":3068,"briefTitle":3069,"status":111,"phases":3070,"primaryCompletion":2751,"completion":2751,"start":3071,"enrollment":1374,"conditions":3072,"interventions":3074},"NCT07547306","Evaluation of Accelerated Bachmann Bundle Area Pacing in Heart Failure With Reduced ejectIon Fraction Who Have electrocarDioGraphic Evidence of Interatrial Block and Indicated for Implantable Cardioverter Defibrillator",[91],"2026-05",[3073],"Heart Failure and Reduced Ejection Fraction",[3053],{"intervention":3076,"totalTrials":121,"cells":3077},"Tagrisso",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3079,"activeCount":99},[],{"trials":3081,"activeCount":99},[],{"trials":3083,"activeCount":99},[],{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":121,"soonestReadout":3094},[3090],{"nctId":3091,"briefTitle":3092,"status":433,"phases":3093,"primaryCompletion":3094,"completion":253,"start":3095,"enrollment":2512,"conditions":3096,"interventions":3098},"NCT03969823","Whole Genomic Landscape of Advanced EGFR-mutant NSCLC",[91],"2026-09-30","2019-05-23",[3097],"Locally Advanced or Metastatic NSCLC",[3076],{"intervention":46,"totalTrials":121,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":121,"soonestReadout":45},[3113],{"nctId":43,"briefTitle":44,"status":433,"phases":3114,"primaryCompletion":45,"completion":488,"start":3115,"enrollment":3116,"conditions":3117,"interventions":3119},[],"2014-03-01",5530,[15,3118],"Atheroscleroses, Coronary",[46],{"intervention":1736,"totalTrials":121,"cells":3121},{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3126,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"trials":3127,"activeCount":99},[],{"trials":3129,"activeCount":99},[],{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":121,"soonestReadout":129},[3134],{"nctId":1729,"briefTitle":1730,"status":111,"phases":3135,"primaryCompletion":129,"completion":129,"start":1220,"enrollment":1732,"conditions":3136,"interventions":3137},[91],[1734],[1736,51],{"intervention":3139,"totalTrials":121,"cells":3140},"TNT with additional consolidation chemotherapy followed by local excision",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":121,"soonestReadout":2751},[3153],{"nctId":3154,"briefTitle":3155,"status":111,"phases":3156,"primaryCompletion":2751,"completion":3157,"start":115,"enrollment":3158,"conditions":3159,"interventions":3165},"NCT07563907","Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer",[91],"2035-12-31",292,[3160,3161,3162,3163,3164],"Organ Preservation","Rectal Cancer Stage I","Total Neoadjuvant Treatment","Consolidation Therapy","Capecitabine",[3139,3166],"TNT followed by local excision",{"intervention":3166,"totalTrials":121,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":121,"soonestReadout":2751},[3181],{"nctId":3154,"briefTitle":3155,"status":111,"phases":3182,"primaryCompletion":2751,"completion":3157,"start":115,"enrollment":3158,"conditions":3183,"interventions":3184},[91],[3160,3161,3162,3163,3164],[3139,3166],{"intervention":3186,"totalTrials":121,"cells":3187},"Intrathecal morphine",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3189,"activeCount":99},[],{"trials":3191,"activeCount":99},[],{"trials":3193,"activeCount":99},[],{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":121,"soonestReadout":253},[3200],{"nctId":3201,"briefTitle":3202,"status":127,"phases":3203,"primaryCompletion":253,"completion":3204,"start":1875,"enrollment":1752,"conditions":3205,"interventions":3208},"NCT06761989","Intrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy",[91],"2027-01-07",[3206,3207],"Pain Management","Pain, Postoperative",[3186],{"intervention":41,"totalTrials":121,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":99},[],{"trials":3218,"activeCount":99},[],{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":121,"soonestReadout":40},[3223],{"nctId":38,"briefTitle":39,"status":433,"phases":3224,"primaryCompletion":40,"completion":253,"start":3225,"enrollment":2801,"conditions":3226,"interventions":3227},[],"2019-08-12",[662],[41],{"intervention":3229,"totalTrials":121,"cells":3230},"Paclitaxel and carboplatin",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"trials":3242,"activeCount":121,"soonestReadout":1419},[3243],{"nctId":3244,"briefTitle":3245,"status":111,"phases":3246,"primaryCompletion":1419,"completion":3247,"start":3248,"enrollment":3249,"conditions":3250,"interventions":3253},"NCT06977594","Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer",[91],"2028-05-31","2025-06-25",1000,[2116,3251,3252],"Endometrial Cancer","Cervical Cancer",[3229,3254,3255,3255],"Standard premedication","Reduced premedication",{"intervention":3254,"totalTrials":121,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":121,"soonestReadout":1419},[3270],{"nctId":3244,"briefTitle":3245,"status":111,"phases":3271,"primaryCompletion":1419,"completion":3247,"start":3248,"enrollment":3249,"conditions":3272,"interventions":3273},[91],[2116,3251,3252],[3229,3254,3255,3255],{"intervention":3255,"totalTrials":121,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3277,"activeCount":99},[],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[],{"trials":3283,"activeCount":99},[],{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":121,"soonestReadout":1419},[3288],{"nctId":3244,"briefTitle":3245,"status":111,"phases":3289,"primaryCompletion":1419,"completion":3247,"start":3248,"enrollment":3249,"conditions":3290,"interventions":3291},[91],[2116,3251,3252],[3229,3254,3255,3255],{"intervention":3293,"totalTrials":121,"cells":3294},"Biologic or targeted synthetic DMARD",{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[],{"trials":3300,"activeCount":99},[],{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":121,"soonestReadout":1046},[3307],{"nctId":3308,"briefTitle":3309,"status":127,"phases":3310,"primaryCompletion":1046,"completion":3311,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3318},"NCT01965132","Korean College of Rheumatology Biologics and Targeted Therapy Registry",[],"2030-06-30","2012-12-01",10000,[3315,3316,3317],"Rheumatoid Arthritis","Ankylosing Spondylitis","Psoriatic Arthritis",[3293],{"intervention":3320,"totalTrials":121,"cells":3321},"rocuronium 0.2 mg\u002Fkg\u002Fhr continuous",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3323,"activeCount":99},[],{"trials":3325,"activeCount":99},[],{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[],{"trials":3331,"activeCount":99},[],{"trials":3333,"activeCount":121,"soonestReadout":3338},[3334],{"nctId":3335,"briefTitle":3336,"status":127,"phases":3337,"primaryCompletion":3338,"completion":3339,"start":3340,"enrollment":1710,"conditions":3341,"interventions":3342},"NCT06679569","Deep Neuromuscular Blockade on Postoperative Pain",[91],"2026-11-06","2026-11-07","2024-11-06",[2664],[3320,3343],"rocuronium 0.6 mg\u002Fkg\u002Fhr continuous",{"intervention":3343,"totalTrials":121,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3352,"PHASE4":3354,"NA":3356},{"trials":3347,"activeCount":99},[],{"trials":3349,"activeCount":99},[],{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[],{"trials":3355,"activeCount":99},[],{"trials":3357,"activeCount":121,"soonestReadout":3338},[3358],{"nctId":3335,"briefTitle":3336,"status":127,"phases":3359,"primaryCompletion":3338,"completion":3339,"start":3340,"enrollment":1710,"conditions":3360,"interventions":3361},[91],[2664],[3320,3343],{"intervention":3363,"totalTrials":121,"cells":3364},"Pharmacologic therapy optimized for Atrial Fibrillation management",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3373,"NA":3375},{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[],{"trials":3374,"activeCount":99},[],{"trials":3376,"activeCount":121,"soonestReadout":129},[3377],{"nctId":3378,"briefTitle":3379,"status":127,"phases":3380,"primaryCompletion":129,"completion":129,"start":3381,"enrollment":1048,"conditions":3382,"interventions":3384},"NCT06699342","Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation",[91],"2025-01-27",[3383],"Atrial Fibrillation (AF)",[3363],{"intervention":3386,"totalTrials":121,"cells":3387},"Local anesthesia and Conscious sedation",{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3389,"activeCount":99},[],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"trials":3395,"activeCount":99},[],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":121,"soonestReadout":3404},[3400],{"nctId":3401,"briefTitle":3402,"status":127,"phases":3403,"primaryCompletion":3404,"completion":3404,"start":3405,"enrollment":3406,"conditions":3407,"interventions":3409},"NCT06426992","Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies",[91],"2026-08-30","2024-04-30",128,[3408],"Liver Malignant Tumors",[3386],{"intervention":3411,"totalTrials":121,"cells":3412},"Exocrine Pancreatic Enzyme",{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3417,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[],{"trials":3418,"activeCount":99},[],{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":121,"soonestReadout":3429},[3425],{"nctId":3426,"briefTitle":3427,"status":127,"phases":3428,"primaryCompletion":3429,"completion":3429,"start":2454,"enrollment":3430,"conditions":3431,"interventions":3435},"NCT05112328","The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding",[91],"2026-07-31",170,[3432,3433,3434],"Critically Ill","Enteral Feeding","Exocrine Pancreatic Insufficiency",[3411],{"intervention":3437,"totalTrials":139,"cells":3438},"Celecoxib",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3451,"PHASE3":3453,"PHASE4":3455,"NA":3490},{"trials":3440,"activeCount":99},[],{"trials":3442,"activeCount":99},[3443],{"nctId":3444,"briefTitle":3445,"status":154,"phases":3446,"primaryCompletion":3447,"completion":3447,"start":2161,"enrollment":170,"conditions":3448,"interventions":3450},"NCT02711579","Impact of Celecoxib on Electrophysiological Property in Brain of Healthy Volunteer",[87],"2017-04-28",[3449],"Electrophysiologic Property of Brain",[3437],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[3457,3468,3477],{"nctId":3458,"briefTitle":3459,"status":166,"phases":3460,"completion":3461,"start":3462,"enrollment":3463,"conditions":3464,"interventions":3467},"NCT00500279","Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial",[90],"2009-10","2006-11",900,[3465,3466],"Angioplasty, Transluminal, Percutaneous Coronary","Coronary Restenosis",[3437],{"nctId":3469,"briefTitle":3470,"status":154,"phases":3471,"primaryCompletion":621,"completion":621,"start":3472,"enrollment":3473,"conditions":3474,"interventions":3476},"NCT00292721","Effects of Celecoxib After Percutaneous Coronary Intervention",[90],"2004-08",260,[3475],"Coronary Arteriosclerosis",[3437],{"nctId":3478,"briefTitle":3479,"status":154,"phases":3480,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":170,"conditions":3483,"interventions":3484},"NCT00882388","The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers",[90],"2005-06","2005-03",[21],[3485,3486,3487,3488,3489],"aspirin","celecoxib","aspirin + celecoxib","aspirin + clopidogrel","aspirin + clopidogrel + celecoxib",{"trials":3491,"activeCount":99},[],{"intervention":666,"totalTrials":139,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3500,"PHASE4":3502,"NA":3536},{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[3504,3515,3528,3532],{"nctId":3505,"briefTitle":3506,"status":154,"phases":3507,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":3116,"conditions":3511,"interventions":3513},"NCT02044250","Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)",[90],"2021-03","2025-10","2014-02",[3512],"Coronary Heart Disease",[3514,666],"Clopidogrel",{"nctId":3516,"briefTitle":3517,"status":154,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":3522,"interventions":3525},"NCT03581409","Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm",[90],"2021-01-22","2018-10-24",198,[3523,3524],"Aneurysm, Cerebral","Endovascular Procedures",[666,3526,3514,3527],"Prasugrel","Cilostazol",{"nctId":656,"briefTitle":657,"status":658,"phases":3529,"primaryCompletion":169,"completion":179,"start":660,"enrollment":99,"conditions":3530,"interventions":3531},[90],[662,663],[665,666],{"nctId":3478,"briefTitle":3479,"status":154,"phases":3533,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":170,"conditions":3534,"interventions":3535},[90],[21],[3485,3486,3487,3488,3489],{"trials":3537,"activeCount":99},[],{"intervention":3527,"totalTrials":139,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3544,"PHASE3":3546,"PHASE4":3548,"NA":3585},{"trials":3541,"activeCount":99},[],{"trials":3543,"activeCount":99},[],{"trials":3545,"activeCount":99},[],{"trials":3547,"activeCount":99},[],{"trials":3549,"activeCount":99},[3550,3561,3572,3581],{"nctId":3551,"briefTitle":3552,"status":154,"phases":3553,"primaryCompletion":3554,"completion":3555,"start":3556,"enrollment":3557,"conditions":3558,"interventions":3560},"NCT01409564","Cilostazol Augmentation Study in Dementia",[90],"2012-06","2013-07","2010-05",46,[3559],"Alzheimer's Dementia",[3527],{"nctId":3562,"briefTitle":3563,"status":154,"phases":3564,"primaryCompletion":168,"completion":2171,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3569},"NCT01291641","Effect of Probucol and\u002For Cilostazol on Mean IMT in Patients With Coronary Heart dIsease",[90],"2011-03",342,[3568],"Hyperlipidemias",[3570,3571,3527],"HMG-CoA Reductase Inhibitor","Probucol",{"nctId":3573,"briefTitle":3574,"status":154,"phases":3575,"primaryCompletion":3576,"completion":3576,"start":3462,"enrollment":3577,"conditions":3578,"interventions":3579},"NCT00776828","The Efficacy of CILostazol ON Ischemic Complications After DES Implantation",[90],"2010-01",960,[15],[3580],"cilostazol",{"nctId":3516,"briefTitle":3517,"status":154,"phases":3582,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":3583,"interventions":3584},[90],[3523,3524],[666,3526,3514,3527],{"trials":3586,"activeCount":99},[],{"intervention":3588,"totalTrials":139,"cells":3589},"Calcitriol",{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3636},{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[],{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[3600,3608,3617,3628],{"nctId":3601,"briefTitle":3602,"status":154,"phases":3603,"primaryCompletion":2383,"completion":2383,"start":2267,"enrollment":850,"conditions":3604,"interventions":3606},"NCT01748396","Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol",[90],[3605],"Chronic Kidney Disease Stage 3",[3588,3607],"Calcium Carbonate",{"nctId":3609,"briefTitle":3610,"status":166,"phases":3611,"primaryCompletion":3612,"start":549,"enrollment":3613,"conditions":3614,"interventions":3616},"NCT01673204","Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy",[90],"2014-04",276,[3615],"Diabetic Nephropathy",[3588],{"nctId":3618,"briefTitle":3619,"status":166,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":2383,"enrollment":3622,"conditions":3623,"interventions":3625},"NCT01765010","The Effect of Inactive and Active Vitamin D on Serum Sclerostin\u002Fdickkopf1 Levels",[90],"2013-03",88,[3624],"Osteoporosis",[3588,3626,3627],"Alfacalcidol","Cholecalciferol",{"nctId":3629,"briefTitle":3630,"status":166,"phases":3631,"primaryCompletion":742,"completion":264,"start":2385,"enrollment":3632,"conditions":3633,"interventions":3635},"NCT01512862","Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients",[90],240,[3634],"Proteinuria",[3588],{"trials":3637,"activeCount":99},[],{"intervention":3639,"totalTrials":599,"cells":3640},"Rosuvastatin",{"EARLY_PHASE1":3641,"PHASE1":3643,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3675},{"trials":3642,"activeCount":99},[],{"trials":3644,"activeCount":99},[3645],{"nctId":3646,"briefTitle":3647,"status":154,"phases":3648,"primaryCompletion":3649,"completion":3649,"start":702,"enrollment":1221,"conditions":3650,"interventions":3652},"NCT03715101","A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the Elderly",[87],"2016-04",[3651],"Elderly",[3639],{"trials":3654,"activeCount":99},[],{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[3659,3666],{"nctId":3660,"briefTitle":3661,"status":154,"phases":3662,"primaryCompletion":2383,"completion":2551,"start":1844,"enrollment":1491,"conditions":3663,"interventions":3665},"NCT01466608","Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients",[90],[3664],"Hypercholesterolemia",[3639],{"nctId":3667,"briefTitle":3668,"status":154,"phases":3669,"primaryCompletion":3670,"completion":3670,"start":3671,"enrollment":158,"conditions":3672,"interventions":3674},"NCT01218347","Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles",[90],"2010-12","2010-10",[3673,3639],"Organic Anion Transporting Polypeptide1B1 (OATP1B1)",[3639],{"trials":3676,"activeCount":99},[],{"intervention":3627,"totalTrials":599,"cells":3678},{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3683,"PHASE3":3695,"PHASE4":3697,"NA":3714},{"trials":3680,"activeCount":99},[],{"trials":3682,"activeCount":99},[],{"trials":3684,"activeCount":99},[3685],{"nctId":3686,"briefTitle":3687,"status":166,"phases":3688,"primaryCompletion":3689,"completion":3690,"start":3691,"enrollment":3622,"conditions":3692,"interventions":3694},"NCT03320915","Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT",[88],"2018-12","2019-12","2017-10-01",[3693],"Hematologic Neoplasms",[3627],{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[3699,3710],{"nctId":3700,"briefTitle":3701,"status":154,"phases":3702,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":1958,"conditions":3705,"interventions":3709},"NCT05216419","Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy",[90],"2024-10-16","2021-06-07",[3706,3707,3708],"Total Thyroidectomy","Hypocalcemia","Vitamin D Deficiency",[3627],{"nctId":3618,"briefTitle":3619,"status":166,"phases":3711,"primaryCompletion":3621,"completion":3621,"start":2383,"enrollment":3622,"conditions":3712,"interventions":3713},[90],[3624],[3588,3626,3627],{"trials":3715,"activeCount":99},[],{"intervention":3717,"totalTrials":599,"cells":3718},"Entecavir",{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3725,"PHASE4":3747,"NA":3760},{"trials":3720,"activeCount":99},[],{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[],{"trials":3726,"activeCount":99},[3727,3736],{"nctId":3728,"briefTitle":3729,"status":154,"phases":3730,"primaryCompletion":2172,"completion":2172,"start":1854,"enrollment":1583,"conditions":3731,"interventions":3734},"NCT01580202","Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine",[89],[3732,3733],"Malignancy","Hepatitis B",[3717,3735],"Lamivudine",{"nctId":3737,"briefTitle":3738,"status":1813,"phases":3739,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":1136,"conditions":3743,"interventions":3746},"NCT01694264","Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)\u002FHBsAb(-) Patients Starting Anti-TNFα",[89],"2015-08-31","2015-12-31","2012-09-01",[3744,3315,3316,3317,3745],"Chronic Hepatitis B","Juvenile Idiopathic Arthritis",[3717],{"trials":3748,"activeCount":99},[3749],{"nctId":3750,"briefTitle":3751,"status":154,"phases":3752,"primaryCompletion":3753,"completion":2128,"start":3612,"enrollment":3754,"conditions":3755,"interventions":3757},"NCT02097004","Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection",[90],"2018-01",111,[3756],"Hepatitis B, Chronic",[3758,3759,3717],"Peginterferon alfa-2a","HBV vaccination",{"trials":3761,"activeCount":99},[],{"intervention":3514,"totalTrials":599,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3792},{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[],{"trials":3773,"activeCount":99},[3774,3778,3782],{"nctId":3505,"briefTitle":3506,"status":154,"phases":3775,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":3116,"conditions":3776,"interventions":3777},[90],[3512],[3514,666],{"nctId":3516,"briefTitle":3517,"status":154,"phases":3779,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":3780,"interventions":3781},[90],[3523,3524],[666,3526,3514,3527],{"nctId":3783,"briefTitle":3784,"status":166,"phases":3785,"primaryCompletion":3786,"completion":3786,"start":168,"enrollment":3787,"conditions":3788,"interventions":3790},"NCT02959606","SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study",[90],"2019-01",272,[3789],"Peripheral Arterial Disease",[3791,3514],"Sarpogrelate SR 300mg",{"trials":3793,"activeCount":99},[],{"intervention":2121,"totalTrials":95,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3808,"NA":3819},{"trials":3797,"activeCount":99},[],{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[3804],{"nctId":2107,"briefTitle":2108,"status":166,"phases":3805,"primaryCompletion":2110,"completion":75,"start":2111,"enrollment":2112,"conditions":3806,"interventions":3807},[89],[2114,2115,2116,2117,2118],[2120,270,2121],{"trials":3809,"activeCount":99},[3810],{"nctId":3811,"briefTitle":3812,"status":166,"phases":3813,"primaryCompletion":3814,"completion":3814,"start":3815,"enrollment":170,"conditions":3816,"interventions":3818},"NCT03401827","The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer",[90],"2019-01-01","2018-03-01",[3817,992],"Pancreatic Adenocarcinoma",[2121],{"trials":3820,"activeCount":99},[],{"intervention":3822,"totalTrials":95,"cells":3823},"Glimepiride",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3830,"PHASE4":3832,"NA":3854},{"trials":3825,"activeCount":99},[],{"trials":3827,"activeCount":99},[],{"trials":3829,"activeCount":99},[],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[3834,3843],{"nctId":3835,"briefTitle":3836,"status":154,"phases":3837,"primaryCompletion":1967,"completion":3838,"start":3621,"enrollment":33,"conditions":3839,"interventions":3841},"NCT01812122","Effects of Vildagliptine and Glimepiride on Glucose Variability",[90],"2015-10",[3840],"Diabetes Mellitus, Non-Insulin-Dependent",[3822,3842],"Vildagliptin",{"nctId":3844,"briefTitle":3845,"status":166,"phases":3846,"primaryCompletion":3847,"completion":2217,"start":3741,"enrollment":3848,"conditions":3849,"interventions":3851},"NCT04470310","Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination",[90],"2019-05-20",99,[3850],"Type 2 Diabetes Mellitus",[3822,3852,3853],"Alogliptin 25Mg Tab","Alogliptin-Pioglitazone 25 Mg-15 Mg Oral",{"trials":3855,"activeCount":99},[],{"intervention":2105,"totalTrials":95,"cells":3857},{"EARLY_PHASE1":3858,"PHASE1":3860,"PHASE2":3862,"PHASE3":3864,"PHASE4":3870,"NA":3883},{"trials":3859,"activeCount":99},[],{"trials":3861,"activeCount":99},[],{"trials":3863,"activeCount":99},[],{"trials":3865,"activeCount":99},[3866],{"nctId":2098,"briefTitle":2099,"status":154,"phases":3867,"primaryCompletion":2101,"completion":2101,"start":742,"enrollment":1048,"conditions":3868,"interventions":3869},[89],[2103],[2105,270],{"trials":3871,"activeCount":99},[3872],{"nctId":3873,"briefTitle":3874,"status":154,"phases":3875,"completion":3876,"start":3877,"enrollment":3878,"conditions":3879,"interventions":3881},"NCT00356954","NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization",[90],"2006-04","2005-02",250,[3880],"Kidney Failure",[3882,2105],"N-acetylcystein",{"trials":3884,"activeCount":99},[],{"intervention":2144,"totalTrials":95,"cells":3886},{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3893,"PHASE4":3895,"NA":3914},{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[],{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[],{"trials":3896,"activeCount":99},[3897,3901],{"nctId":2137,"briefTitle":2138,"status":1813,"phases":3898,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":411,"conditions":3899,"interventions":3900},[90],[2143,2144,2083],[2144,270],{"nctId":3902,"briefTitle":3903,"status":166,"phases":3904,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":850,"conditions":3907,"interventions":3911},"NCT04514731","Magnesium Sulfate and Neuroendocrine Hormone",[90],"2021-12-15","2021-01-21",[3908,2144,3909,3910],"Arthropathy of Knee","Cortisol","Dehydroepiandrosterone",[3912,3913],"Magnesium sulfate","Isotonic Saline",{"trials":3915,"activeCount":99},[],{"intervention":3917,"totalTrials":95,"cells":3918},"Mirabegron",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3947},{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[],{"trials":3924,"activeCount":99},[],{"trials":3926,"activeCount":99},[],{"trials":3928,"activeCount":99},[3929,3939],{"nctId":3930,"briefTitle":3931,"status":166,"phases":3932,"primaryCompletion":3933,"completion":968,"start":3934,"enrollment":2252,"conditions":3935,"interventions":3938},"NCT03412513","Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease",[90],"2018-07-16","2017-07-17",[3936,3937],"Overactive Bladder","Parkinson Disease",[3917],{"nctId":3940,"briefTitle":3941,"status":166,"phases":3942,"primaryCompletion":791,"start":673,"enrollment":3943,"conditions":3944,"interventions":3945},"NCT02361502","MIrabegron With oveRACtive bLadder Symptoms in mEn",[90],462,[3936],[3946],"mirabegron",{"trials":3948,"activeCount":99},[],{"intervention":3950,"totalTrials":95,"cells":3951},"DA-9701",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3981},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[3962,3971],{"nctId":3963,"briefTitle":3964,"status":154,"phases":3965,"primaryCompletion":2161,"completion":179,"start":3966,"enrollment":170,"conditions":3967,"interventions":3969},"NCT03022201","Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease",[90],"2013-05",[3968],"Parkinson's Disease,Idiopathic",[3950,3970],"Domperidone",{"nctId":3972,"briefTitle":3973,"status":154,"phases":3974,"primaryCompletion":3975,"completion":3689,"start":3649,"enrollment":3976,"conditions":3977,"interventions":3979},"NCT02775591","Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms",[90],"2018-06",147,[3937,3978],"Dyspepsia",[3950,3980],"DA-9701 placebo",{"trials":3982,"activeCount":99},[],{"intervention":184,"totalTrials":95,"cells":3984},{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3995,"PHASE4":3997,"NA":4003},{"trials":3986,"activeCount":99},[],{"trials":3988,"activeCount":99},[],{"trials":3990,"activeCount":99},[3991],{"nctId":787,"briefTitle":788,"status":154,"phases":3992,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":3993,"interventions":3994},[88],[794],[796,797,184,772,798],{"trials":3996,"activeCount":99},[],{"trials":3998,"activeCount":99},[3999],{"nctId":175,"briefTitle":176,"status":166,"phases":4000,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":4001,"interventions":4002},[90],[182],[138,184],{"trials":4004,"activeCount":99},[],{"intervention":4006,"totalTrials":95,"cells":4007},"Nilotinib",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4024,"PHASE4":4026,"NA":4037},{"trials":4009,"activeCount":99},[],{"trials":4011,"activeCount":99},[],{"trials":4013,"activeCount":99},[4014],{"nctId":4015,"briefTitle":4016,"status":154,"phases":4017,"primaryCompletion":4018,"completion":4018,"start":4019,"enrollment":1444,"conditions":4020,"interventions":4023},"NCT03932669","Effect of Nilotinib in Cerebellar Ataxia Patients",[88],"2020-08-13","2018-11-19",[4021,4022],"Ataxia, Cerebellar","Ataxia, Progressive",[4006],{"trials":4025,"activeCount":99},[],{"trials":4027,"activeCount":99},[4028],{"nctId":4029,"briefTitle":4030,"status":154,"phases":4031,"primaryCompletion":4032,"completion":4032,"start":4033,"enrollment":2421,"conditions":4034,"interventions":4036},"NCT03332511","Efficacy and Safety of Nilotinib in CML-CP",[90],"2016-10-24","2013-05-06",[4035],"Chronic Myeloid Leukemia, Chronic Phase",[4006],{"trials":4038,"activeCount":99},[],{"intervention":4040,"totalTrials":95,"cells":4041},"Tamsulosin",{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4046,"PHASE3":4048,"PHASE4":4060,"NA":4072},{"trials":4043,"activeCount":99},[],{"trials":4045,"activeCount":99},[],{"trials":4047,"activeCount":99},[],{"trials":4049,"activeCount":99},[4050],{"nctId":4051,"briefTitle":4052,"status":154,"phases":4053,"primaryCompletion":4054,"completion":4054,"start":4055,"enrollment":1743,"conditions":4056,"interventions":4059},"NCT00606983","Prevention of Acute Voiding Difficulty After Radical Proctectomy",[89],"2010-09","2007-05",[4057,4058],"Rectal Cancer","Urinary Retention",[4040],{"trials":4061,"activeCount":99},[4062],{"nctId":4063,"briefTitle":4064,"status":166,"phases":4065,"primaryCompletion":4066,"completion":2172,"start":1843,"enrollment":4067,"conditions":4068,"interventions":4070},"NCT01736033","Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients",[90],"2017-02",545,[4069],"Benign Prostate Hyperplasia",[4040,4071],"Finasteride",{"trials":4073,"activeCount":99},[],{"intervention":162,"totalTrials":95,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4082,"PHASE4":4084,"NA":4100},{"trials":4077,"activeCount":99},[],{"trials":4079,"activeCount":99},[],{"trials":4081,"activeCount":99},[],{"trials":4083,"activeCount":99},[],{"trials":4085,"activeCount":99},[4086,4090],{"nctId":152,"briefTitle":153,"status":154,"phases":4087,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":4088,"interventions":4089},[90],[160],[138,162],{"nctId":4091,"briefTitle":4092,"status":154,"phases":4093,"primaryCompletion":1977,"completion":168,"start":2275,"enrollment":1420,"conditions":4094,"interventions":4096},"NCT02171988","Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)",[90],[4095],"Postural Orthostatic Tachycardia Syndrome",[162,4097,4098,4099],"Bisoprolol","Propranolol+pyridostigmine","Bisoprolol+pyridostgmine",{"trials":4101,"activeCount":99},[],{"intervention":4103,"totalTrials":95,"cells":4104},"Midodrine",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4137},{"trials":4106,"activeCount":99},[],{"trials":4108,"activeCount":99},[],{"trials":4110,"activeCount":99},[],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[4115,4126],{"nctId":4116,"briefTitle":4117,"status":154,"phases":4118,"primaryCompletion":4119,"completion":4120,"start":4121,"enrollment":1048,"conditions":4122,"interventions":4124},"NCT03350659","Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH",[90],"2019-01-29","2019-03-15","2018-01-01",[4123],"Neurogenic Orthostatic Hypotension",[4103,4125],"Atomoxetine",{"nctId":4127,"briefTitle":4128,"status":154,"phases":4129,"primaryCompletion":4130,"completion":4130,"start":701,"enrollment":4131,"conditions":4132,"interventions":4134},"NCT02308124","Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study",[90],"2016-09",87,[4133],"Orthostatic; Hypotension, Neurogenic",[4103,4135,4136],"Pyridostigmine Bromide","Midodrine + pyridostigmine",{"trials":4138,"activeCount":99},[],{"intervention":4140,"totalTrials":121,"cells":4141},"Triple anti-platelet therapy",{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4148,"PHASE4":4150,"NA":4161},{"trials":4143,"activeCount":99},[],{"trials":4145,"activeCount":99},[],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"trials":4151,"activeCount":99},[4152],{"nctId":4153,"briefTitle":4154,"status":166,"phases":4155,"primaryCompletion":752,"completion":1979,"start":4156,"enrollment":4157,"conditions":4158,"interventions":4159},"NCT01267734","Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen",[90],"2010-06",3750,[3512],[4140,4160],"Double-dose clopidogrel anti-platelet therapy",{"trials":4162,"activeCount":99},[],{"intervention":4160,"totalTrials":121,"cells":4164},{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4171,"PHASE4":4173,"NA":4179},{"trials":4166,"activeCount":99},[],{"trials":4168,"activeCount":99},[],{"trials":4170,"activeCount":99},[],{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[4175],{"nctId":4153,"briefTitle":4154,"status":166,"phases":4176,"primaryCompletion":752,"completion":1979,"start":4156,"enrollment":4157,"conditions":4177,"interventions":4178},[90],[3512],[4140,4160],{"trials":4180,"activeCount":99},[],{"intervention":4182,"totalTrials":121,"cells":4183},"generic formulation of atorvastatin",{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4190,"PHASE4":4192,"NA":4203},{"trials":4185,"activeCount":99},[],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"trials":4191,"activeCount":99},[],{"trials":4193,"activeCount":99},[4194],{"nctId":4195,"briefTitle":4196,"status":154,"phases":4197,"primaryCompletion":753,"completion":4198,"start":2150,"enrollment":4199,"conditions":4200,"interventions":4201},"NCT01624207","The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg",[90],"2011-04",376,[3664],[4182,4202],"branded formulation of atorvastatin",{"trials":4204,"activeCount":99},[],{"intervention":4202,"totalTrials":121,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4221},{"trials":4208,"activeCount":99},[],{"trials":4210,"activeCount":99},[],{"trials":4212,"activeCount":99},[],{"trials":4214,"activeCount":99},[],{"trials":4216,"activeCount":99},[4217],{"nctId":4195,"briefTitle":4196,"status":154,"phases":4218,"primaryCompletion":753,"completion":4198,"start":2150,"enrollment":4199,"conditions":4219,"interventions":4220},[90],[3664],[4182,4202],{"trials":4222,"activeCount":99},[],{"intervention":4224,"totalTrials":121,"cells":4225},"Sertraline",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4234,"NA":4244},{"trials":4227,"activeCount":99},[],{"trials":4229,"activeCount":99},[],{"trials":4231,"activeCount":99},[],{"trials":4233,"activeCount":99},[],{"trials":4235,"activeCount":99},[4236],{"nctId":4237,"briefTitle":4238,"status":154,"phases":4239,"primaryCompletion":4240,"completion":2150,"start":4241,"enrollment":2470,"conditions":4242,"interventions":4243},"NCT00969852","Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration",[90],"2009-08","2009-07",[21],[4224],{"trials":4245,"activeCount":99},[],{"intervention":2135,"totalTrials":121,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4252,"PHASE3":4254,"PHASE4":4256,"NA":4262},{"trials":4249,"activeCount":99},[],{"trials":4251,"activeCount":99},[],{"trials":4253,"activeCount":99},[],{"trials":4255,"activeCount":99},[],{"trials":4257,"activeCount":99},[4258],{"nctId":2125,"briefTitle":2126,"status":154,"phases":4259,"primaryCompletion":2128,"completion":2129,"start":2130,"enrollment":2131,"conditions":4260,"interventions":4261},[90],[2133],[2135,270],{"trials":4263,"activeCount":99},[],{"intervention":4265,"totalTrials":121,"cells":4266},"Circadin",{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4273,"PHASE4":4275,"NA":4285},{"trials":4268,"activeCount":99},[],{"trials":4270,"activeCount":99},[],{"trials":4272,"activeCount":99},[],{"trials":4274,"activeCount":99},[],{"trials":4276,"activeCount":99},[4277],{"nctId":4278,"briefTitle":4279,"status":166,"phases":4280,"primaryCompletion":4281,"completion":4281,"start":791,"enrollment":850,"conditions":4282,"interventions":4284},"NCT02836743","Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study",[90],"2017-12-31",[4283],"REM Sleep Behavior Disorder",[4265],{"trials":4286,"activeCount":99},[],{"intervention":4288,"totalTrials":121,"cells":4289},"conventional dose epinephrine",{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4294,"PHASE3":4296,"PHASE4":4298,"NA":4309},{"trials":4291,"activeCount":99},[],{"trials":4293,"activeCount":99},[],{"trials":4295,"activeCount":99},[],{"trials":4297,"activeCount":99},[],{"trials":4299,"activeCount":99},[4300],{"nctId":4301,"briefTitle":4302,"status":166,"phases":4303,"primaryCompletion":1965,"completion":1965,"start":791,"enrollment":463,"conditions":4304,"interventions":4307},"NCT01664507","The Effect and Safety of Low Dose Nebulized Epinephrine in Croup",[90],[4305,4306],"Croup","Epinephrine, Administration, Inhalation",[4288,4308],"low dose epinephrine",{"trials":4310,"activeCount":99},[],{"intervention":4308,"totalTrials":121,"cells":4312},{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4319,"PHASE4":4321,"NA":4327},{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[],{"trials":4320,"activeCount":99},[],{"trials":4322,"activeCount":99},[4323],{"nctId":4301,"briefTitle":4302,"status":166,"phases":4324,"primaryCompletion":1965,"completion":1965,"start":791,"enrollment":463,"conditions":4325,"interventions":4326},[90],[4305,4306],[4288,4308],{"trials":4328,"activeCount":99},[],{"intervention":4330,"totalTrials":121,"cells":4331},"clopidogrel napadisilate + aspirin",{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4349},{"trials":4333,"activeCount":99},[],{"trials":4335,"activeCount":99},[],{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[],{"trials":4341,"activeCount":99},[4342],{"nctId":4343,"briefTitle":4344,"status":154,"phases":4345,"primaryCompletion":1843,"start":3671,"enrollment":2512,"conditions":4346,"interventions":4347},"NCT01584791","Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting",[90],[15],[4330,4348],"clopidogrel bisulfate + aspirin",{"trials":4350,"activeCount":99},[],{"intervention":4348,"totalTrials":121,"cells":4352},{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4367},{"trials":4354,"activeCount":99},[],{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[],{"trials":4362,"activeCount":99},[4363],{"nctId":4343,"briefTitle":4344,"status":154,"phases":4364,"primaryCompletion":1843,"start":3671,"enrollment":2512,"conditions":4365,"interventions":4366},[90],[15],[4330,4348],{"trials":4368,"activeCount":99},[],{"intervention":4370,"totalTrials":121,"cells":4371},"pinaverium bromide",{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4390},{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"trials":4377,"activeCount":99},[],{"trials":4379,"activeCount":99},[],{"trials":4381,"activeCount":99},[4382],{"nctId":4383,"briefTitle":4384,"status":154,"phases":4385,"primaryCompletion":674,"completion":674,"start":703,"enrollment":265,"conditions":4386,"interventions":4388},"NCT02173964","Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)",[90],[4387],"Cancer",[4370,4389],"water",{"trials":4391,"activeCount":99},[],{"intervention":4389,"totalTrials":121,"cells":4393},{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4408},{"trials":4395,"activeCount":99},[],{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[],{"trials":4401,"activeCount":99},[],{"trials":4403,"activeCount":99},[4404],{"nctId":4383,"briefTitle":4384,"status":154,"phases":4405,"primaryCompletion":674,"completion":674,"start":703,"enrollment":265,"conditions":4406,"interventions":4407},[90],[4387],[4370,4389],{"trials":4409,"activeCount":99},[],{"intervention":4411,"totalTrials":121,"cells":4412},"simvastatin\u002Fezetimibe",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4421,"NA":4431},{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[],{"trials":4420,"activeCount":99},[],{"trials":4422,"activeCount":99},[4423],{"nctId":4424,"briefTitle":4425,"status":166,"phases":4426,"primaryCompletion":2420,"completion":2420,"start":4054,"enrollment":516,"conditions":4427,"interventions":4429},"NCT01185236","Study to Compare the Effect of Vytorin (Simvastatin\u002FEzetimibe) 10\u002F20mg Versus Atorvastatin 20mg on ApoB\u002FApoA1 Ratio in Subjects With Diabetes",[90],[4428],"Type 2 Diabetes Mellitus Without Insulin Treatment",[4411,4430],"atorvastatin 20mg",{"trials":4432,"activeCount":99},[],{"intervention":4430,"totalTrials":121,"cells":4434},{"EARLY_PHASE1":4435,"PHASE1":4437,"PHASE2":4439,"PHASE3":4441,"PHASE4":4443,"NA":4449},{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[],{"trials":4442,"activeCount":99},[],{"trials":4444,"activeCount":99},[4445],{"nctId":4424,"briefTitle":4425,"status":166,"phases":4446,"primaryCompletion":2420,"completion":2420,"start":4054,"enrollment":516,"conditions":4447,"interventions":4448},[90],[4428],[4411,4430],{"trials":4450,"activeCount":99},[],{"intervention":4452,"totalTrials":121,"cells":4453},"Aspirin+Clopidogrel\u002FDigoxin",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4471},{"trials":4455,"activeCount":99},[],{"trials":4457,"activeCount":99},[],{"trials":4459,"activeCount":99},[],{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":99},[4464],{"nctId":4465,"briefTitle":4466,"status":154,"phases":4467,"primaryCompletion":3612,"completion":3612,"start":2383,"enrollment":411,"conditions":4468,"interventions":4470},"NCT01775839","Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK\u002FPD of Clopidogrel and PK of Digoxin",[90],[4469],"DRUG REACTIONS",[4452,4452],{"trials":4472,"activeCount":99},[],{"intervention":4474,"totalTrials":121,"cells":4475},"Lacosamide - conventional titration",{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4480,"PHASE3":4482,"PHASE4":4484,"NA":4498},{"trials":4477,"activeCount":99},[],{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[],{"trials":4485,"activeCount":99},[4486],{"nctId":4487,"briefTitle":4488,"status":154,"phases":4489,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":4492,"conditions":4493,"interventions":4495},"NCT03607851","Efficacy and Safety of Rapid Titration Protocols of Lacosamide",[90],"2019-06-07","2018-08-03",75,[4494],"Focal Epilepsy",[4474,4496,4497],"Lacosamide - rapid titration 1","Lacosamide - rapid titration 2",{"trials":4499,"activeCount":99},[],{"intervention":4496,"totalTrials":121,"cells":4501},{"EARLY_PHASE1":4502,"PHASE1":4504,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4516},{"trials":4503,"activeCount":99},[],{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[4512],{"nctId":4487,"briefTitle":4488,"status":154,"phases":4513,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":4492,"conditions":4514,"interventions":4515},[90],[4494],[4474,4496,4497],{"trials":4517,"activeCount":99},[],{"intervention":4497,"totalTrials":121,"cells":4519},{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4534},{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"trials":4529,"activeCount":99},[4530],{"nctId":4487,"briefTitle":4488,"status":154,"phases":4531,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":4492,"conditions":4532,"interventions":4533},[90],[4494],[4474,4496,4497],{"trials":4535,"activeCount":99},[],{"intervention":4537,"totalTrials":121,"cells":4538},"Pitavastatin 4 mg orally daily",{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4545,"PHASE4":4547,"NA":4560},{"trials":4540,"activeCount":99},[],{"trials":4542,"activeCount":99},[],{"trials":4544,"activeCount":99},[],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[4549],{"nctId":4550,"briefTitle":4551,"status":166,"phases":4552,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4556,"interventions":4558},"NCT02940366","Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome",[90],"2019-11-30","2016-12-01",500,[4557],"Metabolic Syndrome",[4537,4559],"Atorvastatin 20 mg orally daily",{"trials":4561,"activeCount":99},[],{"intervention":4559,"totalTrials":121,"cells":4563},{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4578},{"trials":4565,"activeCount":99},[],{"trials":4567,"activeCount":99},[],{"trials":4569,"activeCount":99},[],{"trials":4571,"activeCount":99},[],{"trials":4573,"activeCount":99},[4574],{"nctId":4550,"briefTitle":4551,"status":166,"phases":4575,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4576,"interventions":4577},[90],[4557],[4537,4559],{"trials":4579,"activeCount":99},[],{"intervention":4581,"totalTrials":121,"cells":4582},"3% saline + oral placebo",{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4589,"PHASE4":4591,"NA":4601},{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[],{"trials":4588,"activeCount":99},[],{"trials":4590,"activeCount":99},[],{"trials":4592,"activeCount":99},[4593],{"nctId":4594,"briefTitle":4595,"status":658,"phases":4596,"primaryCompletion":578,"completion":578,"start":1816,"enrollment":99,"conditions":4597,"interventions":4599},"NCT01660867","Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department",[90],[4598],"Acute Bronchiolitis",[4581,4600],"0.9% saline + oral dexamethasone",{"trials":4602,"activeCount":99},[],{"intervention":4600,"totalTrials":121,"cells":4604},{"EARLY_PHASE1":4605,"PHASE1":4607,"PHASE2":4609,"PHASE3":4611,"PHASE4":4613,"NA":4619},{"trials":4606,"activeCount":99},[],{"trials":4608,"activeCount":99},[],{"trials":4610,"activeCount":99},[],{"trials":4612,"activeCount":99},[],{"trials":4614,"activeCount":99},[4615],{"nctId":4594,"briefTitle":4595,"status":658,"phases":4616,"primaryCompletion":578,"completion":578,"start":1816,"enrollment":99,"conditions":4617,"interventions":4618},[90],[4598],[4581,4600],{"trials":4620,"activeCount":99},[],{"intervention":3842,"totalTrials":121,"cells":4622},{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4637},{"trials":4624,"activeCount":99},[],{"trials":4626,"activeCount":99},[],{"trials":4628,"activeCount":99},[],{"trials":4630,"activeCount":99},[],{"trials":4632,"activeCount":99},[4633],{"nctId":3835,"briefTitle":3836,"status":154,"phases":4634,"primaryCompletion":1967,"completion":3838,"start":3621,"enrollment":33,"conditions":4635,"interventions":4636},[90],[3840],[3822,3842],{"trials":4638,"activeCount":99},[],{"intervention":4640,"totalTrials":121,"cells":4641},"MEDICLORE",{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4650,"NA":4663},{"trials":4643,"activeCount":99},[],{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[],{"trials":4651,"activeCount":99},[4652],{"nctId":4653,"briefTitle":4654,"status":154,"phases":4655,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":2232,"conditions":4659,"interventions":4662},"NCT03293186","Anti-adhesive Effect and Safety of \"Thermo-sensitive Adhesion Barrier (MEDICLORE)\"",[90],"2020-12-27","2020-12-31","2017-07-01",[4660,4661],"Adhesion","Thyroidectomy",[4640],{"trials":4664,"activeCount":99},[],{"intervention":3882,"totalTrials":121,"cells":4666},{"EARLY_PHASE1":4667,"PHASE1":4669,"PHASE2":4671,"PHASE3":4673,"PHASE4":4675,"NA":4681},{"trials":4668,"activeCount":99},[],{"trials":4670,"activeCount":99},[],{"trials":4672,"activeCount":99},[],{"trials":4674,"activeCount":99},[],{"trials":4676,"activeCount":99},[4677],{"nctId":3873,"briefTitle":3874,"status":154,"phases":4678,"completion":3876,"start":3877,"enrollment":3878,"conditions":4679,"interventions":4680},[90],[3880],[3882,2105],{"trials":4682,"activeCount":99},[],{"intervention":4684,"totalTrials":121,"cells":4685},"High dose vitamin C",{"EARLY_PHASE1":4686,"PHASE1":4688,"PHASE2":4690,"PHASE3":4692,"PHASE4":4694,"NA":4705},{"trials":4687,"activeCount":99},[],{"trials":4689,"activeCount":99},[],{"trials":4691,"activeCount":99},[],{"trials":4693,"activeCount":99},[],{"trials":4695,"activeCount":99},[4696],{"nctId":4697,"briefTitle":4698,"status":154,"phases":4699,"primaryCompletion":264,"completion":578,"start":2420,"enrollment":2470,"conditions":4700,"interventions":4704},"NCT01413360","The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients",[90],[4701,4702,4703],"Chronic Hepatitis","Chronic Hepatitis C","Chronic Alcoholic Hepatitis",[4684],{"trials":4706,"activeCount":99},[],{"intervention":4708,"totalTrials":121,"cells":4709},"Insulin",{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4716,"PHASE4":4718,"NA":4729},{"trials":4711,"activeCount":99},[],{"trials":4713,"activeCount":99},[],{"trials":4715,"activeCount":99},[],{"trials":4717,"activeCount":99},[],{"trials":4719,"activeCount":99},[4720],{"nctId":4721,"briefTitle":4722,"status":166,"phases":4723,"primaryCompletion":4724,"completion":75,"start":4725,"enrollment":1221,"conditions":4726,"interventions":4728},"NCT03152890","Insulin Therapy for Postreperfusion Hyperglycemia",[90],"2024-12-15","2017-05-15",[4727,1914],"Hyperglycaemia (Diabetic)",[4708],{"trials":4730,"activeCount":99},[],{"intervention":4732,"totalTrials":121,"cells":4733},"NAC Bicarbonate",{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4740,"PHASE4":4742,"NA":4752},{"trials":4735,"activeCount":99},[],{"trials":4737,"activeCount":99},[],{"trials":4739,"activeCount":99},[],{"trials":4741,"activeCount":99},[],{"trials":4743,"activeCount":99},[4744],{"nctId":4745,"briefTitle":4746,"status":166,"phases":4747,"completion":3671,"start":4748,"conditions":4749,"interventions":4751},"NCT00501475","NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED",[90],"2007-03",[4750],"Chronic Renal Failure",[4732],{"trials":4753,"activeCount":99},[],{"intervention":4755,"totalTrials":121,"cells":4756},"Ranibizumab",{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4761,"PHASE3":4763,"PHASE4":4765,"NA":4775},{"trials":4758,"activeCount":99},[],{"trials":4760,"activeCount":99},[],{"trials":4762,"activeCount":99},[],{"trials":4764,"activeCount":99},[],{"trials":4766,"activeCount":99},[4767],{"nctId":4768,"briefTitle":4769,"status":166,"phases":4770,"primaryCompletion":3975,"completion":3786,"start":4130,"enrollment":170,"conditions":4771,"interventions":4773},"NCT02864472","Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose",[90],[4772],"Age-related Macular Degeneration",[4755,4774],"ranibizumab PRN",{"trials":4776,"activeCount":99},[],{"intervention":4774,"totalTrials":121,"cells":4778},{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4783,"PHASE3":4785,"PHASE4":4787,"NA":4793},{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"trials":4784,"activeCount":99},[],{"trials":4786,"activeCount":99},[],{"trials":4788,"activeCount":99},[4789],{"nctId":4768,"briefTitle":4769,"status":166,"phases":4790,"primaryCompletion":3975,"completion":3786,"start":4130,"enrollment":170,"conditions":4791,"interventions":4792},[90],[4772],[4755,4774],{"trials":4794,"activeCount":99},[],{"intervention":4796,"totalTrials":121,"cells":4797},"Duloxetine HCl 30mg",{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4804,"PHASE4":4806,"NA":4816},{"trials":4799,"activeCount":99},[],{"trials":4801,"activeCount":99},[],{"trials":4803,"activeCount":99},[],{"trials":4805,"activeCount":99},[],{"trials":4807,"activeCount":99},[4808],{"nctId":4809,"briefTitle":4810,"status":166,"phases":4811,"primaryCompletion":4812,"completion":3690,"start":3786,"enrollment":2232,"conditions":4813,"interventions":4815},"NCT03792828","Pre-emptive Effect of Duloxetine in the Second Knee in Staged Total Knee Arthroplasty",[90],"2019-10",[4814],"Knee Osteoarthritis",[4796],{"trials":4817,"activeCount":99},[],{"intervention":2389,"totalTrials":121,"cells":4819},{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4826,"PHASE4":4828,"NA":4834},{"trials":4821,"activeCount":99},[],{"trials":4823,"activeCount":99},[],{"trials":4825,"activeCount":99},[],{"trials":4827,"activeCount":99},[],{"trials":4829,"activeCount":99},[4830],{"nctId":2380,"briefTitle":2381,"status":166,"phases":4831,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":2349,"conditions":4832,"interventions":4833},[90],[2387],[2083,2389],{"trials":4835,"activeCount":99},[],{"intervention":4837,"totalTrials":121,"cells":4838},"Ascites replacement with albumin and hartmann's solution",{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4843,"PHASE3":4845,"PHASE4":4847,"NA":4859},{"trials":4840,"activeCount":99},[],{"trials":4842,"activeCount":99},[],{"trials":4844,"activeCount":99},[],{"trials":4846,"activeCount":99},[],{"trials":4848,"activeCount":99},[4849],{"nctId":4850,"briefTitle":4851,"status":154,"phases":4852,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":676,"conditions":4855,"interventions":4857},"NCT04184401","Effect of Ascites Replacement Strategy on Time to 1st Flatus After LDLT",[90],"2021-11-30","2020-01-01",[4856],"Living Donor Liver Transplantation",[4837,4858],"Ascites replacement with hartmann's solution",{"trials":4860,"activeCount":99},[],{"intervention":4858,"totalTrials":121,"cells":4862},{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4877},{"trials":4864,"activeCount":99},[],{"trials":4866,"activeCount":99},[],{"trials":4868,"activeCount":99},[],{"trials":4870,"activeCount":99},[],{"trials":4872,"activeCount":99},[4873],{"nctId":4850,"briefTitle":4851,"status":154,"phases":4874,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":676,"conditions":4875,"interventions":4876},[90],[4856],[4837,4858],{"trials":4878,"activeCount":99},[],{"intervention":3970,"totalTrials":121,"cells":4880},{"EARLY_PHASE1":4881,"PHASE1":4883,"PHASE2":4885,"PHASE3":4887,"PHASE4":4889,"NA":4895},{"trials":4882,"activeCount":99},[],{"trials":4884,"activeCount":99},[],{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[],{"trials":4890,"activeCount":99},[4891],{"nctId":3963,"briefTitle":3964,"status":154,"phases":4892,"primaryCompletion":2161,"completion":179,"start":3966,"enrollment":170,"conditions":4893,"interventions":4894},[90],[3968],[3950,3970],{"trials":4896,"activeCount":99},[],{"intervention":4898,"totalTrials":121,"cells":4899},"Norzyme® 40000 IU",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4919},{"trials":4901,"activeCount":99},[],{"trials":4903,"activeCount":99},[],{"trials":4905,"activeCount":99},[],{"trials":4907,"activeCount":99},[],{"trials":4909,"activeCount":99},[4910],{"nctId":4911,"briefTitle":4912,"status":154,"phases":4913,"primaryCompletion":4914,"completion":4281,"start":3612,"enrollment":4915,"conditions":4916,"interventions":4918},"NCT02127021","The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy",[90],"2017-09-07",304,[4917],"Pancreaticoduodenectomy",[4898],{"trials":4920,"activeCount":99},[],{"intervention":4922,"totalTrials":121,"cells":4923},"transdermal fentanyl matrix, gabapentin",{"EARLY_PHASE1":4924,"PHASE1":4926,"PHASE2":4928,"PHASE3":4930,"PHASE4":4932,"NA":4942},{"trials":4925,"activeCount":99},[],{"trials":4927,"activeCount":99},[],{"trials":4929,"activeCount":99},[],{"trials":4931,"activeCount":99},[],{"trials":4933,"activeCount":99},[4934],{"nctId":4935,"briefTitle":4936,"status":154,"phases":4937,"primaryCompletion":1844,"completion":1844,"start":3556,"enrollment":1958,"conditions":4938,"interventions":4941},"NCT01127100","Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain",[90],[4939,4940],"Neuropathic Pain","Spinal Stenosis",[4922],{"trials":4943,"activeCount":99},[],{"intervention":4945,"totalTrials":121,"cells":4946},"Levodopa dispersible",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4953,"PHASE4":4955,"NA":4964},{"trials":4948,"activeCount":99},[],{"trials":4950,"activeCount":99},[],{"trials":4952,"activeCount":99},[],{"trials":4954,"activeCount":99},[],{"trials":4956,"activeCount":99},[4957],{"nctId":4958,"briefTitle":4959,"status":154,"phases":4960,"primaryCompletion":1965,"completion":3689,"start":1979,"enrollment":170,"conditions":4961,"interventions":4962},"NCT02769793","Efficacy of Levodopa\u002FBenserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON",[90],[3937],[4945,4963],"Levodopa",{"trials":4965,"activeCount":99},[],{"intervention":4963,"totalTrials":121,"cells":4967},{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4972,"PHASE3":4974,"PHASE4":4976,"NA":4982},{"trials":4969,"activeCount":99},[],{"trials":4971,"activeCount":99},[],{"trials":4973,"activeCount":99},[],{"trials":4975,"activeCount":99},[],{"trials":4977,"activeCount":99},[4978],{"nctId":4958,"briefTitle":4959,"status":154,"phases":4979,"primaryCompletion":1965,"completion":3689,"start":1979,"enrollment":170,"conditions":4980,"interventions":4981},[90],[3937],[4945,4963],{"trials":4983,"activeCount":99},[],{"intervention":4985,"totalTrials":121,"cells":4986},"Iodixanol",{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":4993,"PHASE4":4995,"NA":5005},{"trials":4988,"activeCount":99},[],{"trials":4990,"activeCount":99},[],{"trials":4992,"activeCount":99},[],{"trials":4994,"activeCount":99},[],{"trials":4996,"activeCount":99},[4997],{"nctId":4998,"briefTitle":4999,"status":154,"phases":5000,"completion":5001,"start":5002,"conditions":5003,"interventions":5004},"NCT00247325","RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography",[90],"2004-12","2004-01",[3880],[4985],{"trials":5006,"activeCount":99},[],{"intervention":5008,"totalTrials":121,"cells":5009},"gadoxetic acid enhanced liver MRI",{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5029},{"trials":5011,"activeCount":99},[],{"trials":5013,"activeCount":99},[],{"trials":5015,"activeCount":99},[],{"trials":5017,"activeCount":99},[],{"trials":5019,"activeCount":99},[5020],{"nctId":5021,"briefTitle":5022,"status":154,"phases":5023,"primaryCompletion":4066,"completion":5024,"start":2478,"enrollment":1002,"conditions":5025,"interventions":5027},"NCT02854371","Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI",[90],"2018-05",[5026],"Cirrhosis",[5008,5028],"ICG R15",{"trials":5030,"activeCount":99},[],{"intervention":5028,"totalTrials":121,"cells":5032},{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5039,"PHASE4":5041,"NA":5047},{"trials":5034,"activeCount":99},[],{"trials":5036,"activeCount":99},[],{"trials":5038,"activeCount":99},[],{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[5043],{"nctId":5021,"briefTitle":5022,"status":154,"phases":5044,"primaryCompletion":4066,"completion":5024,"start":2478,"enrollment":1002,"conditions":5045,"interventions":5046},[90],[5026],[5008,5028],{"trials":5048,"activeCount":99},[],{"intervention":5050,"totalTrials":121,"cells":5051},"Lactobacillus casei variety rhamnosus granules",{"EARLY_PHASE1":5052,"PHASE1":5054,"PHASE2":5056,"PHASE3":5058,"PHASE4":5060,"NA":5073},{"trials":5053,"activeCount":99},[],{"trials":5055,"activeCount":99},[],{"trials":5057,"activeCount":99},[],{"trials":5059,"activeCount":99},[],{"trials":5061,"activeCount":99},[5062],{"nctId":5063,"briefTitle":5064,"status":166,"phases":5065,"primaryCompletion":548,"completion":579,"start":5066,"enrollment":5067,"conditions":5068,"interventions":5072},"NCT01792739","Lactobacillus Preparation on the Incidence of Diarrhea",[90],"2010-11",124,[5069,5070,5071],"Diarrhea","Death","Pneumonia",[5050],{"trials":5074,"activeCount":99},[],{"intervention":5076,"totalTrials":121,"cells":5077},"DXM + Propofol",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5086,"NA":5097},{"trials":5079,"activeCount":99},[],{"trials":5081,"activeCount":99},[],{"trials":5083,"activeCount":99},[],{"trials":5085,"activeCount":99},[],{"trials":5087,"activeCount":99},[5088],{"nctId":5089,"briefTitle":5090,"status":154,"phases":5091,"primaryCompletion":660,"completion":660,"start":5092,"enrollment":16,"conditions":5093,"interventions":5095},"NCT02102139","Preop Dexmedetomidine Attenuates Haemodynamic Responses to Hydrodissection",[90],"2012-05",[5094],"Robotic Thyroidectomy",[5076,5096],"Saline + Propofol",{"trials":5098,"activeCount":99},[],{"intervention":5096,"totalTrials":121,"cells":5100},{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5109,"NA":5115},{"trials":5102,"activeCount":99},[],{"trials":5104,"activeCount":99},[],{"trials":5106,"activeCount":99},[],{"trials":5108,"activeCount":99},[],{"trials":5110,"activeCount":99},[5111],{"nctId":5089,"briefTitle":5090,"status":154,"phases":5112,"primaryCompletion":660,"completion":660,"start":5092,"enrollment":16,"conditions":5113,"interventions":5114},[90],[5094],[5076,5096],{"trials":5116,"activeCount":99},[],{"intervention":5118,"totalTrials":121,"cells":5119},"Rituximab",{"EARLY_PHASE1":5120,"PHASE1":5122,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5140},{"trials":5121,"activeCount":99},[],{"trials":5123,"activeCount":99},[],{"trials":5125,"activeCount":99},[],{"trials":5127,"activeCount":99},[],{"trials":5129,"activeCount":99},[5130],{"nctId":5131,"briefTitle":5132,"status":154,"phases":5133,"primaryCompletion":5134,"completion":207,"start":5135,"enrollment":1048,"conditions":5136,"interventions":5138},"NCT04033276","IVIG\u002FRituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies",[90],"2021-12-31","2019-01-08",[5137],"Renal Transplant",[5118,5139],"intravenous immune globulin",{"trials":5141,"activeCount":99},[],{"intervention":5139,"totalTrials":121,"cells":5143},{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5150,"PHASE4":5152,"NA":5158},{"trials":5145,"activeCount":99},[],{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[],{"trials":5151,"activeCount":99},[],{"trials":5153,"activeCount":99},[5154],{"nctId":5131,"briefTitle":5132,"status":154,"phases":5155,"primaryCompletion":5134,"completion":207,"start":5135,"enrollment":1048,"conditions":5156,"interventions":5157},[90],[5137],[5118,5139],{"trials":5159,"activeCount":99},[],{"intervention":5161,"totalTrials":121,"cells":5162},"low dose diltiazem",{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5167,"PHASE3":5169,"PHASE4":5171,"NA":5180},{"trials":5164,"activeCount":99},[],{"trials":5166,"activeCount":99},[],{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[],{"trials":5172,"activeCount":99},[5173],{"nctId":5174,"briefTitle":5175,"status":166,"phases":5176,"primaryCompletion":4240,"completion":2420,"start":4240,"enrollment":5177,"conditions":5178,"interventions":5179},"NCT00834925","Low Dose of Diltiazem for Rate Control of Atrial Fibrillation",[90],380,[662],[5161],{"trials":5181,"activeCount":99},[],{"intervention":5183,"totalTrials":121,"cells":5184},"Lucentis",{"EARLY_PHASE1":5185,"PHASE1":5187,"PHASE2":5189,"PHASE3":5191,"PHASE4":5193,"NA":5205},{"trials":5186,"activeCount":99},[],{"trials":5188,"activeCount":99},[],{"trials":5190,"activeCount":99},[],{"trials":5192,"activeCount":99},[],{"trials":5194,"activeCount":99},[5195],{"nctId":5196,"briefTitle":5197,"status":154,"phases":5198,"primaryCompletion":5199,"completion":5200,"start":5201,"enrollment":1221,"conditions":5202,"interventions":5204},"NCT02944227","Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration",[90],"2017-02-16","2017-08-21","2016-03-03",[5203],"Wet Macular Degeneration",[5183],{"trials":5206,"activeCount":99},[],{"intervention":5208,"totalTrials":121,"cells":5209},"Seasonal Influenza vaccine",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5229},{"trials":5211,"activeCount":99},[],{"trials":5213,"activeCount":99},[],{"trials":5215,"activeCount":99},[],{"trials":5217,"activeCount":99},[],{"trials":5219,"activeCount":99},[5220],{"nctId":5221,"briefTitle":5222,"status":154,"phases":5223,"primaryCompletion":2478,"completion":2478,"start":169,"enrollment":5224,"conditions":5225,"interventions":5227},"NCT02748785","MTX Discontinuation and Vaccine Response",[90],277,[5226],"Arthritis, Rheumatoid",[5228,5208],"Methotrexate",{"trials":5230,"activeCount":99},[],{"intervention":5232,"totalTrials":121,"cells":5233},"Dex",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5255},{"trials":5235,"activeCount":99},[],{"trials":5237,"activeCount":99},[],{"trials":5239,"activeCount":99},[],{"trials":5241,"activeCount":99},[],{"trials":5243,"activeCount":99},[5244],{"nctId":5245,"briefTitle":5246,"status":166,"phases":5247,"primaryCompletion":701,"completion":701,"start":675,"enrollment":2295,"conditions":5248,"interventions":5253},"NCT01991223","Dexmedetomidine for Catheter-related Bladder Discomfort",[90],[2025,5249,5250,5251,5252],"Blood Pressure","Nausea","Vomiting","Arrhythmia",[5232,5254],"NS",{"trials":5256,"activeCount":99},[],{"intervention":2156,"totalTrials":121,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5273},{"trials":5260,"activeCount":99},[],{"trials":5262,"activeCount":99},[],{"trials":5264,"activeCount":99},[],{"trials":5266,"activeCount":99},[],{"trials":5268,"activeCount":99},[5269],{"nctId":2147,"briefTitle":2148,"status":154,"phases":5270,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":2153,"conditions":5271,"interventions":5272},[90],[1914,1915],[2156,270],{"trials":5274,"activeCount":99},[],{"intervention":5276,"totalTrials":121,"cells":5277},"Parenteral Nutrition Solutions",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5299},{"trials":5279,"activeCount":99},[],{"trials":5281,"activeCount":99},[],{"trials":5283,"activeCount":99},[],{"trials":5285,"activeCount":99},[],{"trials":5287,"activeCount":99},[5288],{"nctId":5289,"briefTitle":5290,"status":166,"phases":5291,"primaryCompletion":5292,"completion":5292,"start":5293,"enrollment":2455,"conditions":5294,"interventions":5298},"NCT04607057","Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient",[90],"2022-10-30","2020-12-22",[5295,5296,5297],"Gastric Cancer","Gastrectomy","Malnutrition",[5276],{"trials":5300,"activeCount":99},[],{"intervention":5302,"totalTrials":121,"cells":5303},"Cox2 inhibitor",{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5310,"PHASE4":5312,"NA":5322},{"trials":5305,"activeCount":99},[],{"trials":5307,"activeCount":99},[],{"trials":5309,"activeCount":99},[],{"trials":5311,"activeCount":99},[],{"trials":5313,"activeCount":99},[5314],{"nctId":5315,"briefTitle":5316,"status":166,"phases":5317,"primaryCompletion":2172,"completion":2172,"start":5318,"enrollment":5319,"conditions":5320,"interventions":5321},"NCT01111591","Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer",[90],"2008-11",220,[991,35],[5302],{"trials":5323,"activeCount":99},[],{"intervention":4125,"totalTrials":121,"cells":5325},{"EARLY_PHASE1":5326,"PHASE1":5328,"PHASE2":5330,"PHASE3":5332,"PHASE4":5334,"NA":5340},{"trials":5327,"activeCount":99},[],{"trials":5329,"activeCount":99},[],{"trials":5331,"activeCount":99},[],{"trials":5333,"activeCount":99},[],{"trials":5335,"activeCount":99},[5336],{"nctId":4116,"briefTitle":4117,"status":154,"phases":5337,"primaryCompletion":4119,"completion":4120,"start":4121,"enrollment":1048,"conditions":5338,"interventions":5339},[90],[4123],[4103,4125],{"trials":5341,"activeCount":99},[],{"intervention":5343,"totalTrials":121,"cells":5344},"Recombinant zoster vaccination",{"EARLY_PHASE1":5345,"PHASE1":5347,"PHASE2":5349,"PHASE3":5351,"PHASE4":5353,"NA":5366},{"trials":5346,"activeCount":99},[],{"trials":5348,"activeCount":99},[],{"trials":5350,"activeCount":99},[],{"trials":5352,"activeCount":99},[],{"trials":5354,"activeCount":99},[5355],{"nctId":5356,"briefTitle":5357,"status":154,"phases":5358,"primaryCompletion":5359,"completion":5359,"start":5360,"enrollment":5361,"conditions":5362,"interventions":5365},"NCT05898464","Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV",[90],"2026-02-10","2023-06-27",71,[5363,5364],"Vaccination; Infection","Vaccine Adverse Reaction",[5343],{"trials":5367,"activeCount":99},[],{"intervention":3980,"totalTrials":121,"cells":5369},{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5384},{"trials":5371,"activeCount":99},[],{"trials":5373,"activeCount":99},[],{"trials":5375,"activeCount":99},[],{"trials":5377,"activeCount":99},[],{"trials":5379,"activeCount":99},[5380],{"nctId":3972,"briefTitle":3973,"status":154,"phases":5381,"primaryCompletion":3975,"completion":3689,"start":3649,"enrollment":3976,"conditions":5382,"interventions":5383},[90],[3937,3978],[3950,3980],{"trials":5385,"activeCount":99},[],{"intervention":5387,"totalTrials":121,"cells":5388},"AST-120",{"EARLY_PHASE1":5389,"PHASE1":5391,"PHASE2":5393,"PHASE3":5395,"PHASE4":5397,"NA":5406},{"trials":5390,"activeCount":99},[],{"trials":5392,"activeCount":99},[],{"trials":5394,"activeCount":99},[],{"trials":5396,"activeCount":99},[],{"trials":5398,"activeCount":99},[5399],{"nctId":5400,"briefTitle":5401,"status":154,"phases":5402,"primaryCompletion":548,"completion":548,"start":2152,"enrollment":5403,"conditions":5404,"interventions":5405},"NCT00860431","Kremezin Study Against Renal Disease Progression in Korea",[90],578,[663],[5387],{"trials":5407,"activeCount":99},[],{"intervention":5409,"totalTrials":121,"cells":5410},"3-months DAPT",{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5434},{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[],{"trials":5418,"activeCount":99},[],{"trials":5420,"activeCount":99},[5421],{"nctId":5422,"briefTitle":5423,"status":154,"phases":5424,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":5428,"conditions":5429,"interventions":5432},"NCT02601157","Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial",[90],"2021-08-14","2022-08-14","2016-01-18",2173,[439,5430,5431],"Unstable Angina","Non-ST Segment Elevation Myocardial Infarction",[5409,5433],"1-year DAPT",{"trials":5435,"activeCount":99},[],{"intervention":5433,"totalTrials":121,"cells":5437},{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5444,"PHASE4":5446,"NA":5452},{"trials":5439,"activeCount":99},[],{"trials":5441,"activeCount":99},[],{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":99},[],{"trials":5447,"activeCount":99},[5448],{"nctId":5422,"briefTitle":5423,"status":154,"phases":5449,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":5428,"conditions":5450,"interventions":5451},[90],[439,5430,5431],[5409,5433],{"trials":5453,"activeCount":99},[],{"intervention":5455,"totalTrials":121,"cells":5456},"Normal Saline 0.9% 1.2 ml",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5480},{"trials":5458,"activeCount":99},[],{"trials":5460,"activeCount":99},[],{"trials":5462,"activeCount":99},[],{"trials":5464,"activeCount":99},[],{"trials":5466,"activeCount":99},[5467],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5470,"primaryCompletion":5024,"completion":3975,"start":5471,"enrollment":5472,"conditions":5473,"interventions":5475},"NCT03517319","Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity",[90],"2016-09-01",78,[5474],"Spasticity as Sequela of Stroke",[5455,5476,5477,5478,5479],"Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U","Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U","Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U","Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U",{"trials":5481,"activeCount":99},[],{"intervention":5476,"totalTrials":121,"cells":5483},{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5498},{"trials":5485,"activeCount":99},[],{"trials":5487,"activeCount":99},[],{"trials":5489,"activeCount":99},[],{"trials":5491,"activeCount":99},[],{"trials":5493,"activeCount":99},[5494],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5495,"primaryCompletion":5024,"completion":3975,"start":5471,"enrollment":5472,"conditions":5496,"interventions":5497},[90],[5474],[5455,5476,5477,5478,5479],{"trials":5499,"activeCount":99},[],{"intervention":5477,"totalTrials":121,"cells":5501},{"EARLY_PHASE1":5502,"PHASE1":5504,"PHASE2":5506,"PHASE3":5508,"PHASE4":5510,"NA":5516},{"trials":5503,"activeCount":99},[],{"trials":5505,"activeCount":99},[],{"trials":5507,"activeCount":99},[],{"trials":5509,"activeCount":99},[],{"trials":5511,"activeCount":99},[5512],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5513,"primaryCompletion":5024,"completion":3975,"start":5471,"enrollment":5472,"conditions":5514,"interventions":5515},[90],[5474],[5455,5476,5477,5478,5479],{"trials":5517,"activeCount":99},[],{"intervention":5478,"totalTrials":121,"cells":5519},{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5534},{"trials":5521,"activeCount":99},[],{"trials":5523,"activeCount":99},[],{"trials":5525,"activeCount":99},[],{"trials":5527,"activeCount":99},[],{"trials":5529,"activeCount":99},[5530],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5531,"primaryCompletion":5024,"completion":3975,"start":5471,"enrollment":5472,"conditions":5532,"interventions":5533},[90],[5474],[5455,5476,5477,5478,5479],{"trials":5535,"activeCount":99},[],{"intervention":5479,"totalTrials":121,"cells":5537},{"EARLY_PHASE1":5538,"PHASE1":5540,"PHASE2":5542,"PHASE3":5544,"PHASE4":5546,"NA":5552},{"trials":5539,"activeCount":99},[],{"trials":5541,"activeCount":99},[],{"trials":5543,"activeCount":99},[],{"trials":5545,"activeCount":99},[],{"trials":5547,"activeCount":99},[5548],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5549,"primaryCompletion":5024,"completion":3975,"start":5471,"enrollment":5472,"conditions":5550,"interventions":5551},[90],[5474],[5455,5476,5477,5478,5479],{"trials":5553,"activeCount":99},[],{"intervention":5555,"totalTrials":121,"cells":5556},"Aripiprazole 6-week group",{"EARLY_PHASE1":5557,"PHASE1":5559,"PHASE2":5561,"PHASE3":5563,"PHASE4":5565,"NA":5577},{"trials":5558,"activeCount":99},[],{"trials":5560,"activeCount":99},[],{"trials":5562,"activeCount":99},[],{"trials":5564,"activeCount":99},[],{"trials":5566,"activeCount":99},[5567],{"nctId":5568,"briefTitle":5569,"status":154,"phases":5570,"primaryCompletion":168,"completion":5571,"start":5572,"enrollment":3557,"conditions":5573,"interventions":5575},"NCT01696617","Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder",[90],"2019-02","2012-02-10",[5574],"Major Depressive Disorder",[5555,5576],"Aripiprazole 8-week group",{"trials":5578,"activeCount":99},[],{"intervention":5576,"totalTrials":121,"cells":5580},{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5585,"PHASE3":5587,"PHASE4":5589,"NA":5595},{"trials":5582,"activeCount":99},[],{"trials":5584,"activeCount":99},[],{"trials":5586,"activeCount":99},[],{"trials":5588,"activeCount":99},[],{"trials":5590,"activeCount":99},[5591],{"nctId":5568,"briefTitle":5569,"status":154,"phases":5592,"primaryCompletion":168,"completion":5571,"start":5572,"enrollment":3557,"conditions":5593,"interventions":5594},[90],[5574],[5555,5576],{"trials":5596,"activeCount":99},[],{"intervention":5598,"totalTrials":121,"cells":5599},"Advagraf",{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5604,"PHASE3":5606,"PHASE4":5608,"NA":5617},{"trials":5601,"activeCount":99},[],{"trials":5603,"activeCount":99},[],{"trials":5605,"activeCount":99},[],{"trials":5607,"activeCount":99},[],{"trials":5609,"activeCount":99},[5610],{"nctId":5611,"briefTitle":5612,"status":166,"phases":5613,"primaryCompletion":1965,"completion":3689,"start":2052,"enrollment":1795,"conditions":5614,"interventions":5616},"NCT02882113","Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion",[90],[5615],"Liver Dysfunction",[5598],{"trials":5618,"activeCount":99},[],{"intervention":5620,"totalTrials":121,"cells":5621},"Aflibercept Injection [Eylea]",{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5626,"PHASE3":5628,"PHASE4":5630,"NA":5640},{"trials":5623,"activeCount":99},[],{"trials":5625,"activeCount":99},[],{"trials":5627,"activeCount":99},[],{"trials":5629,"activeCount":99},[],{"trials":5631,"activeCount":99},[5632],{"nctId":5633,"briefTitle":5634,"status":154,"phases":5635,"primaryCompletion":1762,"completion":1762,"start":5636,"enrollment":210,"conditions":5637,"interventions":5639},"NCT06330220","Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity",[90],"2021-02-10",[5638],"Age-Related Macular Degeneration",[5620],{"trials":5641,"activeCount":99},[],{"intervention":5643,"totalTrials":121,"cells":5644},"Methylphenidate",{"EARLY_PHASE1":5645,"PHASE1":5647,"PHASE2":5649,"PHASE3":5651,"PHASE4":5653,"NA":5663},{"trials":5646,"activeCount":99},[],{"trials":5648,"activeCount":99},[],{"trials":5650,"activeCount":99},[],{"trials":5652,"activeCount":99},[],{"trials":5654,"activeCount":99},[5655],{"nctId":5656,"briefTitle":5657,"status":166,"phases":5658,"primaryCompletion":2150,"completion":2150,"start":5659,"enrollment":1048,"conditions":5660,"interventions":5662},"NCT00862108","Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)",[90],"2008-09",[5661],"Attention Deficit Hyperactivity Disorder",[5643],{"trials":5664,"activeCount":99},[],{"intervention":3852,"totalTrials":121,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5673,"PHASE4":5675,"NA":5681},{"trials":5668,"activeCount":99},[],{"trials":5670,"activeCount":99},[],{"trials":5672,"activeCount":99},[],{"trials":5674,"activeCount":99},[],{"trials":5676,"activeCount":99},[5677],{"nctId":3844,"briefTitle":3845,"status":166,"phases":5678,"primaryCompletion":3847,"completion":2217,"start":3741,"enrollment":3848,"conditions":5679,"interventions":5680},[90],[3850],[3822,3852,3853],{"trials":5682,"activeCount":99},[],{"intervention":3853,"totalTrials":121,"cells":5684},{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5693,"NA":5699},{"trials":5686,"activeCount":99},[],{"trials":5688,"activeCount":99},[],{"trials":5690,"activeCount":99},[],{"trials":5692,"activeCount":99},[],{"trials":5694,"activeCount":99},[5695],{"nctId":3844,"briefTitle":3845,"status":166,"phases":5696,"primaryCompletion":3847,"completion":2217,"start":3741,"enrollment":3848,"conditions":5697,"interventions":5698},[90],[3850],[3822,3852,3853],{"trials":5700,"activeCount":99},[],{"intervention":5702,"totalTrials":121,"cells":5703},"Beta Blockers Carvedilol Phosphate",{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5708,"PHASE3":5710,"PHASE4":5712,"NA":5723},{"trials":5705,"activeCount":99},[],{"trials":5707,"activeCount":99},[],{"trials":5709,"activeCount":99},[],{"trials":5711,"activeCount":99},[],{"trials":5713,"activeCount":99},[5714],{"nctId":5715,"briefTitle":5716,"status":154,"phases":5717,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":5720,"conditions":5721,"interventions":5722},"NCT03169426","Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning",[90],"2017-11-10","2017-05-17",11,[1666],[5702],{"trials":5724,"activeCount":99},[],{"intervention":5726,"totalTrials":121,"cells":5727},"aspirin + pregrel",{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5747},{"trials":5729,"activeCount":99},[],{"trials":5731,"activeCount":99},[],{"trials":5733,"activeCount":99},[],{"trials":5735,"activeCount":99},[],{"trials":5737,"activeCount":99},[5738],{"nctId":5739,"briefTitle":5740,"status":154,"phases":5741,"primaryCompletion":2251,"completion":2251,"start":675,"enrollment":5742,"conditions":5743,"interventions":5744},"NCT00947843","Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents",[90],306,[3512],[5726,5745,5746],"aspirin + placebo","aspirin + plavix",{"trials":5748,"activeCount":99},[],{"intervention":5745,"totalTrials":121,"cells":5750},{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5757,"PHASE4":5759,"NA":5765},{"trials":5752,"activeCount":99},[],{"trials":5754,"activeCount":99},[],{"trials":5756,"activeCount":99},[],{"trials":5758,"activeCount":99},[],{"trials":5760,"activeCount":99},[5761],{"nctId":5739,"briefTitle":5740,"status":154,"phases":5762,"primaryCompletion":2251,"completion":2251,"start":675,"enrollment":5742,"conditions":5763,"interventions":5764},[90],[3512],[5726,5745,5746],{"trials":5766,"activeCount":99},[],{"intervention":5746,"totalTrials":121,"cells":5768},{"EARLY_PHASE1":5769,"PHASE1":5771,"PHASE2":5773,"PHASE3":5775,"PHASE4":5777,"NA":5783},{"trials":5770,"activeCount":99},[],{"trials":5772,"activeCount":99},[],{"trials":5774,"activeCount":99},[],{"trials":5776,"activeCount":99},[],{"trials":5778,"activeCount":99},[5779],{"nctId":5739,"briefTitle":5740,"status":154,"phases":5780,"primaryCompletion":2251,"completion":2251,"start":675,"enrollment":5742,"conditions":5781,"interventions":5782},[90],[3512],[5726,5745,5746],{"trials":5784,"activeCount":99},[],{"intervention":5786,"totalTrials":121,"cells":5787},"Dextrose 5% in water",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5794,"PHASE4":5796,"NA":5809},{"trials":5789,"activeCount":99},[],{"trials":5791,"activeCount":99},[],{"trials":5793,"activeCount":99},[],{"trials":5795,"activeCount":99},[],{"trials":5797,"activeCount":99},[5798],{"nctId":5799,"briefTitle":5800,"status":154,"phases":5801,"primaryCompletion":5802,"completion":5803,"start":5804,"enrollment":5805,"conditions":5806,"interventions":5808},"NCT04949139","Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia",[90],"2025-01-23","2025-02-22","2021-05-01",178,[5807],"Hypernatremia",[5786],{"trials":5810,"activeCount":99},[],{"intervention":2164,"totalTrials":121,"cells":5812},{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5819,"PHASE4":5821,"NA":5827},{"trials":5814,"activeCount":99},[],{"trials":5816,"activeCount":99},[],{"trials":5818,"activeCount":99},[],{"trials":5820,"activeCount":99},[],{"trials":5822,"activeCount":99},[5823],{"nctId":2158,"briefTitle":2159,"status":154,"phases":5824,"primaryCompletion":2161,"completion":179,"start":169,"enrollment":676,"conditions":5825,"interventions":5826},[90],[518],[2164,2165,2166,2047],{"trials":5828,"activeCount":99},[],{"intervention":2165,"totalTrials":121,"cells":5830},{"EARLY_PHASE1":5831,"PHASE1":5833,"PHASE2":5835,"PHASE3":5837,"PHASE4":5839,"NA":5845},{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[],{"trials":5836,"activeCount":99},[],{"trials":5838,"activeCount":99},[],{"trials":5840,"activeCount":99},[5841],{"nctId":2158,"briefTitle":2159,"status":154,"phases":5842,"primaryCompletion":2161,"completion":179,"start":169,"enrollment":676,"conditions":5843,"interventions":5844},[90],[518],[2164,2165,2166,2047],{"trials":5846,"activeCount":99},[],{"intervention":2176,"totalTrials":121,"cells":5848},{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5863},{"trials":5850,"activeCount":99},[],{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"trials":5858,"activeCount":99},[5859],{"nctId":2168,"briefTitle":2169,"status":154,"phases":5860,"primaryCompletion":2171,"completion":2172,"start":157,"enrollment":28,"conditions":5861,"interventions":5862},[90],[2174],[2176,270],{"trials":5864,"activeCount":99},[],{"intervention":5866,"totalTrials":121,"cells":5867},"Rosuzet tablet 10\u002F5 mg",{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5874,"PHASE4":5876,"NA":5892},{"trials":5869,"activeCount":99},[],{"trials":5871,"activeCount":99},[],{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[],{"trials":5877,"activeCount":99},[5878],{"nctId":5879,"briefTitle":5880,"status":154,"phases":5881,"primaryCompletion":5882,"completion":5883,"start":5884,"enrollment":5885,"conditions":5886,"interventions":5890},"NCT04700436","Efficacy and Safety of EzetimiBe\u002FRosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia",[90],"2021-05-28","2024-02-13","2020-01-03",146,[5887,5888,705,5889],"Endocrine System Diseases","Nutritional and Metabolic Diseases","Dyslipidemias",[5866,5891],"Suvast tablet 10 mg",{"trials":5893,"activeCount":99},[],{"intervention":5891,"totalTrials":121,"cells":5895},{"EARLY_PHASE1":5896,"PHASE1":5898,"PHASE2":5900,"PHASE3":5902,"PHASE4":5904,"NA":5910},{"trials":5897,"activeCount":99},[],{"trials":5899,"activeCount":99},[],{"trials":5901,"activeCount":99},[],{"trials":5903,"activeCount":99},[],{"trials":5905,"activeCount":99},[5906],{"nctId":5879,"briefTitle":5880,"status":154,"phases":5907,"primaryCompletion":5882,"completion":5883,"start":5884,"enrollment":5885,"conditions":5908,"interventions":5909},[90],[5887,5888,705,5889],[5866,5891],{"trials":5911,"activeCount":99},[],{"intervention":5913,"totalTrials":121,"cells":5914},"6-month clopidogrel therapy",{"EARLY_PHASE1":5915,"PHASE1":5917,"PHASE2":5919,"PHASE3":5921,"PHASE4":5923,"NA":5934},{"trials":5916,"activeCount":99},[],{"trials":5918,"activeCount":99},[],{"trials":5920,"activeCount":99},[],{"trials":5922,"activeCount":99},[],{"trials":5924,"activeCount":99},[5925],{"nctId":5926,"briefTitle":5927,"status":154,"phases":5928,"primaryCompletion":264,"completion":3612,"start":5929,"enrollment":5930,"conditions":5931,"interventions":5932},"NCT00698607","Efficacy of Xience\u002FPromus Versus Cypher in rEducing Late Loss After stENTing",[90],"2008-06",1466,[15],[5913,5933],"12-month clopidogrel therapy",{"trials":5935,"activeCount":99},[],{"intervention":5933,"totalTrials":121,"cells":5937},{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5944,"PHASE4":5946,"NA":5952},{"trials":5939,"activeCount":99},[],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"trials":5945,"activeCount":99},[],{"trials":5947,"activeCount":99},[5948],{"nctId":5926,"briefTitle":5927,"status":154,"phases":5949,"primaryCompletion":264,"completion":3612,"start":5929,"enrollment":5930,"conditions":5950,"interventions":5951},[90],[15],[5913,5933],{"trials":5953,"activeCount":99},[],{"intervention":3758,"totalTrials":121,"cells":5955},{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5970},{"trials":5957,"activeCount":99},[],{"trials":5959,"activeCount":99},[],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[5966],{"nctId":3750,"briefTitle":3751,"status":154,"phases":5967,"primaryCompletion":3753,"completion":2128,"start":3612,"enrollment":3754,"conditions":5968,"interventions":5969},[90],[3756],[3758,3759,3717],{"trials":5971,"activeCount":99},[],{"intervention":3759,"totalTrials":121,"cells":5973},{"EARLY_PHASE1":5974,"PHASE1":5976,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5988},{"trials":5975,"activeCount":99},[],{"trials":5977,"activeCount":99},[],{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[],{"trials":5983,"activeCount":99},[5984],{"nctId":3750,"briefTitle":3751,"status":154,"phases":5985,"primaryCompletion":3753,"completion":2128,"start":3612,"enrollment":3754,"conditions":5986,"interventions":5987},[90],[3756],[3758,3759,3717],{"trials":5989,"activeCount":99},[],{"intervention":5991,"totalTrials":121,"cells":5992},"Desvenlafaxine succinate 100mg",{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":5999,"PHASE4":6001,"NA":6012},{"trials":5994,"activeCount":99},[],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[],{"trials":6000,"activeCount":99},[],{"trials":6002,"activeCount":99},[6003],{"nctId":6004,"briefTitle":6005,"status":1813,"phases":6006,"primaryCompletion":4120,"completion":6007,"start":5718,"enrollment":229,"conditions":6008,"interventions":6010},"NCT02819921","Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen",[90],"2019-06-15",[6009,1004],"Hot Flashes",[5991,6011],"Desvenlafaxine succinate 50mg",{"trials":6013,"activeCount":99},[],{"intervention":6011,"totalTrials":121,"cells":6015},{"EARLY_PHASE1":6016,"PHASE1":6018,"PHASE2":6020,"PHASE3":6022,"PHASE4":6024,"NA":6030},{"trials":6017,"activeCount":99},[],{"trials":6019,"activeCount":99},[],{"trials":6021,"activeCount":99},[],{"trials":6023,"activeCount":99},[],{"trials":6025,"activeCount":99},[6026],{"nctId":6004,"briefTitle":6005,"status":1813,"phases":6027,"primaryCompletion":4120,"completion":6007,"start":5718,"enrollment":229,"conditions":6028,"interventions":6029},[90],[6009,1004],[5991,6011],{"trials":6031,"activeCount":99},[],{"intervention":6033,"totalTrials":121,"cells":6034},"CleanViewAL",{"EARLY_PHASE1":6035,"PHASE1":6037,"PHASE2":6039,"PHASE3":6041,"PHASE4":6043,"NA":6056},{"trials":6036,"activeCount":99},[],{"trials":6038,"activeCount":99},[],{"trials":6040,"activeCount":99},[],{"trials":6042,"activeCount":99},[],{"trials":6044,"activeCount":99},[6045],{"nctId":6046,"briefTitle":6047,"status":166,"phases":6048,"primaryCompletion":6049,"completion":5134,"start":6050,"enrollment":380,"conditions":6051,"interventions":6054},"NCT04758156","Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy",[90],"2021-07-31","2019-08-01",[6052,6053],"Colon Adenoma","Colonic Polyp",[6033,6055],"SUPREP",{"trials":6057,"activeCount":99},[],{"intervention":6055,"totalTrials":121,"cells":6059},{"EARLY_PHASE1":6060,"PHASE1":6062,"PHASE2":6064,"PHASE3":6066,"PHASE4":6068,"NA":6074},{"trials":6061,"activeCount":99},[],{"trials":6063,"activeCount":99},[],{"trials":6065,"activeCount":99},[],{"trials":6067,"activeCount":99},[],{"trials":6069,"activeCount":99},[6070],{"nctId":6046,"briefTitle":6047,"status":166,"phases":6071,"primaryCompletion":6049,"completion":5134,"start":6050,"enrollment":380,"conditions":6072,"interventions":6073},[90],[6052,6053],[6033,6055],{"trials":6075,"activeCount":99},[],{"intervention":6077,"totalTrials":121,"cells":6078},"cinacalcet",{"EARLY_PHASE1":6079,"PHASE1":6081,"PHASE2":6083,"PHASE3":6085,"PHASE4":6087,"NA":6097},{"trials":6080,"activeCount":99},[],{"trials":6082,"activeCount":99},[],{"trials":6084,"activeCount":99},[],{"trials":6086,"activeCount":99},[],{"trials":6088,"activeCount":99},[6089],{"nctId":6090,"briefTitle":6091,"status":154,"phases":6092,"primaryCompletion":2419,"completion":3554,"start":4054,"enrollment":569,"conditions":6093,"interventions":6095},"NCT01101113","Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level",[90],[6094],"Secondary Hyperparathyroidism",[6077,6096],"control",{"trials":6098,"activeCount":99},[],{"intervention":6100,"totalTrials":121,"cells":6101},"Niraparib",{"EARLY_PHASE1":6102,"PHASE1":6104,"PHASE2":6106,"PHASE3":6108,"PHASE4":6110,"NA":6122},{"trials":6103,"activeCount":99},[],{"trials":6105,"activeCount":99},[],{"trials":6107,"activeCount":99},[],{"trials":6109,"activeCount":99},[],{"trials":6111,"activeCount":99},[6112],{"nctId":6113,"briefTitle":6114,"status":166,"phases":6115,"primaryCompletion":2565,"completion":2565,"start":6116,"enrollment":2328,"conditions":6117,"interventions":6121},"NCT05187208","PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer",[90],"2022-01",[6118,2116,6119,6120],"Epithelial Ovarian Cancer","Ovarian Cancer Stage III","Ovarian Cancer Stage IV",[6100],{"trials":6123,"activeCount":99},[],{"intervention":6125,"totalTrials":121,"cells":6126},"Scopolamine",{"EARLY_PHASE1":6127,"PHASE1":6129,"PHASE2":6131,"PHASE3":6133,"PHASE4":6135,"NA":6144},{"trials":6128,"activeCount":99},[],{"trials":6130,"activeCount":99},[],{"trials":6132,"activeCount":99},[],{"trials":6134,"activeCount":99},[],{"trials":6136,"activeCount":99},[6137],{"nctId":6138,"briefTitle":6139,"status":166,"phases":6140,"primaryCompletion":2101,"completion":2101,"start":538,"enrollment":1795,"conditions":6141,"interventions":6143},"NCT02968082","The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in MVD Surgery",[90],[6142],"Patients",[6125],{"trials":6145,"activeCount":99},[],{"intervention":2187,"totalTrials":121,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6154,"PHASE4":6156,"NA":6162},{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":99},[],{"trials":6155,"activeCount":99},[],{"trials":6157,"activeCount":99},[6158],{"nctId":2178,"briefTitle":2179,"status":166,"phases":6159,"primaryCompletion":2181,"completion":1135,"start":2182,"enrollment":2183,"conditions":6160,"interventions":6161},[90],[2185],[2187,270],{"trials":6163,"activeCount":99},[],{"intervention":6165,"totalTrials":121,"cells":6166},"oral amoxicillin\u002Fclavulanate 1g",{"EARLY_PHASE1":6167,"PHASE1":6169,"PHASE2":6171,"PHASE3":6173,"PHASE4":6175,"NA":6187},{"trials":6168,"activeCount":99},[],{"trials":6170,"activeCount":99},[],{"trials":6172,"activeCount":99},[],{"trials":6174,"activeCount":99},[],{"trials":6176,"activeCount":99},[6177],{"nctId":6178,"briefTitle":6179,"status":154,"phases":6180,"primaryCompletion":6181,"completion":2523,"start":6182,"enrollment":6183,"conditions":6184,"interventions":6186},"NCT01089218","The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines",[90],"2009-01","2008-04",241,[6185,5071],"Fever",[6165,6096],{"trials":6188,"activeCount":99},[],{"intervention":6190,"totalTrials":121,"cells":6191},"Diltiazem treated group",{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6198,"PHASE4":6200,"NA":6210},{"trials":6193,"activeCount":99},[],{"trials":6195,"activeCount":99},[],{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"trials":6201,"activeCount":99},[6202],{"nctId":6203,"briefTitle":6204,"status":166,"phases":6205,"primaryCompletion":1771,"completion":821,"start":548,"enrollment":1420,"conditions":6206,"interventions":6207},"NCT01162902","Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation",[90],[439],[6190,6208,6209],"Bisoprolol treated group","Candesartan treated group",{"trials":6211,"activeCount":99},[],{"intervention":6208,"totalTrials":121,"cells":6213},{"EARLY_PHASE1":6214,"PHASE1":6216,"PHASE2":6218,"PHASE3":6220,"PHASE4":6222,"NA":6228},{"trials":6215,"activeCount":99},[],{"trials":6217,"activeCount":99},[],{"trials":6219,"activeCount":99},[],{"trials":6221,"activeCount":99},[],{"trials":6223,"activeCount":99},[6224],{"nctId":6203,"briefTitle":6204,"status":166,"phases":6225,"primaryCompletion":1771,"completion":821,"start":548,"enrollment":1420,"conditions":6226,"interventions":6227},[90],[439],[6190,6208,6209],{"trials":6229,"activeCount":99},[],{"intervention":6209,"totalTrials":121,"cells":6231},{"EARLY_PHASE1":6232,"PHASE1":6234,"PHASE2":6236,"PHASE3":6238,"PHASE4":6240,"NA":6246},{"trials":6233,"activeCount":99},[],{"trials":6235,"activeCount":99},[],{"trials":6237,"activeCount":99},[],{"trials":6239,"activeCount":99},[],{"trials":6241,"activeCount":99},[6242],{"nctId":6203,"briefTitle":6204,"status":166,"phases":6243,"primaryCompletion":1771,"completion":821,"start":548,"enrollment":1420,"conditions":6244,"interventions":6245},[90],[439],[6190,6208,6209],{"trials":6247,"activeCount":99},[],{"intervention":6249,"totalTrials":121,"cells":6250},"diacerein",{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6257,"PHASE4":6259,"NA":6270},{"trials":6252,"activeCount":99},[],{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[],{"trials":6258,"activeCount":99},[],{"trials":6260,"activeCount":99},[6261],{"nctId":6262,"briefTitle":6263,"status":154,"phases":6264,"primaryCompletion":3461,"completion":6265,"start":5929,"enrollment":6266,"conditions":6267,"interventions":6269},"NCT00685542","Effect of Diacerein on Hand Osteoarthritis",[90],"2009-12",86,[6268],"Osteoarthritis",[6249],{"trials":6271,"activeCount":99},[],{"intervention":3570,"totalTrials":121,"cells":6273},{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6278,"PHASE3":6280,"PHASE4":6282,"NA":6288},{"trials":6275,"activeCount":99},[],{"trials":6277,"activeCount":99},[],{"trials":6279,"activeCount":99},[],{"trials":6281,"activeCount":99},[],{"trials":6283,"activeCount":99},[6284],{"nctId":3562,"briefTitle":3563,"status":154,"phases":6285,"primaryCompletion":168,"completion":2171,"start":3565,"enrollment":3566,"conditions":6286,"interventions":6287},[90],[3568],[3570,3571,3527],{"trials":6289,"activeCount":99},[],{"intervention":3571,"totalTrials":121,"cells":6291},{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6296,"PHASE3":6298,"PHASE4":6300,"NA":6306},{"trials":6293,"activeCount":99},[],{"trials":6295,"activeCount":99},[],{"trials":6297,"activeCount":99},[],{"trials":6299,"activeCount":99},[],{"trials":6301,"activeCount":99},[6302],{"nctId":3562,"briefTitle":3563,"status":154,"phases":6303,"primaryCompletion":168,"completion":2171,"start":3565,"enrollment":3566,"conditions":6304,"interventions":6305},[90],[3568],[3570,3571,3527],{"trials":6307,"activeCount":99},[],{"intervention":6309,"totalTrials":121,"cells":6310},"N2O gas vs ketamine",{"EARLY_PHASE1":6311,"PHASE1":6313,"PHASE2":6315,"PHASE3":6317,"PHASE4":6319,"NA":6330},{"trials":6312,"activeCount":99},[],{"trials":6314,"activeCount":99},[],{"trials":6316,"activeCount":99},[],{"trials":6318,"activeCount":99},[],{"trials":6320,"activeCount":99},[6321],{"nctId":6322,"briefTitle":6323,"status":154,"phases":6324,"primaryCompletion":6265,"completion":6265,"start":6181,"enrollment":6325,"conditions":6326,"interventions":6329},"NCT00834730","Comparison of N2O Inhalation and Ketamine in Pediatric PSA",[90],32,[6327,6328],"Moderate Sedation","Laceration",[6309],{"trials":6331,"activeCount":99},[],{"intervention":6333,"totalTrials":121,"cells":6334},"Lorazepam",{"EARLY_PHASE1":6335,"PHASE1":6337,"PHASE2":6339,"PHASE3":6341,"PHASE4":6343,"NA":6354},{"trials":6336,"activeCount":99},[],{"trials":6338,"activeCount":99},[],{"trials":6340,"activeCount":99},[],{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":99},[6345],{"nctId":6346,"briefTitle":6347,"status":166,"phases":6348,"primaryCompletion":6349,"completion":3670,"start":2150,"enrollment":6350,"conditions":6351,"interventions":6353},"NCT01121055","Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy",[90],"2010-08",372,[6352],"Patient Satisfaction for Bronchoscopy",[6333,2459],{"trials":6355,"activeCount":99},[],{"intervention":6357,"totalTrials":121,"cells":6358},"FEFINJECT",{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6365,"PHASE4":6367,"NA":6382},{"trials":6360,"activeCount":99},[],{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":99},[],{"trials":6368,"activeCount":99},[6369],{"nctId":6370,"briefTitle":6371,"status":166,"phases":6372,"primaryCompletion":6373,"completion":6374,"start":6375,"enrollment":6376,"conditions":6377,"interventions":6381},"NCT04616092","Effect of Preoperative Intravenous Ferric Carboxymaltose for Clipping Surgery",[90],"2022-11","2023-04","2020-11",130,[6378,6379,6380],"Cerebral Aneurysm Unruptured","Iron Deficiency Anemia","Surgery",[6357],{"trials":6383,"activeCount":99},[],{"intervention":6385,"totalTrials":121,"cells":6386},"Atorvastatin",{"EARLY_PHASE1":6387,"PHASE1":6389,"PHASE2":6391,"PHASE3":6393,"PHASE4":6395,"NA":6406},{"trials":6388,"activeCount":99},[],{"trials":6390,"activeCount":99},[],{"trials":6392,"activeCount":99},[],{"trials":6394,"activeCount":99},[],{"trials":6396,"activeCount":99},[6397],{"nctId":6398,"briefTitle":6399,"status":154,"phases":6400,"primaryCompletion":4241,"completion":4241,"start":5659,"enrollment":6401,"conditions":6402,"interventions":6405},"NCT01285544","The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia",[90],289,[6403,6404,3664],"Dyslipidemia","Cardiovascular Disease",[6385,6385],{"trials":6407,"activeCount":99},[],{"intervention":3607,"totalTrials":121,"cells":6409},{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6414,"PHASE3":6416,"PHASE4":6418,"NA":6424},{"trials":6411,"activeCount":99},[],{"trials":6413,"activeCount":99},[],{"trials":6415,"activeCount":99},[],{"trials":6417,"activeCount":99},[],{"trials":6419,"activeCount":99},[6420],{"nctId":3601,"briefTitle":3602,"status":154,"phases":6421,"primaryCompletion":2383,"completion":2383,"start":2267,"enrollment":850,"conditions":6422,"interventions":6423},[90],[3605],[3588,3607],{"trials":6425,"activeCount":99},[],{"intervention":6427,"totalTrials":121,"cells":6428},"Simvastatin",{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6435,"PHASE4":6437,"NA":6447},{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[],{"trials":6434,"activeCount":99},[],{"trials":6436,"activeCount":99},[],{"trials":6438,"activeCount":99},[6439],{"nctId":6440,"briefTitle":6441,"status":154,"phases":6442,"completion":6443,"start":3877,"enrollment":6444,"conditions":6445,"interventions":6446},"NCT00259441","PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography",[90],"2006-03",320,[3880],[6427],{"trials":6448,"activeCount":99},[],{"intervention":3913,"totalTrials":121,"cells":6450},{"EARLY_PHASE1":6451,"PHASE1":6453,"PHASE2":6455,"PHASE3":6457,"PHASE4":6459,"NA":6465},{"trials":6452,"activeCount":99},[],{"trials":6454,"activeCount":99},[],{"trials":6456,"activeCount":99},[],{"trials":6458,"activeCount":99},[],{"trials":6460,"activeCount":99},[6461],{"nctId":3902,"briefTitle":3903,"status":166,"phases":6462,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":850,"conditions":6463,"interventions":6464},[90],[3908,2144,3909,3910],[3912,3913],{"trials":6466,"activeCount":99},[],{"intervention":6468,"totalTrials":121,"cells":6469},"Chlorhexidine Gluconate 0.12 % Mouthwash",{"EARLY_PHASE1":6470,"PHASE1":6472,"PHASE2":6474,"PHASE3":6476,"PHASE4":6478,"NA":6491},{"trials":6471,"activeCount":99},[],{"trials":6473,"activeCount":99},[],{"trials":6475,"activeCount":99},[],{"trials":6477,"activeCount":99},[],{"trials":6479,"activeCount":99},[6480],{"nctId":6481,"briefTitle":6482,"status":154,"phases":6483,"primaryCompletion":6484,"completion":6485,"start":6486,"enrollment":6487,"conditions":6488,"interventions":6490},"NCT04718922","Chlorhexidine Mouthrinse Before EBUS-TBNA",[90],"2021-06-11","2021-12-11","2021-01-20",112,[6489],"Endobronchial Ultrasound",[6468],{"trials":6492,"activeCount":99},[],{"intervention":6494,"totalTrials":121,"cells":6495},"paliperidone palmitate",{"EARLY_PHASE1":6496,"PHASE1":6498,"PHASE2":6500,"PHASE3":6502,"PHASE4":6504,"NA":6512},{"trials":6497,"activeCount":99},[],{"trials":6499,"activeCount":99},[],{"trials":6501,"activeCount":99},[],{"trials":6503,"activeCount":99},[],{"trials":6505,"activeCount":99},[6506],{"nctId":6507,"briefTitle":6508,"status":154,"phases":6509,"primaryCompletion":821,"completion":821,"start":2420,"enrollment":850,"conditions":6510,"interventions":6511},"NCT01860781","The Effect of Paliperidone Palmitate in Schizophrenia",[90],[32],[6494],{"trials":6513,"activeCount":99},[],{"intervention":6515,"totalTrials":121,"cells":6516},"Mosapride",{"EARLY_PHASE1":6517,"PHASE1":6519,"PHASE2":6521,"PHASE3":6523,"PHASE4":6525,"NA":6535},{"trials":6518,"activeCount":99},[],{"trials":6520,"activeCount":99},[],{"trials":6522,"activeCount":99},[],{"trials":6524,"activeCount":99},[],{"trials":6526,"activeCount":99},[6527],{"nctId":6528,"briefTitle":6529,"status":166,"phases":6530,"primaryCompletion":3649,"completion":168,"start":156,"enrollment":1221,"conditions":6531,"interventions":6534},"NCT02433847","Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects",[90],[6532,6533,21],"Constipated Irritable Bowel Syndrome","Chronic Constipation",[6515],{"trials":6536,"activeCount":99},[],{"intervention":6538,"totalTrials":121,"cells":6539},"Group C : Saline + propofol group",{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6546,"PHASE4":6548,"NA":6559},{"trials":6541,"activeCount":99},[],{"trials":6543,"activeCount":99},[],{"trials":6545,"activeCount":99},[],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[6550],{"nctId":6551,"briefTitle":6552,"status":154,"phases":6553,"primaryCompletion":1816,"completion":1816,"start":5092,"enrollment":6554,"conditions":6555,"interventions":6557},"NCT02097407","Preoperative Dexmedetomidine & EC50 of Propofol",[90],37,[6556],"Urologic Surgery",[6538,6558],"Group D : Dexmedetomidine + propofol group",{"trials":6560,"activeCount":99},[],{"intervention":6558,"totalTrials":121,"cells":6562},{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6567,"PHASE3":6569,"PHASE4":6571,"NA":6577},{"trials":6564,"activeCount":99},[],{"trials":6566,"activeCount":99},[],{"trials":6568,"activeCount":99},[],{"trials":6570,"activeCount":99},[],{"trials":6572,"activeCount":99},[6573],{"nctId":6551,"briefTitle":6552,"status":154,"phases":6574,"primaryCompletion":1816,"completion":1816,"start":5092,"enrollment":6554,"conditions":6575,"interventions":6576},[90],[6556],[6538,6558],{"trials":6578,"activeCount":99},[],{"intervention":6580,"totalTrials":121,"cells":6581},"choline alfoscerate",{"EARLY_PHASE1":6582,"PHASE1":6584,"PHASE2":6586,"PHASE3":6588,"PHASE4":6590,"NA":6601},{"trials":6583,"activeCount":99},[],{"trials":6585,"activeCount":99},[],{"trials":6587,"activeCount":99},[],{"trials":6589,"activeCount":99},[],{"trials":6591,"activeCount":99},[6592],{"nctId":6593,"briefTitle":6594,"status":154,"phases":6595,"primaryCompletion":3621,"completion":3621,"start":5066,"enrollment":6596,"conditions":6597,"interventions":6600},"NCT01363648","The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia",[90],222,[6598,6599],"Cognitive Impairment","Stroke",[6580],{"trials":6602,"activeCount":99},[],{"intervention":6604,"totalTrials":121,"cells":6605},"discontinuation of Sulfonylureas",{"EARLY_PHASE1":6606,"PHASE1":6608,"PHASE2":6610,"PHASE3":6612,"PHASE4":6614,"NA":6625},{"trials":6607,"activeCount":99},[],{"trials":6609,"activeCount":99},[],{"trials":6611,"activeCount":99},[],{"trials":6613,"activeCount":99},[],{"trials":6615,"activeCount":99},[6616],{"nctId":6617,"briefTitle":6618,"status":154,"phases":6619,"primaryCompletion":6620,"completion":6620,"start":6621,"enrollment":265,"conditions":6622,"interventions":6624},"NCT04123587","Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes",[90],"2020-11-30","2019-09-10",[6623],"Diabetes Mellitus",[6604],{"trials":6626,"activeCount":99},[],{"intervention":707,"totalTrials":121,"cells":6628},{"EARLY_PHASE1":6629,"PHASE1":6631,"PHASE2":6633,"PHASE3":6635,"PHASE4":6637,"NA":6643},{"trials":6630,"activeCount":99},[],{"trials":6632,"activeCount":99},[],{"trials":6634,"activeCount":99},[],{"trials":6636,"activeCount":99},[],{"trials":6638,"activeCount":99},[6639],{"nctId":698,"briefTitle":699,"status":154,"phases":6640,"primaryCompletion":701,"completion":702,"start":703,"enrollment":210,"conditions":6641,"interventions":6642},[90],[705],[707,708,468],{"trials":6644,"activeCount":99},[],{"intervention":708,"totalTrials":121,"cells":6646},{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6653,"PHASE4":6655,"NA":6661},{"trials":6648,"activeCount":99},[],{"trials":6650,"activeCount":99},[],{"trials":6652,"activeCount":99},[],{"trials":6654,"activeCount":99},[],{"trials":6656,"activeCount":99},[6657],{"nctId":698,"briefTitle":699,"status":154,"phases":6658,"primaryCompletion":701,"completion":702,"start":703,"enrollment":210,"conditions":6659,"interventions":6660},[90],[705],[707,708,468],{"trials":6662,"activeCount":99},[],{"intervention":3526,"totalTrials":121,"cells":6664},{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6669,"PHASE3":6671,"PHASE4":6673,"NA":6679},{"trials":6666,"activeCount":99},[],{"trials":6668,"activeCount":99},[],{"trials":6670,"activeCount":99},[],{"trials":6672,"activeCount":99},[],{"trials":6674,"activeCount":99},[6675],{"nctId":3516,"briefTitle":3517,"status":154,"phases":6676,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":6677,"interventions":6678},[90],[3523,3524],[666,3526,3514,3527],{"trials":6680,"activeCount":99},[],{"intervention":6682,"totalTrials":121,"cells":6683},"Menatetrenone",{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6690,"PHASE4":6692,"NA":6703},{"trials":6685,"activeCount":99},[],{"trials":6687,"activeCount":99},[],{"trials":6689,"activeCount":99},[],{"trials":6691,"activeCount":99},[],{"trials":6693,"activeCount":99},[6694],{"nctId":6695,"briefTitle":6696,"status":154,"phases":6697,"primaryCompletion":3670,"completion":3670,"start":2499,"enrollment":6698,"conditions":6699,"interventions":6702},"NCT00960973","The Effect of Vitamin K Supplementation on Glucose Metabolism",[90],42,[6700,6701],"Diabetes","Prediabetic State",[6682],{"trials":6704,"activeCount":99},[],{"intervention":6706,"totalTrials":121,"cells":6707},"glycoprotein IIb\u002FIIIa inhibitor",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6714,"PHASE4":6716,"NA":6725},{"trials":6709,"activeCount":99},[],{"trials":6711,"activeCount":99},[],{"trials":6713,"activeCount":99},[],{"trials":6715,"activeCount":99},[],{"trials":6717,"activeCount":99},[6718],{"nctId":6719,"briefTitle":6720,"status":1813,"phases":6721,"primaryCompletion":742,"completion":742,"start":4240,"enrollment":1420,"conditions":6722,"interventions":6724},"NCT01080638","Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.",[90],[1666,6723],"Angioplasty",[6706],{"trials":6726,"activeCount":99},[],{"intervention":6728,"totalTrials":121,"cells":6729},"Clopidogrel+Aspirin",{"EARLY_PHASE1":6730,"PHASE1":6732,"PHASE2":6734,"PHASE3":6736,"PHASE4":6738,"NA":6749},{"trials":6731,"activeCount":99},[],{"trials":6733,"activeCount":99},[],{"trials":6735,"activeCount":99},[],{"trials":6737,"activeCount":99},[],{"trials":6739,"activeCount":99},[6740],{"nctId":6741,"briefTitle":6742,"status":154,"phases":6743,"primaryCompletion":5092,"completion":5092,"start":2385,"enrollment":6744,"conditions":6745,"interventions":6748},"NCT01503658","Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics\u002FPharmacodynamics of Clopidogrel",[90],18,[6746,6747],"Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics\u002FPharmacodynamics of Clopidogrel","Influence of Aspirin on the Pharmacokinetics\u002FPharmacodynamics of Clopidogrel",[6728],{"trials":6750,"activeCount":99},[],{"intervention":4097,"totalTrials":121,"cells":6752},{"EARLY_PHASE1":6753,"PHASE1":6755,"PHASE2":6757,"PHASE3":6759,"PHASE4":6761,"NA":6767},{"trials":6754,"activeCount":99},[],{"trials":6756,"activeCount":99},[],{"trials":6758,"activeCount":99},[],{"trials":6760,"activeCount":99},[],{"trials":6762,"activeCount":99},[6763],{"nctId":4091,"briefTitle":4092,"status":154,"phases":6764,"primaryCompletion":1977,"completion":168,"start":2275,"enrollment":1420,"conditions":6765,"interventions":6766},[90],[4095],[162,4097,4098,4099],{"trials":6768,"activeCount":99},[],{"intervention":4098,"totalTrials":121,"cells":6770},{"EARLY_PHASE1":6771,"PHASE1":6773,"PHASE2":6775,"PHASE3":6777,"PHASE4":6779,"NA":6785},{"trials":6772,"activeCount":99},[],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"trials":6778,"activeCount":99},[],{"trials":6780,"activeCount":99},[6781],{"nctId":4091,"briefTitle":4092,"status":154,"phases":6782,"primaryCompletion":1977,"completion":168,"start":2275,"enrollment":1420,"conditions":6783,"interventions":6784},[90],[4095],[162,4097,4098,4099],{"trials":6786,"activeCount":99},[],{"intervention":4099,"totalTrials":121,"cells":6788},{"EARLY_PHASE1":6789,"PHASE1":6791,"PHASE2":6793,"PHASE3":6795,"PHASE4":6797,"NA":6803},{"trials":6790,"activeCount":99},[],{"trials":6792,"activeCount":99},[],{"trials":6794,"activeCount":99},[],{"trials":6796,"activeCount":99},[],{"trials":6798,"activeCount":99},[6799],{"nctId":4091,"briefTitle":4092,"status":154,"phases":6800,"primaryCompletion":1977,"completion":168,"start":2275,"enrollment":1420,"conditions":6801,"interventions":6802},[90],[4095],[162,4097,4098,4099],{"trials":6804,"activeCount":99},[],{"intervention":6806,"totalTrials":121,"cells":6807},"Pegylated Interferon-alpha2a",{"EARLY_PHASE1":6808,"PHASE1":6810,"PHASE2":6812,"PHASE3":6814,"PHASE4":6816,"NA":6827},{"trials":6809,"activeCount":99},[],{"trials":6811,"activeCount":99},[],{"trials":6813,"activeCount":99},[],{"trials":6815,"activeCount":99},[],{"trials":6817,"activeCount":99},[6818],{"nctId":6819,"briefTitle":6820,"status":154,"phases":6821,"primaryCompletion":6822,"completion":6822,"start":6823,"enrollment":1946,"conditions":6824,"interventions":6825},"NCT00291616","Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B",[90],"2008-08","2005-12",[3744],[6806,6826],"Thymosin alpha1 & Pegylated Interferon-alpha2a",{"trials":6828,"activeCount":99},[],{"intervention":6826,"totalTrials":121,"cells":6830},{"EARLY_PHASE1":6831,"PHASE1":6833,"PHASE2":6835,"PHASE3":6837,"PHASE4":6839,"NA":6845},{"trials":6832,"activeCount":99},[],{"trials":6834,"activeCount":99},[],{"trials":6836,"activeCount":99},[],{"trials":6838,"activeCount":99},[],{"trials":6840,"activeCount":99},[6841],{"nctId":6819,"briefTitle":6820,"status":154,"phases":6842,"primaryCompletion":6822,"completion":6822,"start":6823,"enrollment":1946,"conditions":6843,"interventions":6844},[90],[3744],[6806,6826],{"trials":6846,"activeCount":99},[],{"intervention":4071,"totalTrials":121,"cells":6848},{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6855,"PHASE4":6857,"NA":6863},{"trials":6850,"activeCount":99},[],{"trials":6852,"activeCount":99},[],{"trials":6854,"activeCount":99},[],{"trials":6856,"activeCount":99},[],{"trials":6858,"activeCount":99},[6859],{"nctId":4063,"briefTitle":4064,"status":166,"phases":6860,"primaryCompletion":4066,"completion":2172,"start":1843,"enrollment":4067,"conditions":6861,"interventions":6862},[90],[4069],[4040,4071],{"trials":6864,"activeCount":99},[],{"intervention":6866,"totalTrials":121,"cells":6867},"Vitamin",{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6872,"PHASE3":6874,"PHASE4":6876,"NA":6885},{"trials":6869,"activeCount":99},[],{"trials":6871,"activeCount":99},[],{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":99},[],{"trials":6877,"activeCount":99},[6878],{"nctId":6879,"briefTitle":6880,"status":166,"phases":6881,"primaryCompletion":4156,"completion":6349,"start":6265,"enrollment":1583,"conditions":6882,"interventions":6884},"NCT01127282","The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A",[90],[6883],"H1N1 Influenza",[6866],{"trials":6886,"activeCount":99},[],{"intervention":3626,"totalTrials":121,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6895,"PHASE4":6897,"NA":6903},{"trials":6890,"activeCount":99},[],{"trials":6892,"activeCount":99},[],{"trials":6894,"activeCount":99},[],{"trials":6896,"activeCount":99},[],{"trials":6898,"activeCount":99},[6899],{"nctId":3618,"briefTitle":3619,"status":166,"phases":6900,"primaryCompletion":3621,"completion":3621,"start":2383,"enrollment":3622,"conditions":6901,"interventions":6902},[90],[3624],[3588,3626,3627],{"trials":6904,"activeCount":99},[],{"intervention":6906,"totalTrials":121,"cells":6907},"Cyclosporine A",{"EARLY_PHASE1":6908,"PHASE1":6910,"PHASE2":6912,"PHASE3":6914,"PHASE4":6916,"NA":6926},{"trials":6909,"activeCount":99},[],{"trials":6911,"activeCount":99},[],{"trials":6913,"activeCount":99},[],{"trials":6915,"activeCount":99},[],{"trials":6917,"activeCount":99},[6918],{"nctId":6919,"briefTitle":6920,"status":154,"phases":6921,"primaryCompletion":1978,"completion":1978,"start":6922,"enrollment":158,"conditions":6923,"interventions":6925},"NCT02655705","Comparison Study of Psoriasis Severity Assessment Tools",[90],"2014-08",[6924],"Psoriasis",[6906,5228],{"trials":6927,"activeCount":99},[],{"intervention":6929,"totalTrials":121,"cells":6930},"Precedex",{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6935,"PHASE3":6937,"PHASE4":6939,"NA":6950},{"trials":6932,"activeCount":99},[],{"trials":6934,"activeCount":99},[],{"trials":6936,"activeCount":99},[],{"trials":6938,"activeCount":99},[],{"trials":6940,"activeCount":99},[6941],{"nctId":6942,"briefTitle":6943,"status":154,"phases":6944,"primaryCompletion":4121,"completion":6945,"start":6946,"enrollment":6947,"conditions":6948,"interventions":6949},"NCT02245256","Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients",[90],"2018-02-01","2014-09-01",217,[1914],[6929],{"trials":6951,"activeCount":99},[],{"intervention":6953,"totalTrials":121,"cells":6954},"PK-Merz® 200mg\u002F500ml inj(Amantadine) , Normal saline 500ml inj",{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6961,"PHASE4":6963,"NA":6973},{"trials":6956,"activeCount":99},[],{"trials":6958,"activeCount":99},[],{"trials":6960,"activeCount":99},[],{"trials":6962,"activeCount":99},[],{"trials":6964,"activeCount":99},[6965],{"nctId":6966,"briefTitle":6967,"status":166,"phases":6968,"primaryCompletion":752,"completion":752,"start":4198,"enrollment":1221,"conditions":6969,"interventions":6972},"NCT01313819","The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy",[90],[6970,6971],"Parkinson's Disease","Freezing of Gait",[6953],{"trials":6974,"activeCount":99},[],{"intervention":6976,"totalTrials":121,"cells":6977},"paliperidone",{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6984,"PHASE4":6986,"NA":6994},{"trials":6979,"activeCount":99},[],{"trials":6981,"activeCount":99},[],{"trials":6983,"activeCount":99},[],{"trials":6985,"activeCount":99},[],{"trials":6987,"activeCount":99},[6988],{"nctId":6989,"briefTitle":6990,"status":154,"phases":6991,"primaryCompletion":2052,"completion":538,"start":2420,"enrollment":5720,"conditions":6992,"interventions":6993},"NCT01399450","Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients",[90],[32],[6976],{"trials":6995,"activeCount":99},[],{"intervention":6997,"totalTrials":121,"cells":6998},"Bupropion",{"EARLY_PHASE1":6999,"PHASE1":7001,"PHASE2":7003,"PHASE3":7005,"PHASE4":7007,"NA":7017},{"trials":7000,"activeCount":99},[],{"trials":7002,"activeCount":99},[],{"trials":7004,"activeCount":99},[],{"trials":7006,"activeCount":99},[],{"trials":7008,"activeCount":99},[7009],{"nctId":7010,"briefTitle":7011,"status":154,"phases":7012,"primaryCompletion":2152,"completion":7013,"start":5318,"enrollment":210,"conditions":7014,"interventions":7016},"NCT00846339","PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration",[90],"2009-06",[7015],"Smoking",[6997],{"trials":7018,"activeCount":99},[],{"intervention":3487,"totalTrials":121,"cells":7020},{"EARLY_PHASE1":7021,"PHASE1":7023,"PHASE2":7025,"PHASE3":7027,"PHASE4":7029,"NA":7035},{"trials":7022,"activeCount":99},[],{"trials":7024,"activeCount":99},[],{"trials":7026,"activeCount":99},[],{"trials":7028,"activeCount":99},[],{"trials":7030,"activeCount":99},[7031],{"nctId":3478,"briefTitle":3479,"status":154,"phases":7032,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":170,"conditions":7033,"interventions":7034},[90],[21],[3485,3486,3487,3488,3489],{"trials":7036,"activeCount":99},[],{"intervention":3488,"totalTrials":121,"cells":7038},{"EARLY_PHASE1":7039,"PHASE1":7041,"PHASE2":7043,"PHASE3":7045,"PHASE4":7047,"NA":7053},{"trials":7040,"activeCount":99},[],{"trials":7042,"activeCount":99},[],{"trials":7044,"activeCount":99},[],{"trials":7046,"activeCount":99},[],{"trials":7048,"activeCount":99},[7049],{"nctId":3478,"briefTitle":3479,"status":154,"phases":7050,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":170,"conditions":7051,"interventions":7052},[90],[21],[3485,3486,3487,3488,3489],{"trials":7054,"activeCount":99},[],{"intervention":3489,"totalTrials":121,"cells":7056},{"EARLY_PHASE1":7057,"PHASE1":7059,"PHASE2":7061,"PHASE3":7063,"PHASE4":7065,"NA":7071},{"trials":7058,"activeCount":99},[],{"trials":7060,"activeCount":99},[],{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[],{"trials":7066,"activeCount":99},[7067],{"nctId":3478,"briefTitle":3479,"status":154,"phases":7068,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":170,"conditions":7069,"interventions":7070},[90],[21],[3485,3486,3487,3488,3489],{"trials":7072,"activeCount":99},[],{"intervention":7074,"totalTrials":121,"cells":7075},"morphine sulfate",{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7080,"PHASE3":7082,"PHASE4":7084,"NA":7098},{"trials":7077,"activeCount":99},[],{"trials":7079,"activeCount":99},[],{"trials":7081,"activeCount":99},[],{"trials":7083,"activeCount":99},[],{"trials":7085,"activeCount":99},[7086],{"nctId":7087,"briefTitle":7088,"status":154,"phases":7089,"primaryCompletion":2152,"completion":7090,"start":6182,"enrollment":7091,"conditions":7092,"interventions":7093},"NCT00901628","Periarticular Multimodal Drug Injections in Total Knee Arthroplasty",[90],"2009-04",101,[2526],[7094,7074,7095,7096,7097],"ropivacaine","ketorolac","epinephrine","cefuroxime",{"trials":7099,"activeCount":99},[],{"intervention":7095,"totalTrials":121,"cells":7101},{"EARLY_PHASE1":7102,"PHASE1":7104,"PHASE2":7106,"PHASE3":7108,"PHASE4":7110,"NA":7116},{"trials":7103,"activeCount":99},[],{"trials":7105,"activeCount":99},[],{"trials":7107,"activeCount":99},[],{"trials":7109,"activeCount":99},[],{"trials":7111,"activeCount":99},[7112],{"nctId":7087,"briefTitle":7088,"status":154,"phases":7113,"primaryCompletion":2152,"completion":7090,"start":6182,"enrollment":7091,"conditions":7114,"interventions":7115},[90],[2526],[7094,7074,7095,7096,7097],{"trials":7117,"activeCount":99},[],{"intervention":7097,"totalTrials":121,"cells":7119},{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7126,"PHASE4":7128,"NA":7134},{"trials":7121,"activeCount":99},[],{"trials":7123,"activeCount":99},[],{"trials":7125,"activeCount":99},[],{"trials":7127,"activeCount":99},[],{"trials":7129,"activeCount":99},[7130],{"nctId":7087,"briefTitle":7088,"status":154,"phases":7131,"primaryCompletion":2152,"completion":7090,"start":6182,"enrollment":7091,"conditions":7132,"interventions":7133},[90],[2526],[7094,7074,7095,7096,7097],{"trials":7135,"activeCount":99},[],{"intervention":7137,"totalTrials":121,"cells":7138},"Ketorolac and nefopam balanced analgesia",{"EARLY_PHASE1":7139,"PHASE1":7141,"PHASE2":7143,"PHASE3":7145,"PHASE4":7147,"NA":7158},{"trials":7140,"activeCount":99},[],{"trials":7142,"activeCount":99},[],{"trials":7144,"activeCount":99},[],{"trials":7146,"activeCount":99},[],{"trials":7148,"activeCount":99},[7149],{"nctId":7150,"briefTitle":7151,"status":166,"phases":7152,"primaryCompletion":264,"completion":264,"start":742,"enrollment":3754,"conditions":7153,"interventions":7155},"NCT01543165","Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic",[90],[7154],"Renal Colic",[7137,7156,7157],"Balanced analgesia using ketorolac and morphine","Pain control with single analgesics",{"trials":7159,"activeCount":99},[],{"intervention":7156,"totalTrials":121,"cells":7161},{"EARLY_PHASE1":7162,"PHASE1":7164,"PHASE2":7166,"PHASE3":7168,"PHASE4":7170,"NA":7176},{"trials":7163,"activeCount":99},[],{"trials":7165,"activeCount":99},[],{"trials":7167,"activeCount":99},[],{"trials":7169,"activeCount":99},[],{"trials":7171,"activeCount":99},[7172],{"nctId":7150,"briefTitle":7151,"status":166,"phases":7173,"primaryCompletion":264,"completion":264,"start":742,"enrollment":3754,"conditions":7174,"interventions":7175},[90],[7154],[7137,7156,7157],{"trials":7177,"activeCount":99},[],{"intervention":7157,"totalTrials":121,"cells":7179},{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7184,"PHASE3":7186,"PHASE4":7188,"NA":7194},{"trials":7181,"activeCount":99},[],{"trials":7183,"activeCount":99},[],{"trials":7185,"activeCount":99},[],{"trials":7187,"activeCount":99},[],{"trials":7189,"activeCount":99},[7190],{"nctId":7150,"briefTitle":7151,"status":166,"phases":7191,"primaryCompletion":264,"completion":264,"start":742,"enrollment":3754,"conditions":7192,"interventions":7193},[90],[7154],[7137,7156,7157],{"trials":7195,"activeCount":99},[],{"intervention":7197,"totalTrials":121,"cells":7198},"Prasugrel 5mg",{"EARLY_PHASE1":7199,"PHASE1":7201,"PHASE2":7203,"PHASE3":7205,"PHASE4":7207,"NA":7219},{"trials":7200,"activeCount":99},[],{"trials":7202,"activeCount":99},[],{"trials":7204,"activeCount":99},[],{"trials":7206,"activeCount":99},[],{"trials":7208,"activeCount":99},[7209],{"nctId":7210,"briefTitle":7211,"status":154,"phases":7212,"primaryCompletion":7213,"completion":7214,"start":703,"enrollment":7215,"conditions":7216,"interventions":7218},"NCT02193971","Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)",[90],"2020-10","2024-01",3429,[7217],"Acute Coronary Syndrome",[7197],{"trials":7220,"activeCount":99},[],{"intervention":7222,"totalTrials":121,"cells":7223},"3% hypertonic saline",{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7230,"PHASE4":7232,"NA":7242},{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[],{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[7234],{"nctId":7235,"briefTitle":7236,"status":154,"phases":7237,"primaryCompletion":7238,"completion":7238,"start":2478,"enrollment":5805,"conditions":7239,"interventions":7241},"NCT02887469","Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients",[90],"2019-09-30",[7240],"Hyponatremia Symptomatic",[7222],{"trials":7243,"activeCount":99},[],{"intervention":7245,"totalTrials":121,"cells":7246},"Vitamin C and Vitamin E",{"EARLY_PHASE1":7247,"PHASE1":7249,"PHASE2":7251,"PHASE3":7253,"PHASE4":7255,"NA":7267},{"trials":7248,"activeCount":99},[],{"trials":7250,"activeCount":99},[],{"trials":7252,"activeCount":99},[],{"trials":7254,"activeCount":99},[],{"trials":7256,"activeCount":99},[7257],{"nctId":7258,"briefTitle":7259,"status":1813,"phases":7260,"primaryCompletion":7261,"completion":7261,"start":6946,"enrollment":6444,"conditions":7262,"interventions":7264},"NCT03228238","ANti-Oxidant in Variant Angina (ANOVA) Trial",[90],"2024-06-01",[7263],"Variant Angina",[7245,7265,7266],"Statin","Standard medication for variant angina",{"trials":7268,"activeCount":99},[],{"intervention":7265,"totalTrials":121,"cells":7270},{"EARLY_PHASE1":7271,"PHASE1":7273,"PHASE2":7275,"PHASE3":7277,"PHASE4":7279,"NA":7285},{"trials":7272,"activeCount":99},[],{"trials":7274,"activeCount":99},[],{"trials":7276,"activeCount":99},[],{"trials":7278,"activeCount":99},[],{"trials":7280,"activeCount":99},[7281],{"nctId":7258,"briefTitle":7259,"status":1813,"phases":7282,"primaryCompletion":7261,"completion":7261,"start":6946,"enrollment":6444,"conditions":7283,"interventions":7284},[90],[7263],[7245,7265,7266],{"trials":7286,"activeCount":99},[],{"intervention":7266,"totalTrials":121,"cells":7288},{"EARLY_PHASE1":7289,"PHASE1":7291,"PHASE2":7293,"PHASE3":7295,"PHASE4":7297,"NA":7303},{"trials":7290,"activeCount":99},[],{"trials":7292,"activeCount":99},[],{"trials":7294,"activeCount":99},[],{"trials":7296,"activeCount":99},[],{"trials":7298,"activeCount":99},[7299],{"nctId":7258,"briefTitle":7259,"status":1813,"phases":7300,"primaryCompletion":7261,"completion":7261,"start":6946,"enrollment":6444,"conditions":7301,"interventions":7302},[90],[7263],[7245,7265,7266],{"trials":7304,"activeCount":99},[],{"intervention":7306,"totalTrials":121,"cells":7307},"Atenolol",{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7326},{"trials":7309,"activeCount":99},[],{"trials":7311,"activeCount":99},[],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[],{"trials":7317,"activeCount":99},[7318],{"nctId":7319,"briefTitle":7320,"status":154,"phases":7321,"primaryCompletion":1844,"completion":752,"start":620,"enrollment":210,"conditions":7322,"interventions":7323},"NCT01445964","Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean",[90],[21],[7306,7324,7325],"Atenolol with apple juice 1200 mL","Atenolol with apple juice 600 mL",{"trials":7327,"activeCount":99},[],{"intervention":7324,"totalTrials":121,"cells":7329},{"EARLY_PHASE1":7330,"PHASE1":7332,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7344},{"trials":7331,"activeCount":99},[],{"trials":7333,"activeCount":99},[],{"trials":7335,"activeCount":99},[],{"trials":7337,"activeCount":99},[],{"trials":7339,"activeCount":99},[7340],{"nctId":7319,"briefTitle":7320,"status":154,"phases":7341,"primaryCompletion":1844,"completion":752,"start":620,"enrollment":210,"conditions":7342,"interventions":7343},[90],[21],[7306,7324,7325],{"trials":7345,"activeCount":99},[],{"intervention":7325,"totalTrials":121,"cells":7347},{"EARLY_PHASE1":7348,"PHASE1":7350,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7362},{"trials":7349,"activeCount":99},[],{"trials":7351,"activeCount":99},[],{"trials":7353,"activeCount":99},[],{"trials":7355,"activeCount":99},[],{"trials":7357,"activeCount":99},[7358],{"nctId":7319,"briefTitle":7320,"status":154,"phases":7359,"primaryCompletion":1844,"completion":752,"start":620,"enrollment":210,"conditions":7360,"interventions":7361},[90],[21],[7306,7324,7325],{"trials":7363,"activeCount":99},[],{"intervention":7365,"totalTrials":121,"cells":7366},"dutasteride",{"EARLY_PHASE1":7367,"PHASE1":7369,"PHASE2":7371,"PHASE3":7373,"PHASE4":7375,"NA":7386},{"trials":7368,"activeCount":99},[],{"trials":7370,"activeCount":99},[],{"trials":7372,"activeCount":99},[],{"trials":7374,"activeCount":99},[],{"trials":7376,"activeCount":99},[7377],{"nctId":7378,"briefTitle":7379,"status":154,"phases":7380,"primaryCompletion":7381,"completion":7090,"start":7382,"enrollment":170,"conditions":7383,"interventions":7385},"NCT00880672","Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate",[90],"2008-12","2008-01",[7384],"Benign Prostatic Hyperplasia",[7365],{"trials":7387,"activeCount":99},[],{"intervention":7389,"totalTrials":121,"cells":7390},"Acarbose",{"EARLY_PHASE1":7391,"PHASE1":7393,"PHASE2":7395,"PHASE3":7397,"PHASE4":7399,"NA":7410},{"trials":7392,"activeCount":99},[],{"trials":7394,"activeCount":99},[],{"trials":7396,"activeCount":99},[],{"trials":7398,"activeCount":99},[],{"trials":7400,"activeCount":99},[7401],{"nctId":7402,"briefTitle":7403,"status":166,"phases":7404,"primaryCompletion":821,"start":2041,"enrollment":1002,"conditions":7405,"interventions":7409},"NCT02500329","Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients",[90],[7406,7407,7408,7389],"Endothelial Function","Type 2 Diabetes","Gemigliptin",[7408,7389],{"trials":7411,"activeCount":99},[],{"intervention":4135,"totalTrials":121,"cells":7413},{"EARLY_PHASE1":7414,"PHASE1":7416,"PHASE2":7418,"PHASE3":7420,"PHASE4":7422,"NA":7428},{"trials":7415,"activeCount":99},[],{"trials":7417,"activeCount":99},[],{"trials":7419,"activeCount":99},[],{"trials":7421,"activeCount":99},[],{"trials":7423,"activeCount":99},[7424],{"nctId":4127,"briefTitle":4128,"status":154,"phases":7425,"primaryCompletion":4130,"completion":4130,"start":701,"enrollment":4131,"conditions":7426,"interventions":7427},[90],[4133],[4103,4135,4136],{"trials":7429,"activeCount":99},[],{"intervention":4136,"totalTrials":121,"cells":7431},{"EARLY_PHASE1":7432,"PHASE1":7434,"PHASE2":7436,"PHASE3":7438,"PHASE4":7440,"NA":7446},{"trials":7433,"activeCount":99},[],{"trials":7435,"activeCount":99},[],{"trials":7437,"activeCount":99},[],{"trials":7439,"activeCount":99},[],{"trials":7441,"activeCount":99},[7442],{"nctId":4127,"briefTitle":4128,"status":154,"phases":7443,"primaryCompletion":4130,"completion":4130,"start":701,"enrollment":4131,"conditions":7444,"interventions":7445},[90],[4133],[4103,4135,4136],{"trials":7447,"activeCount":99},[],{"intervention":7449,"totalTrials":121,"cells":7450},"buspirone+alprazolam",{"EARLY_PHASE1":7451,"PHASE1":7453,"PHASE2":7455,"PHASE3":7457,"PHASE4":7459,"NA":7469},{"trials":7452,"activeCount":99},[],{"trials":7454,"activeCount":99},[],{"trials":7456,"activeCount":99},[],{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[7461],{"nctId":7462,"briefTitle":7463,"status":658,"phases":7464,"primaryCompletion":3510,"completion":3510,"start":2419,"enrollment":99,"conditions":7465,"interventions":7467},"NCT01546896","Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder",[90],[7466],"Anxiety Disorder",[7449,7468],"alprazolam",{"trials":7470,"activeCount":99},[],{"intervention":7468,"totalTrials":121,"cells":7472},{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7479,"PHASE4":7481,"NA":7487},{"trials":7474,"activeCount":99},[],{"trials":7476,"activeCount":99},[],{"trials":7478,"activeCount":99},[],{"trials":7480,"activeCount":99},[],{"trials":7482,"activeCount":99},[7483],{"nctId":7462,"briefTitle":7463,"status":658,"phases":7484,"primaryCompletion":3510,"completion":3510,"start":2419,"enrollment":99,"conditions":7485,"interventions":7486},[90],[7466],[7449,7468],{"trials":7488,"activeCount":99},[],{"intervention":7490,"totalTrials":121,"cells":7491},"lacidipine",{"EARLY_PHASE1":7492,"PHASE1":7494,"PHASE2":7496,"PHASE3":7498,"PHASE4":7500,"NA":7510},{"trials":7493,"activeCount":99},[],{"trials":7495,"activeCount":99},[],{"trials":7497,"activeCount":99},[],{"trials":7499,"activeCount":99},[],{"trials":7501,"activeCount":99},[7502],{"nctId":7503,"briefTitle":7504,"status":166,"phases":7505,"completion":5659,"start":7506,"enrollment":319,"conditions":7507,"interventions":7509},"NCT00533858","Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients",[90],"2007-09",[7508],"Hypertension",[7490],{"trials":7511,"activeCount":99},[],{"intervention":7513,"totalTrials":121,"cells":7514},"Perampanel",{"EARLY_PHASE1":7515,"PHASE1":7517,"PHASE2":7519,"PHASE3":7521,"PHASE4":7523,"NA":7534},{"trials":7516,"activeCount":99},[],{"trials":7518,"activeCount":99},[],{"trials":7520,"activeCount":99},[],{"trials":7522,"activeCount":99},[],{"trials":7524,"activeCount":99},[7525],{"nctId":7526,"briefTitle":7527,"status":154,"phases":7528,"primaryCompletion":7529,"completion":7530,"start":168,"enrollment":850,"conditions":7531,"interventions":7533},"NCT02900755","Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy",[90],"2019-04","2020-11-20",[7532],"Electroencephalography",[7513],{"trials":7535,"activeCount":99},[],{"intervention":3791,"totalTrials":121,"cells":7537},{"EARLY_PHASE1":7538,"PHASE1":7540,"PHASE2":7542,"PHASE3":7544,"PHASE4":7546,"NA":7552},{"trials":7539,"activeCount":99},[],{"trials":7541,"activeCount":99},[],{"trials":7543,"activeCount":99},[],{"trials":7545,"activeCount":99},[],{"trials":7547,"activeCount":99},[7548],{"nctId":3783,"briefTitle":3784,"status":166,"phases":7549,"primaryCompletion":3786,"completion":3786,"start":168,"enrollment":3787,"conditions":7550,"interventions":7551},[90],[3789],[3791,3514],{"trials":7553,"activeCount":99},[],{"intervention":7555,"totalTrials":121,"cells":7556},"Remiva",{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7561,"PHASE3":7563,"PHASE4":7565,"NA":7578},{"trials":7558,"activeCount":99},[],{"trials":7560,"activeCount":99},[],{"trials":7562,"activeCount":99},[],{"trials":7564,"activeCount":99},[],{"trials":7566,"activeCount":99},[7567],{"nctId":7568,"briefTitle":7569,"status":154,"phases":7570,"primaryCompletion":179,"completion":179,"start":3838,"enrollment":7571,"conditions":7572,"interventions":7576},"NCT02566733","Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass",[90],56,[7573,7574,7575,2457],"Anesthetics, Intravenous","Pharmacology","Anesthetics",[7555,7577],"Ultiva",{"trials":7579,"activeCount":99},[],{"intervention":7577,"totalTrials":121,"cells":7581},{"EARLY_PHASE1":7582,"PHASE1":7584,"PHASE2":7586,"PHASE3":7588,"PHASE4":7590,"NA":7596},{"trials":7583,"activeCount":99},[],{"trials":7585,"activeCount":99},[],{"trials":7587,"activeCount":99},[],{"trials":7589,"activeCount":99},[],{"trials":7591,"activeCount":99},[7592],{"nctId":7568,"briefTitle":7569,"status":154,"phases":7593,"primaryCompletion":179,"completion":179,"start":3838,"enrollment":7571,"conditions":7594,"interventions":7595},[90],[7573,7574,7575,2457],[7555,7577],{"trials":7597,"activeCount":99},[],{"intervention":7599,"totalTrials":121,"cells":7600},"Tramadol",{"EARLY_PHASE1":7601,"PHASE1":7603,"PHASE2":7605,"PHASE3":7607,"PHASE4":7609,"NA":7619},{"trials":7602,"activeCount":99},[],{"trials":7604,"activeCount":99},[],{"trials":7606,"activeCount":99},[],{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[7611],{"nctId":7612,"briefTitle":7613,"status":154,"phases":7614,"primaryCompletion":2052,"completion":4066,"start":1771,"enrollment":7615,"conditions":7616,"interventions":7617},"NCT02416804","Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery",[90],69,[4940,3207],[7618,7599],"Buprenorphine",{"trials":7620,"activeCount":99},[],{"intervention":7622,"totalTrials":121,"cells":7623},"Brimonidine\u002FTimolol mixed combination",{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7628,"PHASE3":7630,"PHASE4":7632,"NA":7643},{"trials":7625,"activeCount":99},[],{"trials":7627,"activeCount":99},[],{"trials":7629,"activeCount":99},[],{"trials":7631,"activeCount":99},[],{"trials":7633,"activeCount":99},[7634],{"nctId":7635,"briefTitle":7636,"status":166,"phases":7637,"primaryCompletion":2420,"completion":1816,"start":3671,"enrollment":7638,"conditions":7639,"interventions":7641},"NCT01446497","Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma",[90],22,[7640],"Normal Tension Glaucoma",[7622,7642],"Timolol",{"trials":7644,"activeCount":99},[],{"intervention":7642,"totalTrials":121,"cells":7646},{"EARLY_PHASE1":7647,"PHASE1":7649,"PHASE2":7651,"PHASE3":7653,"PHASE4":7655,"NA":7661},{"trials":7648,"activeCount":99},[],{"trials":7650,"activeCount":99},[],{"trials":7652,"activeCount":99},[],{"trials":7654,"activeCount":99},[],{"trials":7656,"activeCount":99},[7657],{"nctId":7635,"briefTitle":7636,"status":166,"phases":7658,"primaryCompletion":2420,"completion":1816,"start":3671,"enrollment":7638,"conditions":7659,"interventions":7660},[90],[7640],[7622,7642],{"trials":7662,"activeCount":99},[],{"intervention":7664,"totalTrials":121,"cells":7665},"Mirapex ER",{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7672,"PHASE4":7674,"NA":7683},{"trials":7667,"activeCount":99},[],{"trials":7669,"activeCount":99},[],{"trials":7671,"activeCount":99},[],{"trials":7673,"activeCount":99},[],{"trials":7675,"activeCount":99},[7676],{"nctId":7677,"briefTitle":7678,"status":166,"phases":7679,"primaryCompletion":1816,"completion":549,"start":7680,"enrollment":380,"conditions":7681,"interventions":7682},"NCT01515774","Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)",[90],"2011-09",[6970],[7664],{"trials":7684,"activeCount":99},[],{"intervention":7686,"totalTrials":121,"cells":7687},"Tenofovir",{"EARLY_PHASE1":7688,"PHASE1":7690,"PHASE2":7692,"PHASE3":7694,"PHASE4":7696,"NA":7705},{"trials":7689,"activeCount":99},[],{"trials":7691,"activeCount":99},[],{"trials":7693,"activeCount":99},[],{"trials":7695,"activeCount":99},[],{"trials":7697,"activeCount":99},[7698],{"nctId":7699,"briefTitle":7700,"status":166,"phases":7701,"primaryCompletion":3975,"completion":1966,"start":674,"enrollment":2232,"conditions":7702,"interventions":7704},"NCT02585947","To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma",[90],[7703],"Non-Hodgkin's Lymphoma, Burkitt's",[7686],{"trials":7706,"activeCount":99},[],{"intervention":7708,"totalTrials":121,"cells":7709},"Dysport®",{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7714,"PHASE3":7716,"PHASE4":7718,"NA":7730},{"trials":7711,"activeCount":99},[],{"trials":7713,"activeCount":99},[],{"trials":7715,"activeCount":99},[],{"trials":7717,"activeCount":99},[],{"trials":7719,"activeCount":99},[7720],{"nctId":7721,"briefTitle":7722,"status":154,"phases":7723,"primaryCompletion":753,"completion":7724,"start":4240,"enrollment":7725,"conditions":7726,"interventions":7728},"NCT00950664","A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia",[90],"2011-07",103,[7727],"Cervical Dystonia",[7708,7729],"Botox®",{"trials":7731,"activeCount":99},[],{"intervention":7729,"totalTrials":121,"cells":7733},{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7738,"PHASE3":7740,"PHASE4":7742,"NA":7748},{"trials":7735,"activeCount":99},[],{"trials":7737,"activeCount":99},[],{"trials":7739,"activeCount":99},[],{"trials":7741,"activeCount":99},[],{"trials":7743,"activeCount":99},[7744],{"nctId":7721,"briefTitle":7722,"status":154,"phases":7745,"primaryCompletion":753,"completion":7724,"start":4240,"enrollment":7725,"conditions":7746,"interventions":7747},[90],[7727],[7708,7729],{"trials":7749,"activeCount":99},[],{"intervention":7751,"totalTrials":121,"cells":7752},"colchicine",{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7757,"PHASE3":7759,"PHASE4":7761,"NA":7769},{"trials":7754,"activeCount":99},[],{"trials":7756,"activeCount":99},[],{"trials":7758,"activeCount":99},[],{"trials":7760,"activeCount":99},[],{"trials":7762,"activeCount":99},[7763],{"nctId":7764,"briefTitle":7765,"status":154,"phases":7766,"primaryCompletion":3670,"start":3670,"enrollment":180,"conditions":7767,"interventions":7768},"NCT01173107","A Pilot Study for PK\u002FPD Parameter of Colchicine in Chronic Kidney Disease Patient.",[90],[663],[7751],{"trials":7770,"activeCount":99},[],{"intervention":7772,"totalTrials":121,"cells":7773},"Ropinirole Prolonged release",{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7778,"PHASE3":7780,"PHASE4":7782,"NA":7790},{"trials":7775,"activeCount":99},[],{"trials":7777,"activeCount":99},[],{"trials":7779,"activeCount":99},[],{"trials":7781,"activeCount":99},[],{"trials":7783,"activeCount":99},[7784],{"nctId":7785,"briefTitle":7786,"status":154,"phases":7787,"primaryCompletion":3670,"completion":3670,"start":2499,"enrollment":1772,"conditions":7788,"interventions":7789},"NCT00986245","Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily",[90],[3937],[7772],{"trials":7791,"activeCount":99},[],{"intervention":7793,"totalTrials":1036,"cells":7794},"Udenafil",{"EARLY_PHASE1":7795,"PHASE1":7797,"PHASE2":7799,"PHASE3":7809,"PHASE4":7841,"NA":7843},{"trials":7796,"activeCount":99},[],{"trials":7798,"activeCount":99},[],{"trials":7800,"activeCount":99},[7801],{"nctId":7802,"briefTitle":7803,"status":154,"phases":7804,"primaryCompletion":2385,"completion":2385,"start":2152,"enrollment":3557,"conditions":7805,"interventions":7808},"NCT00607282","Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer",[88],[7806,7807,4057],"Erectile Dysfunction","Sigmoid Colon Cancer",[7793],{"trials":7810,"activeCount":99},[7811,7818,7825,7832],{"nctId":7812,"briefTitle":7813,"status":1813,"phases":7814,"primaryCompletion":732,"completion":732,"start":752,"enrollment":16,"conditions":7815,"interventions":7817},"NCT01646515","Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure",[89],[7816],"Systolic Heart Failure",[7793],{"nctId":7819,"briefTitle":7820,"status":166,"phases":7821,"primaryCompletion":264,"completion":264,"start":660,"enrollment":170,"conditions":7822,"interventions":7824},"NCT01696240","A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]",[89],[7823],"Mild Pulmonary Hypertension",[7793],{"nctId":7826,"briefTitle":7827,"status":166,"phases":7828,"primaryCompletion":2384,"completion":3966,"start":549,"enrollment":1946,"conditions":7829,"interventions":7831},"NCT01599117","A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]",[89],[7830],"Diastolic Heart Failure",[7793],{"nctId":7833,"briefTitle":7834,"status":154,"phases":7835,"primaryCompletion":3565,"completion":620,"start":2150,"enrollment":25,"conditions":7836,"interventions":7840},"NCT01364181","The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients",[89],[7837,7838,7839],"Dyspnea","Chronic Obstructive Pulmonary Disease","Pulmonary Hypertension",[7793],{"trials":7842,"activeCount":99},[],{"trials":7844,"activeCount":99},[],{"intervention":7846,"totalTrials":599,"cells":7847},"5-fluorouracil",{"EARLY_PHASE1":7848,"PHASE1":7850,"PHASE2":7852,"PHASE3":7871,"PHASE4":7885,"NA":7887},{"trials":7849,"activeCount":99},[],{"trials":7851,"activeCount":99},[],{"trials":7853,"activeCount":99},[7854,7863],{"nctId":7855,"briefTitle":7856,"status":166,"phases":7857,"primaryCompletion":75,"completion":1000,"start":7858,"enrollment":380,"conditions":7859,"interventions":7860},"NCT04371224","NaliCap (Irinotecan Liposome (Nal-IRI)\u002FCapecitabine) vs. NAPOLI (Nal-IRI\u002F5-FU\u002FLV) ) in Advanced Pancreatic Cancer",[88],"2020-06-23",[35],[7861,3164,7846,7862],"Irinotecan Liposomal Injection [Onivyde]","Leucovorin",{"nctId":7864,"briefTitle":7865,"status":658,"phases":7866,"primaryCompletion":674,"completion":674,"start":674,"enrollment":99,"conditions":7867,"interventions":7869},"NCT01953406","The Efficacy of 5-fluorouracil\u002FMitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma",[88],[18,7868],"Lung Metastasis",[7846,7870],"Mitomycin",{"trials":7872,"activeCount":99},[7873],{"nctId":7874,"briefTitle":7875,"status":154,"phases":7876,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":7878,"interventions":7879},"NCT02114359","Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer",[89],"2020-02",[5295],[7880,7881,7882,7883,3164,7884,7846],"Capecitabine\u002Fcisplatin","S-1\u002Fcisplatin","Capecitabine\u002Foxaliplatin","5-fluorouracil\u002Foxaliplatin","S-1",{"trials":7886,"activeCount":99},[],{"trials":7888,"activeCount":99},[],{"intervention":7890,"totalTrials":599,"cells":7891},"smallpox vaccine CJ-50300",{"EARLY_PHASE1":7892,"PHASE1":7894,"PHASE2":7896,"PHASE3":7898,"PHASE4":7921,"NA":7923},{"trials":7893,"activeCount":99},[],{"trials":7895,"activeCount":99},[],{"trials":7897,"activeCount":99},[],{"trials":7899,"activeCount":99},[7900,7907,7914],{"nctId":7901,"briefTitle":7902,"status":154,"phases":7903,"primaryCompletion":3670,"completion":753,"start":3461,"enrollment":3622,"conditions":7904,"interventions":7906},"NCT01056770","Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers",[89],[7905],"Smallpox",[7890],{"nctId":7908,"briefTitle":7909,"status":154,"phases":7910,"primaryCompletion":5929,"completion":7381,"start":7382,"enrollment":7911,"conditions":7912,"interventions":7913},"NCT00607243","Safety and Efficacy of CJ-50300 in Healthy Volunteers",[88,89],123,[7905],[7890],{"nctId":7915,"briefTitle":7916,"status":154,"phases":7917,"primaryCompletion":7724,"completion":752,"start":3671,"enrollment":7918,"conditions":7919,"interventions":7920},"NCT01317238","Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers",[89],145,[7905],[7890],{"trials":7922,"activeCount":99},[],{"trials":7924,"activeCount":99},[],{"intervention":3164,"totalTrials":95,"cells":7926},{"EARLY_PHASE1":7927,"PHASE1":7929,"PHASE2":7931,"PHASE3":7937,"PHASE4":7943,"NA":7945},{"trials":7928,"activeCount":99},[],{"trials":7930,"activeCount":99},[],{"trials":7932,"activeCount":99},[7933],{"nctId":7855,"briefTitle":7856,"status":166,"phases":7934,"primaryCompletion":75,"completion":1000,"start":7858,"enrollment":380,"conditions":7935,"interventions":7936},[88],[35],[7861,3164,7846,7862],{"trials":7938,"activeCount":99},[7939],{"nctId":7874,"briefTitle":7875,"status":154,"phases":7940,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":7941,"interventions":7942},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":7944,"activeCount":99},[],{"trials":7946,"activeCount":99},[],{"intervention":7948,"totalTrials":95,"cells":7949},"Quetiapine",{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7963,"PHASE3":7965,"PHASE4":7976,"NA":7978},{"trials":7951,"activeCount":99},[],{"trials":7953,"activeCount":99},[7954],{"nctId":7955,"briefTitle":7956,"status":154,"phases":7957,"primaryCompletion":1957,"completion":1957,"start":7958,"enrollment":170,"conditions":7959,"interventions":7960},"NCT01871701","Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs",[87],"2012-11",[21],[7961,7948,7962],"Escitalopram","Moxifloxacin",{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[7967],{"nctId":7968,"briefTitle":7969,"status":166,"phases":7970,"primaryCompletion":4130,"start":2622,"enrollment":7971,"conditions":7972,"interventions":7974},"NCT02297763","Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients",[89],194,[7973],"Delirium",[7975],"quetiapine",{"trials":7977,"activeCount":99},[],{"trials":7979,"activeCount":99},[],{"intervention":7981,"totalTrials":95,"cells":7982},"Losartan",{"EARLY_PHASE1":7983,"PHASE1":7985,"PHASE2":7987,"PHASE3":7989,"PHASE4":8005,"NA":8007},{"trials":7984,"activeCount":99},[],{"trials":7986,"activeCount":99},[],{"trials":7988,"activeCount":99},[],{"trials":7990,"activeCount":99},[7991,7997],{"nctId":7992,"briefTitle":7993,"status":154,"phases":7994,"primaryCompletion":2052,"completion":4130,"start":2041,"enrollment":265,"conditions":7995,"interventions":7996},"NCT02232763","Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria",[89],[3634],[7981],{"nctId":7998,"briefTitle":7999,"status":154,"phases":8000,"primaryCompletion":168,"completion":8001,"start":2294,"enrollment":6554,"conditions":8002,"interventions":8004},"NCT02232776","Efficacy and Safety of Losartan in Children With Ig A Nephropathy",[89],"2017-04",[8003],"Glomerulonephritis, IGA",[7981],{"trials":8006,"activeCount":99},[],{"trials":8008,"activeCount":99},[],{"intervention":8010,"totalTrials":95,"cells":8011},"Placebos",{"EARLY_PHASE1":8012,"PHASE1":8014,"PHASE2":8016,"PHASE3":8029,"PHASE4":8041,"NA":8043},{"trials":8013,"activeCount":99},[],{"trials":8015,"activeCount":99},[],{"trials":8017,"activeCount":99},[8018],{"nctId":8019,"briefTitle":8020,"status":166,"phases":8021,"primaryCompletion":8022,"completion":4854,"start":8023,"enrollment":8024,"conditions":8025,"interventions":8027},"NCT03051360","PCSK9 Inhibitors in the Progression of Aortic Stenosis",[88],"2019-12-31","2017-06-01",140,[8026],"Aortic Valve Stenosis",[8028,8010],"PCSK9 Inhibitor [EPC]",{"trials":8030,"activeCount":99},[8031],{"nctId":8032,"briefTitle":8033,"status":154,"phases":8034,"primaryCompletion":8035,"completion":8035,"start":8036,"enrollment":2349,"conditions":8037,"interventions":8039},"NCT04161027","RCT for Pregabalin in Restless Legs Syndrome in South Korea",[89],"2022-04-04","2020-02-24",[8038],"Restless Legs Syndrome",[8040,8010],"Pregabalin 75mg",{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"intervention":8046,"totalTrials":95,"cells":8047},"Sirolimus",{"EARLY_PHASE1":8048,"PHASE1":8050,"PHASE2":8052,"PHASE3":8061,"PHASE4":8070,"NA":8072},{"trials":8049,"activeCount":99},[],{"trials":8051,"activeCount":99},[],{"trials":8053,"activeCount":99},[8054],{"nctId":8055,"briefTitle":8056,"status":154,"phases":8057,"primaryCompletion":2161,"completion":2161,"start":3556,"enrollment":2183,"conditions":8058,"interventions":8059},"NCT01374750","Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)",[88],[18],[8046,8060],"m-TOR inhibitor free",{"trials":8062,"activeCount":99},[8063],{"nctId":8064,"briefTitle":8065,"status":166,"phases":8066,"primaryCompletion":2041,"completion":1967,"start":7680,"enrollment":2053,"conditions":8067,"interventions":8069},"NCT01680250","Sirolimus for Massive Polycystic Liver",[88,89],[8068],"Polycystic Kidney Diseases",[8046],{"trials":8071,"activeCount":99},[],{"trials":8073,"activeCount":99},[],{"intervention":8075,"totalTrials":95,"cells":8076},"Oxycodone, 1.00 mg dose",{"EARLY_PHASE1":8077,"PHASE1":8079,"PHASE2":8081,"PHASE3":8083,"PHASE4":8101,"NA":8103},{"trials":8078,"activeCount":99},[],{"trials":8080,"activeCount":99},[],{"trials":8082,"activeCount":99},[],{"trials":8084,"activeCount":99},[8085,8095],{"nctId":8086,"briefTitle":8087,"status":154,"phases":8088,"primaryCompletion":8089,"completion":8089,"start":3649,"enrollment":8090,"conditions":8091,"interventions":8092},"NCT02732262","Optimal Dose of i.v Oxycodone for Postoperative Pain",[89],"2018-07",134,[2025],[8075,8093,8094],"Oxycodone, 0.03 mg\u002Fkg dose","Oxycodone, 0.02 mg\u002Fkg dose",{"nctId":8096,"briefTitle":8097,"status":658,"phases":8098,"primaryCompletion":2251,"completion":168,"start":2443,"enrollment":99,"conditions":8099,"interventions":8100},"NCT02240602","Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery",[89],[2025],[8075,8093,8094],{"trials":8102,"activeCount":99},[],{"trials":8104,"activeCount":99},[],{"intervention":8093,"totalTrials":95,"cells":8106},{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8111,"PHASE3":8113,"PHASE4":8123,"NA":8125},{"trials":8108,"activeCount":99},[],{"trials":8110,"activeCount":99},[],{"trials":8112,"activeCount":99},[],{"trials":8114,"activeCount":99},[8115,8119],{"nctId":8086,"briefTitle":8087,"status":154,"phases":8116,"primaryCompletion":8089,"completion":8089,"start":3649,"enrollment":8090,"conditions":8117,"interventions":8118},[89],[2025],[8075,8093,8094],{"nctId":8096,"briefTitle":8097,"status":658,"phases":8120,"primaryCompletion":2251,"completion":168,"start":2443,"enrollment":99,"conditions":8121,"interventions":8122},[89],[2025],[8075,8093,8094],{"trials":8124,"activeCount":99},[],{"trials":8126,"activeCount":99},[],{"intervention":8094,"totalTrials":95,"cells":8128},{"EARLY_PHASE1":8129,"PHASE1":8131,"PHASE2":8133,"PHASE3":8135,"PHASE4":8145,"NA":8147},{"trials":8130,"activeCount":99},[],{"trials":8132,"activeCount":99},[],{"trials":8134,"activeCount":99},[],{"trials":8136,"activeCount":99},[8137,8141],{"nctId":8086,"briefTitle":8087,"status":154,"phases":8138,"primaryCompletion":8089,"completion":8089,"start":3649,"enrollment":8090,"conditions":8139,"interventions":8140},[89],[2025],[8075,8093,8094],{"nctId":8096,"briefTitle":8097,"status":658,"phases":8142,"primaryCompletion":2251,"completion":168,"start":2443,"enrollment":99,"conditions":8143,"interventions":8144},[89],[2025],[8075,8093,8094],{"trials":8146,"activeCount":99},[],{"trials":8148,"activeCount":99},[],{"intervention":8150,"totalTrials":95,"cells":8151},"Standard treatment",{"EARLY_PHASE1":8152,"PHASE1":8154,"PHASE2":8156,"PHASE3":8158,"PHASE4":8176,"NA":8178},{"trials":8153,"activeCount":99},[],{"trials":8155,"activeCount":99},[],{"trials":8157,"activeCount":99},[],{"trials":8159,"activeCount":99},[8160,8168],{"nctId":8161,"briefTitle":8162,"status":154,"phases":8163,"primaryCompletion":1979,"completion":1979,"start":1957,"enrollment":1743,"conditions":8164,"interventions":8166},"NCT01959074","The Effect of Naftopidil for the Double-J Stent Discomfort",[89],[8165],"Disorder of Urinary Stent",[8167,8150],"Naftopidil",{"nctId":8169,"briefTitle":8170,"status":154,"phases":8171,"primaryCompletion":1967,"completion":1967,"start":1957,"enrollment":1420,"conditions":8172,"interventions":8174},"NCT01952314","Medical Expulsive Therapy for Ureter Stone Using Naftopidil",[89],[8173],"Ureter Stones",[8175,8150],"Naftopidil 75mg",{"trials":8177,"activeCount":99},[],{"trials":8179,"activeCount":99},[],{"intervention":8181,"totalTrials":121,"cells":8182},"lipoprostaglandin E1",{"EARLY_PHASE1":8183,"PHASE1":8185,"PHASE2":8187,"PHASE3":8189,"PHASE4":8200,"NA":8202},{"trials":8184,"activeCount":99},[],{"trials":8186,"activeCount":99},[],{"trials":8188,"activeCount":99},[],{"trials":8190,"activeCount":99},[8191],{"nctId":8192,"briefTitle":8193,"status":166,"phases":8194,"primaryCompletion":3690,"completion":8195,"start":1771,"enrollment":850,"conditions":8196,"interventions":8199},"NCT02338440","Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT",[88,89],"2021-12",[8197,8198],"Veno-occlusive Disease","Child",[8181],{"trials":8201,"activeCount":99},[],{"trials":8203,"activeCount":99},[],{"intervention":8205,"totalTrials":121,"cells":8206},"MTX-hold",{"EARLY_PHASE1":8207,"PHASE1":8209,"PHASE2":8211,"PHASE3":8213,"PHASE4":8227,"NA":8229},{"trials":8208,"activeCount":99},[],{"trials":8210,"activeCount":99},[],{"trials":8212,"activeCount":99},[],{"trials":8214,"activeCount":99},[8215],{"nctId":8216,"briefTitle":8217,"status":154,"phases":8218,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":8221,"conditions":8222,"interventions":8226},"NCT05069714","One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.",[89],"2022-09-30","2021-10-01",184,[3315,8223,8224,8225],"Autoimmune Diseases","Influenza","Vaccine Reaction",[8205],{"trials":8228,"activeCount":99},[],{"trials":8230,"activeCount":99},[],{"intervention":8232,"totalTrials":121,"cells":8233},"vinorelbine plus cisplatin",{"EARLY_PHASE1":8234,"PHASE1":8236,"PHASE2":8238,"PHASE3":8240,"PHASE4":8250,"NA":8252},{"trials":8235,"activeCount":99},[],{"trials":8237,"activeCount":99},[],{"trials":8239,"activeCount":99},[],{"trials":8241,"activeCount":99},[8242],{"nctId":8243,"briefTitle":8244,"status":166,"phases":8245,"primaryCompletion":1966,"completion":765,"start":2294,"enrollment":8246,"conditions":8247,"interventions":8249},"NCT02281708","Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma",[89],1012,[8248],"Stage Ib Lung Carcinoma",[8232],{"trials":8251,"activeCount":99},[],{"trials":8253,"activeCount":99},[],{"intervention":7880,"totalTrials":121,"cells":8255},{"EARLY_PHASE1":8256,"PHASE1":8258,"PHASE2":8260,"PHASE3":8262,"PHASE4":8268,"NA":8270},{"trials":8257,"activeCount":99},[],{"trials":8259,"activeCount":99},[],{"trials":8261,"activeCount":99},[],{"trials":8263,"activeCount":99},[8264],{"nctId":7874,"briefTitle":7875,"status":154,"phases":8265,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":8266,"interventions":8267},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":8269,"activeCount":99},[],{"trials":8271,"activeCount":99},[],{"intervention":7881,"totalTrials":121,"cells":8273},{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8278,"PHASE3":8280,"PHASE4":8286,"NA":8288},{"trials":8275,"activeCount":99},[],{"trials":8277,"activeCount":99},[],{"trials":8279,"activeCount":99},[],{"trials":8281,"activeCount":99},[8282],{"nctId":7874,"briefTitle":7875,"status":154,"phases":8283,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":8284,"interventions":8285},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":8287,"activeCount":99},[],{"trials":8289,"activeCount":99},[],{"intervention":7882,"totalTrials":121,"cells":8291},{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8296,"PHASE3":8298,"PHASE4":8304,"NA":8306},{"trials":8293,"activeCount":99},[],{"trials":8295,"activeCount":99},[],{"trials":8297,"activeCount":99},[],{"trials":8299,"activeCount":99},[8300],{"nctId":7874,"briefTitle":7875,"status":154,"phases":8301,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":8302,"interventions":8303},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":8305,"activeCount":99},[],{"trials":8307,"activeCount":99},[],{"intervention":7883,"totalTrials":121,"cells":8309},{"EARLY_PHASE1":8310,"PHASE1":8312,"PHASE2":8314,"PHASE3":8316,"PHASE4":8322,"NA":8324},{"trials":8311,"activeCount":99},[],{"trials":8313,"activeCount":99},[],{"trials":8315,"activeCount":99},[],{"trials":8317,"activeCount":99},[8318],{"nctId":7874,"briefTitle":7875,"status":154,"phases":8319,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":8320,"interventions":8321},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":8323,"activeCount":99},[],{"trials":8325,"activeCount":99},[],{"intervention":7884,"totalTrials":121,"cells":8327},{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8332,"PHASE3":8334,"PHASE4":8340,"NA":8342},{"trials":8329,"activeCount":99},[],{"trials":8331,"activeCount":99},[],{"trials":8333,"activeCount":99},[],{"trials":8335,"activeCount":99},[8336],{"nctId":7874,"briefTitle":7875,"status":154,"phases":8337,"primaryCompletion":7877,"completion":7877,"start":3510,"enrollment":3754,"conditions":8338,"interventions":8339},[89],[5295],[7880,7881,7882,7883,3164,7884,7846],{"trials":8341,"activeCount":99},[],{"trials":8343,"activeCount":99},[],{"intervention":8345,"totalTrials":121,"cells":8346},"Rabeprazole 20mg bid",{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8351,"PHASE3":8353,"PHASE4":8365,"NA":8367},{"trials":8348,"activeCount":99},[],{"trials":8350,"activeCount":99},[],{"trials":8352,"activeCount":99},[],{"trials":8354,"activeCount":99},[8355],{"nctId":8356,"briefTitle":8357,"status":154,"phases":8358,"primaryCompletion":8359,"completion":8359,"start":8360,"enrollment":550,"conditions":8361,"interventions":8363},"NCT04001400","Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.",[89],"2014-05-21","2012-10-10",[8362],"Esophageal Disease",[8345,8364],"Rabeprazole 20mg qd",{"trials":8366,"activeCount":99},[],{"trials":8368,"activeCount":99},[],{"intervention":8364,"totalTrials":121,"cells":8370},{"EARLY_PHASE1":8371,"PHASE1":8373,"PHASE2":8375,"PHASE3":8377,"PHASE4":8383,"NA":8385},{"trials":8372,"activeCount":99},[],{"trials":8374,"activeCount":99},[],{"trials":8376,"activeCount":99},[],{"trials":8378,"activeCount":99},[8379],{"nctId":8356,"briefTitle":8357,"status":154,"phases":8380,"primaryCompletion":8359,"completion":8359,"start":8360,"enrollment":550,"conditions":8381,"interventions":8382},[89],[8362],[8345,8364],{"trials":8384,"activeCount":99},[],{"trials":8386,"activeCount":99},[],{"intervention":8388,"totalTrials":121,"cells":8389},"Ropivacaine with epinephrine",{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8394,"PHASE3":8396,"PHASE4":8406,"NA":8408},{"trials":8391,"activeCount":99},[],{"trials":8393,"activeCount":99},[],{"trials":8395,"activeCount":99},[],{"trials":8397,"activeCount":99},[8398],{"nctId":8399,"briefTitle":8400,"status":154,"phases":8401,"primaryCompletion":2161,"completion":179,"start":1957,"enrollment":2512,"conditions":8402,"interventions":8405},"NCT02112370","Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy",[89],[8403,8404],"Thyroid Neoplasm","Goiter",[8388],{"trials":8407,"activeCount":99},[],{"trials":8409,"activeCount":99},[],{"intervention":2096,"totalTrials":121,"cells":8411},{"EARLY_PHASE1":8412,"PHASE1":8414,"PHASE2":8416,"PHASE3":8418,"PHASE4":8424,"NA":8426},{"trials":8413,"activeCount":99},[],{"trials":8415,"activeCount":99},[],{"trials":8417,"activeCount":99},[],{"trials":8419,"activeCount":99},[8420],{"nctId":2087,"briefTitle":2088,"status":154,"phases":8421,"primaryCompletion":1863,"completion":2090,"start":2091,"enrollment":2092,"conditions":8422,"interventions":8423},[88,89],[2094],[2096,270],{"trials":8425,"activeCount":99},[],{"trials":8427,"activeCount":99},[],{"intervention":8429,"totalTrials":121,"cells":8430},"Cyclosporine",{"EARLY_PHASE1":8431,"PHASE1":8433,"PHASE2":8435,"PHASE3":8437,"PHASE4":8448,"NA":8450},{"trials":8432,"activeCount":99},[],{"trials":8434,"activeCount":99},[],{"trials":8436,"activeCount":99},[],{"trials":8438,"activeCount":99},[8439],{"nctId":8440,"briefTitle":8441,"status":154,"phases":8442,"primaryCompletion":8443,"completion":8443,"start":1844,"enrollment":1048,"conditions":8444,"interventions":8446},"NCT01788501","Tacrolimus\u002FMethotrexate Versus Cyclosporine\u002FMethotrexate for Prophylaxis of Graft Versus Host Disease",[88,89],"2017-03-01",[8445],"Graft vs Host Disease",[8447,8429,5228],"Tacrolimus",{"trials":8449,"activeCount":99},[],{"trials":8451,"activeCount":99},[],{"intervention":8453,"totalTrials":121,"cells":8454},"MTX",{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8459,"PHASE3":8461,"PHASE4":8471,"NA":8473},{"trials":8456,"activeCount":99},[],{"trials":8458,"activeCount":99},[],{"trials":8460,"activeCount":99},[],{"trials":8462,"activeCount":99},[8463],{"nctId":8464,"briefTitle":8465,"status":166,"phases":8466,"primaryCompletion":8467,"completion":8467,"start":8468,"enrollment":170,"conditions":8469,"interventions":8470},"NCT05313061","MTX Hold During Covid-19 Booster",[89],"2022-12-30","2021-12-29",[3315],[8453],{"trials":8472,"activeCount":99},[],{"trials":8474,"activeCount":99},[],{"intervention":8476,"totalTrials":121,"cells":8477},"Lenalidomide 25mg",{"EARLY_PHASE1":8478,"PHASE1":8480,"PHASE2":8482,"PHASE3":8484,"PHASE4":8495,"NA":8497},{"trials":8479,"activeCount":99},[],{"trials":8481,"activeCount":99},[],{"trials":8483,"activeCount":99},[],{"trials":8485,"activeCount":99},[8486],{"nctId":8487,"briefTitle":8488,"status":154,"phases":8489,"primaryCompletion":8490,"completion":8490,"start":8491,"enrollment":95,"conditions":8492,"interventions":8494},"NCT04298372","Frontline Lenalidomide for AL Amyloidosis Involving Myocardium",[89],"2021-11-25","2019-02-20",[8493],"Amyloidosis Cardiac",[8476],{"trials":8496,"activeCount":99},[],{"trials":8498,"activeCount":99},[],{"intervention":8500,"totalTrials":121,"cells":8501},"Early intravenous tranexamic acid administration",{"EARLY_PHASE1":8502,"PHASE1":8504,"PHASE2":8506,"PHASE3":8508,"PHASE4":8518,"NA":8520},{"trials":8503,"activeCount":99},[],{"trials":8505,"activeCount":99},[],{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[8510],{"nctId":8511,"briefTitle":8512,"status":166,"phases":8513,"primaryCompletion":2443,"completion":1967,"start":549,"enrollment":8514,"conditions":8515,"interventions":8517},"NCT01713101","Tranexamic Acid for Upper Gastrointestinal Bleeding",[89],414,[8516],"Acute Upper Gastrointestinal Hemorrhage",[8500],{"trials":8519,"activeCount":99},[],{"trials":8521,"activeCount":99},[],{"intervention":8523,"totalTrials":121,"cells":8524},"Shinbaro",{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8529,"PHASE3":8531,"PHASE4":8540,"NA":8542},{"trials":8526,"activeCount":99},[],{"trials":8528,"activeCount":99},[],{"trials":8530,"activeCount":99},[],{"trials":8532,"activeCount":99},[8533],{"nctId":8534,"briefTitle":8535,"status":154,"phases":8536,"primaryCompletion":701,"completion":701,"start":548,"enrollment":5319,"conditions":8537,"interventions":8539},"NCT01910116","Efficacy of Shinabro in Hand Osteoarthritis",[88,89],[8538],"Hand Osteoarthritis",[8523],{"trials":8541,"activeCount":99},[],{"trials":8543,"activeCount":99},[],{"intervention":8545,"totalTrials":121,"cells":8546},"Rifaximin",{"EARLY_PHASE1":8547,"PHASE1":8549,"PHASE2":8551,"PHASE3":8553,"PHASE4":8563,"NA":8565},{"trials":8548,"activeCount":99},[],{"trials":8550,"activeCount":99},[],{"trials":8552,"activeCount":99},[],{"trials":8554,"activeCount":99},[8555],{"nctId":8556,"briefTitle":8557,"status":658,"phases":8558,"primaryCompletion":821,"completion":821,"start":732,"enrollment":99,"conditions":8559,"interventions":8561},"NCT02011841","Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients",[89],[8560],"Spontaneous Bacterial Peritonitis",[8545,8562],"Ciprofloxacin",{"trials":8564,"activeCount":99},[],{"trials":8566,"activeCount":99},[],{"intervention":8562,"totalTrials":121,"cells":8568},{"EARLY_PHASE1":8569,"PHASE1":8571,"PHASE2":8573,"PHASE3":8575,"PHASE4":8581,"NA":8583},{"trials":8570,"activeCount":99},[],{"trials":8572,"activeCount":99},[],{"trials":8574,"activeCount":99},[],{"trials":8576,"activeCount":99},[8577],{"nctId":8556,"briefTitle":8557,"status":658,"phases":8578,"primaryCompletion":821,"completion":821,"start":732,"enrollment":99,"conditions":8579,"interventions":8580},[89],[8560],[8545,8562],{"trials":8582,"activeCount":99},[],{"trials":8584,"activeCount":99},[],{"intervention":8586,"totalTrials":121,"cells":8587},"Intravenous methylene blue administration",{"EARLY_PHASE1":8588,"PHASE1":8590,"PHASE2":8592,"PHASE3":8594,"PHASE4":8605,"NA":8607},{"trials":8589,"activeCount":99},[],{"trials":8591,"activeCount":99},[],{"trials":8593,"activeCount":99},[],{"trials":8595,"activeCount":99},[8596],{"nctId":8597,"briefTitle":8598,"status":166,"phases":8599,"primaryCompletion":791,"completion":2171,"start":1815,"enrollment":8600,"conditions":8601,"interventions":8604},"NCT01797978","Methylene Blue in Severe Sepsis and Septic Shock",[89],354,[8602,8603],"Severe Sepsis","Septic Shock",[8586],{"trials":8606,"activeCount":99},[],{"trials":8608,"activeCount":99},[],{"intervention":8610,"totalTrials":121,"cells":8611},"Neoadjuvant chemoradiation",{"EARLY_PHASE1":8612,"PHASE1":8614,"PHASE2":8616,"PHASE3":8618,"PHASE4":8626,"NA":8628},{"trials":8613,"activeCount":99},[],{"trials":8615,"activeCount":99},[],{"trials":8617,"activeCount":99},[],{"trials":8619,"activeCount":99},[8620],{"nctId":8621,"briefTitle":8622,"status":154,"phases":8623,"primaryCompletion":3753,"completion":3753,"start":1844,"enrollment":265,"conditions":8624,"interventions":8625},"NCT01458717","Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer",[88,89],[35],[8610],{"trials":8627,"activeCount":99},[],{"trials":8629,"activeCount":99},[],{"intervention":8631,"totalTrials":121,"cells":8632},"G-CSF with\u002Fwithout darbepoetin, peripheral blood stem cell",{"EARLY_PHASE1":8633,"PHASE1":8635,"PHASE2":8637,"PHASE3":8639,"PHASE4":8647,"NA":8649},{"trials":8634,"activeCount":99},[],{"trials":8636,"activeCount":99},[],{"trials":8638,"activeCount":99},[],{"trials":8640,"activeCount":99},[8641],{"nctId":8642,"briefTitle":8643,"status":166,"phases":8644,"completion":2523,"start":4748,"enrollment":2349,"conditions":8645,"interventions":8646},"NCT00501917","MAGIC Cell-5-Combicytokine Trial",[88,89],[438],[8631],{"trials":8648,"activeCount":99},[],{"trials":8650,"activeCount":99},[],{"intervention":8652,"totalTrials":121,"cells":8653},"heparinized saline priming group",{"EARLY_PHASE1":8654,"PHASE1":8656,"PHASE2":8658,"PHASE3":8660,"PHASE4":8669,"NA":8671},{"trials":8655,"activeCount":99},[],{"trials":8657,"activeCount":99},[],{"trials":8659,"activeCount":99},[],{"trials":8661,"activeCount":99},[8662],{"nctId":8663,"briefTitle":8664,"status":166,"phases":8665,"primaryCompletion":2551,"completion":2551,"start":2419,"enrollment":319,"conditions":8666,"interventions":8667},"NCT01486485","Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)",[89],[133],[8652,8668],"nafamostat infusion after heparinized saline priming",{"trials":8670,"activeCount":99},[],{"trials":8672,"activeCount":99},[],{"intervention":8668,"totalTrials":121,"cells":8674},{"EARLY_PHASE1":8675,"PHASE1":8677,"PHASE2":8679,"PHASE3":8681,"PHASE4":8687,"NA":8689},{"trials":8676,"activeCount":99},[],{"trials":8678,"activeCount":99},[],{"trials":8680,"activeCount":99},[],{"trials":8682,"activeCount":99},[8683],{"nctId":8663,"briefTitle":8664,"status":166,"phases":8684,"primaryCompletion":2551,"completion":2551,"start":2419,"enrollment":319,"conditions":8685,"interventions":8686},[89],[133],[8652,8668],{"trials":8688,"activeCount":99},[],{"trials":8690,"activeCount":99},[],{"intervention":8692,"totalTrials":121,"cells":8693},"Surgiguard",{"EARLY_PHASE1":8694,"PHASE1":8696,"PHASE2":8698,"PHASE3":8700,"PHASE4":8711,"NA":8713},{"trials":8695,"activeCount":99},[],{"trials":8697,"activeCount":99},[],{"trials":8699,"activeCount":99},[],{"trials":8701,"activeCount":99},[8702],{"nctId":8703,"briefTitle":8704,"status":154,"phases":8705,"primaryCompletion":8706,"completion":8706,"start":8707,"enrollment":1946,"conditions":8708,"interventions":8710},"NCT03374397","PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy",[89],"2019-08-31","2017-12-06",[8709],"Ovarian Cyst Benign",[8692],{"trials":8712,"activeCount":99},[],{"trials":8714,"activeCount":99},[],{"intervention":554,"totalTrials":121,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8721,"PHASE3":8723,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":99},[],{"trials":8720,"activeCount":99},[],{"trials":8722,"activeCount":99},[],{"trials":8724,"activeCount":99},[8725],{"nctId":545,"briefTitle":546,"status":154,"phases":8726,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":8727,"interventions":8728},[88,89],[552],[554,258],{"trials":8730,"activeCount":99},[],{"trials":8732,"activeCount":99},[],{"intervention":8734,"totalTrials":121,"cells":8735},"Shingrix",{"EARLY_PHASE1":8736,"PHASE1":8738,"PHASE2":8740,"PHASE3":8742,"PHASE4":8755,"NA":8757},{"trials":8737,"activeCount":99},[],{"trials":8739,"activeCount":99},[],{"trials":8741,"activeCount":99},[],{"trials":8743,"activeCount":99},[8744],{"nctId":8745,"briefTitle":8746,"status":166,"phases":8747,"primaryCompletion":8748,"completion":8748,"start":8749,"enrollment":8750,"conditions":8751,"interventions":8754},"NCT06001606","Immunogenicity, Reactogenicity of Shingrix in SLE",[89],"2025-04-24","2023-05-08",63,[8752,8753,8225],"Zoster","Systemic Lupus Erythematosus",[8734],{"trials":8756,"activeCount":99},[],{"trials":8758,"activeCount":99},[],{"intervention":8760,"totalTrials":121,"cells":8761},"Leuplin or zoladex",{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8768,"PHASE4":8779,"NA":8781},{"trials":8763,"activeCount":99},[],{"trials":8765,"activeCount":99},[],{"trials":8767,"activeCount":99},[],{"trials":8769,"activeCount":99},[8770],{"nctId":8771,"briefTitle":8772,"status":166,"phases":8773,"primaryCompletion":8774,"completion":75,"start":8775,"enrollment":2455,"conditions":8776,"interventions":8778},"NCT03664895","Density Lowering Effect of \"OFS Add on to TMX\"(DELFINO Trial)",[89],"2024-12-02","2018-09-03",[8777],"Breast Cancer Invasive",[8760],{"trials":8780,"activeCount":99},[],{"trials":8782,"activeCount":99},[],{"intervention":8040,"totalTrials":121,"cells":8784},{"EARLY_PHASE1":8785,"PHASE1":8787,"PHASE2":8789,"PHASE3":8791,"PHASE4":8797,"NA":8799},{"trials":8786,"activeCount":99},[],{"trials":8788,"activeCount":99},[],{"trials":8790,"activeCount":99},[],{"trials":8792,"activeCount":99},[8793],{"nctId":8032,"briefTitle":8033,"status":154,"phases":8794,"primaryCompletion":8035,"completion":8035,"start":8036,"enrollment":2349,"conditions":8795,"interventions":8796},[89],[8038],[8040,8010],{"trials":8798,"activeCount":99},[],{"trials":8800,"activeCount":99},[],{"intervention":8802,"totalTrials":121,"cells":8803},"Hydroxychloroquine",{"EARLY_PHASE1":8804,"PHASE1":8806,"PHASE2":8808,"PHASE3":8810,"PHASE4":8820,"NA":8822},{"trials":8805,"activeCount":99},[],{"trials":8807,"activeCount":99},[],{"trials":8809,"activeCount":99},[],{"trials":8811,"activeCount":99},[8812],{"nctId":8813,"briefTitle":8814,"status":154,"phases":8815,"primaryCompletion":2551,"completion":2551,"start":7724,"enrollment":19,"conditions":8816,"interventions":8819},"NCT01601028","Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome",[89],[8223,8817,8818],"Sjogren's Syndrome","Dry Eye",[8802],{"trials":8821,"activeCount":99},[],{"trials":8823,"activeCount":99},[],{"intervention":3735,"totalTrials":121,"cells":8825},{"EARLY_PHASE1":8826,"PHASE1":8828,"PHASE2":8830,"PHASE3":8832,"PHASE4":8838,"NA":8840},{"trials":8827,"activeCount":99},[],{"trials":8829,"activeCount":99},[],{"trials":8831,"activeCount":99},[],{"trials":8833,"activeCount":99},[8834],{"nctId":3728,"briefTitle":3729,"status":154,"phases":8835,"primaryCompletion":2172,"completion":2172,"start":1854,"enrollment":1583,"conditions":8836,"interventions":8837},[89],[3732,3733],[3717,3735],{"trials":8839,"activeCount":99},[],{"trials":8841,"activeCount":99},[],{"intervention":8843,"totalTrials":121,"cells":8844},"clino-san vaginal lubricant",{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8849,"PHASE3":8851,"PHASE4":8863,"NA":8865},{"trials":8846,"activeCount":99},[],{"trials":8848,"activeCount":99},[],{"trials":8850,"activeCount":99},[],{"trials":8852,"activeCount":99},[8853],{"nctId":8854,"briefTitle":8855,"status":154,"phases":8856,"primaryCompletion":7381,"completion":8857,"start":8858,"enrollment":8859,"conditions":8860,"interventions":8862},"NCT00607295","Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients",[89],"2009-02","2007-12",98,[24,8861],"Vaginal Atrophy",[8843],{"trials":8864,"activeCount":99},[],{"trials":8866,"activeCount":99},[],{"intervention":8868,"totalTrials":121,"cells":8869},"Lactate-containing vaginal lubricant",{"EARLY_PHASE1":8870,"PHASE1":8872,"PHASE2":8874,"PHASE3":8876,"PHASE4":8887,"NA":8889},{"trials":8871,"activeCount":99},[],{"trials":8873,"activeCount":99},[],{"trials":8875,"activeCount":99},[],{"trials":8877,"activeCount":99},[8878],{"nctId":8879,"briefTitle":8880,"status":154,"phases":8881,"primaryCompletion":2443,"completion":2443,"start":2499,"enrollment":8882,"conditions":8883,"interventions":8886},"NCT00981305","Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors",[89],136,[8884,8885],"Sexual Dysfunction","Breast Cancer Survivors",[8868],{"trials":8888,"activeCount":99},[],{"trials":8890,"activeCount":99},[],{"intervention":8892,"totalTrials":121,"cells":8893},"CJ Plasma Solution A",{"EARLY_PHASE1":8894,"PHASE1":8896,"PHASE2":8898,"PHASE3":8900,"PHASE4":8914,"NA":8916},{"trials":8895,"activeCount":99},[],{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[8902],{"nctId":8903,"briefTitle":8904,"status":154,"phases":8905,"primaryCompletion":8906,"completion":8907,"start":538,"enrollment":8908,"conditions":8909,"interventions":8912},"NCT02799368","Balanced Salt Solution Versus 0.9% Saline Infusion for Prevention of Contrast-induced Acute Kidney Injury (BASIC Trial)",[89],"2019-05","2020-03",493,[133,8910,8911],"Renal Insufficiency, Chronic","Contrast Media Reaction",[8892,8913],"CJ 0.9% Normal Saline",{"trials":8915,"activeCount":99},[],{"trials":8917,"activeCount":99},[],{"intervention":8913,"totalTrials":121,"cells":8919},{"EARLY_PHASE1":8920,"PHASE1":8922,"PHASE2":8924,"PHASE3":8926,"PHASE4":8932,"NA":8934},{"trials":8921,"activeCount":99},[],{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[],{"trials":8927,"activeCount":99},[8928],{"nctId":8903,"briefTitle":8904,"status":154,"phases":8929,"primaryCompletion":8906,"completion":8907,"start":538,"enrollment":8908,"conditions":8930,"interventions":8931},[89],[133,8910,8911],[8892,8913],{"trials":8933,"activeCount":99},[],{"trials":8935,"activeCount":99},[],{"intervention":2120,"totalTrials":121,"cells":8937},{"EARLY_PHASE1":8938,"PHASE1":8940,"PHASE2":8942,"PHASE3":8944,"PHASE4":8950,"NA":8952},{"trials":8939,"activeCount":99},[],{"trials":8941,"activeCount":99},[],{"trials":8943,"activeCount":99},[],{"trials":8945,"activeCount":99},[8946],{"nctId":2107,"briefTitle":2108,"status":166,"phases":8947,"primaryCompletion":2110,"completion":75,"start":2111,"enrollment":2112,"conditions":8948,"interventions":8949},[89],[2114,2115,2116,2117,2118],[2120,270,2121],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"intervention":8955,"totalTrials":121,"cells":8956},"Two cycles of neoadjuvant chemotherapy",{"EARLY_PHASE1":8957,"PHASE1":8959,"PHASE2":8961,"PHASE3":8963,"PHASE4":8975,"NA":8977},{"trials":8958,"activeCount":99},[],{"trials":8960,"activeCount":99},[],{"trials":8962,"activeCount":99},[],{"trials":8964,"activeCount":99},[8965],{"nctId":8966,"briefTitle":8967,"status":166,"phases":8968,"primaryCompletion":1863,"completion":1863,"start":8969,"enrollment":8970,"conditions":8971,"interventions":8974},"NCT03693248","Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer",[89],"2018-12-19",298,[8972,6120,2117,8973],"Ovarian Cancer Stage IIIC","Peritoneal Cancer",[8955],{"trials":8976,"activeCount":99},[],{"trials":8978,"activeCount":99},[],{"intervention":8980,"totalTrials":121,"cells":8981},"prostaglandin I2 analogue",{"EARLY_PHASE1":8982,"PHASE1":8984,"PHASE2":8986,"PHASE3":8988,"PHASE4":8997,"NA":8999},{"trials":8983,"activeCount":99},[],{"trials":8985,"activeCount":99},[],{"trials":8987,"activeCount":99},[],{"trials":8989,"activeCount":99},[8990],{"nctId":8991,"briefTitle":8992,"status":154,"phases":8993,"primaryCompletion":264,"completion":2444,"start":7013,"enrollment":170,"conditions":8994,"interventions":8996},"NCT01056835","Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy",[89],[8995],"Chronic Allograft Nephropathy",[8980],{"trials":8998,"activeCount":99},[],{"trials":9000,"activeCount":99},[],{"intervention":9002,"totalTrials":121,"cells":9003},"levofloxacin, moxifloxacin",{"EARLY_PHASE1":9004,"PHASE1":9006,"PHASE2":9008,"PHASE3":9010,"PHASE4":9020,"NA":9022},{"trials":9005,"activeCount":99},[],{"trials":9007,"activeCount":99},[],{"trials":9009,"activeCount":99},[],{"trials":9011,"activeCount":99},[9012],{"nctId":9013,"briefTitle":9014,"status":1813,"phases":9015,"primaryCompletion":2267,"completion":549,"start":2150,"enrollment":9016,"conditions":9017,"interventions":9019},"NCT01055145","Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients",[89],182,[9018],"TB",[9002],{"trials":9021,"activeCount":99},[],{"trials":9023,"activeCount":99},[],{"intervention":9025,"totalTrials":121,"cells":9026},"tranexamic acid, placebo",{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9031,"PHASE3":9033,"PHASE4":9042,"NA":9044},{"trials":9028,"activeCount":99},[],{"trials":9030,"activeCount":99},[],{"trials":9032,"activeCount":99},[],{"trials":9034,"activeCount":99},[9035],{"nctId":9036,"briefTitle":9037,"status":658,"phases":9038,"primaryCompletion":3555,"completion":264,"start":7724,"enrollment":99,"conditions":9039,"interventions":9041},"NCT01167764","Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis",[89],[9040],"Hemoptysis",[9025],{"trials":9043,"activeCount":99},[],{"trials":9045,"activeCount":99},[],{"intervention":2516,"totalTrials":121,"cells":9047},{"EARLY_PHASE1":9048,"PHASE1":9050,"PHASE2":9052,"PHASE3":9054,"PHASE4":9060,"NA":9062},{"trials":9049,"activeCount":99},[],{"trials":9051,"activeCount":99},[],{"trials":9053,"activeCount":99},[],{"trials":9055,"activeCount":99},[9056],{"nctId":2507,"briefTitle":2508,"status":166,"phases":9057,"primaryCompletion":2510,"completion":318,"start":2511,"enrollment":2512,"conditions":9058,"interventions":9059},[88,89],[2514],[2299,2516],{"trials":9061,"activeCount":99},[],{"trials":9063,"activeCount":99},[],{"intervention":9065,"totalTrials":121,"cells":9066},"GnRH antagonist",{"EARLY_PHASE1":9067,"PHASE1":9069,"PHASE2":9071,"PHASE3":9073,"PHASE4":9085,"NA":9087},{"trials":9068,"activeCount":99},[],{"trials":9070,"activeCount":99},[],{"trials":9072,"activeCount":99},[],{"trials":9074,"activeCount":99},[9075],{"nctId":9076,"briefTitle":9077,"status":154,"phases":9078,"primaryCompletion":9079,"completion":9079,"start":2394,"enrollment":1136,"conditions":9080,"interventions":9083},"NCT01402336","GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer",[89],"2016-12-31",[9081,9082],"Infertility","Polycystic Ovary Syndrome",[9065,9084],"Conventional GnRH agonist",{"trials":9086,"activeCount":99},[],{"trials":9088,"activeCount":99},[],{"intervention":9084,"totalTrials":121,"cells":9090},{"EARLY_PHASE1":9091,"PHASE1":9093,"PHASE2":9095,"PHASE3":9097,"PHASE4":9103,"NA":9105},{"trials":9092,"activeCount":99},[],{"trials":9094,"activeCount":99},[],{"trials":9096,"activeCount":99},[],{"trials":9098,"activeCount":99},[9099],{"nctId":9076,"briefTitle":9077,"status":154,"phases":9100,"primaryCompletion":9079,"completion":9079,"start":2394,"enrollment":1136,"conditions":9101,"interventions":9102},[89],[9081,9082],[9065,9084],{"trials":9104,"activeCount":99},[],{"trials":9106,"activeCount":99},[],{"intervention":9108,"totalTrials":121,"cells":9109},"Ginseol Kg1",{"EARLY_PHASE1":9110,"PHASE1":9112,"PHASE2":9114,"PHASE3":9116,"PHASE4":9126,"NA":9128},{"trials":9111,"activeCount":99},[],{"trials":9113,"activeCount":99},[],{"trials":9115,"activeCount":99},[],{"trials":9117,"activeCount":99},[9118],{"nctId":9119,"briefTitle":9120,"status":166,"phases":9121,"primaryCompletion":3554,"completion":742,"start":7680,"enrollment":2232,"conditions":9122,"interventions":9125},"NCT01483430","Effect of Ginseol Kg1 on Blood Pressure Lowering",[89],[9123,9124],"Prehypertension","Hypertension, Stage I",[9108,9108],{"trials":9127,"activeCount":99},[],{"trials":9129,"activeCount":99},[],{"intervention":9131,"totalTrials":121,"cells":9132},"eradication treatment of Helicobacter pylori infection",{"EARLY_PHASE1":9133,"PHASE1":9135,"PHASE2":9137,"PHASE3":9139,"PHASE4":9153,"NA":9155},{"trials":9134,"activeCount":99},[],{"trials":9136,"activeCount":99},[],{"trials":9138,"activeCount":99},[],{"trials":9140,"activeCount":99},[9141],{"nctId":9142,"briefTitle":9143,"status":154,"phases":9144,"primaryCompletion":619,"completion":619,"start":9145,"enrollment":9146,"conditions":9147,"interventions":9152},"NCT01510730","Helicobacter Pylori Eradication After Endoscopic Resection of Gastric Tumors",[89],"2005-01",855,[9148,9149,9150,9151],"Gastric Tumor","Helicobacter Pylori","Endoscopic Resection","Metachronous Neoplasms",[9131],{"trials":9154,"activeCount":99},[],{"trials":9156,"activeCount":99},[],{"intervention":9158,"totalTrials":121,"cells":9159},"treatment : H. pylori eradication",{"EARLY_PHASE1":9160,"PHASE1":9162,"PHASE2":9164,"PHASE3":9166,"PHASE4":9178,"NA":9180},{"trials":9161,"activeCount":99},[],{"trials":9163,"activeCount":99},[],{"trials":9165,"activeCount":99},[],{"trials":9167,"activeCount":99},[9168],{"nctId":9169,"briefTitle":9170,"status":166,"phases":9171,"primaryCompletion":9172,"completion":178,"start":9173,"enrollment":1002,"conditions":9174,"interventions":9177},"NCT03177629","H. Pylori Eradication for Moderate ITP",[89],"2020-06","2017-05-23",[9175,9149,9176],"Immune Thrombocytopenic Purpura","Immune Thrombocytopenia",[9158],{"trials":9179,"activeCount":99},[],{"trials":9181,"activeCount":99},[],{"intervention":9183,"totalTrials":121,"cells":9184},"Limaprost",{"EARLY_PHASE1":9185,"PHASE1":9187,"PHASE2":9189,"PHASE3":9191,"PHASE4":9200,"NA":9202},{"trials":9186,"activeCount":99},[],{"trials":9188,"activeCount":99},[],{"trials":9190,"activeCount":99},[],{"trials":9192,"activeCount":99},[9193],{"nctId":9194,"briefTitle":9195,"status":154,"phases":9196,"primaryCompletion":45,"completion":917,"start":6946,"enrollment":319,"conditions":9197,"interventions":9199},"NCT02125981","The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy",[89],[9198],"Cervical Myelopathy",[9183],{"trials":9201,"activeCount":99},[],{"trials":9203,"activeCount":99},[],{"intervention":9205,"totalTrials":121,"cells":9206},"Mitiglinide",{"EARLY_PHASE1":9207,"PHASE1":9209,"PHASE2":9211,"PHASE3":9213,"PHASE4":9224,"NA":9226},{"trials":9208,"activeCount":99},[],{"trials":9210,"activeCount":99},[],{"trials":9212,"activeCount":99},[],{"trials":9214,"activeCount":99},[9215],{"nctId":9216,"briefTitle":9217,"status":154,"phases":9218,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":7918,"conditions":9222,"interventions":9223},"NCT01037842","Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus",[89],"2008-03","2008-05","2006-08",[7407],[9205],{"trials":9225,"activeCount":99},[],{"trials":9227,"activeCount":99},[],{"intervention":9229,"totalTrials":121,"cells":9230},"Pantoprazole",{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9235,"PHASE3":9237,"PHASE4":9248,"NA":9250},{"trials":9232,"activeCount":99},[],{"trials":9234,"activeCount":99},[],{"trials":9236,"activeCount":99},[],{"trials":9238,"activeCount":99},[9239],{"nctId":9240,"briefTitle":9241,"status":154,"phases":9242,"primaryCompletion":9243,"completion":9243,"start":9244,"enrollment":1444,"conditions":9245,"interventions":9246},"NCT03998969","Efficacy of DA-5204 on Gastroesophageal Reflux Disease",[89],"2018-12-11","2016-06-01",[8362],[9229,9247],"DA-5204",{"trials":9249,"activeCount":99},[],{"trials":9251,"activeCount":99},[],{"intervention":9247,"totalTrials":121,"cells":9253},{"EARLY_PHASE1":9254,"PHASE1":9256,"PHASE2":9258,"PHASE3":9260,"PHASE4":9266,"NA":9268},{"trials":9255,"activeCount":99},[],{"trials":9257,"activeCount":99},[],{"trials":9259,"activeCount":99},[],{"trials":9261,"activeCount":99},[9262],{"nctId":9240,"briefTitle":9241,"status":154,"phases":9263,"primaryCompletion":9243,"completion":9243,"start":9244,"enrollment":1444,"conditions":9264,"interventions":9265},[89],[8362],[9229,9247],{"trials":9267,"activeCount":99},[],{"trials":9269,"activeCount":99},[],{"intervention":8167,"totalTrials":121,"cells":9271},{"EARLY_PHASE1":9272,"PHASE1":9274,"PHASE2":9276,"PHASE3":9278,"PHASE4":9284,"NA":9286},{"trials":9273,"activeCount":99},[],{"trials":9275,"activeCount":99},[],{"trials":9277,"activeCount":99},[],{"trials":9279,"activeCount":99},[9280],{"nctId":8161,"briefTitle":8162,"status":154,"phases":9281,"primaryCompletion":1979,"completion":1979,"start":1957,"enrollment":1743,"conditions":9282,"interventions":9283},[89],[8165],[8167,8150],{"trials":9285,"activeCount":99},[],{"trials":9287,"activeCount":99},[],{"intervention":9289,"totalTrials":121,"cells":9290},"2L Coolprep®",{"EARLY_PHASE1":9291,"PHASE1":9293,"PHASE2":9295,"PHASE3":9297,"PHASE4":9312,"NA":9314},{"trials":9292,"activeCount":99},[],{"trials":9294,"activeCount":99},[],{"trials":9296,"activeCount":99},[],{"trials":9298,"activeCount":99},[9299],{"nctId":9300,"briefTitle":9301,"status":154,"phases":9302,"primaryCompletion":9303,"completion":9304,"start":9305,"enrollment":9306,"conditions":9307,"interventions":9310},"NCT01745835","Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation",[89],"2013-08-31","2014-01-31","2013-01-30",196,[9308,9309],"Healthy Person","Bowel Preparation Before Colonoscopy",[9289,9311],"1L Coolprep® and Bisacodyl",{"trials":9313,"activeCount":99},[],{"trials":9315,"activeCount":99},[],{"intervention":9311,"totalTrials":121,"cells":9317},{"EARLY_PHASE1":9318,"PHASE1":9320,"PHASE2":9322,"PHASE3":9324,"PHASE4":9330,"NA":9332},{"trials":9319,"activeCount":99},[],{"trials":9321,"activeCount":99},[],{"trials":9323,"activeCount":99},[],{"trials":9325,"activeCount":99},[9326],{"nctId":9300,"briefTitle":9301,"status":154,"phases":9327,"primaryCompletion":9303,"completion":9304,"start":9305,"enrollment":9306,"conditions":9328,"interventions":9329},[89],[9308,9309],[9289,9311],{"trials":9331,"activeCount":99},[],{"trials":9333,"activeCount":99},[],{"intervention":8175,"totalTrials":121,"cells":9335},{"EARLY_PHASE1":9336,"PHASE1":9338,"PHASE2":9340,"PHASE3":9342,"PHASE4":9348,"NA":9350},{"trials":9337,"activeCount":99},[],{"trials":9339,"activeCount":99},[],{"trials":9341,"activeCount":99},[],{"trials":9343,"activeCount":99},[9344],{"nctId":8169,"briefTitle":8170,"status":154,"phases":9345,"primaryCompletion":1967,"completion":1967,"start":1957,"enrollment":1420,"conditions":9346,"interventions":9347},[89],[8173],[8175,8150],{"trials":9349,"activeCount":99},[],{"trials":9351,"activeCount":99},[],{"intervention":9353,"totalTrials":121,"cells":9354},"Udenafil or Amlodipine",{"EARLY_PHASE1":9355,"PHASE1":9357,"PHASE2":9359,"PHASE3":9361,"PHASE4":9370,"NA":9372},{"trials":9356,"activeCount":99},[],{"trials":9358,"activeCount":99},[],{"trials":9360,"activeCount":99},[],{"trials":9362,"activeCount":99},[9363],{"nctId":9364,"briefTitle":9365,"status":154,"phases":9366,"primaryCompletion":620,"completion":2394,"start":753,"enrollment":1161,"conditions":9367,"interventions":9369},"NCT01280266","Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon",[88,89],[9368],"Raynaud Phenomenon",[9353],{"trials":9371,"activeCount":99},[],{"trials":9373,"activeCount":99},[],{"intervention":9375,"totalTrials":1036,"cells":9376},"Busulfan",{"EARLY_PHASE1":9377,"PHASE1":9379,"PHASE2":9388,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9378,"activeCount":99},[],{"trials":9380,"activeCount":99},[9381],{"nctId":9382,"briefTitle":9383,"status":154,"phases":9384,"primaryCompletion":1843,"completion":1843,"start":7381,"enrollment":850,"conditions":9385,"interventions":9387},"NCT01018446","Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling",[87],[9386],"Hematopoietic Stem Cell Transplantation",[9375],{"trials":9389,"activeCount":99},[9390,9399,9406,9415],{"nctId":9391,"briefTitle":9392,"status":166,"phases":9393,"primaryCompletion":9394,"completion":9394,"start":9395,"enrollment":1036,"conditions":9396,"interventions":9398},"NCT02034630","Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD",[87,88],"2023-12","2014-07-21",[9397],"Genetic Rare Disease",[9375],{"nctId":9400,"briefTitle":9401,"status":166,"phases":9402,"primaryCompletion":264,"completion":264,"start":753,"enrollment":9403,"conditions":9404,"interventions":9405},"NCT01274195","Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML",[88],27,[9386],[9375],{"nctId":9407,"briefTitle":9408,"status":166,"phases":9409,"primaryCompletion":9394,"completion":9394,"start":9410,"enrollment":9411,"conditions":9412,"interventions":9414},"NCT02047578","Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.",[88],"2014-02-05",38,[9413],"Acute Lymphoblastic Leukemia",[9375],{"nctId":9416,"briefTitle":9417,"status":166,"phases":9418,"primaryCompletion":264,"completion":264,"start":753,"enrollment":1036,"conditions":9419,"interventions":9421},"NCT01338675","Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)",[87,88],[9420],"Chronic Granulomatous Disease",[9375],{"trials":9423,"activeCount":99},[],{"trials":9425,"activeCount":99},[],{"trials":9427,"activeCount":99},[],{"intervention":9429,"totalTrials":599,"cells":9430},"Clarithromycin",{"EARLY_PHASE1":9431,"PHASE1":9433,"PHASE2":9456,"PHASE3":9466,"PHASE4":9468,"NA":9470},{"trials":9432,"activeCount":99},[],{"trials":9434,"activeCount":99},[9435,9445],{"nctId":9436,"briefTitle":9437,"status":154,"phases":9438,"primaryCompletion":9439,"completion":9440,"start":9441,"enrollment":33,"conditions":9442,"interventions":9444},"NCT03366974","Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers",[87],"2018-02-13","2018-12-12","2017-12-28",[9443],"Healthy Volunteers",[735,9429],{"nctId":9446,"briefTitle":9447,"status":154,"phases":9448,"primaryCompletion":9449,"completion":9450,"start":9451,"enrollment":6325,"conditions":9452,"interventions":9453},"NCT02975037","Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors",[87],"2017-03-04","2017-06-23","2017-02-06",[21],[9454,9429,9455],"Sildenafil","Itraconazole",{"trials":9457,"activeCount":99},[9458],{"nctId":9459,"briefTitle":9460,"status":1813,"phases":9461,"primaryCompletion":3612,"completion":3612,"start":1815,"enrollment":525,"conditions":9462,"interventions":9465},"NCT01851954","Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)",[88],[9463,9464],"Very Low Birth Weight Infant","Ureaplasma\u002FMycoplasma Positive",[9429],{"trials":9467,"activeCount":99},[],{"trials":9469,"activeCount":99},[],{"trials":9471,"activeCount":99},[],{"intervention":9473,"totalTrials":599,"cells":9474},"RAD001",{"EARLY_PHASE1":9475,"PHASE1":9477,"PHASE2":9479,"PHASE3":9504,"PHASE4":9506,"NA":9508},{"trials":9476,"activeCount":99},[],{"trials":9478,"activeCount":99},[],{"trials":9480,"activeCount":99},[9481,9487,9496],{"nctId":9482,"briefTitle":9483,"status":154,"phases":9484,"primaryCompletion":3671,"completion":742,"start":6181,"enrollment":2532,"conditions":9485,"interventions":9486},"NCT00830895","RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)",[88],[1675],[9473],{"nctId":9488,"briefTitle":9489,"status":154,"phases":9490,"primaryCompletion":620,"completion":742,"start":9491,"enrollment":9492,"conditions":9493,"interventions":9495},"NCT01152840","Study of RAD001 in Adenoid Cystic Carcinoma",[88],"2008-07",33,[9494],"Adenoid Cystic Carcinoma",[9473],{"nctId":9497,"briefTitle":9498,"status":154,"phases":9499,"primaryCompletion":620,"completion":752,"start":9491,"enrollment":9492,"conditions":9500,"interventions":9503},"NCT01152827","RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid",[88],[413,9501,9502],"Extra-adrenal Paraganglioma","Non-functioning Carcinoid",[9473],{"trials":9505,"activeCount":99},[],{"trials":9507,"activeCount":99},[],{"trials":9509,"activeCount":99},[],{"intervention":9511,"totalTrials":599,"cells":9512},"Docetaxel",{"EARLY_PHASE1":9513,"PHASE1":9515,"PHASE2":9517,"PHASE3":9544,"PHASE4":9546,"NA":9548},{"trials":9514,"activeCount":99},[],{"trials":9516,"activeCount":99},[],{"trials":9518,"activeCount":99},[9519,9528,9536],{"nctId":9520,"briefTitle":9521,"status":166,"phases":9522,"primaryCompletion":9523,"completion":2356,"start":9524,"enrollment":463,"conditions":9525,"interventions":9527},"NCT03209206","The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence",[88],"2020-06-19","2017-06-28",[9526],"Urothelial Carcinoma",[9511],{"nctId":9529,"briefTitle":9530,"status":154,"phases":9531,"primaryCompletion":5659,"completion":2394,"start":9532,"enrollment":5472,"conditions":9533,"interventions":9534},"NCT01396655","PET in Breast Cancer Receiving Neoadjuvant Chemotherapy",[88],"2006-07",[24],[9535],"docetaxel",{"nctId":9537,"briefTitle":9538,"status":154,"phases":9539,"primaryCompletion":7958,"completion":2551,"start":6182,"enrollment":1889,"conditions":9540,"interventions":9542},"NCT00623558","Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)",[88],[9541],"Head and Neck Neoplasm",[9543,9511,1086],"Cetuximab",{"trials":9545,"activeCount":99},[],{"trials":9547,"activeCount":99},[],{"trials":9549,"activeCount":99},[],{"intervention":9551,"totalTrials":95,"cells":9552},"Sugammadex Injection 2mg\u002Fkg",{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9557,"PHASE3":9576,"PHASE4":9578,"NA":9580},{"trials":9554,"activeCount":99},[],{"trials":9556,"activeCount":99},[],{"trials":9558,"activeCount":99},[9559,9568],{"nctId":9560,"briefTitle":9561,"status":154,"phases":9562,"primaryCompletion":1784,"completion":1784,"start":3225,"enrollment":170,"conditions":9563,"interventions":9564},"NCT03943888","Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children",[88],[30,2664],[9551,9565,9566,9567],"Sugammadex Injection 4mg\u002Fkg","Sugammadex Injection 8mg\u002Fkg","Neuromuscular reversal agent",{"nctId":9569,"briefTitle":9570,"status":154,"phases":9571,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":6325,"conditions":9574,"interventions":9575},"NCT04347486","Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children",[88],"2021-12-07","2020-04-29",[30,2664],[9551,9565,9566,9567],{"trials":9577,"activeCount":99},[],{"trials":9579,"activeCount":99},[],{"trials":9581,"activeCount":99},[],{"intervention":9565,"totalTrials":95,"cells":9583},{"EARLY_PHASE1":9584,"PHASE1":9586,"PHASE2":9588,"PHASE3":9598,"PHASE4":9600,"NA":9602},{"trials":9585,"activeCount":99},[],{"trials":9587,"activeCount":99},[],{"trials":9589,"activeCount":99},[9590,9594],{"nctId":9560,"briefTitle":9561,"status":154,"phases":9591,"primaryCompletion":1784,"completion":1784,"start":3225,"enrollment":170,"conditions":9592,"interventions":9593},[88],[30,2664],[9551,9565,9566,9567],{"nctId":9569,"briefTitle":9570,"status":154,"phases":9595,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":6325,"conditions":9596,"interventions":9597},[88],[30,2664],[9551,9565,9566,9567],{"trials":9599,"activeCount":99},[],{"trials":9601,"activeCount":99},[],{"trials":9603,"activeCount":99},[],{"intervention":9566,"totalTrials":95,"cells":9605},{"EARLY_PHASE1":9606,"PHASE1":9608,"PHASE2":9610,"PHASE3":9620,"PHASE4":9622,"NA":9624},{"trials":9607,"activeCount":99},[],{"trials":9609,"activeCount":99},[],{"trials":9611,"activeCount":99},[9612,9616],{"nctId":9560,"briefTitle":9561,"status":154,"phases":9613,"primaryCompletion":1784,"completion":1784,"start":3225,"enrollment":170,"conditions":9614,"interventions":9615},[88],[30,2664],[9551,9565,9566,9567],{"nctId":9569,"briefTitle":9570,"status":154,"phases":9617,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":6325,"conditions":9618,"interventions":9619},[88],[30,2664],[9551,9565,9566,9567],{"trials":9621,"activeCount":99},[],{"trials":9623,"activeCount":99},[],{"trials":9625,"activeCount":99},[],{"intervention":9567,"totalTrials":95,"cells":9627},{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9642,"PHASE4":9644,"NA":9646},{"trials":9629,"activeCount":99},[],{"trials":9631,"activeCount":99},[],{"trials":9633,"activeCount":99},[9634,9638],{"nctId":9560,"briefTitle":9561,"status":154,"phases":9635,"primaryCompletion":1784,"completion":1784,"start":3225,"enrollment":170,"conditions":9636,"interventions":9637},[88],[30,2664],[9551,9565,9566,9567],{"nctId":9569,"briefTitle":9570,"status":154,"phases":9639,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":6325,"conditions":9640,"interventions":9641},[88],[30,2664],[9551,9565,9566,9567],{"trials":9643,"activeCount":99},[],{"trials":9645,"activeCount":99},[],{"trials":9647,"activeCount":99},[],{"intervention":9649,"totalTrials":95,"cells":9650},"Durvalumab,Tremelimumab",{"EARLY_PHASE1":9651,"PHASE1":9653,"PHASE2":9655,"PHASE3":9679,"PHASE4":9681,"NA":9683},{"trials":9652,"activeCount":99},[],{"trials":9654,"activeCount":99},[],{"trials":9656,"activeCount":99},[9657,9667],{"nctId":9658,"briefTitle":9659,"status":154,"phases":9660,"primaryCompletion":9661,"completion":9662,"start":2141,"enrollment":6744,"conditions":9663,"interventions":9666},"NCT06446570","Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma",[88],"2019-02-22","2021-06-03",[9664,9665],"HNSCC","Head and Neck Neoplasms",[9649],{"nctId":9668,"briefTitle":9669,"status":154,"phases":9670,"primaryCompletion":9671,"completion":9672,"start":2141,"enrollment":1583,"conditions":9673,"interventions":9674},"NCT03292250","Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]",[88],"2020-03-01","2022-03-10",[9664,9665],[9675,9676,9677,9678,9649],"BYL719","Poziotinib","Nintedanib","Abemaciclib",{"trials":9680,"activeCount":99},[],{"trials":9682,"activeCount":99},[],{"trials":9684,"activeCount":99},[],{"intervention":9686,"totalTrials":95,"cells":9687},"Clonazepam",{"EARLY_PHASE1":9688,"PHASE1":9690,"PHASE2":9692,"PHASE3":9709,"PHASE4":9711,"NA":9713},{"trials":9689,"activeCount":99},[],{"trials":9691,"activeCount":99},[],{"trials":9693,"activeCount":99},[9694,9703],{"nctId":9695,"briefTitle":9696,"status":166,"phases":9697,"primaryCompletion":3690,"completion":3690,"start":2052,"enrollment":850,"conditions":9698,"interventions":9699},"NCT02789592","Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease",[88],[4283,3937],[9700,9686,9701,9702],"Melatonin PR","Melatonin PR placebo","Clonazepam placebo",{"nctId":9704,"briefTitle":9705,"status":154,"phases":9706,"primaryCompletion":1978,"completion":1978,"start":2622,"enrollment":170,"conditions":9707,"interventions":9708},"NCT02312908","Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism",[88],[4283],[9686],{"trials":9710,"activeCount":99},[],{"trials":9712,"activeCount":99},[],{"trials":9714,"activeCount":99},[],{"intervention":9454,"totalTrials":95,"cells":9716},{"EARLY_PHASE1":9717,"PHASE1":9719,"PHASE2":9725,"PHASE3":9734,"PHASE4":9736,"NA":9738},{"trials":9718,"activeCount":99},[],{"trials":9720,"activeCount":99},[9721],{"nctId":9446,"briefTitle":9447,"status":154,"phases":9722,"primaryCompletion":9449,"completion":9450,"start":9451,"enrollment":6325,"conditions":9723,"interventions":9724},[87],[21],[9454,9429,9455],{"trials":9726,"activeCount":99},[9727],{"nctId":9728,"briefTitle":9729,"status":154,"phases":9730,"primaryCompletion":2251,"completion":2251,"start":2294,"enrollment":1221,"conditions":9731,"interventions":9733},"NCT02244528","PK Study of Sildenafil in Neonate",[88],[9732],"Neonates and Preterm Infants",[9454],{"trials":9735,"activeCount":99},[],{"trials":9737,"activeCount":99},[],{"trials":9739,"activeCount":99},[],{"intervention":796,"totalTrials":95,"cells":9741},{"EARLY_PHASE1":9742,"PHASE1":9744,"PHASE2":9746,"PHASE3":9756,"PHASE4":9758,"NA":9760},{"trials":9743,"activeCount":99},[],{"trials":9745,"activeCount":99},[],{"trials":9747,"activeCount":99},[9748,9752],{"nctId":787,"briefTitle":788,"status":154,"phases":9749,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":9750,"interventions":9751},[88],[794],[796,797,184,772,798],{"nctId":818,"briefTitle":819,"status":166,"phases":9753,"primaryCompletion":821,"completion":179,"start":732,"enrollment":822,"conditions":9754,"interventions":9755},[88],[824],[796,773],{"trials":9757,"activeCount":99},[],{"trials":9759,"activeCount":99},[],{"trials":9761,"activeCount":99},[],{"intervention":9763,"totalTrials":95,"cells":9764},"Pembrolizumab",{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9769,"PHASE3":9792,"PHASE4":9794,"NA":9796},{"trials":9766,"activeCount":99},[],{"trials":9768,"activeCount":99},[],{"trials":9770,"activeCount":99},[9771,9780],{"nctId":9772,"briefTitle":9773,"status":154,"phases":9774,"primaryCompletion":9775,"completion":9775,"start":9776,"enrollment":1246,"conditions":9777,"interventions":9779},"NCT04227509","Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma",[88],"2024-08-21","2020-06-04",[9778],"Nasopharyngeal Carcinoma",[9763],{"nctId":9781,"briefTitle":9782,"status":166,"phases":9783,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":9786,"interventions":9787},"NCT04447092","Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer",[88],"2020-07-01",77,[35,992],[1085,9788,9763,9789,7862,9790,9791],"Nab-paclitaxel","Oxaliplatin","Irinotecan","5FU",{"trials":9793,"activeCount":99},[],{"trials":9795,"activeCount":99},[],{"trials":9797,"activeCount":99},[],{"intervention":9799,"totalTrials":95,"cells":9800},"Valproic Acid",{"EARLY_PHASE1":9801,"PHASE1":9803,"PHASE2":9805,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9802,"activeCount":99},[],{"trials":9804,"activeCount":99},[],{"trials":9806,"activeCount":99},[9807,9816],{"nctId":9808,"briefTitle":9809,"status":154,"phases":9810,"primaryCompletion":5092,"completion":3554,"start":7680,"enrollment":170,"conditions":9811,"interventions":9814},"NCT01548066","The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss",[88],[9812,9813],"Androgenetic Alopecia","Male Pattern Baldness",[9799,9815],"Control placebo",{"nctId":9817,"briefTitle":9818,"status":154,"phases":9819,"primaryCompletion":2551,"completion":674,"start":3565,"enrollment":380,"conditions":9820,"interventions":9826},"NCT01399515","Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa",[88],[9821,9822,9823,9824,9825],"Retinitis Pigmentosa","Retinal Diseases","Eye Diseases","Eye Disease, Hereditary","Retinal Degeneration",[9799],{"trials":9828,"activeCount":99},[],{"trials":9830,"activeCount":99},[],{"trials":9832,"activeCount":99},[],{"intervention":7870,"totalTrials":95,"cells":9834},{"EARLY_PHASE1":9835,"PHASE1":9837,"PHASE2":9839,"PHASE3":9854,"PHASE4":9856,"NA":9858},{"trials":9836,"activeCount":99},[],{"trials":9838,"activeCount":99},[],{"trials":9840,"activeCount":99},[9841,9850],{"nctId":9842,"briefTitle":9843,"status":1813,"phases":9844,"primaryCompletion":3649,"completion":3649,"start":674,"enrollment":1036,"conditions":9845,"interventions":9847},"NCT01171482","Comparison Study of Sorafenib and 5-fluorouracil\u002FMitomycin for Metastatic Hepatocellular Carcinoma",[88],[9846],"Carcinoma, Hepatocellular",[9848,7870,9849],"5-FU","sorafenib",{"nctId":7864,"briefTitle":7865,"status":658,"phases":9851,"primaryCompletion":674,"completion":674,"start":674,"enrollment":99,"conditions":9852,"interventions":9853},[88],[18,7868],[7846,7870],{"trials":9855,"activeCount":99},[],{"trials":9857,"activeCount":99},[],{"trials":9859,"activeCount":99},[],{"intervention":9849,"totalTrials":95,"cells":9861},{"EARLY_PHASE1":9862,"PHASE1":9864,"PHASE2":9866,"PHASE3":9879,"PHASE4":9881,"NA":9883},{"trials":9863,"activeCount":99},[],{"trials":9865,"activeCount":99},[],{"trials":9867,"activeCount":99},[9868,9872],{"nctId":9842,"briefTitle":9843,"status":1813,"phases":9869,"primaryCompletion":3649,"completion":3649,"start":674,"enrollment":1036,"conditions":9870,"interventions":9871},[88],[9846],[9848,7870,9849],{"nctId":9873,"briefTitle":9874,"status":1813,"phases":9875,"primaryCompletion":821,"completion":821,"start":3554,"enrollment":95,"conditions":9876,"interventions":9877},"NCT01480817","Sorafenib VS TACE in HCC Patients With Portal Vein Invasion",[88],[18],[9878],"Sorafenib",{"trials":9880,"activeCount":99},[],{"trials":9882,"activeCount":99},[],{"trials":9884,"activeCount":99},[],{"intervention":994,"totalTrials":95,"cells":9886},{"EARLY_PHASE1":9887,"PHASE1":9889,"PHASE2":9891,"PHASE3":9901,"PHASE4":9903,"NA":9905},{"trials":9888,"activeCount":99},[],{"trials":9890,"activeCount":99},[],{"trials":9892,"activeCount":99},[9893,9897],{"nctId":1068,"briefTitle":1069,"status":166,"phases":9894,"primaryCompletion":75,"completion":1000,"start":988,"enrollment":1071,"conditions":9895,"interventions":9896},[88],[991,992],[994,995],{"nctId":985,"briefTitle":986,"status":166,"phases":9898,"primaryCompletion":75,"completion":75,"start":988,"enrollment":989,"conditions":9899,"interventions":9900},[88],[991,992],[994,995,976],{"trials":9902,"activeCount":99},[],{"trials":9904,"activeCount":99},[],{"trials":9906,"activeCount":99},[],{"intervention":1085,"totalTrials":95,"cells":9908},{"EARLY_PHASE1":9909,"PHASE1":9911,"PHASE2":9913,"PHASE3":9923,"PHASE4":9925,"NA":9927},{"trials":9910,"activeCount":99},[],{"trials":9912,"activeCount":99},[],{"trials":9914,"activeCount":99},[9915,9919],{"nctId":1075,"briefTitle":1076,"status":166,"phases":9916,"primaryCompletion":1078,"completion":75,"start":1079,"enrollment":1080,"conditions":9917,"interventions":9918},[88],[1082],[995,1084,1085,1086],{"nctId":9781,"briefTitle":9782,"status":166,"phases":9920,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":9921,"interventions":9922},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":9924,"activeCount":99},[],{"trials":9926,"activeCount":99},[],{"trials":9928,"activeCount":99},[],{"intervention":2599,"totalTrials":95,"cells":9930},{"EARLY_PHASE1":9931,"PHASE1":9933,"PHASE2":9935,"PHASE3":9945,"PHASE4":9947,"NA":9949},{"trials":9932,"activeCount":99},[],{"trials":9934,"activeCount":99},[],{"trials":9936,"activeCount":99},[9937,9941],{"nctId":2590,"briefTitle":2591,"status":658,"phases":9938,"primaryCompletion":2593,"completion":874,"start":2593,"enrollment":99,"conditions":9939,"interventions":9940},[87,88],[2595,2596,2597],[2332,2599],{"nctId":2601,"briefTitle":2602,"status":154,"phases":9942,"primaryCompletion":2604,"completion":2605,"start":2606,"enrollment":1170,"conditions":9943,"interventions":9944},[87,88],[2596,2608,2609,2610],[2332,2599],{"trials":9946,"activeCount":99},[],{"trials":9948,"activeCount":99},[],{"trials":9950,"activeCount":99},[],{"intervention":9952,"totalTrials":95,"cells":9953},"Axitinib",{"EARLY_PHASE1":9954,"PHASE1":9956,"PHASE2":9958,"PHASE3":9977,"PHASE4":9979,"NA":9981},{"trials":9955,"activeCount":99},[],{"trials":9957,"activeCount":99},[],{"trials":9959,"activeCount":99},[9960,9969],{"nctId":9961,"briefTitle":9962,"status":154,"phases":9963,"primaryCompletion":9964,"completion":9965,"start":4130,"enrollment":1795,"conditions":9966,"interventions":9968},"NCT02859012","Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma",[88],"2017-12","2020-08",[9967],"Recurrent ACC, metastaticACC, Unreaectable ACC",[9952],{"nctId":9970,"briefTitle":9971,"status":154,"phases":9972,"primaryCompletion":1979,"completion":168,"start":1815,"enrollment":16,"conditions":9973,"interventions":9976},"NCT01798446","A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus",[88],[1675,9974,9975],"Nonclear Cell","Temsirolimus Resistance",[9952],{"trials":9978,"activeCount":99},[],{"trials":9980,"activeCount":99},[],{"trials":9982,"activeCount":99},[],{"intervention":9790,"totalTrials":95,"cells":9984},{"EARLY_PHASE1":9985,"PHASE1":9987,"PHASE2":9996,"PHASE3":10002,"PHASE4":10004,"NA":10006},{"trials":9986,"activeCount":99},[],{"trials":9988,"activeCount":99},[9989],{"nctId":9990,"briefTitle":9991,"status":166,"phases":9992,"primaryCompletion":264,"completion":264,"start":5066,"enrollment":6744,"conditions":9993,"interventions":9995},"NCT01239485","Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents",[87],[9994],"Acute Leukemia",[9790],{"trials":9997,"activeCount":99},[9998],{"nctId":9781,"briefTitle":9782,"status":166,"phases":9999,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":10000,"interventions":10001},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":10003,"activeCount":99},[],{"trials":10005,"activeCount":99},[],{"trials":10007,"activeCount":99},[],{"intervention":10009,"totalTrials":95,"cells":10010},"Micafungin",{"EARLY_PHASE1":10011,"PHASE1":10013,"PHASE2":10015,"PHASE3":10033,"PHASE4":10035,"NA":10037},{"trials":10012,"activeCount":99},[],{"trials":10014,"activeCount":99},[],{"trials":10016,"activeCount":99},[10017,10024],{"nctId":10018,"briefTitle":10019,"status":154,"phases":10020,"primaryCompletion":8023,"completion":8023,"start":10021,"enrollment":569,"conditions":10022,"interventions":10023},"NCT02440178","Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia",[88],"2015-09-19",[9994],[10009],{"nctId":10025,"briefTitle":10026,"status":166,"phases":10027,"primaryCompletion":578,"completion":578,"start":2420,"enrollment":6487,"conditions":10028,"interventions":10031},"NCT01417169","Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation",[88],[10029,10030],"Neutropenia","Fungal Disease",[10032],"micafungin",{"trials":10034,"activeCount":99},[],{"trials":10036,"activeCount":99},[],{"trials":10038,"activeCount":99},[],{"intervention":7862,"totalTrials":95,"cells":10040},{"EARLY_PHASE1":10041,"PHASE1":10043,"PHASE2":10045,"PHASE3":10055,"PHASE4":10057,"NA":10059},{"trials":10042,"activeCount":99},[],{"trials":10044,"activeCount":99},[],{"trials":10046,"activeCount":99},[10047,10051],{"nctId":7855,"briefTitle":7856,"status":166,"phases":10048,"primaryCompletion":75,"completion":1000,"start":7858,"enrollment":380,"conditions":10049,"interventions":10050},[88],[35],[7861,3164,7846,7862],{"nctId":9781,"briefTitle":9782,"status":166,"phases":10052,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":10053,"interventions":10054},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":10056,"activeCount":99},[],{"trials":10058,"activeCount":99},[],{"trials":10060,"activeCount":99},[],{"intervention":9678,"totalTrials":95,"cells":10062},{"EARLY_PHASE1":10063,"PHASE1":10065,"PHASE2":10067,"PHASE3":10080,"PHASE4":10082,"NA":10084},{"trials":10064,"activeCount":99},[],{"trials":10066,"activeCount":99},[],{"trials":10068,"activeCount":99},[10069,10073],{"nctId":9668,"briefTitle":9669,"status":154,"phases":10070,"primaryCompletion":9671,"completion":9672,"start":2141,"enrollment":1583,"conditions":10071,"interventions":10072},[88],[9664,9665],[9675,9676,9677,9678,9649],{"nctId":10074,"briefTitle":10075,"status":166,"phases":10076,"primaryCompletion":4854,"completion":4657,"start":10077,"enrollment":6325,"conditions":10078,"interventions":10079},"NCT03356587","A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy",[88],"2017-10-16",[9664,9665],[9678],{"trials":10081,"activeCount":99},[],{"trials":10083,"activeCount":99},[],{"trials":10085,"activeCount":99},[],{"intervention":10087,"totalTrials":95,"cells":10088},"Busulfan, etoposide, cytarabine, and melphalan",{"EARLY_PHASE1":10089,"PHASE1":10091,"PHASE2":10093,"PHASE3":10109,"PHASE4":10111,"NA":10113},{"trials":10090,"activeCount":99},[],{"trials":10092,"activeCount":99},[],{"trials":10094,"activeCount":99},[10095,10103],{"nctId":10096,"briefTitle":10097,"status":166,"phases":10098,"primaryCompletion":578,"start":10099,"enrollment":6698,"conditions":10100,"interventions":10102},"NCT01178645","Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma",[88],"2010-07",[10101],"Non-Hodgkin Lymphoma",[10087],{"nctId":10104,"briefTitle":10105,"status":166,"phases":10106,"primaryCompletion":578,"start":10099,"enrollment":6698,"conditions":10107,"interventions":10108},"NCT01178658","Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma",[88],[10101],[10087],{"trials":10110,"activeCount":99},[],{"trials":10112,"activeCount":99},[],{"trials":10114,"activeCount":99},[],{"intervention":10116,"totalTrials":121,"cells":10117},"rhEGF + povidone iodine, chlorhexidine, & nystatin",{"EARLY_PHASE1":10118,"PHASE1":10120,"PHASE2":10122,"PHASE3":10131,"PHASE4":10133,"NA":10135},{"trials":10119,"activeCount":99},[],{"trials":10121,"activeCount":99},[],{"trials":10123,"activeCount":99},[10124],{"nctId":10125,"briefTitle":10126,"status":154,"phases":10127,"primaryCompletion":2294,"completion":2294,"start":8857,"enrollment":2541,"conditions":10128,"interventions":10130},"NCT00845819","Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies",[88],[10129],"Oral Mucositis",[10116],{"trials":10132,"activeCount":99},[],{"trials":10134,"activeCount":99},[],{"trials":10136,"activeCount":99},[],{"intervention":10138,"totalTrials":121,"cells":10139},"Drug: G-CSF",{"EARLY_PHASE1":10140,"PHASE1":10142,"PHASE2":10144,"PHASE3":10153,"PHASE4":10155,"NA":10157},{"trials":10141,"activeCount":99},[],{"trials":10143,"activeCount":99},[],{"trials":10145,"activeCount":99},[10146],{"nctId":10147,"briefTitle":10148,"status":1813,"phases":10149,"completion":3877,"start":10150,"enrollment":1221,"conditions":10151,"interventions":10152},"NCT00307879","Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion",[88],"2004-03",[1666],[10138],{"trials":10154,"activeCount":99},[],{"trials":10156,"activeCount":99},[],{"trials":10158,"activeCount":99},[],{"intervention":10160,"totalTrials":121,"cells":10161},"Osimertinib 80 MG [Tagrisso]",{"EARLY_PHASE1":10162,"PHASE1":10164,"PHASE2":10166,"PHASE3":10176,"PHASE4":10178,"NA":10180},{"trials":10163,"activeCount":99},[],{"trials":10165,"activeCount":99},[],{"trials":10167,"activeCount":99},[10168],{"nctId":10169,"briefTitle":10170,"status":154,"phases":10171,"primaryCompletion":10172,"completion":10172,"start":10173,"enrollment":1170,"conditions":10174,"interventions":10175},"NCT03414814","Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation",[88],"2021-08-03","2018-01-04",[3097],[10160],{"trials":10177,"activeCount":99},[],{"trials":10179,"activeCount":99},[],{"trials":10181,"activeCount":99},[],{"intervention":10183,"totalTrials":121,"cells":10184},"pembrolizumab, paclitaxel",{"EARLY_PHASE1":10185,"PHASE1":10187,"PHASE2":10189,"PHASE3":10199,"PHASE4":10201,"NA":10203},{"trials":10186,"activeCount":99},[],{"trials":10188,"activeCount":99},[],{"trials":10190,"activeCount":99},[10191],{"nctId":10192,"briefTitle":10193,"status":154,"phases":10194,"primaryCompletion":9964,"completion":10195,"start":169,"enrollment":1071,"conditions":10196,"interventions":10198},"NCT02551432","Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer",[88],"2018-02",[10197],"Small Cell Lung Cancer",[10183],{"trials":10200,"activeCount":99},[],{"trials":10202,"activeCount":99},[],{"trials":10204,"activeCount":99},[],{"intervention":10206,"totalTrials":121,"cells":10207},"Romiplostim and danazol",{"EARLY_PHASE1":10208,"PHASE1":10210,"PHASE2":10212,"PHASE3":10223,"PHASE4":10225,"NA":10227},{"trials":10209,"activeCount":99},[],{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":99},[10214],{"nctId":10215,"briefTitle":10216,"status":166,"phases":10217,"primaryCompletion":10218,"completion":10219,"start":9671,"enrollment":10220,"conditions":10221,"interventions":10222},"NCT04289207","Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia",[88],"2020-09-01","2021-03-01",55,[9176],[10206],{"trials":10224,"activeCount":99},[],{"trials":10226,"activeCount":99},[],{"trials":10228,"activeCount":99},[],{"intervention":10230,"totalTrials":121,"cells":10231},"Ruxolitinib",{"EARLY_PHASE1":10232,"PHASE1":10234,"PHASE2":10236,"PHASE3":10247,"PHASE4":10249,"NA":10251},{"trials":10233,"activeCount":99},[],{"trials":10235,"activeCount":99},[],{"trials":10237,"activeCount":99},[10238],{"nctId":10239,"briefTitle":10240,"status":166,"phases":10241,"primaryCompletion":10242,"completion":2673,"start":10243,"enrollment":28,"conditions":10244,"interventions":10246},"NCT03558607","The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm",[87,88],"2022-04-30","2018-05-17",[10245],"Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder",[10230],{"trials":10248,"activeCount":99},[],{"trials":10250,"activeCount":99},[],{"trials":10252,"activeCount":99},[],{"intervention":10254,"totalTrials":121,"cells":10255},"Thiotepa in conditioning before transplantation",{"EARLY_PHASE1":10256,"PHASE1":10258,"PHASE2":10260,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10257,"activeCount":99},[],{"trials":10259,"activeCount":99},[],{"trials":10261,"activeCount":99},[10262],{"nctId":10263,"briefTitle":10264,"status":1813,"phases":10265,"primaryCompletion":10266,"completion":10266,"start":10267,"enrollment":28,"conditions":10268,"interventions":10270},"NCT06625359","High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma",[88],"2024-09-30","2015-06-01",[10269],"Central Nervous System Lymphoma",[10254],{"trials":10272,"activeCount":99},[],{"trials":10274,"activeCount":99},[],{"trials":10276,"activeCount":99},[],{"intervention":10278,"totalTrials":121,"cells":10279},"Omega-3",{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10294,"PHASE4":10296,"NA":10298},{"trials":10281,"activeCount":99},[],{"trials":10283,"activeCount":99},[],{"trials":10285,"activeCount":99},[10286],{"nctId":10287,"briefTitle":10288,"status":166,"phases":10289,"primaryCompletion":10290,"completion":10290,"start":2478,"enrollment":850,"conditions":10291,"interventions":10293},"NCT02899741","Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study",[88],"2018-11",[10292],"Epilepsy",[10278],{"trials":10295,"activeCount":99},[],{"trials":10297,"activeCount":99},[],{"trials":10299,"activeCount":99},[],{"intervention":10301,"totalTrials":121,"cells":10302},"G-CSF",{"EARLY_PHASE1":10303,"PHASE1":10305,"PHASE2":10307,"PHASE3":10316,"PHASE4":10318,"NA":10320},{"trials":10304,"activeCount":99},[],{"trials":10306,"activeCount":99},[],{"trials":10308,"activeCount":99},[10309],{"nctId":10310,"briefTitle":10311,"status":154,"phases":10312,"completion":10313,"start":10150,"enrollment":594,"conditions":10314,"interventions":10315},"NCT00291629","Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES",[88],"2007-08",[1666],[10301],{"trials":10317,"activeCount":99},[],{"trials":10319,"activeCount":99},[],{"trials":10321,"activeCount":99},[],{"intervention":10323,"totalTrials":121,"cells":10324},"PF00299804",{"EARLY_PHASE1":10325,"PHASE1":10327,"PHASE2":10329,"PHASE3":10339,"PHASE4":10341,"NA":10343},{"trials":10326,"activeCount":99},[],{"trials":10328,"activeCount":99},[],{"trials":10330,"activeCount":99},[10331],{"nctId":10332,"briefTitle":10333,"status":154,"phases":10334,"primaryCompletion":7724,"completion":660,"start":10099,"enrollment":1125,"conditions":10335,"interventions":10338},"NCT01152853","PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer",[88],[10336,10337],"Advanced Gastric Cancer","HER2",[10323],{"trials":10340,"activeCount":99},[],{"trials":10342,"activeCount":99},[],{"trials":10344,"activeCount":99},[],{"intervention":2045,"totalTrials":121,"cells":10346},{"EARLY_PHASE1":10347,"PHASE1":10349,"PHASE2":10351,"PHASE3":10357,"PHASE4":10359,"NA":10361},{"trials":10348,"activeCount":99},[],{"trials":10350,"activeCount":99},[],{"trials":10352,"activeCount":99},[10353],{"nctId":2036,"briefTitle":2037,"status":154,"phases":10354,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":411,"conditions":10355,"interventions":10356},[88],[2043],[2045,2046,2047],{"trials":10358,"activeCount":99},[],{"trials":10360,"activeCount":99},[],{"trials":10362,"activeCount":99},[],{"intervention":2046,"totalTrials":121,"cells":10364},{"EARLY_PHASE1":10365,"PHASE1":10367,"PHASE2":10369,"PHASE3":10375,"PHASE4":10377,"NA":10379},{"trials":10366,"activeCount":99},[],{"trials":10368,"activeCount":99},[],{"trials":10370,"activeCount":99},[10371],{"nctId":2036,"briefTitle":2037,"status":154,"phases":10372,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":411,"conditions":10373,"interventions":10374},[88],[2043],[2045,2046,2047],{"trials":10376,"activeCount":99},[],{"trials":10378,"activeCount":99},[],{"trials":10380,"activeCount":99},[],{"intervention":10382,"totalTrials":121,"cells":10383},"Irradiated donor lymphocyte",{"EARLY_PHASE1":10384,"PHASE1":10386,"PHASE2":10388,"PHASE3":10398,"PHASE4":10400,"NA":10402},{"trials":10385,"activeCount":99},[],{"trials":10387,"activeCount":99},[],{"trials":10389,"activeCount":99},[10390],{"nctId":10391,"briefTitle":10392,"status":1813,"phases":10393,"primaryCompletion":156,"completion":156,"start":2551,"enrollment":10394,"conditions":10395,"interventions":10397},"NCT01925118","Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2",[88],9,[10396],"Metastatic Malignant Melanoma and Renal Cell Carcinoma",[10382],{"trials":10399,"activeCount":99},[],{"trials":10401,"activeCount":99},[],{"trials":10403,"activeCount":99},[],{"intervention":10405,"totalTrials":121,"cells":10406},"Ramipril",{"EARLY_PHASE1":10407,"PHASE1":10409,"PHASE2":10411,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10408,"activeCount":99},[],{"trials":10410,"activeCount":99},[],{"trials":10412,"activeCount":99},[10413],{"nctId":10414,"briefTitle":10415,"status":154,"phases":10416,"primaryCompletion":10417,"completion":10417,"start":10418,"enrollment":1048,"conditions":10419,"interventions":10421},"NCT01402479","An Open-labeled Trial of Ramipril in Patients With Migraine",[88],"2005-07","2004-10",[10420],"Migraine With Hypertension",[10405],{"trials":10423,"activeCount":99},[],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"intervention":10429,"totalTrials":121,"cells":10430},"Nivolumab",{"EARLY_PHASE1":10431,"PHASE1":10433,"PHASE2":10435,"PHASE3":10446,"PHASE4":10448,"NA":10450},{"trials":10432,"activeCount":99},[],{"trials":10434,"activeCount":99},[],{"trials":10436,"activeCount":99},[10437],{"nctId":10438,"briefTitle":10439,"status":166,"phases":10440,"primaryCompletion":10441,"completion":10442,"start":6050,"enrollment":2232,"conditions":10443,"interventions":10445},"NCT04061863","Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer",[87,88],"2022-04","2022-12",[10444],"Metastatic Breast Cancer",[10429],{"trials":10447,"activeCount":99},[],{"trials":10449,"activeCount":99},[],{"trials":10451,"activeCount":99},[],{"intervention":10453,"totalTrials":121,"cells":10454},"Irinotecan combination chemotherapy",{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10467,"PHASE4":10469,"NA":10471},{"trials":10456,"activeCount":99},[],{"trials":10458,"activeCount":99},[],{"trials":10460,"activeCount":99},[10461],{"nctId":10462,"briefTitle":10463,"status":166,"phases":10464,"primaryCompletion":4130,"completion":168,"start":2385,"enrollment":170,"conditions":10465,"interventions":10466},"NCT01535183","Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents",[88],[1846],[10453],{"trials":10468,"activeCount":99},[],{"trials":10470,"activeCount":99},[],{"trials":10472,"activeCount":99},[],{"intervention":9700,"totalTrials":121,"cells":10474},{"EARLY_PHASE1":10475,"PHASE1":10477,"PHASE2":10479,"PHASE3":10485,"PHASE4":10487,"NA":10489},{"trials":10476,"activeCount":99},[],{"trials":10478,"activeCount":99},[],{"trials":10480,"activeCount":99},[10481],{"nctId":9695,"briefTitle":9696,"status":166,"phases":10482,"primaryCompletion":3690,"completion":3690,"start":2052,"enrollment":850,"conditions":10483,"interventions":10484},[88],[4283,3937],[9700,9686,9701,9702],{"trials":10486,"activeCount":99},[],{"trials":10488,"activeCount":99},[],{"trials":10490,"activeCount":99},[],{"intervention":9701,"totalTrials":121,"cells":10492},{"EARLY_PHASE1":10493,"PHASE1":10495,"PHASE2":10497,"PHASE3":10503,"PHASE4":10505,"NA":10507},{"trials":10494,"activeCount":99},[],{"trials":10496,"activeCount":99},[],{"trials":10498,"activeCount":99},[10499],{"nctId":9695,"briefTitle":9696,"status":166,"phases":10500,"primaryCompletion":3690,"completion":3690,"start":2052,"enrollment":850,"conditions":10501,"interventions":10502},[88],[4283,3937],[9700,9686,9701,9702],{"trials":10504,"activeCount":99},[],{"trials":10506,"activeCount":99},[],{"trials":10508,"activeCount":99},[],{"intervention":9702,"totalTrials":121,"cells":10510},{"EARLY_PHASE1":10511,"PHASE1":10513,"PHASE2":10515,"PHASE3":10521,"PHASE4":10523,"NA":10525},{"trials":10512,"activeCount":99},[],{"trials":10514,"activeCount":99},[],{"trials":10516,"activeCount":99},[10517],{"nctId":9695,"briefTitle":9696,"status":166,"phases":10518,"primaryCompletion":3690,"completion":3690,"start":2052,"enrollment":850,"conditions":10519,"interventions":10520},[88],[4283,3937],[9700,9686,9701,9702],{"trials":10522,"activeCount":99},[],{"trials":10524,"activeCount":99},[],{"trials":10526,"activeCount":99},[],{"intervention":2059,"totalTrials":121,"cells":10528},{"EARLY_PHASE1":10529,"PHASE1":10531,"PHASE2":10533,"PHASE3":10539,"PHASE4":10541,"NA":10543},{"trials":10530,"activeCount":99},[],{"trials":10532,"activeCount":99},[],{"trials":10534,"activeCount":99},[10535],{"nctId":2049,"briefTitle":2050,"status":166,"phases":10536,"primaryCompletion":2052,"completion":2052,"start":1967,"enrollment":2053,"conditions":10537,"interventions":10538},[88],[2055,2056,2057],[2059,270],{"trials":10540,"activeCount":99},[],{"trials":10542,"activeCount":99},[],{"trials":10544,"activeCount":99},[],{"intervention":10546,"totalTrials":121,"cells":10547},"Paclitaxel and irinotecan",{"EARLY_PHASE1":10548,"PHASE1":10550,"PHASE2":10552,"PHASE3":10560,"PHASE4":10562,"NA":10564},{"trials":10549,"activeCount":99},[],{"trials":10551,"activeCount":99},[],{"trials":10553,"activeCount":99},[10554],{"nctId":10555,"briefTitle":10556,"status":154,"phases":10557,"primaryCompletion":2394,"completion":2420,"start":7382,"enrollment":6698,"conditions":10558,"interventions":10559},"NCT01136031","Paclitaxel and Irinotecan in Advanced Gastric Cancer",[87,88],[10336],[10546],{"trials":10561,"activeCount":99},[],{"trials":10563,"activeCount":99},[],{"trials":10565,"activeCount":99},[],{"intervention":10567,"totalTrials":121,"cells":10568},"MEK162+capecitabine",{"EARLY_PHASE1":10569,"PHASE1":10571,"PHASE2":10573,"PHASE3":10583,"PHASE4":10585,"NA":10587},{"trials":10570,"activeCount":99},[],{"trials":10572,"activeCount":99},[],{"trials":10574,"activeCount":99},[10575],{"nctId":10576,"briefTitle":10577,"status":154,"phases":10578,"primaryCompletion":10579,"completion":10579,"start":3649,"enrollment":1080,"conditions":10580,"interventions":10582},"NCT02773459","MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer",[87,88],"2019-01-07",[10581],"Biliary Tract Cancer",[10567],{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":99},[],{"trials":10588,"activeCount":99},[],{"intervention":10590,"totalTrials":121,"cells":10591},"Lamotrigine",{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10596,"PHASE3":10607,"PHASE4":10609,"NA":10611},{"trials":10593,"activeCount":99},[],{"trials":10595,"activeCount":99},[],{"trials":10597,"activeCount":99},[10598],{"nctId":10599,"briefTitle":10600,"status":166,"phases":10601,"primaryCompletion":10602,"completion":10602,"start":10603,"enrollment":850,"conditions":10604,"interventions":10606},"NCT03220256","Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients",[88],"2018-08-01","2016-08-02",[10605],"Lamotrigine Allergy",[10590],{"trials":10608,"activeCount":99},[],{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[],{"intervention":10614,"totalTrials":121,"cells":10615},"Gemcitabine+ nivolumab",{"EARLY_PHASE1":10616,"PHASE1":10618,"PHASE2":10620,"PHASE3":10631,"PHASE4":10633,"NA":10635},{"trials":10617,"activeCount":99},[],{"trials":10619,"activeCount":99},[],{"trials":10621,"activeCount":99},[10622],{"nctId":10623,"briefTitle":10624,"status":154,"phases":10625,"primaryCompletion":10626,"completion":10626,"start":10627,"enrollment":9411,"conditions":10628,"interventions":10630},"NCT06440187","Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11",[88],"2021-04-30","2018-06-08",[10629],"Recurrent or Metastatic Nasopharyngeal Carcinom",[10614],{"trials":10632,"activeCount":99},[],{"trials":10634,"activeCount":99},[],{"trials":10636,"activeCount":99},[],{"intervention":10638,"totalTrials":121,"cells":10639},"Rituximab + MG4101",{"EARLY_PHASE1":10640,"PHASE1":10642,"PHASE2":10644,"PHASE3":10655,"PHASE4":10657,"NA":10659},{"trials":10641,"activeCount":99},[],{"trials":10643,"activeCount":99},[],{"trials":10645,"activeCount":99},[10646],{"nctId":10647,"briefTitle":10648,"status":1813,"phases":10649,"primaryCompletion":10650,"completion":10650,"start":10651,"enrollment":210,"conditions":10652,"interventions":10654},"NCT03578198","Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)",[88],"2022-04-07","2018-11-08",[10653],"CD20-positive Non-Hodgkin Lymphoma",[10638],{"trials":10656,"activeCount":99},[],{"trials":10658,"activeCount":99},[],{"trials":10660,"activeCount":99},[],{"intervention":2588,"totalTrials":121,"cells":10662},{"EARLY_PHASE1":10663,"PHASE1":10665,"PHASE2":10667,"PHASE3":10673,"PHASE4":10675,"NA":10677},{"trials":10664,"activeCount":99},[],{"trials":10666,"activeCount":99},[],{"trials":10668,"activeCount":99},[10669],{"nctId":2581,"briefTitle":2582,"status":166,"phases":10670,"primaryCompletion":2584,"completion":2584,"start":2251,"enrollment":850,"conditions":10671,"interventions":10672},[88],[2586],[2588,2332],{"trials":10674,"activeCount":99},[],{"trials":10676,"activeCount":99},[],{"trials":10678,"activeCount":99},[],{"intervention":10680,"totalTrials":121,"cells":10681},"azacitidine plus R-GDP",{"EARLY_PHASE1":10682,"PHASE1":10684,"PHASE2":10686,"PHASE3":10699,"PHASE4":10701,"NA":10703},{"trials":10683,"activeCount":99},[],{"trials":10685,"activeCount":99},[],{"trials":10687,"activeCount":99},[10688],{"nctId":10689,"briefTitle":10690,"status":166,"phases":10691,"primaryCompletion":4853,"completion":10692,"start":10693,"enrollment":9403,"conditions":10694,"interventions":10698},"NCT03719989","Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[88],"2023-11-30","2018-12-01",[10695,10696,10697],"Diffuse Large B Cell Lymphoma","Relapsed Non Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma",[10680],{"trials":10700,"activeCount":99},[],{"trials":10702,"activeCount":99},[],{"trials":10704,"activeCount":99},[],{"intervention":10706,"totalTrials":121,"cells":10707},"Drug Combinations",{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10712,"PHASE3":10726,"PHASE4":10728,"NA":10730},{"trials":10709,"activeCount":99},[],{"trials":10711,"activeCount":99},[],{"trials":10713,"activeCount":99},[10714],{"nctId":10715,"briefTitle":10716,"status":166,"phases":10717,"primaryCompletion":10718,"completion":10719,"start":10720,"enrollment":9492,"conditions":10721,"interventions":10725},"NCT04065308","Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma",[88],"2019-12-21","2021-09-30","2019-01-14",[10722,10723,10724],"Multiple Myeloma in Relapse","Plasmacytoma","Daratumumab",[10706],{"trials":10727,"activeCount":99},[],{"trials":10729,"activeCount":99},[],{"trials":10731,"activeCount":99},[],{"intervention":1140,"totalTrials":121,"cells":10733},{"EARLY_PHASE1":10734,"PHASE1":10736,"PHASE2":10738,"PHASE3":10744,"PHASE4":10746,"NA":10748},{"trials":10735,"activeCount":99},[],{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[10740],{"nctId":1131,"briefTitle":1132,"status":166,"phases":10741,"primaryCompletion":1134,"completion":75,"start":1135,"enrollment":1136,"conditions":10742,"interventions":10743},[88],[1138],[1140,1111],{"trials":10745,"activeCount":99},[],{"trials":10747,"activeCount":99},[],{"trials":10749,"activeCount":99},[],{"intervention":10751,"totalTrials":121,"cells":10752},"FOLFIRINOX or Gemcitabine based chemotherapy",{"EARLY_PHASE1":10753,"PHASE1":10755,"PHASE2":10757,"PHASE3":10767,"PHASE4":10769,"NA":10771},{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[10759],{"nctId":10760,"briefTitle":10761,"status":166,"phases":10762,"primaryCompletion":10763,"completion":10763,"start":2478,"enrollment":1743,"conditions":10764,"interventions":10766},"NCT02862015","Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients",[88],"2019-07",[10765],"Cancer, Pancreas",[10751],{"trials":10768,"activeCount":99},[],{"trials":10770,"activeCount":99},[],{"trials":10772,"activeCount":99},[],{"intervention":10774,"totalTrials":121,"cells":10775},"Bromfenac Sodium",{"EARLY_PHASE1":10776,"PHASE1":10778,"PHASE2":10780,"PHASE3":10791,"PHASE4":10793,"NA":10795},{"trials":10777,"activeCount":99},[],{"trials":10779,"activeCount":99},[],{"trials":10781,"activeCount":99},[10782],{"nctId":10783,"briefTitle":10784,"status":166,"phases":10785,"primaryCompletion":10786,"completion":10786,"start":10787,"enrollment":19,"conditions":10788,"interventions":10790},"NCT05107921","Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy",[88],"2024-10-20","2021-11-01",[10789],"Familial Exudative Vitreoretinopathies",[10774],{"trials":10792,"activeCount":99},[],{"trials":10794,"activeCount":99},[],{"trials":10796,"activeCount":99},[],{"intervention":10798,"totalTrials":121,"cells":10799},"HDCT 1",{"EARLY_PHASE1":10800,"PHASE1":10802,"PHASE2":10804,"PHASE3":10813,"PHASE4":10815,"NA":10817},{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[],{"trials":10805,"activeCount":99},[10806],{"nctId":10807,"briefTitle":10808,"status":166,"phases":10809,"primaryCompletion":3510,"completion":3510,"start":3565,"enrollment":9492,"conditions":10810,"interventions":10812},"NCT01342237","Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors",[88],[10811],"Brain Tumors",[10798],{"trials":10814,"activeCount":99},[],{"trials":10816,"activeCount":99},[],{"trials":10818,"activeCount":99},[],{"intervention":797,"totalTrials":121,"cells":10820},{"EARLY_PHASE1":10821,"PHASE1":10823,"PHASE2":10825,"PHASE3":10831,"PHASE4":10833,"NA":10835},{"trials":10822,"activeCount":99},[],{"trials":10824,"activeCount":99},[],{"trials":10826,"activeCount":99},[10827],{"nctId":787,"briefTitle":788,"status":154,"phases":10828,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":10829,"interventions":10830},[88],[794],[796,797,184,772,798],{"trials":10832,"activeCount":99},[],{"trials":10834,"activeCount":99},[],{"trials":10836,"activeCount":99},[],{"intervention":798,"totalTrials":121,"cells":10838},{"EARLY_PHASE1":10839,"PHASE1":10841,"PHASE2":10843,"PHASE3":10849,"PHASE4":10851,"NA":10853},{"trials":10840,"activeCount":99},[],{"trials":10842,"activeCount":99},[],{"trials":10844,"activeCount":99},[10845],{"nctId":787,"briefTitle":788,"status":154,"phases":10846,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":10847,"interventions":10848},[88],[794],[796,797,184,772,798],{"trials":10850,"activeCount":99},[],{"trials":10852,"activeCount":99},[],{"trials":10854,"activeCount":99},[],{"intervention":10856,"totalTrials":121,"cells":10857},"Vortioxetine",{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10873,"PHASE4":10875,"NA":10877},{"trials":10859,"activeCount":99},[],{"trials":10861,"activeCount":99},[],{"trials":10863,"activeCount":99},[10864],{"nctId":10865,"briefTitle":10866,"status":166,"phases":10867,"primaryCompletion":10868,"completion":10868,"start":10869,"enrollment":1743,"conditions":10870,"interventions":10872},"NCT03598868","Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression",[88],"2021-09-25","2018-08-08",[10871],"Bipolar Disorder Depression",[10856],{"trials":10874,"activeCount":99},[],{"trials":10876,"activeCount":99},[],{"trials":10878,"activeCount":99},[],{"intervention":10880,"totalTrials":121,"cells":10881},"Camostat mesylate",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10899,"PHASE4":10901,"NA":10903},{"trials":10883,"activeCount":99},[],{"trials":10885,"activeCount":99},[],{"trials":10887,"activeCount":99},[10888],{"nctId":10889,"briefTitle":10890,"status":154,"phases":10891,"primaryCompletion":10892,"completion":10893,"start":593,"enrollment":1196,"conditions":10894,"interventions":10898},"NCT05474664","Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation",[88],"2024-07-12","2024-10-08",[10895,10896,10897],"Fontan Operation","Protein-Losing Enteropathy","Camostat Mesylate",[10880],{"trials":10900,"activeCount":99},[],{"trials":10902,"activeCount":99},[],{"trials":10904,"activeCount":99},[],{"intervention":10906,"totalTrials":121,"cells":10907},"TH-302 monotherapy",{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10912,"PHASE3":10920,"PHASE4":10922,"NA":10924},{"trials":10909,"activeCount":99},[],{"trials":10911,"activeCount":99},[],{"trials":10913,"activeCount":99},[10914],{"nctId":10915,"briefTitle":10916,"status":154,"phases":10917,"primaryCompletion":2101,"completion":2101,"start":702,"enrollment":411,"conditions":10918,"interventions":10919},"NCT02433639","Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer",[88],[10581],[10906],{"trials":10921,"activeCount":99},[],{"trials":10923,"activeCount":99},[],{"trials":10925,"activeCount":99},[],{"intervention":9815,"totalTrials":121,"cells":10927},{"EARLY_PHASE1":10928,"PHASE1":10930,"PHASE2":10932,"PHASE3":10938,"PHASE4":10940,"NA":10942},{"trials":10929,"activeCount":99},[],{"trials":10931,"activeCount":99},[],{"trials":10933,"activeCount":99},[10934],{"nctId":9808,"briefTitle":9809,"status":154,"phases":10935,"primaryCompletion":5092,"completion":3554,"start":7680,"enrollment":170,"conditions":10936,"interventions":10937},[88],[9812,9813],[9799,9815],{"trials":10939,"activeCount":99},[],{"trials":10941,"activeCount":99},[],{"trials":10943,"activeCount":99},[],{"intervention":10945,"totalTrials":121,"cells":10946},"Mirabegron 50 MG",{"EARLY_PHASE1":10947,"PHASE1":10949,"PHASE2":10951,"PHASE3":10963,"PHASE4":10965,"NA":10967},{"trials":10948,"activeCount":99},[],{"trials":10950,"activeCount":99},[],{"trials":10952,"activeCount":99},[10953],{"nctId":10954,"briefTitle":10955,"status":166,"phases":10956,"primaryCompletion":10957,"completion":10958,"start":10959,"enrollment":2053,"conditions":10960,"interventions":10961},"NCT06181591","A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)",[88],"2025-04-01","2025-04-15","2024-04-01",[3936],[10945,10962],"Oxybutynin Chloride 5 MG",{"trials":10964,"activeCount":99},[],{"trials":10966,"activeCount":99},[],{"trials":10968,"activeCount":99},[],{"intervention":10962,"totalTrials":121,"cells":10970},{"EARLY_PHASE1":10971,"PHASE1":10973,"PHASE2":10975,"PHASE3":10981,"PHASE4":10983,"NA":10985},{"trials":10972,"activeCount":99},[],{"trials":10974,"activeCount":99},[],{"trials":10976,"activeCount":99},[10977],{"nctId":10954,"briefTitle":10955,"status":166,"phases":10978,"primaryCompletion":10957,"completion":10958,"start":10959,"enrollment":2053,"conditions":10979,"interventions":10980},[88],[3936],[10945,10962],{"trials":10982,"activeCount":99},[],{"trials":10984,"activeCount":99},[],{"trials":10986,"activeCount":99},[],{"intervention":10988,"totalTrials":121,"cells":10989},"docetaxel+CDDP",{"EARLY_PHASE1":10990,"PHASE1":10992,"PHASE2":10994,"PHASE3":11004,"PHASE4":11006,"NA":11008},{"trials":10991,"activeCount":99},[],{"trials":10993,"activeCount":99},[],{"trials":10995,"activeCount":99},[10996],{"nctId":10997,"briefTitle":10998,"status":1813,"phases":10999,"primaryCompletion":7724,"completion":7724,"start":7381,"enrollment":594,"conditions":11000,"interventions":11002},"NCT00805012","Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)",[88],[11001],"Head and Neck Squamous Cell Carcinoma",[10988,11003],"docetaxel+S-1",{"trials":11005,"activeCount":99},[],{"trials":11007,"activeCount":99},[],{"trials":11009,"activeCount":99},[],{"intervention":11003,"totalTrials":121,"cells":11011},{"EARLY_PHASE1":11012,"PHASE1":11014,"PHASE2":11016,"PHASE3":11022,"PHASE4":11024,"NA":11026},{"trials":11013,"activeCount":99},[],{"trials":11015,"activeCount":99},[],{"trials":11017,"activeCount":99},[11018],{"nctId":10997,"briefTitle":10998,"status":1813,"phases":11019,"primaryCompletion":7724,"completion":7724,"start":7381,"enrollment":594,"conditions":11020,"interventions":11021},[88],[11001],[10988,11003],{"trials":11023,"activeCount":99},[],{"trials":11025,"activeCount":99},[],{"trials":11027,"activeCount":99},[],{"intervention":9848,"totalTrials":121,"cells":11029},{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11034,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11031,"activeCount":99},[],{"trials":11033,"activeCount":99},[],{"trials":11035,"activeCount":99},[11036],{"nctId":9842,"briefTitle":9843,"status":1813,"phases":11037,"primaryCompletion":3649,"completion":3649,"start":674,"enrollment":1036,"conditions":11038,"interventions":11039},[88],[9846],[9848,7870,9849],{"trials":11041,"activeCount":99},[],{"trials":11043,"activeCount":99},[],{"trials":11045,"activeCount":99},[],{"intervention":11047,"totalTrials":121,"cells":11048},"Dopamine",{"EARLY_PHASE1":11049,"PHASE1":11051,"PHASE2":11053,"PHASE3":11062,"PHASE4":11064,"NA":11066},{"trials":11050,"activeCount":99},[],{"trials":11052,"activeCount":99},[],{"trials":11054,"activeCount":99},[11055],{"nctId":11056,"briefTitle":11057,"status":166,"phases":11058,"primaryCompletion":1010,"completion":1010,"start":11059,"enrollment":850,"conditions":11060,"interventions":11061},"NCT04525495","Dopamine in Neonate",[88],"2020-04-01",[9732],[11047],{"trials":11063,"activeCount":99},[],{"trials":11065,"activeCount":99},[],{"trials":11067,"activeCount":99},[],{"intervention":11069,"totalTrials":121,"cells":11070},"Acalabrutinib",{"EARLY_PHASE1":11071,"PHASE1":11073,"PHASE2":11075,"PHASE3":11086,"PHASE4":11088,"NA":11090},{"trials":11072,"activeCount":99},[],{"trials":11074,"activeCount":99},[],{"trials":11076,"activeCount":99},[11077],{"nctId":11078,"briefTitle":11079,"status":154,"phases":11080,"primaryCompletion":11081,"completion":11081,"start":11082,"enrollment":569,"conditions":11083,"interventions":11085},"NCT04094142","Acalabrutinib With Rituximab and Lenalidomide in Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[88],"2022-05-15","2019-07-09",[11084],"Non-hodgkin Lymphoma,B Cell",[11069],{"trials":11087,"activeCount":99},[],{"trials":11089,"activeCount":99},[],{"trials":11091,"activeCount":99},[],{"intervention":11093,"totalTrials":121,"cells":11094},"genexolPM + cisplatin",{"EARLY_PHASE1":11095,"PHASE1":11097,"PHASE2":11099,"PHASE3":11109,"PHASE4":11111,"NA":11113},{"trials":11096,"activeCount":99},[],{"trials":11098,"activeCount":99},[],{"trials":11100,"activeCount":99},[11101],{"nctId":11102,"briefTitle":11103,"status":154,"phases":11104,"primaryCompletion":3649,"completion":11105,"start":1815,"enrollment":1246,"conditions":11106,"interventions":11108},"NCT01689194","Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer",[88],"2017-08-31",[11107],"Locally Advanced Head and Neck Squamous Cell Carcinoma",[11093],{"trials":11110,"activeCount":99},[],{"trials":11112,"activeCount":99},[],{"trials":11114,"activeCount":99},[],{"intervention":11116,"totalTrials":121,"cells":11117},"Proleukin",{"EARLY_PHASE1":11118,"PHASE1":11120,"PHASE2":11122,"PHASE3":11132,"PHASE4":11134,"NA":11136},{"trials":11119,"activeCount":99},[],{"trials":11121,"activeCount":99},[],{"trials":11123,"activeCount":99},[11124],{"nctId":11125,"briefTitle":11126,"status":154,"phases":11127,"primaryCompletion":11128,"completion":11128,"start":1978,"enrollment":2470,"conditions":11129,"interventions":11131},"NCT02714959","IL-2 in Refractory Autoimmune Encephalitis",[87,88],"2019-06-12",[11130],"Encephalitis",[11116],{"trials":11133,"activeCount":99},[],{"trials":11135,"activeCount":99},[],{"trials":11137,"activeCount":99},[],{"intervention":1084,"totalTrials":121,"cells":11139},{"EARLY_PHASE1":11140,"PHASE1":11142,"PHASE2":11144,"PHASE3":11150,"PHASE4":11152,"NA":11154},{"trials":11141,"activeCount":99},[],{"trials":11143,"activeCount":99},[],{"trials":11145,"activeCount":99},[11146],{"nctId":1075,"briefTitle":1076,"status":166,"phases":11147,"primaryCompletion":1078,"completion":75,"start":1079,"enrollment":1080,"conditions":11148,"interventions":11149},[88],[1082],[995,1084,1085,1086],{"trials":11151,"activeCount":99},[],{"trials":11153,"activeCount":99},[],{"trials":11155,"activeCount":99},[],{"intervention":11157,"totalTrials":121,"cells":11158},"Pemetrexed + Vinorelbine",{"EARLY_PHASE1":11159,"PHASE1":11161,"PHASE2":11163,"PHASE3":11175,"PHASE4":11177,"NA":11179},{"trials":11160,"activeCount":99},[],{"trials":11162,"activeCount":99},[],{"trials":11164,"activeCount":99},[11165],{"nctId":11166,"briefTitle":11167,"status":154,"phases":11168,"primaryCompletion":11169,"completion":11170,"start":11171,"enrollment":28,"conditions":11172,"interventions":11173},"NCT03242616","PemVin vs Vin in Previously Treated Metastatic Breast Cancer",[88],"2023-12-05","2024-04-15","2017-02-17",[1004],[11157,11174],"Vinorelbine",{"trials":11176,"activeCount":99},[],{"trials":11178,"activeCount":99},[],{"trials":11180,"activeCount":99},[],{"intervention":11174,"totalTrials":121,"cells":11182},{"EARLY_PHASE1":11183,"PHASE1":11185,"PHASE2":11187,"PHASE3":11193,"PHASE4":11195,"NA":11197},{"trials":11184,"activeCount":99},[],{"trials":11186,"activeCount":99},[],{"trials":11188,"activeCount":99},[11189],{"nctId":11166,"briefTitle":11167,"status":154,"phases":11190,"primaryCompletion":11169,"completion":11170,"start":11171,"enrollment":28,"conditions":11191,"interventions":11192},[88],[1004],[11157,11174],{"trials":11194,"activeCount":99},[],{"trials":11196,"activeCount":99},[],{"trials":11198,"activeCount":99},[],{"intervention":11200,"totalTrials":121,"cells":11201},"[11C] -verapamil PET",{"EARLY_PHASE1":11202,"PHASE1":11204,"PHASE2":11206,"PHASE3":11214,"PHASE4":11216,"NA":11218},{"trials":11203,"activeCount":99},[],{"trials":11205,"activeCount":99},[],{"trials":11207,"activeCount":99},[11208],{"nctId":11209,"briefTitle":11210,"status":166,"phases":11211,"primaryCompletion":1957,"completion":578,"start":3966,"enrollment":850,"conditions":11212,"interventions":11213},"NCT02144792","Development and Clinical Application of [11C]Verapamil-PET",[88],[10292],[11200],{"trials":11215,"activeCount":99},[],{"trials":11217,"activeCount":99},[],{"trials":11219,"activeCount":99},[],{"intervention":11221,"totalTrials":121,"cells":11222},"midazolam and fentanyl citrate",{"EARLY_PHASE1":11223,"PHASE1":11225,"PHASE2":11227,"PHASE3":11237,"PHASE4":11239,"NA":11241},{"trials":11224,"activeCount":99},[],{"trials":11226,"activeCount":99},[],{"trials":11228,"activeCount":99},[11229],{"nctId":11230,"briefTitle":11231,"status":154,"phases":11232,"primaryCompletion":1771,"completion":1771,"start":157,"enrollment":2053,"conditions":11233,"interventions":11235},"NCT02172014","Safety and Efficacy of Fentanyl Citrate in Children",[88],[11234],"Children",[11221,11236],"midazolam and normal saline",{"trials":11238,"activeCount":99},[],{"trials":11240,"activeCount":99},[],{"trials":11242,"activeCount":99},[],{"intervention":11236,"totalTrials":121,"cells":11244},{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11249,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11246,"activeCount":99},[],{"trials":11248,"activeCount":99},[],{"trials":11250,"activeCount":99},[11251],{"nctId":11230,"briefTitle":11231,"status":154,"phases":11252,"primaryCompletion":1771,"completion":1771,"start":157,"enrollment":2053,"conditions":11253,"interventions":11254},[88],[11234],[11221,11236],{"trials":11256,"activeCount":99},[],{"trials":11258,"activeCount":99},[],{"trials":11260,"activeCount":99},[],{"intervention":11262,"totalTrials":121,"cells":11263},"levetiracetam",{"EARLY_PHASE1":11264,"PHASE1":11266,"PHASE2":11268,"PHASE3":11279,"PHASE4":11281,"NA":11283},{"trials":11265,"activeCount":99},[],{"trials":11267,"activeCount":99},[],{"trials":11269,"activeCount":99},[11270],{"nctId":11271,"briefTitle":11272,"status":166,"phases":11273,"primaryCompletion":11274,"completion":11275,"start":2052,"enrollment":550,"conditions":11276,"interventions":11278},"NCT02815410","Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients",[88],"2019-06","2022-06",[11277],"Glioblastoma Multiforme",[11262],{"trials":11280,"activeCount":99},[],{"trials":11282,"activeCount":99},[],{"trials":11284,"activeCount":99},[],{"intervention":11286,"totalTrials":121,"cells":11287},"Bortezomib, Cytarabine, Dexamethasone, Pegteograstim",{"EARLY_PHASE1":11288,"PHASE1":11290,"PHASE2":11292,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11289,"activeCount":99},[],{"trials":11291,"activeCount":99},[],{"trials":11293,"activeCount":99},[11294],{"nctId":11295,"briefTitle":11296,"status":154,"phases":11297,"primaryCompletion":11298,"completion":1010,"start":11299,"enrollment":1196,"conditions":11300,"interventions":11302},"NCT02840539","Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma",[88],"2021-03-31","2016-10-11",[11301],"Mantle Cell Lymphoma",[11286],{"trials":11304,"activeCount":99},[],{"trials":11306,"activeCount":99},[],{"trials":11308,"activeCount":99},[],{"intervention":2070,"totalTrials":121,"cells":11310},{"EARLY_PHASE1":11311,"PHASE1":11313,"PHASE2":11315,"PHASE3":11321,"PHASE4":11323,"NA":11325},{"trials":11312,"activeCount":99},[],{"trials":11314,"activeCount":99},[],{"trials":11316,"activeCount":99},[11317],{"nctId":2061,"briefTitle":2062,"status":154,"phases":11318,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":850,"conditions":11319,"interventions":11320},[88],[2068],[2070,2071,2072,270],{"trials":11322,"activeCount":99},[],{"trials":11324,"activeCount":99},[],{"trials":11326,"activeCount":99},[],{"intervention":2071,"totalTrials":121,"cells":11328},{"EARLY_PHASE1":11329,"PHASE1":11331,"PHASE2":11333,"PHASE3":11339,"PHASE4":11341,"NA":11343},{"trials":11330,"activeCount":99},[],{"trials":11332,"activeCount":99},[],{"trials":11334,"activeCount":99},[11335],{"nctId":2061,"briefTitle":2062,"status":154,"phases":11336,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":850,"conditions":11337,"interventions":11338},[88],[2068],[2070,2071,2072,270],{"trials":11340,"activeCount":99},[],{"trials":11342,"activeCount":99},[],{"trials":11344,"activeCount":99},[],{"intervention":2072,"totalTrials":121,"cells":11346},{"EARLY_PHASE1":11347,"PHASE1":11349,"PHASE2":11351,"PHASE3":11357,"PHASE4":11359,"NA":11361},{"trials":11348,"activeCount":99},[],{"trials":11350,"activeCount":99},[],{"trials":11352,"activeCount":99},[11353],{"nctId":2061,"briefTitle":2062,"status":154,"phases":11354,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":850,"conditions":11355,"interventions":11356},[88],[2068],[2070,2071,2072,270],{"trials":11358,"activeCount":99},[],{"trials":11360,"activeCount":99},[],{"trials":11362,"activeCount":99},[],{"intervention":11364,"totalTrials":121,"cells":11365},"brentuximab vedotin",{"EARLY_PHASE1":11366,"PHASE1":11368,"PHASE2":11370,"PHASE3":11381,"PHASE4":11383,"NA":11385},{"trials":11367,"activeCount":99},[],{"trials":11369,"activeCount":99},[],{"trials":11371,"activeCount":99},[11372],{"nctId":11373,"briefTitle":11374,"status":154,"phases":11375,"primaryCompletion":11376,"completion":11376,"start":11377,"enrollment":22,"conditions":11378,"interventions":11380},"NCT02388490","Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas",[88],"2019-04-02","2016-03-25",[11379],"Relapsed or Refractory EBV-and CD30-positive Lymphomas",[11364],{"trials":11382,"activeCount":99},[],{"trials":11384,"activeCount":99},[],{"trials":11386,"activeCount":99},[],{"intervention":11388,"totalTrials":121,"cells":11389},"MG4101",{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11394,"PHASE3":11406,"PHASE4":11408,"NA":11410},{"trials":11391,"activeCount":99},[],{"trials":11393,"activeCount":99},[],{"trials":11395,"activeCount":99},[11396],{"nctId":11397,"briefTitle":11398,"status":154,"phases":11399,"primaryCompletion":11400,"completion":11401,"start":11402,"enrollment":5720,"conditions":11403,"interventions":11405},"NCT03349502","MG4101 for Refractory or Relapsed AML",[88],"2020-03-30","2020-04-30","2017-11-01",[11404],"Acute Myeloid Leukemia",[11388],{"trials":11407,"activeCount":99},[],{"trials":11409,"activeCount":99},[],{"trials":11411,"activeCount":99},[],{"intervention":11413,"totalTrials":121,"cells":11414},"Decitabine with GemOx",{"EARLY_PHASE1":11415,"PHASE1":11417,"PHASE2":11419,"PHASE3":11431,"PHASE4":11433,"NA":11435},{"trials":11416,"activeCount":99},[],{"trials":11418,"activeCount":99},[],{"trials":11420,"activeCount":99},[11421],{"nctId":11422,"briefTitle":11423,"status":1813,"phases":11424,"primaryCompletion":11425,"completion":2305,"start":11426,"enrollment":28,"conditions":11427,"interventions":11429},"NCT06941688","Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed\u002FRefractory Peripheral T-cell Lymphoma",[88],"2024-08-13","2020-11-13",[11428],"Peripheral T-cell Lymphoma (PTCL)",[11413,11430],"GemOx",{"trials":11432,"activeCount":99},[],{"trials":11434,"activeCount":99},[],{"trials":11436,"activeCount":99},[],{"intervention":11430,"totalTrials":121,"cells":11438},{"EARLY_PHASE1":11439,"PHASE1":11441,"PHASE2":11443,"PHASE3":11449,"PHASE4":11451,"NA":11453},{"trials":11440,"activeCount":99},[],{"trials":11442,"activeCount":99},[],{"trials":11444,"activeCount":99},[11445],{"nctId":11422,"briefTitle":11423,"status":1813,"phases":11446,"primaryCompletion":11425,"completion":2305,"start":11426,"enrollment":28,"conditions":11447,"interventions":11448},[88],[11428],[11413,11430],{"trials":11450,"activeCount":99},[],{"trials":11452,"activeCount":99},[],{"trials":11454,"activeCount":99},[],{"intervention":7861,"totalTrials":121,"cells":11456},{"EARLY_PHASE1":11457,"PHASE1":11459,"PHASE2":11461,"PHASE3":11467,"PHASE4":11469,"NA":11471},{"trials":11458,"activeCount":99},[],{"trials":11460,"activeCount":99},[],{"trials":11462,"activeCount":99},[11463],{"nctId":7855,"briefTitle":7856,"status":166,"phases":11464,"primaryCompletion":75,"completion":1000,"start":7858,"enrollment":380,"conditions":11465,"interventions":11466},[88],[35],[7861,3164,7846,7862],{"trials":11468,"activeCount":99},[],{"trials":11470,"activeCount":99},[],{"trials":11472,"activeCount":99},[],{"intervention":11474,"totalTrials":121,"cells":11475},"Posaconazole",{"EARLY_PHASE1":11476,"PHASE1":11478,"PHASE2":11480,"PHASE3":11493,"PHASE4":11495,"NA":11497},{"trials":11477,"activeCount":99},[],{"trials":11479,"activeCount":99},[],{"trials":11481,"activeCount":99},[11482],{"nctId":11483,"briefTitle":11484,"status":154,"phases":11485,"primaryCompletion":11486,"completion":11486,"start":11487,"enrollment":1221,"conditions":11488,"interventions":11492},"NCT03318159","Posaconazole Prophylaxis During ATG Treatment for hMDS\u002FAA Patients",[88],"2023-07-15","2018-04-20",[11489,11490,11491],"Aplastic Anemia","Myelodysplastic Syndromes","Fungal Infection",[11474],{"trials":11494,"activeCount":99},[],{"trials":11496,"activeCount":99},[],{"trials":11498,"activeCount":99},[],{"intervention":11500,"totalTrials":121,"cells":11501},"Haploidentical NK cell",{"EARLY_PHASE1":11502,"PHASE1":11504,"PHASE2":11506,"PHASE3":11515,"PHASE4":11517,"NA":11519},{"trials":11503,"activeCount":99},[],{"trials":11505,"activeCount":99},[],{"trials":11507,"activeCount":99},[11508],{"nctId":11509,"briefTitle":11510,"status":154,"phases":11511,"primaryCompletion":619,"completion":1854,"start":8857,"enrollment":210,"conditions":11512,"interventions":11514},"NCT00846833","Haploidentical NK Cell Infusion in Malignant Melanoma",[87,88],[11513],"Melanoma",[11500],{"trials":11516,"activeCount":99},[],{"trials":11518,"activeCount":99},[],{"trials":11520,"activeCount":99},[],{"intervention":9675,"totalTrials":121,"cells":11522},{"EARLY_PHASE1":11523,"PHASE1":11525,"PHASE2":11527,"PHASE3":11533,"PHASE4":11535,"NA":11537},{"trials":11524,"activeCount":99},[],{"trials":11526,"activeCount":99},[],{"trials":11528,"activeCount":99},[11529],{"nctId":9668,"briefTitle":9669,"status":154,"phases":11530,"primaryCompletion":9671,"completion":9672,"start":2141,"enrollment":1583,"conditions":11531,"interventions":11532},[88],[9664,9665],[9675,9676,9677,9678,9649],{"trials":11534,"activeCount":99},[],{"trials":11536,"activeCount":99},[],{"trials":11538,"activeCount":99},[],{"intervention":9676,"totalTrials":121,"cells":11540},{"EARLY_PHASE1":11541,"PHASE1":11543,"PHASE2":11545,"PHASE3":11551,"PHASE4":11553,"NA":11555},{"trials":11542,"activeCount":99},[],{"trials":11544,"activeCount":99},[],{"trials":11546,"activeCount":99},[11547],{"nctId":9668,"briefTitle":9669,"status":154,"phases":11548,"primaryCompletion":9671,"completion":9672,"start":2141,"enrollment":1583,"conditions":11549,"interventions":11550},[88],[9664,9665],[9675,9676,9677,9678,9649],{"trials":11552,"activeCount":99},[],{"trials":11554,"activeCount":99},[],{"trials":11556,"activeCount":99},[],{"intervention":9677,"totalTrials":121,"cells":11558},{"EARLY_PHASE1":11559,"PHASE1":11561,"PHASE2":11563,"PHASE3":11569,"PHASE4":11571,"NA":11573},{"trials":11560,"activeCount":99},[],{"trials":11562,"activeCount":99},[],{"trials":11564,"activeCount":99},[11565],{"nctId":9668,"briefTitle":9669,"status":154,"phases":11566,"primaryCompletion":9671,"completion":9672,"start":2141,"enrollment":1583,"conditions":11567,"interventions":11568},[88],[9664,9665],[9675,9676,9677,9678,9649],{"trials":11570,"activeCount":99},[],{"trials":11572,"activeCount":99},[],{"trials":11574,"activeCount":99},[],{"intervention":11576,"totalTrials":121,"cells":11577},"Durvalumab + doxorubicin + ifosfamide",{"EARLY_PHASE1":11578,"PHASE1":11580,"PHASE2":11582,"PHASE3":11594,"PHASE4":11596,"NA":11598},{"trials":11579,"activeCount":99},[],{"trials":11581,"activeCount":99},[],{"trials":11583,"activeCount":99},[11584],{"nctId":11585,"briefTitle":11586,"status":154,"phases":11587,"primaryCompletion":11588,"completion":11589,"start":11590,"enrollment":33,"conditions":11591,"interventions":11593},"NCT04224337","Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma",[88],"2023-08-14","2025-05-07","2020-06-11",[11592],"Carcinoma, Non-Small-Cell Lung",[11576],{"trials":11595,"activeCount":99},[],{"trials":11597,"activeCount":99},[],{"trials":11599,"activeCount":99},[],{"intervention":11601,"totalTrials":121,"cells":11602},"Propess insertion group",{"EARLY_PHASE1":11603,"PHASE1":11605,"PHASE2":11607,"PHASE3":11620,"PHASE4":11622,"NA":11624},{"trials":11604,"activeCount":99},[],{"trials":11606,"activeCount":99},[],{"trials":11608,"activeCount":99},[11609],{"nctId":11610,"briefTitle":11611,"status":154,"phases":11612,"primaryCompletion":11613,"completion":11614,"start":11615,"enrollment":11616,"conditions":11617,"interventions":11619},"NCT01916291","Safety and Efficacy of Dinoprostone (Propess) in the Women With Premature Rupture of Membrane or Gestational Age \u003C38",[88],"2018-08-14","2019-04-04","2013-08-25",189,[11618],"Induction of Labor",[11601],{"trials":11621,"activeCount":99},[],{"trials":11623,"activeCount":99},[],{"trials":11625,"activeCount":99},[],{"intervention":11627,"totalTrials":121,"cells":11628},"remicade",{"EARLY_PHASE1":11629,"PHASE1":11631,"PHASE2":11633,"PHASE3":11644,"PHASE4":11646,"NA":11648},{"trials":11630,"activeCount":99},[],{"trials":11632,"activeCount":99},[],{"trials":11634,"activeCount":99},[11635],{"nctId":11636,"briefTitle":11637,"status":166,"phases":11638,"primaryCompletion":11639,"completion":11640,"start":2622,"enrollment":5720,"conditions":11641,"interventions":11643},"NCT02457585","Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis",[88],"2017-08","2018-04",[11642],"Takayasu's Arteritis",[11627],{"trials":11645,"activeCount":99},[],{"trials":11647,"activeCount":99},[],{"trials":11649,"activeCount":99},[],{"intervention":11651,"totalTrials":121,"cells":11652},"gemcitabine and cisplatin",{"EARLY_PHASE1":11653,"PHASE1":11655,"PHASE2":11657,"PHASE3":11665,"PHASE4":11667,"NA":11669},{"trials":11654,"activeCount":99},[],{"trials":11656,"activeCount":99},[],{"trials":11658,"activeCount":99},[11659],{"nctId":11660,"briefTitle":11661,"status":154,"phases":11662,"primaryCompletion":2394,"completion":2394,"start":5001,"enrollment":1444,"conditions":11663,"interventions":11664},"NCT01396681","Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer",[88],[35],[11651],{"trials":11666,"activeCount":99},[],{"trials":11668,"activeCount":99},[],{"trials":11670,"activeCount":99},[],{"intervention":11672,"totalTrials":121,"cells":11673},"Fluconazole",{"EARLY_PHASE1":11674,"PHASE1":11676,"PHASE2":11678,"PHASE3":11686,"PHASE4":11688,"NA":11690},{"trials":11675,"activeCount":99},[],{"trials":11677,"activeCount":99},[],{"trials":11679,"activeCount":99},[11680],{"nctId":11681,"briefTitle":11682,"status":154,"phases":11683,"primaryCompletion":2294,"completion":2294,"start":660,"enrollment":180,"conditions":11684,"interventions":11685},"NCT01683760","Pharmacokinetic Study of Fluconazole in Premature Infants",[88],[9463],[11672],{"trials":11687,"activeCount":99},[],{"trials":11689,"activeCount":99},[],{"trials":11691,"activeCount":99},[],{"intervention":11693,"totalTrials":121,"cells":11694},"induction chemotherapy",{"EARLY_PHASE1":11695,"PHASE1":11697,"PHASE2":11699,"PHASE3":11708,"PHASE4":11710,"NA":11712},{"trials":11696,"activeCount":99},[],{"trials":11698,"activeCount":99},[],{"trials":11700,"activeCount":99},[11701],{"nctId":11702,"briefTitle":11703,"status":154,"phases":11704,"primaryCompletion":7013,"completion":10099,"start":11705,"enrollment":1958,"conditions":11706,"interventions":11707},"NCT01247493","Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)",[88],"2007-06",[11404],[11693],{"trials":11709,"activeCount":99},[],{"trials":11711,"activeCount":99},[],{"trials":11713,"activeCount":99},[],{"intervention":11715,"totalTrials":121,"cells":11716},"Fludarabine",{"EARLY_PHASE1":11717,"PHASE1":11719,"PHASE2":11721,"PHASE3":11732,"PHASE4":11734,"NA":11736},{"trials":11718,"activeCount":99},[],{"trials":11720,"activeCount":99},[],{"trials":11722,"activeCount":99},[11723],{"nctId":11724,"briefTitle":11725,"status":166,"phases":11726,"primaryCompletion":2041,"completion":2041,"start":11727,"enrollment":3557,"conditions":11728,"interventions":11731},"NCT01472055","Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation",[88],"2011-10",[9994,11729,11730],"Chronic Leukemia","Severe Aplastic Anemia",[11715],{"trials":11733,"activeCount":99},[],{"trials":11735,"activeCount":99},[],{"trials":11737,"activeCount":99},[],{"intervention":11739,"totalTrials":121,"cells":11740},"High dose IVIG and B cell depleting agents",{"EARLY_PHASE1":11741,"PHASE1":11743,"PHASE2":11745,"PHASE3":11754,"PHASE4":11756,"NA":11758},{"trials":11742,"activeCount":99},[],{"trials":11744,"activeCount":99},[],{"trials":11746,"activeCount":99},[11747],{"nctId":11748,"briefTitle":11749,"status":166,"phases":11750,"primaryCompletion":732,"completion":791,"start":3576,"enrollment":95,"conditions":11751,"interventions":11753},"NCT01502267","Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant",[88],[11752],"End Stage Renal Disease",[11739],{"trials":11755,"activeCount":99},[],{"trials":11757,"activeCount":99},[],{"trials":11759,"activeCount":99},[],{"intervention":11761,"totalTrials":121,"cells":11762},"Dienogest",{"EARLY_PHASE1":11763,"PHASE1":11765,"PHASE2":11767,"PHASE3":11778,"PHASE4":11780,"NA":11782},{"trials":11764,"activeCount":99},[],{"trials":11766,"activeCount":99},[],{"trials":11768,"activeCount":99},[11769],{"nctId":11770,"briefTitle":11771,"status":658,"phases":11772,"primaryCompletion":11773,"completion":11773,"start":2101,"enrollment":99,"conditions":11774,"interventions":11777},"NCT02728245","Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma",[88],"2018-03",[11775,11776],"Ovarian Reserve","Endometriosis",[11761],{"trials":11779,"activeCount":99},[],{"trials":11781,"activeCount":99},[],{"trials":11783,"activeCount":99},[],{"intervention":9788,"totalTrials":121,"cells":11785},{"EARLY_PHASE1":11786,"PHASE1":11788,"PHASE2":11790,"PHASE3":11796,"PHASE4":11798,"NA":11800},{"trials":11787,"activeCount":99},[],{"trials":11789,"activeCount":99},[],{"trials":11791,"activeCount":99},[11792],{"nctId":9781,"briefTitle":9782,"status":166,"phases":11793,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":11794,"interventions":11795},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":11797,"activeCount":99},[],{"trials":11799,"activeCount":99},[],{"trials":11801,"activeCount":99},[],{"intervention":9789,"totalTrials":121,"cells":11803},{"EARLY_PHASE1":11804,"PHASE1":11806,"PHASE2":11808,"PHASE3":11814,"PHASE4":11816,"NA":11818},{"trials":11805,"activeCount":99},[],{"trials":11807,"activeCount":99},[],{"trials":11809,"activeCount":99},[11810],{"nctId":9781,"briefTitle":9782,"status":166,"phases":11811,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":11812,"interventions":11813},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":11815,"activeCount":99},[],{"trials":11817,"activeCount":99},[],{"trials":11819,"activeCount":99},[],{"intervention":9791,"totalTrials":121,"cells":11821},{"EARLY_PHASE1":11822,"PHASE1":11824,"PHASE2":11826,"PHASE3":11832,"PHASE4":11834,"NA":11836},{"trials":11823,"activeCount":99},[],{"trials":11825,"activeCount":99},[],{"trials":11827,"activeCount":99},[11828],{"nctId":9781,"briefTitle":9782,"status":166,"phases":11829,"primaryCompletion":75,"completion":1000,"start":9784,"enrollment":9785,"conditions":11830,"interventions":11831},[88],[35,992],[1085,9788,9763,9789,7862,9790,9791],{"trials":11833,"activeCount":99},[],{"trials":11835,"activeCount":99},[],{"trials":11837,"activeCount":99},[],{"intervention":11839,"totalTrials":121,"cells":11840},"bendamustine plus rituximab",{"EARLY_PHASE1":11841,"PHASE1":11843,"PHASE2":11845,"PHASE3":11854,"PHASE4":11856,"NA":11858},{"trials":11842,"activeCount":99},[],{"trials":11844,"activeCount":99},[],{"trials":11846,"activeCount":99},[11847],{"nctId":11848,"briefTitle":11849,"status":154,"phases":11850,"primaryCompletion":4812,"completion":4812,"start":156,"enrollment":9403,"conditions":11851,"interventions":11853},"NCT02433795","Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",[88],[11852],"Marginal Zone B-cell Lymphoma",[11839],{"trials":11855,"activeCount":99},[],{"trials":11857,"activeCount":99},[],{"trials":11859,"activeCount":99},[],{"intervention":11861,"totalTrials":121,"cells":11862},"MCS110\u002FPDR001 combination",{"EARLY_PHASE1":11863,"PHASE1":11865,"PHASE2":11867,"PHASE3":11876,"PHASE4":11878,"NA":11880},{"trials":11864,"activeCount":99},[],{"trials":11866,"activeCount":99},[],{"trials":11868,"activeCount":99},[11869],{"nctId":11870,"briefTitle":11871,"status":166,"phases":11872,"primaryCompletion":8022,"completion":8022,"start":11873,"enrollment":850,"conditions":11874,"interventions":11875},"NCT03694977","Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer",[88],"2019-01-17",[5295],[11861],{"trials":11877,"activeCount":99},[],{"trials":11879,"activeCount":99},[],{"trials":11881,"activeCount":99},[],{"intervention":9543,"totalTrials":121,"cells":11883},{"EARLY_PHASE1":11884,"PHASE1":11886,"PHASE2":11888,"PHASE3":11894,"PHASE4":11896,"NA":11898},{"trials":11885,"activeCount":99},[],{"trials":11887,"activeCount":99},[],{"trials":11889,"activeCount":99},[11890],{"nctId":9537,"briefTitle":9538,"status":154,"phases":11891,"primaryCompletion":7958,"completion":2551,"start":6182,"enrollment":1889,"conditions":11892,"interventions":11893},[88],[9541],[9543,9511,1086],{"trials":11895,"activeCount":99},[],{"trials":11897,"activeCount":99},[],{"trials":11899,"activeCount":99},[],{"intervention":11901,"totalTrials":121,"cells":11902},"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU",{"EARLY_PHASE1":11903,"PHASE1":11905,"PHASE2":11907,"PHASE3":11917,"PHASE4":11919,"NA":11921},{"trials":11904,"activeCount":99},[],{"trials":11906,"activeCount":99},[],{"trials":11908,"activeCount":99},[11909],{"nctId":11910,"briefTitle":11911,"status":166,"phases":11912,"primaryCompletion":11913,"completion":11913,"start":157,"enrollment":6325,"conditions":11914,"interventions":11916},"NCT01886248","Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation",[88],"2021-08",[11915],"Hepatic Veno-Occlusive Disease",[11901],{"trials":11918,"activeCount":99},[],{"trials":11920,"activeCount":99},[],{"trials":11922,"activeCount":99},[],{"intervention":11924,"totalTrials":121,"cells":11925},"Pazopanib",{"EARLY_PHASE1":11926,"PHASE1":11928,"PHASE2":11930,"PHASE3":11939,"PHASE4":11941,"NA":11943},{"trials":11927,"activeCount":99},[],{"trials":11929,"activeCount":99},[],{"trials":11931,"activeCount":99},[11932],{"nctId":11933,"briefTitle":11934,"status":1813,"phases":11935,"primaryCompletion":4130,"completion":537,"start":3612,"enrollment":525,"conditions":11936,"interventions":11938},"NCT02113826","Pazopanib for Metastatic Alveolar Soft Part Sarcoma",[88],[11937],"Metastatic Alveolar Soft Part Sarcoma",[11924],{"trials":11940,"activeCount":99},[],{"trials":11942,"activeCount":99},[],{"trials":11944,"activeCount":99},[],{"intervention":11946,"totalTrials":121,"cells":11947},"Pegylated liposomal doxorubicin plus Bortezomib",{"EARLY_PHASE1":11948,"PHASE1":11950,"PHASE2":11952,"PHASE3":11964,"PHASE4":11966,"NA":11968},{"trials":11949,"activeCount":99},[],{"trials":11951,"activeCount":99},[],{"trials":11953,"activeCount":99},[11954],{"nctId":11955,"briefTitle":11956,"status":166,"phases":11957,"primaryCompletion":11958,"completion":11958,"start":11959,"enrollment":2053,"conditions":11960,"interventions":11963},"NCT03509246","Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients",[88],"2022-03","2018-05-15",[11961,11962],"Ovarian Neoplasm Epithelial","High Grade Serous Carcinoma",[11946],{"trials":11965,"activeCount":99},[],{"trials":11967,"activeCount":99},[],{"trials":11969,"activeCount":99},[],{"intervention":11971,"totalTrials":121,"cells":11972},"gemcitabine, cisplatin, capecitabine",{"EARLY_PHASE1":11973,"PHASE1":11975,"PHASE2":11977,"PHASE3":11986,"PHASE4":11988,"NA":11990},{"trials":11974,"activeCount":99},[],{"trials":11976,"activeCount":99},[],{"trials":11978,"activeCount":99},[11979],{"nctId":11980,"briefTitle":11981,"status":154,"phases":11982,"primaryCompletion":2394,"completion":2394,"start":5001,"enrollment":11983,"conditions":11984,"interventions":11985},"NCT01396668","Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer",[88],35,[35],[11971],{"trials":11987,"activeCount":99},[],{"trials":11989,"activeCount":99},[],{"trials":11991,"activeCount":99},[],{"intervention":11993,"totalTrials":121,"cells":11994},"Imatinib mesylate, Mycophenolate mofetil",{"EARLY_PHASE1":11995,"PHASE1":11997,"PHASE2":11999,"PHASE3":12009,"PHASE4":12011,"NA":12013},{"trials":11996,"activeCount":99},[],{"trials":11998,"activeCount":99},[],{"trials":12000,"activeCount":99},[12001],{"nctId":12002,"briefTitle":12003,"status":1813,"phases":12004,"primaryCompletion":12005,"completion":12005,"start":2551,"enrollment":10394,"conditions":12006,"interventions":12008},"NCT01898377","Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic\u002FFibrotic cGVHD in Children",[88],"2018-02-14",[12007],"Chronic Graft-versus-host Disease",[11993],{"trials":12010,"activeCount":99},[],{"trials":12012,"activeCount":99},[],{"trials":12014,"activeCount":99},[],{"intervention":12016,"totalTrials":121,"cells":12017},"MODIFIED FOLFOX6",{"EARLY_PHASE1":12018,"PHASE1":12020,"PHASE2":12022,"PHASE3":12031,"PHASE4":12033,"NA":12035},{"trials":12019,"activeCount":99},[],{"trials":12021,"activeCount":99},[],{"trials":12023,"activeCount":99},[12024],{"nctId":12025,"briefTitle":12026,"status":154,"phases":12027,"primaryCompletion":2394,"completion":2394,"start":12028,"enrollment":1946,"conditions":12029,"interventions":12030},"NCT02142322","Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer",[88],"2004-06",[10336],[12016],{"trials":12032,"activeCount":99},[],{"trials":12034,"activeCount":99},[],{"trials":12036,"activeCount":99},[],{"intervention":12038,"totalTrials":121,"cells":12039},"TKI258 (Dovitinib):",{"EARLY_PHASE1":12040,"PHASE1":12042,"PHASE2":12044,"PHASE3":12052,"PHASE4":12054,"NA":12056},{"trials":12041,"activeCount":99},[],{"trials":12043,"activeCount":99},[],{"trials":12045,"activeCount":99},[12046],{"nctId":12047,"briefTitle":12048,"status":154,"phases":12049,"primaryCompletion":264,"completion":701,"start":7680,"enrollment":9492,"conditions":12050,"interventions":12051},"NCT01417143","Dovitinib in Adenoid Cystic Carcinoma",[88],[9494],[12038],{"trials":12053,"activeCount":99},[],{"trials":12055,"activeCount":99},[],{"trials":12057,"activeCount":99},[],{"intervention":12059,"totalTrials":121,"cells":12060},"SOX",{"EARLY_PHASE1":12061,"PHASE1":12063,"PHASE2":12065,"PHASE3":12074,"PHASE4":12076,"NA":12078},{"trials":12062,"activeCount":99},[],{"trials":12064,"activeCount":99},[],{"trials":12066,"activeCount":99},[12067],{"nctId":12068,"briefTitle":12069,"status":166,"phases":12070,"primaryCompletion":264,"completion":264,"start":620,"enrollment":9411,"conditions":12071,"interventions":12073},"NCT01429961","Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma",[88],[12072],"Advanced Hepatocellular Carcinoma",[12059],{"trials":12075,"activeCount":99},[],{"trials":12077,"activeCount":99},[],{"trials":12079,"activeCount":99},[],{"intervention":12081,"totalTrials":121,"cells":12082},"mFOLFOX6",{"EARLY_PHASE1":12083,"PHASE1":12085,"PHASE2":12087,"PHASE3":12095,"PHASE4":12097,"NA":12099},{"trials":12084,"activeCount":99},[],{"trials":12086,"activeCount":99},[],{"trials":12088,"activeCount":99},[12089],{"nctId":12090,"briefTitle":12091,"status":154,"phases":12092,"primaryCompletion":5929,"start":10418,"enrollment":1946,"conditions":12093,"interventions":12094},"NCT01851941","A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer",[88],[10336],[12081],{"trials":12096,"activeCount":99},[],{"trials":12098,"activeCount":99},[],{"trials":12100,"activeCount":99},[],{"intervention":8028,"totalTrials":121,"cells":12102},{"EARLY_PHASE1":12103,"PHASE1":12105,"PHASE2":12107,"PHASE3":12113,"PHASE4":12115,"NA":12117},{"trials":12104,"activeCount":99},[],{"trials":12106,"activeCount":99},[],{"trials":12108,"activeCount":99},[12109],{"nctId":8019,"briefTitle":8020,"status":166,"phases":12110,"primaryCompletion":8022,"completion":4854,"start":8023,"enrollment":8024,"conditions":12111,"interventions":12112},[88],[8026],[8028,8010],{"trials":12114,"activeCount":99},[],{"trials":12116,"activeCount":99},[],{"trials":12118,"activeCount":99},[],{"intervention":12120,"totalTrials":121,"cells":12121},"Avelumab",{"EARLY_PHASE1":12122,"PHASE1":12124,"PHASE2":12126,"PHASE3":12136,"PHASE4":12138,"NA":12140},{"trials":12123,"activeCount":99},[],{"trials":12125,"activeCount":99},[],{"trials":12127,"activeCount":99},[12128],{"nctId":12129,"briefTitle":12130,"status":154,"phases":12131,"primaryCompletion":8022,"completion":12132,"start":12133,"enrollment":850,"conditions":12134,"interventions":12135},"NCT03389126","Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment",[88],"2020-01-31","2017-12-01",[9846],[12120],{"trials":12137,"activeCount":99},[],{"trials":12139,"activeCount":99},[],{"trials":12141,"activeCount":99},[],{"intervention":8060,"totalTrials":121,"cells":12143},{"EARLY_PHASE1":12144,"PHASE1":12146,"PHASE2":12148,"PHASE3":12154,"PHASE4":12156,"NA":12158},{"trials":12145,"activeCount":99},[],{"trials":12147,"activeCount":99},[],{"trials":12149,"activeCount":99},[12150],{"nctId":8055,"briefTitle":8056,"status":154,"phases":12151,"primaryCompletion":2161,"completion":2161,"start":3556,"enrollment":2183,"conditions":12152,"interventions":12153},[88],[18],[8046,8060],{"trials":12155,"activeCount":99},[],{"trials":12157,"activeCount":99},[],{"trials":12159,"activeCount":99},[],{"intervention":12161,"totalTrials":121,"cells":12162},"Temozolomide",{"EARLY_PHASE1":12163,"PHASE1":12165,"PHASE2":12167,"PHASE3":12177,"PHASE4":12179,"NA":12181},{"trials":12164,"activeCount":99},[],{"trials":12166,"activeCount":99},[],{"trials":12168,"activeCount":99},[12169],{"nctId":12170,"briefTitle":12171,"status":154,"phases":12172,"primaryCompletion":169,"completion":1978,"start":3966,"enrollment":25,"conditions":12173,"interventions":12176},"NCT01847235","Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial",[88],[12174,12175],"Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma",[12161],{"trials":12178,"activeCount":99},[],{"trials":12180,"activeCount":99},[],{"trials":12182,"activeCount":99},[],{"intervention":12184,"totalTrials":121,"cells":12185},"durvalumab + tremelimumab",{"EARLY_PHASE1":12186,"PHASE1":12188,"PHASE2":12190,"PHASE3":12201,"PHASE4":12203,"NA":12205},{"trials":12187,"activeCount":99},[],{"trials":12189,"activeCount":99},[],{"trials":12191,"activeCount":99},[12192],{"nctId":12193,"briefTitle":12194,"status":154,"phases":12195,"primaryCompletion":12196,"completion":4553,"start":12197,"enrollment":6325,"conditions":12198,"interventions":12200},"NCT03022500","Pulmonary sarcomatoid_MEDI4736+Treme",[88],"2018-02-28","2017-05-18",[12199],"Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC",[12184],{"trials":12202,"activeCount":99},[],{"trials":12204,"activeCount":99},[],{"trials":12206,"activeCount":99},[],{"intervention":12208,"totalTrials":121,"cells":12209},"Panax Ginseng",{"EARLY_PHASE1":12210,"PHASE1":12212,"PHASE2":12214,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12211,"activeCount":99},[],{"trials":12213,"activeCount":99},[],{"trials":12215,"activeCount":99},[12216],{"nctId":12217,"briefTitle":12218,"status":154,"phases":12219,"completion":12220,"start":12221,"conditions":12222,"interventions":12225},"NCT00391833","Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease",[87,88],"2005-10","2004-04",[12223,12224],"Alzheimer's Disease","Memory Decline",[12208],{"trials":12227,"activeCount":99},[],{"trials":12229,"activeCount":99},[],{"trials":12231,"activeCount":99},[],{"intervention":12233,"totalTrials":121,"cells":12234},"TS-1 and Eloxatin",{"EARLY_PHASE1":12235,"PHASE1":12237,"PHASE2":12239,"PHASE3":12247,"PHASE4":12249,"NA":12251},{"trials":12236,"activeCount":99},[],{"trials":12238,"activeCount":99},[],{"trials":12240,"activeCount":99},[12241],{"nctId":12242,"briefTitle":12243,"status":154,"phases":12244,"primaryCompletion":579,"completion":579,"start":7506,"enrollment":4131,"conditions":12245,"interventions":12246},"NCT00527930","Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer",[88],[1004],[12233],{"trials":12248,"activeCount":99},[],{"trials":12250,"activeCount":99},[],{"trials":12252,"activeCount":99},[],{"intervention":12254,"totalTrials":121,"cells":12255},"Sunitinib",{"EARLY_PHASE1":12256,"PHASE1":12258,"PHASE2":12260,"PHASE3":12269,"PHASE4":12271,"NA":12273},{"trials":12257,"activeCount":99},[],{"trials":12259,"activeCount":99},[],{"trials":12261,"activeCount":99},[12262],{"nctId":12263,"briefTitle":12264,"status":154,"phases":12265,"primaryCompletion":9964,"completion":263,"start":3838,"enrollment":22,"conditions":12266,"interventions":12268},"NCT02623127","A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma",[88],[12267],"Thymic Carcinoma",[12254],{"trials":12270,"activeCount":99},[],{"trials":12272,"activeCount":99},[],{"trials":12274,"activeCount":99},[],{"intervention":9455,"totalTrials":599,"cells":12276},{"EARLY_PHASE1":12277,"PHASE1":12279,"PHASE2":12296,"PHASE3":12298,"PHASE4":12300,"NA":12302},{"trials":12278,"activeCount":99},[],{"trials":12280,"activeCount":99},[12281,12285,12289],{"nctId":729,"briefTitle":730,"status":154,"phases":12282,"primaryCompletion":702,"completion":702,"start":732,"enrollment":411,"conditions":12283,"interventions":12284},[87],[21],[735,736,737],{"nctId":9446,"briefTitle":9447,"status":154,"phases":12286,"primaryCompletion":9449,"completion":9450,"start":9451,"enrollment":6325,"conditions":12287,"interventions":12288},[87],[21],[9454,9429,9455],{"nctId":12290,"briefTitle":12291,"status":154,"phases":12292,"primaryCompletion":3670,"completion":752,"start":7013,"enrollment":525,"conditions":12293,"interventions":12295},"NCT01409018","Pharmacokinetics of Itraconazole in Pediatric Cancer Patients",[87],[12294],"Pediatric, Cancer",[9455],{"trials":12297,"activeCount":99},[],{"trials":12299,"activeCount":99},[],{"trials":12301,"activeCount":99},[],{"trials":12303,"activeCount":99},[],{"intervention":7962,"totalTrials":95,"cells":12305},{"EARLY_PHASE1":12306,"PHASE1":12308,"PHASE2":12321,"PHASE3":12323,"PHASE4":12325,"NA":12327},{"trials":12307,"activeCount":99},[],{"trials":12309,"activeCount":99},[12310,12317],{"nctId":12311,"briefTitle":12312,"status":154,"phases":12313,"primaryCompletion":2551,"completion":579,"start":2383,"enrollment":19,"conditions":12314,"interventions":12316},"NCT01756521","A Study Study to Investigate the Effect on QT\u002FQTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects",[87],[12315],"the Effect of Moxifloxacin on QT\u002FQTc Interval",[7962],{"nctId":7955,"briefTitle":7956,"status":154,"phases":12318,"primaryCompletion":1957,"completion":1957,"start":7958,"enrollment":170,"conditions":12319,"interventions":12320},[87],[21],[7961,7948,7962],{"trials":12322,"activeCount":99},[],{"trials":12324,"activeCount":99},[],{"trials":12326,"activeCount":99},[],{"trials":12328,"activeCount":99},[],{"intervention":12330,"totalTrials":95,"cells":12331},"Esomeprazole 40 mg",{"EARLY_PHASE1":12332,"PHASE1":12334,"PHASE2":12360,"PHASE3":12362,"PHASE4":12364,"NA":12366},{"trials":12333,"activeCount":99},[],{"trials":12335,"activeCount":99},[12336,12348],{"nctId":12337,"briefTitle":12338,"status":154,"phases":12339,"primaryCompletion":12340,"completion":10172,"start":12341,"enrollment":1196,"conditions":12342,"interventions":12344},"NCT04568772","Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers",[87],"2021-07-08","2020-11-25",[12343],"Gastroesophageal Reflux Disease",[12345,12346,12330,12347],"Atovaquone \u002F Proguanil 250\u002F100 mg","Tegoprazan 50 mg","Vonoprazan 20 mg",{"nctId":12349,"briefTitle":12350,"status":154,"phases":12351,"primaryCompletion":12352,"completion":12353,"start":12354,"enrollment":12355,"conditions":12356,"interventions":12358},"NCT04942652","Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers",[87],"2021-08-06","2021-08-24","2021-07-13",13,[12357],"Achlorhydria",[12359,12330],"Itraconazole 200 mg",{"trials":12361,"activeCount":99},[],{"trials":12363,"activeCount":99},[],{"trials":12365,"activeCount":99},[],{"trials":12367,"activeCount":99},[],{"intervention":12369,"totalTrials":95,"cells":12370},"Ursodeoxycholic Acid",{"EARLY_PHASE1":12371,"PHASE1":12373,"PHASE2":12392,"PHASE3":12394,"PHASE4":12396,"NA":12398},{"trials":12372,"activeCount":99},[],{"trials":12374,"activeCount":99},[12375,12382],{"nctId":12376,"briefTitle":12377,"status":166,"phases":12378,"primaryCompletion":2052,"completion":2052,"start":2161,"enrollment":33,"conditions":12379,"interventions":12381},"NCT02789644","Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA Administration",[87],[12380],"Aged",[12369],{"nctId":12383,"briefTitle":12384,"status":166,"phases":12385,"primaryCompletion":2172,"start":2478,"enrollment":850,"conditions":12386,"interventions":12389},"NCT03000218","Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems",[87],[12387,12388],"Overweight","Abnormal Liver Function Tests",[12390,12391],"Ursodeoxycholic acid","Metformin",{"trials":12393,"activeCount":99},[],{"trials":12395,"activeCount":99},[],{"trials":12397,"activeCount":99},[],{"trials":12399,"activeCount":99},[],{"intervention":12401,"totalTrials":121,"cells":12402},"Voriconazole Oral Product",{"EARLY_PHASE1":12403,"PHASE1":12405,"PHASE2":12415,"PHASE3":12417,"PHASE4":12419,"NA":12421},{"trials":12404,"activeCount":99},[],{"trials":12406,"activeCount":99},[12407],{"nctId":12408,"briefTitle":12409,"status":154,"phases":12410,"primaryCompletion":12411,"completion":12411,"start":12412,"enrollment":5720,"conditions":12413,"interventions":12414},"NCT03760276","A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen",[87],"2018-10-28","2018-08-20",[11491],[12401],{"trials":12416,"activeCount":99},[],{"trials":12418,"activeCount":99},[],{"trials":12420,"activeCount":99},[],{"trials":12422,"activeCount":99},[],{"intervention":12424,"totalTrials":121,"cells":12425},"KD101",{"EARLY_PHASE1":12426,"PHASE1":12428,"PHASE2":12440,"PHASE3":12442,"PHASE4":12444,"NA":12446},{"trials":12427,"activeCount":99},[],{"trials":12429,"activeCount":99},[12430],{"nctId":12431,"briefTitle":12432,"status":154,"phases":12433,"primaryCompletion":12434,"completion":12435,"start":12436,"enrollment":525,"conditions":12437,"interventions":12439},"NCT02819934","A Phase I Study to Investigate the ADME of KD101",[87],"2016-06-06","2018-12-15","2016-05-20",[12438],"Obesity",[12424],{"trials":12441,"activeCount":99},[],{"trials":12443,"activeCount":99},[],{"trials":12445,"activeCount":99},[],{"trials":12447,"activeCount":99},[],{"intervention":12449,"totalTrials":121,"cells":12450},"Theragene®,Ad5-yCD\u002FmutTKSR39rep-ADP",{"EARLY_PHASE1":12451,"PHASE1":12453,"PHASE2":12461,"PHASE3":12463,"PHASE4":12465,"NA":12467},{"trials":12452,"activeCount":99},[],{"trials":12454,"activeCount":99},[12455],{"nctId":12456,"briefTitle":12457,"status":154,"phases":12458,"primaryCompletion":10290,"completion":7529,"start":2478,"enrollment":10394,"conditions":12459,"interventions":12460},"NCT02894944","Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer",[87],[35],[12449],{"trials":12462,"activeCount":99},[],{"trials":12464,"activeCount":99},[],{"trials":12466,"activeCount":99},[],{"trials":12468,"activeCount":99},[],{"intervention":12345,"totalTrials":121,"cells":12470},{"EARLY_PHASE1":12471,"PHASE1":12473,"PHASE2":12479,"PHASE3":12481,"PHASE4":12483,"NA":12485},{"trials":12472,"activeCount":99},[],{"trials":12474,"activeCount":99},[12475],{"nctId":12337,"briefTitle":12338,"status":154,"phases":12476,"primaryCompletion":12340,"completion":10172,"start":12341,"enrollment":1196,"conditions":12477,"interventions":12478},[87],[12343],[12345,12346,12330,12347],{"trials":12480,"activeCount":99},[],{"trials":12482,"activeCount":99},[],{"trials":12484,"activeCount":99},[],{"trials":12486,"activeCount":99},[],{"intervention":12346,"totalTrials":121,"cells":12488},{"EARLY_PHASE1":12489,"PHASE1":12491,"PHASE2":12497,"PHASE3":12499,"PHASE4":12501,"NA":12503},{"trials":12490,"activeCount":99},[],{"trials":12492,"activeCount":99},[12493],{"nctId":12337,"briefTitle":12338,"status":154,"phases":12494,"primaryCompletion":12340,"completion":10172,"start":12341,"enrollment":1196,"conditions":12495,"interventions":12496},[87],[12343],[12345,12346,12330,12347],{"trials":12498,"activeCount":99},[],{"trials":12500,"activeCount":99},[],{"trials":12502,"activeCount":99},[],{"trials":12504,"activeCount":99},[],{"intervention":12347,"totalTrials":121,"cells":12506},{"EARLY_PHASE1":12507,"PHASE1":12509,"PHASE2":12515,"PHASE3":12517,"PHASE4":12519,"NA":12521},{"trials":12508,"activeCount":99},[],{"trials":12510,"activeCount":99},[12511],{"nctId":12337,"briefTitle":12338,"status":154,"phases":12512,"primaryCompletion":12340,"completion":10172,"start":12341,"enrollment":1196,"conditions":12513,"interventions":12514},[87],[12343],[12345,12346,12330,12347],{"trials":12516,"activeCount":99},[],{"trials":12518,"activeCount":99},[],{"trials":12520,"activeCount":99},[],{"trials":12522,"activeCount":99},[],{"intervention":12524,"totalTrials":121,"cells":12525},"Low-dose GC1109",{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12540,"PHASE3":12542,"PHASE4":12544,"NA":12546},{"trials":12527,"activeCount":99},[],{"trials":12529,"activeCount":99},[12530],{"nctId":12531,"briefTitle":12532,"status":154,"phases":12533,"primaryCompletion":6265,"completion":6265,"start":8857,"enrollment":1221,"conditions":12534,"interventions":12536},"NCT01867957","Efficacy and Safety of Anthrax Vaccine, GC1109",[87],[12535],"Anthrax",[12524,12537,12538,12539],"High-dose GC1109","Low-dose Placebo","High-dose Placebo",{"trials":12541,"activeCount":99},[],{"trials":12543,"activeCount":99},[],{"trials":12545,"activeCount":99},[],{"trials":12547,"activeCount":99},[],{"intervention":12537,"totalTrials":121,"cells":12549},{"EARLY_PHASE1":12550,"PHASE1":12552,"PHASE2":12558,"PHASE3":12560,"PHASE4":12562,"NA":12564},{"trials":12551,"activeCount":99},[],{"trials":12553,"activeCount":99},[12554],{"nctId":12531,"briefTitle":12532,"status":154,"phases":12555,"primaryCompletion":6265,"completion":6265,"start":8857,"enrollment":1221,"conditions":12556,"interventions":12557},[87],[12535],[12524,12537,12538,12539],{"trials":12559,"activeCount":99},[],{"trials":12561,"activeCount":99},[],{"trials":12563,"activeCount":99},[],{"trials":12565,"activeCount":99},[],{"intervention":12538,"totalTrials":121,"cells":12567},{"EARLY_PHASE1":12568,"PHASE1":12570,"PHASE2":12576,"PHASE3":12578,"PHASE4":12580,"NA":12582},{"trials":12569,"activeCount":99},[],{"trials":12571,"activeCount":99},[12572],{"nctId":12531,"briefTitle":12532,"status":154,"phases":12573,"primaryCompletion":6265,"completion":6265,"start":8857,"enrollment":1221,"conditions":12574,"interventions":12575},[87],[12535],[12524,12537,12538,12539],{"trials":12577,"activeCount":99},[],{"trials":12579,"activeCount":99},[],{"trials":12581,"activeCount":99},[],{"trials":12583,"activeCount":99},[],{"intervention":12539,"totalTrials":121,"cells":12585},{"EARLY_PHASE1":12586,"PHASE1":12588,"PHASE2":12594,"PHASE3":12596,"PHASE4":12598,"NA":12600},{"trials":12587,"activeCount":99},[],{"trials":12589,"activeCount":99},[12590],{"nctId":12531,"briefTitle":12532,"status":154,"phases":12591,"primaryCompletion":6265,"completion":6265,"start":8857,"enrollment":1221,"conditions":12592,"interventions":12593},[87],[12535],[12524,12537,12538,12539],{"trials":12595,"activeCount":99},[],{"trials":12597,"activeCount":99},[],{"trials":12599,"activeCount":99},[],{"trials":12601,"activeCount":99},[],{"intervention":12603,"totalTrials":121,"cells":12604},"GCPGC, Neulasta, Placebo",{"EARLY_PHASE1":12605,"PHASE1":12607,"PHASE2":12615,"PHASE3":12617,"PHASE4":12619,"NA":12621},{"trials":12606,"activeCount":99},[],{"trials":12608,"activeCount":99},[12609],{"nctId":12610,"briefTitle":12611,"status":154,"phases":12612,"primaryCompletion":6181,"completion":2499,"start":5659,"enrollment":9411,"conditions":12613,"interventions":12614},"NCT00969826","Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor",[87],[21],[12603],{"trials":12616,"activeCount":99},[],{"trials":12618,"activeCount":99},[],{"trials":12620,"activeCount":99},[],{"trials":12622,"activeCount":99},[],{"intervention":12624,"totalTrials":121,"cells":12625},"buscopan",{"EARLY_PHASE1":12626,"PHASE1":12628,"PHASE2":12637,"PHASE3":12639,"PHASE4":12641,"NA":12643},{"trials":12627,"activeCount":99},[],{"trials":12629,"activeCount":99},[12630],{"nctId":12631,"briefTitle":12632,"status":154,"phases":12633,"primaryCompletion":7381,"completion":7381,"start":12634,"conditions":12635,"interventions":12636},"NCT00646061","Pain Control in Renal Colic",[87],"2007-11",[7154],[12624],{"trials":12638,"activeCount":99},[],{"trials":12640,"activeCount":99},[],{"trials":12642,"activeCount":99},[],{"trials":12644,"activeCount":99},[],{"intervention":12646,"totalTrials":121,"cells":12647},"C1K",{"EARLY_PHASE1":12648,"PHASE1":12650,"PHASE2":12662,"PHASE3":12664,"PHASE4":12666,"NA":12668},{"trials":12649,"activeCount":99},[],{"trials":12651,"activeCount":99},[12652],{"nctId":12653,"briefTitle":12654,"status":154,"phases":12655,"primaryCompletion":12656,"completion":12657,"start":12658,"enrollment":11983,"conditions":12659,"interventions":12661},"NCT05980065","To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects",[87],"2023-06-13","2023-10-04","2022-12-20",[12660],"Healthy Subjects",[12646,12646,12646,12646,12646],{"trials":12663,"activeCount":99},[],{"trials":12665,"activeCount":99},[],{"trials":12667,"activeCount":99},[],{"trials":12669,"activeCount":99},[],{"intervention":12671,"totalTrials":121,"cells":12672},"PHI-101",{"EARLY_PHASE1":12673,"PHASE1":12675,"PHASE2":12686,"PHASE3":12688,"PHASE4":12690,"NA":12692},{"trials":12674,"activeCount":99},[],{"trials":12676,"activeCount":99},[12677],{"nctId":12678,"briefTitle":12679,"status":166,"phases":12680,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":6698,"conditions":12683,"interventions":12685},"NCT04842370","Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML",[87],"2022-05-21","2020-06-08",[12684],"Relapsed or Refractory Acute Myeloid Leukemia",[12671],{"trials":12687,"activeCount":99},[],{"trials":12689,"activeCount":99},[],{"trials":12691,"activeCount":99},[],{"trials":12693,"activeCount":99},[],{"intervention":12359,"totalTrials":121,"cells":12695},{"EARLY_PHASE1":12696,"PHASE1":12698,"PHASE2":12704,"PHASE3":12706,"PHASE4":12708,"NA":12710},{"trials":12697,"activeCount":99},[],{"trials":12699,"activeCount":99},[12700],{"nctId":12349,"briefTitle":12350,"status":154,"phases":12701,"primaryCompletion":12352,"completion":12353,"start":12354,"enrollment":12355,"conditions":12702,"interventions":12703},[87],[12357],[12359,12330],{"trials":12705,"activeCount":99},[],{"trials":12707,"activeCount":99},[],{"trials":12709,"activeCount":99},[],{"trials":12711,"activeCount":99},[],{"intervention":12713,"totalTrials":121,"cells":12714},"Omeprazole",{"EARLY_PHASE1":12715,"PHASE1":12717,"PHASE2":12726,"PHASE3":12728,"PHASE4":12730,"NA":12732},{"trials":12716,"activeCount":99},[],{"trials":12718,"activeCount":99},[12719],{"nctId":12720,"briefTitle":12721,"status":154,"phases":12722,"primaryCompletion":578,"start":2041,"enrollment":411,"conditions":12723,"interventions":12725},"NCT02299687","Influence of CYP2C19 Polymorphism on PK\u002FPD of Omeprazole",[87],[12724],"Stomach Ulcer",[12713],{"trials":12727,"activeCount":99},[],{"trials":12729,"activeCount":99},[],{"trials":12731,"activeCount":99},[],{"trials":12733,"activeCount":99},[],{"intervention":745,"totalTrials":121,"cells":12735},{"EARLY_PHASE1":12736,"PHASE1":12738,"PHASE2":12744,"PHASE3":12746,"PHASE4":12748,"NA":12750},{"trials":12737,"activeCount":99},[],{"trials":12739,"activeCount":99},[12740],{"nctId":739,"briefTitle":740,"status":154,"phases":12741,"primaryCompletion":548,"completion":548,"start":742,"enrollment":33,"conditions":12742,"interventions":12743},[87],[21],[735,745,722],{"trials":12745,"activeCount":99},[],{"trials":12747,"activeCount":99},[],{"trials":12749,"activeCount":99},[],{"trials":12751,"activeCount":99},[],{"intervention":12753,"totalTrials":121,"cells":12754},"Experimental DW224aa",{"EARLY_PHASE1":12755,"PHASE1":12757,"PHASE2":12766,"PHASE3":12768,"PHASE4":12770,"NA":12772},{"trials":12756,"activeCount":99},[],{"trials":12758,"activeCount":99},[12759],{"nctId":12760,"briefTitle":12761,"status":154,"phases":12762,"primaryCompletion":620,"start":4198,"enrollment":6325,"conditions":12763,"interventions":12764},"NCT01341249","A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a",[87],[21],[12753,12765],"Experimental DW224a",{"trials":12767,"activeCount":99},[],{"trials":12769,"activeCount":99},[],{"trials":12771,"activeCount":99},[],{"trials":12773,"activeCount":99},[],{"intervention":12765,"totalTrials":121,"cells":12775},{"EARLY_PHASE1":12776,"PHASE1":12778,"PHASE2":12784,"PHASE3":12786,"PHASE4":12788,"NA":12790},{"trials":12777,"activeCount":99},[],{"trials":12779,"activeCount":99},[12780],{"nctId":12760,"briefTitle":12761,"status":154,"phases":12781,"primaryCompletion":620,"start":4198,"enrollment":6325,"conditions":12782,"interventions":12783},[87],[21],[12753,12765],{"trials":12785,"activeCount":99},[],{"trials":12787,"activeCount":99},[],{"trials":12789,"activeCount":99},[],{"trials":12791,"activeCount":99},[],{"intervention":12793,"totalTrials":121,"cells":12794},"Levofloxacin and Streptomycin added",{"EARLY_PHASE1":12795,"PHASE1":12797,"PHASE2":12806,"PHASE3":12808,"PHASE4":12810,"NA":12812},{"trials":12796,"activeCount":99},[],{"trials":12798,"activeCount":99},[12799],{"nctId":12800,"briefTitle":12801,"status":154,"phases":12802,"primaryCompletion":264,"completion":732,"start":675,"enrollment":33,"conditions":12803,"interventions":12804},"NCT02128308","Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents",[87],[21],[12793,12805],"Moxifloxacin and Kanamycin added",{"trials":12807,"activeCount":99},[],{"trials":12809,"activeCount":99},[],{"trials":12811,"activeCount":99},[],{"trials":12813,"activeCount":99},[],{"intervention":12805,"totalTrials":121,"cells":12815},{"EARLY_PHASE1":12816,"PHASE1":12818,"PHASE2":12824,"PHASE3":12826,"PHASE4":12828,"NA":12830},{"trials":12817,"activeCount":99},[],{"trials":12819,"activeCount":99},[12820],{"nctId":12800,"briefTitle":12801,"status":154,"phases":12821,"primaryCompletion":264,"completion":732,"start":675,"enrollment":33,"conditions":12822,"interventions":12823},[87],[21],[12793,12805],{"trials":12825,"activeCount":99},[],{"trials":12827,"activeCount":99},[],{"trials":12829,"activeCount":99},[],{"trials":12831,"activeCount":99},[],{"intervention":12833,"totalTrials":121,"cells":12834},"Captopril 12.5 Mg",{"EARLY_PHASE1":12835,"PHASE1":12837,"PHASE2":12849,"PHASE3":12851,"PHASE4":12853,"NA":12855},{"trials":12836,"activeCount":99},[],{"trials":12838,"activeCount":99},[12839],{"nctId":12840,"briefTitle":12841,"status":154,"phases":12842,"primaryCompletion":12843,"completion":10959,"start":12844,"enrollment":210,"conditions":12845,"interventions":12846},"NCT06292091","A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril",[87],"2024-03-27","2024-02-28",[7508],[12833,12847,12848],"Sodium bicarbonate 4 G","Torsemide 20 MG",{"trials":12850,"activeCount":99},[],{"trials":12852,"activeCount":99},[],{"trials":12854,"activeCount":99},[],{"trials":12856,"activeCount":99},[],{"intervention":12847,"totalTrials":121,"cells":12858},{"EARLY_PHASE1":12859,"PHASE1":12861,"PHASE2":12867,"PHASE3":12869,"PHASE4":12871,"NA":12873},{"trials":12860,"activeCount":99},[],{"trials":12862,"activeCount":99},[12863],{"nctId":12840,"briefTitle":12841,"status":154,"phases":12864,"primaryCompletion":12843,"completion":10959,"start":12844,"enrollment":210,"conditions":12865,"interventions":12866},[87],[7508],[12833,12847,12848],{"trials":12868,"activeCount":99},[],{"trials":12870,"activeCount":99},[],{"trials":12872,"activeCount":99},[],{"trials":12874,"activeCount":99},[],{"intervention":12848,"totalTrials":121,"cells":12876},{"EARLY_PHASE1":12877,"PHASE1":12879,"PHASE2":12885,"PHASE3":12887,"PHASE4":12889,"NA":12891},{"trials":12878,"activeCount":99},[],{"trials":12880,"activeCount":99},[12881],{"nctId":12840,"briefTitle":12841,"status":154,"phases":12882,"primaryCompletion":12843,"completion":10959,"start":12844,"enrollment":210,"conditions":12883,"interventions":12884},[87],[7508],[12833,12847,12848],{"trials":12886,"activeCount":99},[],{"trials":12888,"activeCount":99},[],{"trials":12890,"activeCount":99},[],{"trials":12892,"activeCount":99},[],{"intervention":12894,"totalTrials":121,"cells":12895},"YH12852",{"EARLY_PHASE1":12896,"PHASE1":12898,"PHASE2":12910,"PHASE3":12912,"PHASE4":12914,"NA":12916},{"trials":12897,"activeCount":99},[],{"trials":12899,"activeCount":99},[12900],{"nctId":12901,"briefTitle":12902,"status":154,"phases":12903,"primaryCompletion":12904,"completion":12904,"start":12905,"enrollment":2470,"conditions":12906,"interventions":12908},"NCT03381703","Investigation of the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852",[87],"2017-03-29","2017-03-16",[12907],"Constipation",[12894,12909],"14C-labeled YH12852",{"trials":12911,"activeCount":99},[],{"trials":12913,"activeCount":99},[],{"trials":12915,"activeCount":99},[],{"trials":12917,"activeCount":99},[],{"intervention":12909,"totalTrials":121,"cells":12919},{"EARLY_PHASE1":12920,"PHASE1":12922,"PHASE2":12928,"PHASE3":12930,"PHASE4":12932,"NA":12934},{"trials":12921,"activeCount":99},[],{"trials":12923,"activeCount":99},[12924],{"nctId":12901,"briefTitle":12902,"status":154,"phases":12925,"primaryCompletion":12904,"completion":12904,"start":12905,"enrollment":2470,"conditions":12926,"interventions":12927},[87],[12907],[12894,12909],{"trials":12929,"activeCount":99},[],{"trials":12931,"activeCount":99},[],{"trials":12933,"activeCount":99},[],{"trials":12935,"activeCount":99},[],{"intervention":12937,"totalTrials":121,"cells":12938},"HCP0910 and HGP1011",{"EARLY_PHASE1":12939,"PHASE1":12941,"PHASE2":12950,"PHASE3":12952,"PHASE4":12954,"NA":12956},{"trials":12940,"activeCount":99},[],{"trials":12942,"activeCount":99},[12943],{"nctId":12944,"briefTitle":12945,"status":154,"phases":12946,"primaryCompletion":3838,"completion":3838,"start":2443,"enrollment":2470,"conditions":12947,"interventions":12949},"NCT02441114","Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)",[87],[12948],"Pulmonary Disease, Chronic Obstructive",[12937],{"trials":12951,"activeCount":99},[],{"trials":12953,"activeCount":99},[],{"trials":12955,"activeCount":99},[],{"trials":12957,"activeCount":99},[],{"intervention":12959,"totalTrials":121,"cells":12960},"Vfend (voriconazole) intravenous",{"EARLY_PHASE1":12961,"PHASE1":12963,"PHASE2":12973,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12962,"activeCount":99},[],{"trials":12964,"activeCount":99},[12965],{"nctId":12966,"briefTitle":12967,"status":154,"phases":12968,"primaryCompletion":538,"completion":12969,"start":4130,"enrollment":210,"conditions":12970,"interventions":12971},"NCT02906176","Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM",[87],"2017-01",[9443],[12959,12972],"Vfend (voriconazole)",{"trials":12974,"activeCount":99},[],{"trials":12976,"activeCount":99},[],{"trials":12978,"activeCount":99},[],{"trials":12980,"activeCount":99},[],{"intervention":12972,"totalTrials":121,"cells":12982},{"EARLY_PHASE1":12983,"PHASE1":12985,"PHASE2":12991,"PHASE3":12993,"PHASE4":12995,"NA":12997},{"trials":12984,"activeCount":99},[],{"trials":12986,"activeCount":99},[12987],{"nctId":12966,"briefTitle":12967,"status":154,"phases":12988,"primaryCompletion":538,"completion":12969,"start":4130,"enrollment":210,"conditions":12989,"interventions":12990},[87],[9443],[12959,12972],{"trials":12992,"activeCount":99},[],{"trials":12994,"activeCount":99},[],{"trials":12996,"activeCount":99},[],{"trials":12998,"activeCount":99},[],{"intervention":13000,"totalTrials":121,"cells":13001},"PHI-101 administration",{"EARLY_PHASE1":13002,"PHASE1":13004,"PHASE2":13017,"PHASE3":13019,"PHASE4":13021,"NA":13023},{"trials":13003,"activeCount":99},[],{"trials":13005,"activeCount":99},[13006],{"nctId":13007,"briefTitle":13008,"status":166,"phases":13009,"primaryCompletion":1863,"completion":1863,"start":13010,"enrollment":2307,"conditions":13011,"interventions":13016},"NCT04678102","Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)",[87],"2020-12-17",[13012,13013,13014,13015],"Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Carcinoma","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma",[13000],{"trials":13018,"activeCount":99},[],{"trials":13020,"activeCount":99},[],{"trials":13022,"activeCount":99},[],{"trials":13024,"activeCount":99},[],{"intervention":13026,"totalTrials":121,"cells":13027},"cell-culture derived smallpox vaccine",{"EARLY_PHASE1":13028,"PHASE1":13030,"PHASE2":13040,"PHASE3":13042,"PHASE4":13044,"NA":13046},{"trials":13029,"activeCount":99},[],{"trials":13031,"activeCount":99},[13032],{"nctId":13033,"briefTitle":13034,"status":154,"phases":13035,"completion":13036,"start":13037,"enrollment":411,"conditions":13038,"interventions":13039},"NCT00336635","Safety and Immunogenicity of CJ-50300",[87],"2007-02","2006-06",[7905],[13026],{"trials":13041,"activeCount":99},[],{"trials":13043,"activeCount":99},[],{"trials":13045,"activeCount":99},[],{"trials":13047,"activeCount":99},[],{"intervention":13049,"totalTrials":121,"cells":13050},"Allogeneic NK cells",{"EARLY_PHASE1":13051,"PHASE1":13053,"PHASE2":13063,"PHASE3":13065,"PHASE4":13067,"NA":13069},{"trials":13052,"activeCount":99},[],{"trials":13054,"activeCount":99},[13055],{"nctId":13056,"briefTitle":13057,"status":154,"phases":13058,"primaryCompletion":1816,"completion":3621,"start":4054,"enrollment":6744,"conditions":13059,"interventions":13062},"NCT01212341","Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor",[87],[13060,13061],"Malignant Lymphomas","Solid Tumors",[13049],{"trials":13064,"activeCount":99},[],{"trials":13066,"activeCount":99},[],{"trials":13068,"activeCount":99},[],{"trials":13070,"activeCount":99},[],{"intervention":13072,"totalTrials":121,"cells":13073},"G-colony stimulating factor",{"EARLY_PHASE1":13074,"PHASE1":13076,"PHASE2":13084,"PHASE3":13086,"PHASE4":13088,"NA":13090},{"trials":13075,"activeCount":99},[],{"trials":13077,"activeCount":99},[13078],{"nctId":13079,"briefTitle":13080,"status":154,"phases":13081,"primaryCompletion":3555,"completion":6922,"start":2385,"enrollment":10394,"conditions":13082,"interventions":13083},"NCT01503749","Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis",[87],[2360],[13072],{"trials":13085,"activeCount":99},[],{"trials":13087,"activeCount":99},[],{"trials":13089,"activeCount":99},[],{"trials":13091,"activeCount":99},[],{"intervention":13093,"totalTrials":121,"cells":13094},"Pregabalin",{"EARLY_PHASE1":13095,"PHASE1":13097,"PHASE2":13108,"PHASE3":13110,"PHASE4":13112,"NA":13114},{"trials":13096,"activeCount":99},[],{"trials":13098,"activeCount":99},[13099],{"nctId":13100,"briefTitle":13101,"status":166,"phases":13102,"primaryCompletion":8022,"completion":8022,"start":13103,"enrollment":1795,"conditions":13104,"interventions":13106},"NCT03618589","Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy",[87],"2016-11-26",[13105],"Pain, Neuropathic",[13093,13107],"Opioid",{"trials":13109,"activeCount":99},[],{"trials":13111,"activeCount":99},[],{"trials":13113,"activeCount":99},[],{"trials":13115,"activeCount":99},[],{"intervention":13117,"totalTrials":121,"cells":13118},"Sitagliptin",{"EARLY_PHASE1":13119,"PHASE1":13121,"PHASE2":13129,"PHASE3":13131,"PHASE4":13133,"NA":13135},{"trials":13120,"activeCount":99},[],{"trials":13122,"activeCount":99},[13123],{"nctId":13124,"briefTitle":13125,"status":154,"phases":13126,"primaryCompletion":2499,"start":7381,"enrollment":210,"conditions":13127,"interventions":13128},"NCT00960453","Clinical Trial to Investigate the Pharmacokinetics\u002FPharmacodynamics of Sitagliptin",[87],[6623],[13117],{"trials":13130,"activeCount":99},[],{"trials":13132,"activeCount":99},[],{"trials":13134,"activeCount":99},[],{"trials":13136,"activeCount":99},[],{"intervention":13138,"totalTrials":121,"cells":13139},"Melphalan",{"EARLY_PHASE1":13140,"PHASE1":13142,"PHASE2":13152,"PHASE3":13154,"PHASE4":13156,"NA":13158},{"trials":13141,"activeCount":99},[],{"trials":13143,"activeCount":99},[13144],{"nctId":13145,"briefTitle":13146,"status":166,"phases":13147,"primaryCompletion":13148,"completion":13148,"start":13149,"enrollment":1221,"conditions":13150,"interventions":13151},"NCT04937634","Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation",[87],"2023-09","2020-09-11",[9386],[13138],{"trials":13153,"activeCount":99},[],{"trials":13155,"activeCount":99},[],{"trials":13157,"activeCount":99},[],{"trials":13159,"activeCount":99},[],{"intervention":13161,"totalTrials":121,"cells":13162},"Metformin and Pyrimethamine",{"EARLY_PHASE1":13163,"PHASE1":13165,"PHASE2":13173,"PHASE3":13175,"PHASE4":13177,"NA":13179},{"trials":13164,"activeCount":99},[],{"trials":13166,"activeCount":99},[13167],{"nctId":13168,"briefTitle":13169,"status":154,"phases":13170,"primaryCompletion":2551,"start":157,"enrollment":1221,"conditions":13171,"interventions":13172},"NCT01973933","Clinical Trial to Investigate the Pharmacokinetic\u002FPharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR",[87],[21],[13161],{"trials":13174,"activeCount":99},[],{"trials":13176,"activeCount":99},[],{"trials":13178,"activeCount":99},[],{"trials":13180,"activeCount":99},[],{"intervention":13182,"totalTrials":121,"cells":13183},"Blinatumomab for",{"EARLY_PHASE1":13184,"PHASE1":13186,"PHASE2":13197,"PHASE3":13199,"PHASE4":13201,"NA":13203},{"trials":13185,"activeCount":99},[],{"trials":13187,"activeCount":99},[13188],{"nctId":13189,"briefTitle":13190,"status":166,"phases":13191,"primaryCompletion":13192,"completion":70,"start":632,"enrollment":1221,"conditions":13193,"interventions":13196},"NCT04604691","Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)",[87],"2023-03",[13194,13195],"Pediatric ALL, B Cell","Minimal Residual Disease",[13182],{"trials":13198,"activeCount":99},[],{"trials":13200,"activeCount":99},[],{"trials":13202,"activeCount":99},[],{"trials":13204,"activeCount":99},[],{"intervention":13206,"totalTrials":121,"cells":13207},"Augmentin tab",{"EARLY_PHASE1":13208,"PHASE1":13210,"PHASE2":13218,"PHASE3":13220,"PHASE4":13222,"NA":13224},{"trials":13209,"activeCount":99},[],{"trials":13211,"activeCount":99},[13212],{"nctId":13213,"briefTitle":13214,"status":154,"phases":13215,"primaryCompletion":3838,"start":673,"enrollment":28,"conditions":13216,"interventions":13217},"NCT02431832","Exploration of microRNA and Metabolomics Biomarkers Predicting Drug Induced Liver Injury in Elderly People",[87],[21],[13206],{"trials":13219,"activeCount":99},[],{"trials":13221,"activeCount":99},[],{"trials":13223,"activeCount":99},[],{"trials":13225,"activeCount":99},[],{"intervention":13227,"totalTrials":121,"cells":13228},"weekly paclitaxel",{"EARLY_PHASE1":13229,"PHASE1":13231,"PHASE2":13242,"PHASE3":13244,"PHASE4":13246,"NA":13248},{"trials":13230,"activeCount":99},[],{"trials":13232,"activeCount":99},[13233],{"nctId":13234,"briefTitle":13235,"status":154,"phases":13236,"primaryCompletion":2101,"completion":2101,"start":578,"enrollment":210,"conditions":13237,"interventions":13240},"NCT02344095","A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer",[87],[13238,13239,2118],"Epithelial Ovarian Carcinoma","Fallopian Tube Carcinoma",[13227,13241],"weekly cisplatin",{"trials":13243,"activeCount":99},[],{"trials":13245,"activeCount":99},[],{"trials":13247,"activeCount":99},[],{"trials":13249,"activeCount":99},[],{"intervention":13241,"totalTrials":121,"cells":13251},{"EARLY_PHASE1":13252,"PHASE1":13254,"PHASE2":13260,"PHASE3":13262,"PHASE4":13264,"NA":13266},{"trials":13253,"activeCount":99},[],{"trials":13255,"activeCount":99},[13256],{"nctId":13234,"briefTitle":13235,"status":154,"phases":13257,"primaryCompletion":2101,"completion":2101,"start":578,"enrollment":210,"conditions":13258,"interventions":13259},[87],[13238,13239,2118],[13227,13241],{"trials":13261,"activeCount":99},[],{"trials":13263,"activeCount":99},[],{"trials":13265,"activeCount":99},[],{"trials":13267,"activeCount":99},[],{"intervention":13269,"totalTrials":121,"cells":13270},"Midazolam I.V.",{"EARLY_PHASE1":13271,"PHASE1":13273,"PHASE2":13281,"PHASE3":13283,"PHASE4":13285,"NA":13287},{"trials":13272,"activeCount":99},[],{"trials":13274,"activeCount":99},[13275],{"nctId":13276,"briefTitle":13277,"status":154,"phases":13278,"primaryCompletion":156,"completion":3649,"start":578,"enrollment":2328,"conditions":13279,"interventions":13280},"NCT02579434","Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics",[87],[9443],[13269],{"trials":13282,"activeCount":99},[],{"trials":13284,"activeCount":99},[],{"trials":13286,"activeCount":99},[],{"trials":13288,"activeCount":99},[],{"intervention":13290,"totalTrials":121,"cells":13291},"Carvedilol",{"EARLY_PHASE1":13292,"PHASE1":13294,"PHASE2":13302,"PHASE3":13304,"PHASE4":13306,"NA":13308},{"trials":13293,"activeCount":99},[],{"trials":13295,"activeCount":99},[13296],{"nctId":13297,"briefTitle":13298,"status":154,"phases":13299,"primaryCompletion":701,"completion":578,"start":2041,"enrollment":411,"conditions":13300,"interventions":13301},"NCT02286934","Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol",[87],[21],[13290],{"trials":13303,"activeCount":99},[],{"trials":13305,"activeCount":99},[],{"trials":13307,"activeCount":99},[],{"trials":13309,"activeCount":99},[],{"intervention":13311,"totalTrials":121,"cells":13312},"Vancomycin 250Mg",{"EARLY_PHASE1":13313,"PHASE1":13315,"PHASE2":13325,"PHASE3":13327,"PHASE4":13329,"NA":13331},{"trials":13314,"activeCount":99},[],{"trials":13316,"activeCount":99},[13317],{"nctId":13318,"briefTitle":13319,"status":154,"phases":13320,"primaryCompletion":13321,"completion":13321,"start":8707,"enrollment":525,"conditions":13322,"interventions":13324},"NCT03403972","Evaluate the Effects of the Environmental Change in Intestine by Antibiotics on the Pharmacokinetic Characteristics of Simvastatin in Healthy Male Volunteers",[87],"2018-01-11",[13323],"Simvastatin Pharmacokinetics and Gut Microbiome",[13311],{"trials":13326,"activeCount":99},[],{"trials":13328,"activeCount":99},[],{"trials":13330,"activeCount":99},[],{"trials":13332,"activeCount":99},[],{"intervention":13334,"totalTrials":121,"cells":13335},"KRN1493",{"EARLY_PHASE1":13336,"PHASE1":13338,"PHASE2":13346,"PHASE3":13348,"PHASE4":13350,"NA":13352},{"trials":13337,"activeCount":99},[],{"trials":13339,"activeCount":99},[13340],{"nctId":13341,"briefTitle":13342,"status":154,"phases":13343,"primaryCompletion":6181,"completion":7013,"start":5318,"enrollment":19,"conditions":13344,"interventions":13345},"NCT00952094","Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493",[87],[21],[13334],{"trials":13347,"activeCount":99},[],{"trials":13349,"activeCount":99},[],{"trials":13351,"activeCount":99},[],{"trials":13353,"activeCount":99},[],{"intervention":13355,"totalTrials":121,"cells":13356},"Oseltamivir 75 mg 1 cap",{"EARLY_PHASE1":13357,"PHASE1":13359,"PHASE2":13367,"PHASE3":13369,"PHASE4":13371,"NA":13373},{"trials":13358,"activeCount":99},[],{"trials":13360,"activeCount":99},[13361],{"nctId":13362,"briefTitle":13363,"status":154,"phases":13364,"primaryCompletion":264,"completion":264,"start":3555,"enrollment":1221,"conditions":13365,"interventions":13366},"NCT01902342","A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir",[87],[21],[13355],{"trials":13368,"activeCount":99},[],{"trials":13370,"activeCount":99},[],{"trials":13372,"activeCount":99},[],{"trials":13374,"activeCount":99},[],{"intervention":214,"totalTrials":121,"cells":13376},{"EARLY_PHASE1":13377,"PHASE1":13379,"PHASE2":13385,"PHASE3":13387,"PHASE4":13389,"NA":13391},{"trials":13378,"activeCount":99},[],{"trials":13380,"activeCount":99},[13381],{"nctId":204,"briefTitle":205,"status":154,"phases":13382,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":13383,"interventions":13384},[87],[212],[214,215,197],{"trials":13386,"activeCount":99},[],{"trials":13388,"activeCount":99},[],{"trials":13390,"activeCount":99},[],{"trials":13392,"activeCount":99},[],{"intervention":215,"totalTrials":121,"cells":13394},{"EARLY_PHASE1":13395,"PHASE1":13397,"PHASE2":13403,"PHASE3":13405,"PHASE4":13407,"NA":13409},{"trials":13396,"activeCount":99},[],{"trials":13398,"activeCount":99},[13399],{"nctId":204,"briefTitle":205,"status":154,"phases":13400,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":13401,"interventions":13402},[87],[212],[214,215,197],{"trials":13404,"activeCount":99},[],{"trials":13406,"activeCount":99},[],{"trials":13408,"activeCount":99},[],{"trials":13410,"activeCount":99},[],{"intervention":13412,"totalTrials":121,"cells":13413},"Augmentin",{"EARLY_PHASE1":13414,"PHASE1":13416,"PHASE2":13424,"PHASE3":13426,"PHASE4":13428,"NA":13430},{"trials":13415,"activeCount":99},[],{"trials":13417,"activeCount":99},[13418],{"nctId":13419,"briefTitle":13420,"status":154,"phases":13421,"primaryCompletion":6922,"completion":2041,"start":264,"enrollment":6325,"conditions":13422,"interventions":13423},"NCT02143323","A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)",[87],[21],[13412],{"trials":13425,"activeCount":99},[],{"trials":13427,"activeCount":99},[],{"trials":13429,"activeCount":99},[],{"trials":13431,"activeCount":99},[],{"intervention":13433,"totalTrials":121,"cells":13434},"Cholestyramine Resin",{"EARLY_PHASE1":13435,"PHASE1":13437,"PHASE2":13448,"PHASE3":13450,"PHASE4":13452,"NA":13454},{"trials":13436,"activeCount":99},[],{"trials":13438,"activeCount":99},[13439],{"nctId":13440,"briefTitle":13441,"status":154,"phases":13442,"primaryCompletion":2231,"completion":13443,"start":13444,"enrollment":1170,"conditions":13445,"interventions":13447},"NCT04335526","A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles",[87],"2020-10-21","2020-05-01",[13446],"Human Microbiome",[13433],{"trials":13449,"activeCount":99},[],{"trials":13451,"activeCount":99},[],{"trials":13453,"activeCount":99},[],{"trials":13455,"activeCount":99},[],{"intervention":13457,"totalTrials":121,"cells":13458},"Metformin and Pantoprazole",{"EARLY_PHASE1":13459,"PHASE1":13461,"PHASE2":13470,"PHASE3":13472,"PHASE4":13474,"NA":13476},{"trials":13460,"activeCount":99},[],{"trials":13462,"activeCount":99},[13463],{"nctId":13464,"briefTitle":13465,"status":154,"phases":13466,"primaryCompletion":742,"completion":742,"start":1816,"enrollment":411,"conditions":13467,"interventions":13468},"NCT01857609","Clinical Trial to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin",[87],[21],[12391,13457,13469],"Metformin and Rabeprazole",{"trials":13471,"activeCount":99},[],{"trials":13473,"activeCount":99},[],{"trials":13475,"activeCount":99},[],{"trials":13477,"activeCount":99},[],{"intervention":13469,"totalTrials":121,"cells":13479},{"EARLY_PHASE1":13480,"PHASE1":13482,"PHASE2":13488,"PHASE3":13490,"PHASE4":13492,"NA":13494},{"trials":13481,"activeCount":99},[],{"trials":13483,"activeCount":99},[13484],{"nctId":13464,"briefTitle":13465,"status":154,"phases":13485,"primaryCompletion":742,"completion":742,"start":1816,"enrollment":411,"conditions":13486,"interventions":13487},[87],[21],[12391,13457,13469],{"trials":13489,"activeCount":99},[],{"trials":13491,"activeCount":99},[],{"trials":13493,"activeCount":99},[],{"trials":13495,"activeCount":99},[],{"intervention":13497,"totalTrials":95,"cells":13498},"Cetylpyridinium Chloride",{"EARLY_PHASE1":13499,"PHASE1":13519,"PHASE2":13521,"PHASE3":13523,"PHASE4":13525,"NA":13527},{"trials":13500,"activeCount":99},[13501,13510],{"nctId":13502,"briefTitle":13503,"status":154,"phases":13504,"primaryCompletion":13505,"completion":13505,"start":13506,"enrollment":1743,"conditions":13507,"interventions":13509},"NCT02575235","Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia",[86],"2016-07-01","2015-10-01",[13508],"Sarcopenia",[13497],{"nctId":13511,"briefTitle":13512,"status":154,"phases":13513,"primaryCompletion":674,"completion":674,"start":13514,"enrollment":13515,"conditions":13516,"interventions":13517},"NCT02297997","Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy",[86],"2014-11-13",65,[13508],[13518],"cetylpyridinium chloride",{"trials":13520,"activeCount":99},[],{"trials":13522,"activeCount":99},[],{"trials":13524,"activeCount":99},[],{"trials":13526,"activeCount":99},[],{"trials":13528,"activeCount":99},[],{"intervention":13530,"totalTrials":121,"cells":13531},"ALLO-ASC(allogeneic adipose derived mesenchymal stem cell)",{"EARLY_PHASE1":13532,"PHASE1":13540,"PHASE2":13542,"PHASE3":13544,"PHASE4":13546,"NA":13548},{"trials":13533,"activeCount":99},[13534],{"nctId":13535,"briefTitle":13536,"status":154,"phases":13537,"primaryCompletion":2052,"completion":11640,"start":3966,"enrollment":210,"conditions":13538,"interventions":13539},"NCT01856140","Treatment of Tendon Injury Using Mesenchymal Stem Cells",[86],[2068],[13530],{"trials":13541,"activeCount":99},[],{"trials":13543,"activeCount":99},[],{"trials":13545,"activeCount":99},[],{"trials":13547,"activeCount":99},[],{"trials":13549,"activeCount":99},[],{"intervention":13551,"totalTrials":121,"cells":13552},"Paclitaxel",{"EARLY_PHASE1":13553,"PHASE1":13564,"PHASE2":13566,"PHASE3":13568,"PHASE4":13570,"NA":13572},{"trials":13554,"activeCount":99},[13555],{"nctId":13556,"briefTitle":13557,"status":154,"phases":13558,"primaryCompletion":13559,"completion":13559,"start":13560,"enrollment":95,"conditions":13561,"interventions":13563},"NCT04046016","A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor",[86],"2018-12-24","2018-07-03",[13562],"Solid Tumor",[13551],{"trials":13565,"activeCount":99},[],{"trials":13567,"activeCount":99},[],{"trials":13569,"activeCount":99},[],{"trials":13571,"activeCount":99},[],{"trials":13573,"activeCount":99},[],{"intervention":13575,"totalTrials":121,"cells":13576},"Saxenda",{"EARLY_PHASE1":13577,"PHASE1":13591,"PHASE2":13593,"PHASE3":13595,"PHASE4":13597,"NA":13599},{"trials":13578,"activeCount":99},[13579],{"nctId":13580,"briefTitle":13581,"status":166,"phases":13582,"primaryCompletion":13583,"completion":13584,"start":13585,"enrollment":1048,"conditions":13586,"interventions":13590},"NCT06217848","The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study",[86],"2024-02-08","2024-03-08","2022-11-28",[13587,13588,13589],"Panhypopituitarism","Craniopharyngioma","Hypothalamic Obesity",[13575],{"trials":13592,"activeCount":99},[],{"trials":13594,"activeCount":99},[],{"trials":13596,"activeCount":99},[],{"trials":13598,"activeCount":99},[],{"trials":13600,"activeCount":99},[],{"intervention":13602,"totalTrials":121,"cells":13603},"GX-I7 or [14C] GX-I7",{"EARLY_PHASE1":13604,"PHASE1":13615,"PHASE2":13617,"PHASE3":13619,"PHASE4":13621,"NA":13623},{"trials":13605,"activeCount":99},[13606],{"nctId":13607,"briefTitle":13608,"status":166,"phases":13609,"primaryCompletion":13610,"completion":13444,"start":13611,"enrollment":210,"conditions":13612,"interventions":13614},"NCT04283695","To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers",[86],"2019-08-30","2019-07-03",[13613],"Leukopenia",[13602],{"trials":13616,"activeCount":99},[],{"trials":13618,"activeCount":99},[],{"trials":13620,"activeCount":99},[],{"trials":13622,"activeCount":99},[],{"trials":13624,"activeCount":99},[],{"intervention":13626,"totalTrials":121,"cells":13627},"YH4808 PO and [14C]-YH4808 IV",{"EARLY_PHASE1":13628,"PHASE1":13636,"PHASE2":13638,"PHASE3":13640,"PHASE4":13642,"NA":13644},{"trials":13629,"activeCount":99},[13630],{"nctId":13631,"briefTitle":13632,"status":154,"phases":13633,"primaryCompletion":3612,"completion":3612,"start":2275,"enrollment":1802,"conditions":13634,"interventions":13635},"NCT02072447","Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study",[86],[12343],[13626],{"trials":13637,"activeCount":99},[],{"trials":13639,"activeCount":99},[],{"trials":13641,"activeCount":99},[],{"trials":13643,"activeCount":99},[],{"trials":13645,"activeCount":99},[],{"intervention":12391,"totalTrials":10394,"cells":13647},{"EARLY_PHASE1":13648,"PHASE1":13650,"PHASE2":13673,"PHASE3":13690,"PHASE4":13692,"NA":13707},{"trials":13649,"activeCount":99},[],{"trials":13651,"activeCount":99},[13652,13659,13665,13669],{"nctId":13653,"briefTitle":13654,"status":154,"phases":13655,"primaryCompletion":732,"start":2551,"enrollment":210,"conditions":13656,"interventions":13658},"NCT02125305","Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly",[87],[13657],"Healthy Elderly",[12391],{"nctId":13660,"briefTitle":13661,"status":154,"phases":13662,"primaryCompletion":2041,"start":1957,"enrollment":1221,"conditions":13663,"interventions":13664},"NCT02712619","Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers",[87],[21],[12391],{"nctId":12383,"briefTitle":12384,"status":166,"phases":13666,"primaryCompletion":2172,"start":2478,"enrollment":850,"conditions":13667,"interventions":13668},[87],[12387,12388],[12390,12391],{"nctId":13464,"briefTitle":13465,"status":154,"phases":13670,"primaryCompletion":742,"completion":742,"start":1816,"enrollment":411,"conditions":13671,"interventions":13672},[87],[21],[12391,13457,13469],{"trials":13674,"activeCount":99},[13675,13682],{"nctId":13676,"briefTitle":13677,"status":154,"phases":13678,"primaryCompletion":3565,"completion":752,"start":7013,"enrollment":13679,"conditions":13680,"interventions":13681},"NCT00909506","Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients",[88],105,[24],[12391,12391],{"nctId":13683,"briefTitle":13684,"status":154,"phases":13685,"primaryCompletion":11640,"completion":1965,"start":5092,"enrollment":13686,"conditions":13687,"interventions":13689},"NCT01589367","Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer",[88],208,[13688],"Hormone Receptor Positive Malignant Neoplasm of Breast",[12391],{"trials":13691,"activeCount":99},[],{"trials":13693,"activeCount":99},[13694,13700],{"nctId":13695,"briefTitle":13696,"status":1813,"phases":13697,"primaryCompletion":702,"completion":702,"start":660,"enrollment":1170,"conditions":13698,"interventions":13699},"NCT01654640","The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine",[90],[32],[12391],{"nctId":13701,"briefTitle":13702,"status":166,"phases":13703,"primaryCompletion":821,"start":578,"enrollment":7638,"conditions":13704,"interventions":13705},"NCT02501616","Effect of Dapagliflozine on Systemic and Renal Endothelial Function",[90],[7406,7407],[12391,13706],"Dapagliflozin",{"trials":13708,"activeCount":99},[13709],{"nctId":13710,"briefTitle":13711,"status":154,"phases":13712,"primaryCompletion":13713,"completion":13713,"start":10693,"enrollment":1221,"conditions":13714,"interventions":13715},"NCT03809260","A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin",[91],"2019-02-28",[13446],[12391,13716,12391],"Vancomycin",{"intervention":8447,"totalTrials":1802,"cells":13718},{"EARLY_PHASE1":13719,"PHASE1":13721,"PHASE2":13730,"PHASE3":13740,"PHASE4":13769,"NA":13778},{"trials":13720,"activeCount":99},[],{"trials":13722,"activeCount":99},[13723],{"nctId":13724,"briefTitle":13725,"status":154,"phases":13726,"primaryCompletion":3649,"completion":3649,"start":3838,"enrollment":6744,"conditions":13727,"interventions":13728},"NCT02743247","Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults",[87],[9443],[8447,13729],"Mycophenolate mofetil",{"trials":13731,"activeCount":99},[13732],{"nctId":13733,"briefTitle":13734,"status":166,"phases":13735,"completion":9219,"start":7506,"enrollment":10394,"conditions":13736,"interventions":13738},"NCT00569101","A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis",[88],[13737],"Lupus Nephritis",[13739],"tacrolimus",{"trials":13741,"activeCount":99},[13742,13751,13755,13762],{"nctId":13743,"briefTitle":13744,"status":154,"phases":13745,"primaryCompletion":3621,"start":7724,"conditions":13746,"interventions":13750},"NCT01476488","Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients",[88,89],[13747,13748,13749],"Kidney Transplantation","Pediatric Patients","Maintenance With Tacrolimus",[13739],{"nctId":8440,"briefTitle":8441,"status":154,"phases":13752,"primaryCompletion":8443,"completion":8443,"start":1844,"enrollment":1048,"conditions":13753,"interventions":13754},[88,89],[8445],[8447,8429,5228],{"nctId":13756,"briefTitle":13757,"status":154,"phases":13758,"primaryCompletion":578,"start":5659,"enrollment":180,"conditions":13759,"interventions":13761},"NCT01055964","a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients",[89],[13760,8447],"Pharmacokinetics",[8447],{"nctId":13763,"briefTitle":13764,"status":154,"phases":13765,"primaryCompletion":7724,"completion":7724,"start":4156,"enrollment":1221,"conditions":13766,"interventions":13768},"NCT01084980","Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome",[88,89],[13767],"Minimal Change Disease",[8447],{"trials":13770,"activeCount":99},[13771],{"nctId":13772,"briefTitle":13773,"status":154,"phases":13774,"primaryCompletion":548,"completion":579,"start":10099,"enrollment":9785,"conditions":13775,"interventions":13777},"NCT01162005","Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children",[90],[13776],"Nephrotic Syndrome",[8447],{"trials":13779,"activeCount":99},[13780],{"nctId":13781,"briefTitle":13782,"status":166,"phases":13783,"primaryCompletion":2251,"completion":2251,"start":2161,"enrollment":170,"conditions":13784,"interventions":13785},"NCT02808065","Validation of Population Pharmacokinetic Model Derived From Healthy Volunteer in Kidney Transplant Recipients",[],[13747],[8447,13729],{"intervention":735,"totalTrials":1802,"cells":13787},{"EARLY_PHASE1":13788,"PHASE1":13790,"PHASE2":13810,"PHASE3":13812,"PHASE4":13814,"NA":13820},{"trials":13789,"activeCount":99},[],{"trials":13791,"activeCount":99},[13792,13796,13800,13804],{"nctId":729,"briefTitle":730,"status":154,"phases":13793,"primaryCompletion":702,"completion":702,"start":732,"enrollment":411,"conditions":13794,"interventions":13795},[87],[21],[735,736,737],{"nctId":739,"briefTitle":740,"status":154,"phases":13797,"primaryCompletion":548,"completion":548,"start":742,"enrollment":33,"conditions":13798,"interventions":13799},[87],[21],[735,745,722],{"nctId":9436,"briefTitle":9437,"status":154,"phases":13801,"primaryCompletion":9439,"completion":9440,"start":9441,"enrollment":33,"conditions":13802,"interventions":13803},[87],[9443],[735,9429],{"nctId":13805,"briefTitle":13806,"status":154,"phases":13807,"primaryCompletion":5066,"completion":753,"start":3671,"enrollment":411,"conditions":13808,"interventions":13809},"NCT01215214","Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics",[87],[21],[2448],{"trials":13811,"activeCount":99},[],{"trials":13813,"activeCount":99},[],{"trials":13815,"activeCount":99},[13816],{"nctId":2193,"briefTitle":2194,"status":166,"phases":13817,"primaryCompletion":2196,"completion":1863,"start":2197,"enrollment":1011,"conditions":13818,"interventions":13819},[90],[2199],[735,270],{"trials":13821,"activeCount":99},[13822,13826,13836],{"nctId":2440,"briefTitle":2441,"status":154,"phases":13823,"primaryCompletion":2443,"completion":821,"start":2444,"enrollment":2421,"conditions":13824,"interventions":13825},[91],[2446],[2448,2083],{"nctId":13827,"briefTitle":13828,"status":166,"phases":13829,"primaryCompletion":13830,"completion":13830,"start":13831,"enrollment":5319,"conditions":13832,"interventions":13834},"NCT03940391","Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy",[91],"2020-04-14","2019-05-01",[13833],"Endoscopy",[13835,735],"Chlorpheniramine and midazolam",{"nctId":13837,"briefTitle":13838,"status":154,"phases":13839,"primaryCompletion":13840,"completion":13840,"start":13841,"enrollment":6554,"conditions":13842,"interventions":13845},"NCT03055663","Sedation Using Virtual Reality During Surgery Under Spinal Anesthesia",[91],"2017-10-31","2017-02-20",[13843,13844],"Sedation","Spinal Anesthesia",[735],{"intervention":1727,"totalTrials":1802,"cells":13847},{"EARLY_PHASE1":13848,"PHASE1":13850,"PHASE2":13852,"PHASE3":13854,"PHASE4":13856,"NA":13866},{"trials":13849,"activeCount":99},[],{"trials":13851,"activeCount":99},[],{"trials":13853,"activeCount":99},[],{"trials":13855,"activeCount":99},[],{"trials":13857,"activeCount":99},[13858,13862],{"nctId":1910,"briefTitle":1911,"status":154,"phases":13859,"primaryCompletion":675,"completion":264,"start":742,"enrollment":1444,"conditions":13860,"interventions":13861},[90],[1914,1915],[1917,1727],{"nctId":1919,"briefTitle":1920,"status":154,"phases":13863,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":676,"conditions":13864,"interventions":13865},[90],[1925,1926],[1668,1727],{"trials":13867,"activeCount":99},[13868,13872,13876,13880,13884,13888],{"nctId":1943,"briefTitle":1944,"status":154,"phases":13869,"primaryCompletion":675,"completion":675,"start":742,"enrollment":1946,"conditions":13870,"interventions":13871},[],[30],[1668,1727],{"nctId":1860,"briefTitle":1861,"status":658,"phases":13873,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":13874,"interventions":13875},[91],[1866],[1868,1858,1668,1727,1869,1870],{"nctId":1954,"briefTitle":1955,"status":154,"phases":13877,"primaryCompletion":703,"completion":703,"start":1957,"enrollment":1958,"conditions":13878,"interventions":13879},[91],[1774,1775,27,1776],[1668,1727],{"nctId":1717,"briefTitle":1718,"status":154,"phases":13881,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":13882,"interventions":13883},[91],[1725],[51,1727],{"nctId":1749,"briefTitle":1750,"status":154,"phases":13885,"primaryCompletion":578,"completion":578,"start":703,"enrollment":1752,"conditions":13886,"interventions":13887},[91],[1754],[1756,1757],{"nctId":1790,"briefTitle":1791,"status":154,"phases":13889,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":1795,"conditions":13890,"interventions":13891},[91],[1797,1798],[1727,1756,1800],{"intervention":13893,"totalTrials":525,"cells":13894},"escitalopram",{"EARLY_PHASE1":13895,"PHASE1":13897,"PHASE2":13909,"PHASE3":13918,"PHASE4":13920,"NA":13936},{"trials":13896,"activeCount":99},[],{"trials":13898,"activeCount":99},[13899,13903],{"nctId":7955,"briefTitle":7956,"status":154,"phases":13900,"primaryCompletion":1957,"completion":1957,"start":7958,"enrollment":170,"conditions":13901,"interventions":13902},[87],[21],[7961,7948,7962],{"nctId":13904,"briefTitle":13905,"status":154,"phases":13906,"primaryCompletion":2275,"completion":2275,"start":548,"enrollment":210,"conditions":13907,"interventions":13908},"NCT02122939","A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers",[87],[21],[7961],{"trials":13910,"activeCount":99},[13911],{"nctId":13912,"briefTitle":13913,"status":166,"phases":13914,"primaryCompletion":3510,"completion":3510,"start":5318,"enrollment":1071,"conditions":13915,"interventions":13917},"NCT01008098","Neuroprotective\u002FNeurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder",[88],[13916],"Posttraumatic Stress Disorder",[13893],{"trials":13919,"activeCount":99},[],{"trials":13921,"activeCount":99},[13922,13930],{"nctId":13923,"briefTitle":13924,"status":154,"phases":13925,"primaryCompletion":753,"completion":753,"start":5659,"enrollment":13926,"conditions":13927,"interventions":13929},"NCT00723060","Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder",[90],176,[13928],"Obsessive Compulsive Disorder",[13893],{"nctId":13931,"briefTitle":13932,"status":154,"phases":13933,"primaryCompletion":179,"completion":168,"start":5092,"enrollment":1795,"conditions":13934,"interventions":13935},"NCT01594866","Lexapro®'s Efficacy After Dose Escalation in Remission Study",[90],[5574],[13893,13893],{"trials":13937,"activeCount":99},[13938],{"nctId":13939,"briefTitle":13940,"status":154,"phases":13941,"primaryCompletion":7680,"completion":7680,"start":5318,"enrollment":989,"conditions":13942,"interventions":13943},"NCT00702780","Progression Delaying Effect of Escitalopram in Alzheimer's Disease",[91],[12223],[13893],{"intervention":2459,"totalTrials":525,"cells":13945},{"EARLY_PHASE1":13946,"PHASE1":13948,"PHASE2":13950,"PHASE3":13952,"PHASE4":13954,"NA":13968},{"trials":13947,"activeCount":99},[],{"trials":13949,"activeCount":99},[],{"trials":13951,"activeCount":99},[],{"trials":13953,"activeCount":99},[],{"trials":13955,"activeCount":99},[13956,13960,13964],{"nctId":6090,"briefTitle":6091,"status":154,"phases":13957,"primaryCompletion":2419,"completion":3554,"start":4054,"enrollment":569,"conditions":13958,"interventions":13959},[90],[6094],[6077,6096],{"nctId":6178,"briefTitle":6179,"status":154,"phases":13961,"primaryCompletion":6181,"completion":2523,"start":6182,"enrollment":6183,"conditions":13962,"interventions":13963},[90],[6185,5071],[6165,6096],{"nctId":6346,"briefTitle":6347,"status":166,"phases":13965,"primaryCompletion":6349,"completion":3670,"start":2150,"enrollment":6350,"conditions":13966,"interventions":13967},[90],[6352],[6333,2459],{"trials":13969,"activeCount":99},[13970,13978,13986],{"nctId":13971,"briefTitle":13972,"status":166,"phases":13973,"primaryCompletion":10099,"completion":4198,"start":3556,"enrollment":1048,"conditions":13974,"interventions":13976},"NCT01131741","Comparison of Perfusion Index, T Wave Amplitude, Systolic Blood Pressure and Heart Rate",[91],[13975],"Injections, Intravenous",[13977,2459],"Epinephrine",{"nctId":13979,"briefTitle":13980,"status":154,"phases":13981,"primaryCompletion":2294,"completion":2294,"start":6922,"enrollment":265,"conditions":13982,"interventions":13984},"NCT02213848","Effect of Calcium Chloride on Recovery From Neuromuscular Blockade",[91],[13983],"Residual Neuromuscular Blockade",[13985,6096],"Calcium",{"nctId":2450,"briefTitle":2451,"status":154,"phases":13987,"primaryCompletion":2305,"completion":2453,"start":2454,"enrollment":2455,"conditions":13988,"interventions":13989},[91],[118,2457],[2083,2459],{"intervention":2166,"totalTrials":139,"cells":13991},{"EARLY_PHASE1":13992,"PHASE1":13994,"PHASE2":13996,"PHASE3":13998,"PHASE4":14000,"NA":14006},{"trials":13993,"activeCount":99},[],{"trials":13995,"activeCount":99},[],{"trials":13997,"activeCount":99},[],{"trials":13999,"activeCount":99},[],{"trials":14001,"activeCount":99},[14002],{"nctId":2158,"briefTitle":2159,"status":154,"phases":14003,"primaryCompletion":2161,"completion":179,"start":169,"enrollment":676,"conditions":14004,"interventions":14005},[90],[518],[2164,2165,2166,2047],{"trials":14007,"activeCount":99},[14008,14022,14030],{"nctId":14009,"briefTitle":14010,"status":154,"phases":14011,"primaryCompletion":14012,"completion":14013,"start":14014,"enrollment":1221,"conditions":14015,"interventions":14020},"NCT05049278","Effects of Vasopressor on the Graft Blood Flow in TRAM",[91],"2022-02-23","2023-02-23","2021-09-24",[14016,14017,14018,14019],"Blood Flow","Anastomotic Failure of Flap","Flap Necrosis","Flap Ischemia",[14021,2166],"Norepinephrine",{"nctId":14023,"briefTitle":14024,"status":154,"phases":14025,"primaryCompletion":7680,"completion":11727,"start":2151,"enrollment":594,"conditions":14026,"interventions":14028},"NCT01080625","Effect of Epinephrine\u002F Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation",[91],[14027],"Hypotension After Reperfusion in Liver Transplantation",[14029,7096],"phenylephrine",{"nctId":14031,"briefTitle":14032,"status":154,"phases":14033,"primaryCompletion":14034,"completion":14035,"start":14036,"enrollment":2232,"conditions":14037,"interventions":14039},"NCT04214145","The Effect of Vasopressors on Cerebral Oxygentaion During Off Pump CABG",[91],"2021-09-02","2021-09-03","2020-01-07",[14038],"Cerebral Oxygen Saturation",[2166,14021,14040],"Vasopressin",{"intervention":637,"totalTrials":139,"cells":14042},{"EARLY_PHASE1":14043,"PHASE1":14045,"PHASE2":14047,"PHASE3":14049,"PHASE4":14051,"NA":14057},{"trials":14044,"activeCount":99},[],{"trials":14046,"activeCount":99},[],{"trials":14048,"activeCount":99},[],{"trials":14050,"activeCount":99},[],{"trials":14052,"activeCount":99},[14053],{"nctId":2399,"briefTitle":2400,"status":154,"phases":14054,"primaryCompletion":1843,"completion":1843,"start":2394,"enrollment":2402,"conditions":14055,"interventions":14056},[90],[2404],[1870,2083],{"trials":14058,"activeCount":99},[14059,14070,14074],{"nctId":14060,"briefTitle":14061,"status":154,"phases":14062,"primaryCompletion":14063,"completion":14064,"start":14065,"enrollment":7571,"conditions":14066,"interventions":14068},"NCT03105115","Effect of Intrathecal Fentanyl on Spinal Anesthesia During Dexmedetomidine Infusion",[91],"2017-10-24","2017-10-26","2017-05-25",[14067],"Anesthesia, Spinal",[637,14069],"bupivacaine only",{"nctId":629,"briefTitle":630,"status":154,"phases":14071,"primaryCompletion":632,"completion":633,"start":634,"enrollment":180,"conditions":14072,"interventions":14073},[91],[465],[637,638],{"nctId":1860,"briefTitle":1861,"status":658,"phases":14075,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":14076,"interventions":14077},[91],[1866],[1868,1858,1668,1727,1869,1870],{"intervention":5228,"totalTrials":139,"cells":14079},{"EARLY_PHASE1":14080,"PHASE1":14082,"PHASE2":14084,"PHASE3":14086,"PHASE4":14092,"NA":14102},{"trials":14081,"activeCount":99},[],{"trials":14083,"activeCount":99},[],{"trials":14085,"activeCount":99},[],{"trials":14087,"activeCount":99},[14088],{"nctId":8440,"briefTitle":8441,"status":154,"phases":14089,"primaryCompletion":8443,"completion":8443,"start":1844,"enrollment":1048,"conditions":14090,"interventions":14091},[88,89],[8445],[8447,8429,5228],{"trials":14093,"activeCount":99},[14094,14098],{"nctId":5221,"briefTitle":5222,"status":154,"phases":14095,"primaryCompletion":2478,"completion":2478,"start":169,"enrollment":5224,"conditions":14096,"interventions":14097},[90],[5226],[5228,5208],{"nctId":6919,"briefTitle":6920,"status":154,"phases":14099,"primaryCompletion":1978,"completion":1978,"start":6922,"enrollment":158,"conditions":14100,"interventions":14101},[90],[6924],[6906,5228],{"trials":14103,"activeCount":99},[14104],{"nctId":14105,"briefTitle":14106,"status":166,"phases":14107,"primaryCompletion":11639,"completion":11639,"start":4130,"enrollment":14108,"conditions":14109,"interventions":14110},"NCT02897011","2-week dc of MTX and Influenza Vaccination in RA",[91],318,[3315,8224,5228],[5228],{"intervention":1686,"totalTrials":139,"cells":14112},{"EARLY_PHASE1":14113,"PHASE1":14115,"PHASE2":14117,"PHASE3":14119,"PHASE4":14121,"NA":14136},{"trials":14114,"activeCount":99},[],{"trials":14116,"activeCount":99},[],{"trials":14118,"activeCount":99},[],{"trials":14120,"activeCount":99},[],{"trials":14122,"activeCount":99},[14123,14127],{"nctId":2407,"briefTitle":2408,"status":154,"phases":14124,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":1752,"conditions":14125,"interventions":14126},[90],[2413],[1686,2083],{"nctId":14128,"briefTitle":14129,"status":154,"phases":14130,"primaryCompletion":14131,"completion":14131,"start":14132,"enrollment":2421,"conditions":14133,"interventions":14135},"NCT05760534","Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia",[90],"2025-11-25","2023-03-06",[2143,14134],"Arthritis Hip",[1686],{"trials":14137,"activeCount":99},[14138,14142],{"nctId":1679,"briefTitle":1680,"status":658,"phases":14139,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":99,"conditions":14140,"interventions":14141},[91],[518],[1686,51],{"nctId":14143,"briefTitle":14144,"status":166,"phases":14145,"primaryCompletion":14146,"completion":14147,"start":14148,"enrollment":676,"conditions":14149,"interventions":14150},"NCT05557253","Effects of Remimazolam on the Intraoperative Hemodynamics in Bypass Surgery",[91],"2023-10-30","2023-12-30","2022-10-20",[1891],[1686,14151],"Balanced Anesthesia",{"intervention":13729,"totalTrials":139,"cells":14153},{"EARLY_PHASE1":14154,"PHASE1":14156,"PHASE2":14170,"PHASE3":14172,"PHASE4":14174,"NA":14182},{"trials":14155,"activeCount":99},[],{"trials":14157,"activeCount":99},[14158,14166],{"nctId":14159,"briefTitle":14160,"status":166,"phases":14161,"primaryCompletion":3047,"completion":3509,"start":14162,"enrollment":1221,"conditions":14163,"interventions":14164},"NCT04868786","Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation",[87],"2020-10-26",[9386],[14165],"Mycophenolate Mofetil",{"nctId":13724,"briefTitle":13725,"status":154,"phases":14167,"primaryCompletion":3649,"completion":3649,"start":3838,"enrollment":6744,"conditions":14168,"interventions":14169},[87],[9443],[8447,13729],{"trials":14171,"activeCount":99},[],{"trials":14173,"activeCount":99},[],{"trials":14175,"activeCount":99},[14176],{"nctId":14177,"briefTitle":14178,"status":154,"phases":14179,"primaryCompletion":168,"completion":168,"start":548,"enrollment":158,"conditions":14180,"interventions":14181},"NCT01895894","Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome",[90],[13776],[13729],{"trials":14183,"activeCount":99},[14184],{"nctId":13781,"briefTitle":13782,"status":166,"phases":14185,"primaryCompletion":2251,"completion":2251,"start":2161,"enrollment":170,"conditions":14186,"interventions":14187},[],[13747],[8447,13729],{"intervention":14189,"totalTrials":599,"cells":14190},"Voriconazole",{"EARLY_PHASE1":14191,"PHASE1":14193,"PHASE2":14208,"PHASE3":14210,"PHASE4":14212,"NA":14214},{"trials":14192,"activeCount":99},[],{"trials":14194,"activeCount":99},[14195,14202],{"nctId":14196,"briefTitle":14197,"status":154,"phases":14198,"primaryCompletion":2152,"completion":2152,"start":7381,"enrollment":210,"conditions":14199,"interventions":14201},"NCT01080651","Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole",[87],[14200],"Invasive Aspergillosis",[14189],{"nctId":14203,"briefTitle":14204,"status":154,"phases":14205,"primaryCompletion":2152,"completion":2152,"start":7381,"enrollment":6744,"conditions":14206,"interventions":14207},"NCT00942773","Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole",[87],[21],[14189],{"trials":14209,"activeCount":99},[],{"trials":14211,"activeCount":99},[],{"trials":14213,"activeCount":99},[],{"trials":14215,"activeCount":99},[14216],{"nctId":14217,"briefTitle":14218,"status":154,"phases":14219,"primaryCompletion":752,"completion":1843,"start":5318,"enrollment":2421,"conditions":14220,"interventions":14222},"NCT00890708","Therapeutic Drug Monitoring of Voriconazole",[91],[14221],"Mycoses",[14189],{"intervention":1086,"totalTrials":599,"cells":14224},{"EARLY_PHASE1":14225,"PHASE1":14227,"PHASE2":14229,"PHASE3":14239,"PHASE4":14241,"NA":14243},{"trials":14226,"activeCount":99},[],{"trials":14228,"activeCount":99},[],{"trials":14230,"activeCount":99},[14231,14235],{"nctId":1075,"briefTitle":1076,"status":166,"phases":14232,"primaryCompletion":1078,"completion":75,"start":1079,"enrollment":1080,"conditions":14233,"interventions":14234},[88],[1082],[995,1084,1085,1086],{"nctId":9537,"briefTitle":9538,"status":154,"phases":14236,"primaryCompletion":7958,"completion":2551,"start":6182,"enrollment":1889,"conditions":14237,"interventions":14238},[88],[9541],[9543,9511,1086],{"trials":14240,"activeCount":99},[],{"trials":14242,"activeCount":99},[],{"trials":14244,"activeCount":99},[14245],{"nctId":14246,"briefTitle":14247,"status":658,"phases":14248,"primaryCompletion":168,"completion":168,"start":3555,"enrollment":99,"conditions":14249,"interventions":14250},"NCT01857726","Comparison of TACE Versus TACE\u002FTACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion",[91],[18],[14251,1086],"Doxorubicin",{"intervention":1714,"totalTrials":599,"cells":14253},{"EARLY_PHASE1":14254,"PHASE1":14256,"PHASE2":14258,"PHASE3":14260,"PHASE4":14262,"NA":14264},{"trials":14255,"activeCount":99},[],{"trials":14257,"activeCount":99},[],{"trials":14259,"activeCount":99},[],{"trials":14261,"activeCount":99},[],{"trials":14263,"activeCount":99},[],{"trials":14265,"activeCount":99},[14266,14272,14276],{"nctId":14267,"briefTitle":14268,"status":154,"phases":14269,"primaryCompletion":821,"completion":821,"start":673,"enrollment":1374,"conditions":14270,"interventions":14271},"NCT02471521","Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children",[91],[8198,27],[1714],{"nctId":1705,"briefTitle":1706,"status":154,"phases":14273,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1710,"conditions":14274,"interventions":14275},[91],[1712],[1694,51,1714,1715],{"nctId":14277,"briefTitle":14278,"status":154,"phases":14279,"primaryCompletion":14280,"completion":14280,"start":14281,"enrollment":1221,"conditions":14282,"interventions":14284},"NCT03658057","Measurement of the Skin Sympathetic Nerve Activity",[91],"2018-11-01","2018-08-31",[14283],"Skin Sympathetic Nerve Activity During General Anesthesia in Patients Undergoing Breast Cancer Surgery",[1714],{"intervention":14286,"totalTrials":599,"cells":14287},"aripiprazole",{"EARLY_PHASE1":14288,"PHASE1":14290,"PHASE2":14292,"PHASE3":14294,"PHASE4":14296,"NA":14315},{"trials":14289,"activeCount":99},[],{"trials":14291,"activeCount":99},[],{"trials":14293,"activeCount":99},[],{"trials":14295,"activeCount":99},[],{"trials":14297,"activeCount":99},[14298,14306],{"nctId":14299,"briefTitle":14300,"status":154,"phases":14301,"primaryCompletion":2419,"completion":2419,"start":7381,"enrollment":1125,"conditions":14302,"interventions":14305},"NCT00845988","Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders",[90],[14303,14304],"Bipolar Disorders","Metabolic Complication",[14286],{"nctId":14307,"briefTitle":14308,"status":154,"phases":14309,"primaryCompletion":14310,"completion":14311,"start":6823,"enrollment":14312,"conditions":14313,"interventions":14314},"NCT00328367","Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia",[90],"2006-12","2008-02",61,[32],[14286],{"trials":14316,"activeCount":99},[14317],{"nctId":14318,"briefTitle":14319,"status":154,"phases":14320,"primaryCompletion":3556,"completion":2385,"start":6181,"enrollment":1170,"conditions":14321,"interventions":14326},"NCT01562808","Change in Brain Metabolism and Cognitive Function by Aripiprazole",[91],[14322,14323,14324,14325],"Antipsychotics","Cognition","Brain Metabolism","Dopamine Receptor Occupancy",[14327],"Aripiprazole",{"intervention":14329,"totalTrials":599,"cells":14330},"Tranexamic Acid",{"EARLY_PHASE1":14331,"PHASE1":14333,"PHASE2":14343,"PHASE3":14345,"PHASE4":14347,"NA":14356},{"trials":14332,"activeCount":99},[],{"trials":14334,"activeCount":99},[14335],{"nctId":14336,"briefTitle":14337,"status":166,"phases":14338,"primaryCompletion":702,"completion":1979,"start":701,"enrollment":14339,"conditions":14340,"interventions":14342},"NCT02286973","Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty",[87],264,[14341],"Degenerative Arthritis",[14329],{"trials":14344,"activeCount":99},[],{"trials":14346,"activeCount":99},[],{"trials":14348,"activeCount":99},[14349],{"nctId":14350,"briefTitle":14351,"status":166,"phases":14352,"primaryCompletion":5571,"completion":5571,"start":14353,"enrollment":2252,"conditions":14354,"interventions":14355},"NCT03109652","Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients",[90],"2017-07-10",[4814],[14329],{"trials":14357,"activeCount":99},[14358],{"nctId":14359,"briefTitle":14360,"status":166,"phases":14361,"primaryCompletion":14362,"completion":14363,"start":14364,"enrollment":463,"conditions":14365,"interventions":14367},"NCT06091891","Tranexamic Acid in Pediatric Scoliosis Surgery",[91],"2025-08-01","2025-09-01","2023-10-16",[14366],"Scoliosis",[14368,14369],"Tranexamic acid","Tranexamic acid infusion under ROTEM-guidance",{"intervention":7096,"totalTrials":599,"cells":14371},{"EARLY_PHASE1":14372,"PHASE1":14374,"PHASE2":14376,"PHASE3":14378,"PHASE4":14380,"NA":14386},{"trials":14373,"activeCount":99},[],{"trials":14375,"activeCount":99},[],{"trials":14377,"activeCount":99},[],{"trials":14379,"activeCount":99},[],{"trials":14381,"activeCount":99},[14382],{"nctId":7087,"briefTitle":7088,"status":154,"phases":14383,"primaryCompletion":2152,"completion":7090,"start":6182,"enrollment":7091,"conditions":14384,"interventions":14385},[90],[2526],[7094,7074,7095,7096,7097],{"trials":14387,"activeCount":99},[14388,14392],{"nctId":13971,"briefTitle":13972,"status":166,"phases":14389,"primaryCompletion":10099,"completion":4198,"start":3556,"enrollment":1048,"conditions":14390,"interventions":14391},[91],[13975],[13977,2459],{"nctId":14023,"briefTitle":14024,"status":154,"phases":14393,"primaryCompletion":7680,"completion":11727,"start":2151,"enrollment":594,"conditions":14394,"interventions":14395},[91],[14027],[14029,7096],{"intervention":14397,"totalTrials":599,"cells":14398},"low dose remifentanil",{"EARLY_PHASE1":14399,"PHASE1":14401,"PHASE2":14403,"PHASE3":14413,"PHASE4":14415,"NA":14417},{"trials":14400,"activeCount":99},[],{"trials":14402,"activeCount":99},[],{"trials":14404,"activeCount":99},[14405],{"nctId":14406,"briefTitle":14407,"status":154,"phases":14408,"primaryCompletion":1854,"completion":1854,"start":752,"enrollment":14409,"conditions":14410,"interventions":14412},"NCT01477892","Evaluation of Safety and Efficacy of Remifentanil in Pediatric Population",[87,88],14,[14411],"Infant, Preterm",[14397],{"trials":14414,"activeCount":99},[],{"trials":14416,"activeCount":99},[],{"trials":14418,"activeCount":99},[14419,14423],{"nctId":2313,"briefTitle":2314,"status":154,"phases":14420,"primaryCompletion":702,"completion":702,"start":701,"enrollment":1889,"conditions":14421,"interventions":14422},[91],[2025],[2318,2319,2320,2321],{"nctId":14424,"briefTitle":14425,"status":154,"phases":14426,"primaryCompletion":702,"start":703,"enrollment":1374,"conditions":14427,"interventions":14430},"NCT02243254","Prevention of Remifentanil-induced Postoperative Hyperalgesia With Intravenous Ibuprofen",[91],[14428,1858,14429,3207],"Ibuprofen","Hyperalgesia",[14431,14428,14397],"high dose remifentanil",{"intervention":14433,"totalTrials":599,"cells":14434},"Lansoprazole",{"EARLY_PHASE1":14435,"PHASE1":14437,"PHASE2":14439,"PHASE3":14456,"PHASE4":14458,"NA":14460},{"trials":14436,"activeCount":99},[],{"trials":14438,"activeCount":99},[],{"trials":14440,"activeCount":99},[14441,14449],{"nctId":14442,"briefTitle":14443,"status":154,"phases":14444,"primaryCompletion":703,"completion":703,"start":548,"enrollment":210,"conditions":14445,"interventions":14448},"NCT01946971","Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)",[87,88],[14446,14447],"Premature Infants","Gastroesophageal Reflux",[14433],{"nctId":14450,"briefTitle":14451,"status":154,"phases":14452,"primaryCompletion":3966,"completion":157,"start":2383,"enrollment":1036,"conditions":14453,"interventions":14455},"NCT01778101","Lansoprazole in Preterm Infants With Reflux",[88],[1818,14454],"Gastrointestinal Reflux",[14433],{"trials":14457,"activeCount":99},[],{"trials":14459,"activeCount":99},[],{"trials":14461,"activeCount":99},[14462],{"nctId":14463,"briefTitle":14464,"status":154,"phases":14465,"primaryCompletion":3565,"completion":3565,"start":6265,"enrollment":850,"conditions":14466,"interventions":14467},"NCT01039558","The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease",[91],[12343],[14468,14469],"ecabet sodium","lansoprazole",{"intervention":7094,"totalTrials":599,"cells":14471},{"EARLY_PHASE1":14472,"PHASE1":14474,"PHASE2":14476,"PHASE3":14478,"PHASE4":14480,"NA":14486},{"trials":14473,"activeCount":99},[],{"trials":14475,"activeCount":99},[],{"trials":14477,"activeCount":99},[],{"trials":14479,"activeCount":99},[],{"trials":14481,"activeCount":99},[14482],{"nctId":7087,"briefTitle":7088,"status":154,"phases":14483,"primaryCompletion":2152,"completion":7090,"start":6182,"enrollment":7091,"conditions":14484,"interventions":14485},[90],[2526],[7094,7074,7095,7096,7097],{"trials":14487,"activeCount":99},[14488,14498],{"nctId":14489,"briefTitle":14490,"status":154,"phases":14491,"primaryCompletion":14013,"completion":14492,"start":14493,"enrollment":1048,"conditions":14494,"interventions":14496},"NCT05015907","Ultrasound-guided Selective Supraclavicular Nerve Block for Postoperative Pain Control in Pediatric Patients.",[91],"2023-02-24","2021-10-22",[14495],"Cancer Pediatric",[14497],"Ropivacaine",{"nctId":14499,"briefTitle":14500,"status":166,"phases":14501,"primaryCompletion":673,"completion":2443,"start":3510,"enrollment":2307,"conditions":14502,"interventions":14504},"NCT02007850","Effect of Mode of Femoral Nerve Analgesia on Quadriceps Muscle Strength",[91],[14503],"Muscle Weakness",[7094],{"intervention":2505,"totalTrials":599,"cells":14506},{"EARLY_PHASE1":14507,"PHASE1":14509,"PHASE2":14511,"PHASE3":14513,"PHASE4":14519,"NA":14521},{"trials":14508,"activeCount":99},[],{"trials":14510,"activeCount":99},[],{"trials":14512,"activeCount":99},[],{"trials":14514,"activeCount":99},[14515],{"nctId":2496,"briefTitle":2497,"status":154,"phases":14516,"primaryCompletion":619,"start":2499,"enrollment":2500,"conditions":14517,"interventions":14518},[89],[2502],[2504,2505],{"trials":14520,"activeCount":99},[],{"trials":14522,"activeCount":99},[14523,14527],{"nctId":2548,"briefTitle":2549,"status":166,"phases":14524,"primaryCompletion":742,"completion":2551,"start":1816,"enrollment":1743,"conditions":14525,"interventions":14526},[91],[518,2553,2554,2555],[2504,2505,2505],{"nctId":14528,"briefTitle":14529,"status":166,"phases":14530,"primaryCompletion":5092,"completion":5092,"start":1844,"enrollment":14531,"conditions":14532,"interventions":14535},"NCT01477242","The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department",[91],266,[14533,14534],"Sedation and Analgesia","Side Effect of Drug",[14536],"Ondansetron",{"intervention":2311,"totalTrials":599,"cells":14538},{"EARLY_PHASE1":14539,"PHASE1":14541,"PHASE2":14543,"PHASE3":14545,"PHASE4":14547,"NA":14549},{"trials":14540,"activeCount":99},[],{"trials":14542,"activeCount":99},[],{"trials":14544,"activeCount":99},[],{"trials":14546,"activeCount":99},[],{"trials":14548,"activeCount":99},[],{"trials":14550,"activeCount":99},[14551,14555,14559],{"nctId":2301,"briefTitle":2302,"status":166,"phases":14552,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":14553,"interventions":14554},[91],[2309],[2311,270],{"nctId":2334,"briefTitle":2335,"status":154,"phases":14556,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":380,"conditions":14557,"interventions":14558},[91],[2340,2341],[2311,270],{"nctId":2344,"briefTitle":2345,"status":154,"phases":14560,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":14561,"interventions":14562},[91],[2340],[2311,270],{"intervention":14564,"totalTrials":95,"cells":14565},"Lupeol",{"EARLY_PHASE1":14566,"PHASE1":14568,"PHASE2":14570,"PHASE3":14572,"PHASE4":14574,"NA":14576},{"trials":14567,"activeCount":99},[],{"trials":14569,"activeCount":99},[],{"trials":14571,"activeCount":99},[],{"trials":14573,"activeCount":99},[],{"trials":14575,"activeCount":99},[],{"trials":14577,"activeCount":99},[14578,14586],{"nctId":14579,"briefTitle":14580,"status":154,"phases":14581,"primaryCompletion":1957,"completion":1957,"start":6265,"enrollment":22,"conditions":14582,"interventions":14584},"NCT02152865","Clinical Trial of Lupeol for Mild-moderate Acne",[91],[14583],"Acne",[14564,14585],"Control vehicle",{"nctId":14587,"briefTitle":14588,"status":154,"phases":14589,"primaryCompletion":2041,"completion":2041,"start":6922,"enrollment":33,"conditions":14590,"interventions":14591},"NCT02205892","Clinical Study for Topical Lupeol in Acne",[91],[14583],[14564],{"intervention":14593,"totalTrials":95,"cells":14594},"Erythropoietin",{"EARLY_PHASE1":14595,"PHASE1":14597,"PHASE2":14599,"PHASE3":14601,"PHASE4":14603,"NA":14613},{"trials":14596,"activeCount":99},[],{"trials":14598,"activeCount":99},[],{"trials":14600,"activeCount":99},[],{"trials":14602,"activeCount":99},[],{"trials":14604,"activeCount":99},[14605],{"nctId":14606,"briefTitle":14607,"status":658,"phases":14608,"primaryCompletion":14609,"completion":14609,"start":168,"enrollment":99,"conditions":14610,"interventions":14612},"NCT03004209","Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients",[90],"2018-02-06",[14611],"Autoimmune Encephalitis",[14593],{"trials":14614,"activeCount":99},[14615],{"nctId":2281,"briefTitle":2282,"status":166,"phases":14616,"primaryCompletion":1863,"completion":1863,"start":2284,"enrollment":1795,"conditions":14617,"interventions":14618},[91],[1971,2286,2287],[2289,270],{"intervention":14021,"totalTrials":95,"cells":14620},{"EARLY_PHASE1":14621,"PHASE1":14623,"PHASE2":14625,"PHASE3":14627,"PHASE4":14629,"NA":14631},{"trials":14622,"activeCount":99},[],{"trials":14624,"activeCount":99},[],{"trials":14626,"activeCount":99},[],{"trials":14628,"activeCount":99},[],{"trials":14630,"activeCount":99},[],{"trials":14632,"activeCount":99},[14633,14637],{"nctId":14009,"briefTitle":14010,"status":154,"phases":14634,"primaryCompletion":14012,"completion":14013,"start":14014,"enrollment":1221,"conditions":14635,"interventions":14636},[91],[14016,14017,14018,14019],[14021,2166],{"nctId":14031,"briefTitle":14032,"status":154,"phases":14638,"primaryCompletion":14034,"completion":14035,"start":14036,"enrollment":2232,"conditions":14639,"interventions":14640},[91],[14038],[2166,14021,14040],{"intervention":13716,"totalTrials":95,"cells":14642},{"EARLY_PHASE1":14643,"PHASE1":14645,"PHASE2":14647,"PHASE3":14657,"PHASE4":14659,"NA":14661},{"trials":14644,"activeCount":99},[],{"trials":14646,"activeCount":99},[],{"trials":14648,"activeCount":99},[14649],{"nctId":14650,"briefTitle":14651,"status":154,"phases":14652,"primaryCompletion":9964,"completion":9964,"start":2551,"enrollment":1221,"conditions":14653,"interventions":14656},"NCT01925066","Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation",[88],[14654,14655],"Pneumonia, Staphylococcal","Methicillin-Resistant Staphylococcus Aureus",[13716],{"trials":14658,"activeCount":99},[],{"trials":14660,"activeCount":99},[],{"trials":14662,"activeCount":99},[14663],{"nctId":13710,"briefTitle":13711,"status":154,"phases":14664,"primaryCompletion":13713,"completion":13713,"start":10693,"enrollment":1221,"conditions":14665,"interventions":14666},[91],[13446],[12391,13716,12391],{"intervention":1656,"totalTrials":95,"cells":14668},{"EARLY_PHASE1":14669,"PHASE1":14671,"PHASE2":14673,"PHASE3":14685,"PHASE4":14687,"NA":14689},{"trials":14670,"activeCount":99},[],{"trials":14672,"activeCount":99},[],{"trials":14674,"activeCount":99},[14675],{"nctId":14676,"briefTitle":14677,"status":166,"phases":14678,"primaryCompletion":14679,"completion":75,"start":14680,"enrollment":1048,"conditions":14681,"interventions":14683},"NCT05975255","Dose Finding Study for Remimazolam in Children",[88],"2024-10-31","2023-11-16",[14682],"Drug Effect",[14684],"Remimazolam besylate",{"trials":14686,"activeCount":99},[],{"trials":14688,"activeCount":99},[],{"trials":14690,"activeCount":99},[14691],{"nctId":1648,"briefTitle":1649,"status":154,"phases":14692,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1002,"conditions":14693,"interventions":14694},[91],[1654],[1656,1657,51],{"intervention":1657,"totalTrials":95,"cells":14696},{"EARLY_PHASE1":14697,"PHASE1":14699,"PHASE2":14701,"PHASE3":14703,"PHASE4":14705,"NA":14707},{"trials":14698,"activeCount":99},[],{"trials":14700,"activeCount":99},[],{"trials":14702,"activeCount":99},[],{"trials":14704,"activeCount":99},[],{"trials":14706,"activeCount":99},[],{"trials":14708,"activeCount":99},[14709,14713],{"nctId":1648,"briefTitle":1649,"status":154,"phases":14710,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1002,"conditions":14711,"interventions":14712},[91],[1654],[1656,1657,51],{"nctId":1688,"briefTitle":1689,"status":154,"phases":14714,"primaryCompletion":1691,"completion":1691,"start":1652,"enrollment":569,"conditions":14715,"interventions":14716},[91],[1654],[1694,1657,51],{"intervention":14718,"totalTrials":95,"cells":14719},"Ketamine",{"EARLY_PHASE1":14720,"PHASE1":14722,"PHASE2":14724,"PHASE3":14726,"PHASE4":14728,"NA":14730},{"trials":14721,"activeCount":99},[],{"trials":14723,"activeCount":99},[],{"trials":14725,"activeCount":99},[],{"trials":14727,"activeCount":99},[],{"trials":14729,"activeCount":99},[],{"trials":14731,"activeCount":99},[14732,14741],{"nctId":14733,"briefTitle":14734,"status":166,"phases":14735,"primaryCompletion":578,"completion":578,"start":264,"enrollment":1011,"conditions":14736,"interventions":14740},"NCT01997801","Ketamine in Robot-assisted Thyroidectomy",[91],[14737,14738,14739],"Thyroid","Acute Pain","Chronic Pain",[14718,5254],{"nctId":14742,"briefTitle":14743,"status":154,"phases":14744,"primaryCompletion":3481,"completion":3481,"start":12221,"enrollment":14745,"conditions":14746,"interventions":14748},"NCT01017393","Preemptive Low-dose Epidural Ketamine for Preventing Chronic Post-thoracotomy Pain",[91],209,[14747],"Chronic Post-thoracotomy Pain",[14718,14749],"ketamine free",{"intervention":5254,"totalTrials":95,"cells":14751},{"EARLY_PHASE1":14752,"PHASE1":14754,"PHASE2":14756,"PHASE3":14758,"PHASE4":14760,"NA":14766},{"trials":14753,"activeCount":99},[],{"trials":14755,"activeCount":99},[],{"trials":14757,"activeCount":99},[],{"trials":14759,"activeCount":99},[],{"trials":14761,"activeCount":99},[14762],{"nctId":5245,"briefTitle":5246,"status":166,"phases":14763,"primaryCompletion":701,"completion":701,"start":675,"enrollment":2295,"conditions":14764,"interventions":14765},[90],[2025,5249,5250,5251,5252],[5232,5254],{"trials":14767,"activeCount":99},[14768],{"nctId":14733,"briefTitle":14734,"status":166,"phases":14769,"primaryCompletion":578,"completion":578,"start":264,"enrollment":1011,"conditions":14770,"interventions":14771},[91],[14737,14738,14739],[14718,5254],{"intervention":14773,"totalTrials":95,"cells":14774},"Povidone-Iodine",{"EARLY_PHASE1":14775,"PHASE1":14777,"PHASE2":14779,"PHASE3":14781,"PHASE4":14783,"NA":14795},{"trials":14776,"activeCount":99},[],{"trials":14778,"activeCount":99},[],{"trials":14780,"activeCount":99},[],{"trials":14782,"activeCount":99},[],{"trials":14784,"activeCount":99},[14785],{"nctId":14786,"briefTitle":14787,"status":166,"phases":14788,"primaryCompletion":3838,"completion":821,"start":2294,"enrollment":14789,"conditions":14790,"interventions":14794},"NCT02245334","A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy",[90],1578,[14791,14792,14793],"Infection","Prostatic Diseases","Misadventure During Aspirating Needle Biopsy",[14773],{"trials":14796,"activeCount":99},[14797],{"nctId":14798,"briefTitle":14799,"status":166,"phases":14800,"primaryCompletion":1000,"completion":14801,"start":8195,"enrollment":14802,"conditions":14803,"interventions":14806},"NCT05122169","Skip Prep of Vaginal Delivery to Prevent Puerperal \u002F Perinatal Infection in Vaginal Delivery",[91],"2026-05-31",4140,[14804,14805],"Vaginal Delivery","Surgical Site Infection",[14773,14807],"Chlorhexidine",{"intervention":14809,"totalTrials":95,"cells":14810},"Oxytocin",{"EARLY_PHASE1":14811,"PHASE1":14813,"PHASE2":14815,"PHASE3":14817,"PHASE4":14819,"NA":14821},{"trials":14812,"activeCount":99},[],{"trials":14814,"activeCount":99},[],{"trials":14816,"activeCount":99},[],{"trials":14818,"activeCount":99},[],{"trials":14820,"activeCount":99},[],{"trials":14822,"activeCount":99},[14823,14832],{"nctId":14824,"briefTitle":14825,"status":154,"phases":14826,"primaryCompletion":263,"completion":263,"start":3838,"enrollment":14827,"conditions":14828,"interventions":14830},"NCT02618096","Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Multiparous Women at Term",[91],154,[14829],"Failed Induction of Labor",[14809,14831],"Dinoprostone",{"nctId":14833,"briefTitle":14834,"status":154,"phases":14835,"primaryCompletion":8089,"completion":8089,"start":702,"enrollment":8024,"conditions":14836,"interventions":14837},"NCT02416583","Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term",[91],[14829],[14809,14831],{"intervention":14831,"totalTrials":95,"cells":14839},{"EARLY_PHASE1":14840,"PHASE1":14842,"PHASE2":14844,"PHASE3":14846,"PHASE4":14848,"NA":14850},{"trials":14841,"activeCount":99},[],{"trials":14843,"activeCount":99},[],{"trials":14845,"activeCount":99},[],{"trials":14847,"activeCount":99},[],{"trials":14849,"activeCount":99},[],{"trials":14851,"activeCount":99},[14852,14856],{"nctId":14824,"briefTitle":14825,"status":154,"phases":14853,"primaryCompletion":263,"completion":263,"start":3838,"enrollment":14827,"conditions":14854,"interventions":14855},[91],[14829],[14809,14831],{"nctId":14833,"briefTitle":14834,"status":154,"phases":14857,"primaryCompletion":8089,"completion":8089,"start":702,"enrollment":8024,"conditions":14858,"interventions":14859},[91],[14829],[14809,14831],{"intervention":14861,"totalTrials":95,"cells":14862},"Gabapentin",{"EARLY_PHASE1":14863,"PHASE1":14865,"PHASE2":14867,"PHASE3":14869,"PHASE4":14871,"NA":14880},{"trials":14864,"activeCount":99},[],{"trials":14866,"activeCount":99},[],{"trials":14868,"activeCount":99},[],{"trials":14870,"activeCount":99},[],{"trials":14872,"activeCount":99},[14873],{"nctId":14874,"briefTitle":14875,"status":166,"phases":14876,"primaryCompletion":1977,"completion":1977,"start":703,"enrollment":1444,"conditions":14877,"interventions":14878},"NCT02127853","Effect of Gabapentin on Pain of the Second Cataract Surgery",[90],[14429],[14879],"gabapentin",{"trials":14881,"activeCount":99},[14882],{"nctId":14883,"briefTitle":14884,"status":154,"phases":14885,"primaryCompletion":5884,"completion":5884,"start":14886,"enrollment":1011,"conditions":14887,"interventions":14889},"NCT03826615","Gabapentin Pretreatment for Staged Bilateral Cataract Operations",[91],"2019-02-01",[14429,14888],"Cataract Bilateral Nos",[14861],{"intervention":14891,"totalTrials":95,"cells":14892},"Rocuronium bromide",{"EARLY_PHASE1":14893,"PHASE1":14895,"PHASE2":14897,"PHASE3":14899,"PHASE4":14901,"NA":14912},{"trials":14894,"activeCount":99},[],{"trials":14896,"activeCount":99},[],{"trials":14898,"activeCount":99},[],{"trials":14900,"activeCount":99},[],{"trials":14902,"activeCount":99},[14903],{"nctId":14904,"briefTitle":14905,"status":166,"phases":14906,"primaryCompletion":537,"completion":11773,"start":14907,"enrollment":1444,"conditions":14908,"interventions":14910},"NCT03060707","Continuous Infusion Versus Intermittent Bolus Injection of Rocuronium",[90],"2017-03-23",[14909,27],"Muscle Relaxation",[14911],"Rocuronium Bromide",{"trials":14913,"activeCount":99},[14914],{"nctId":14915,"briefTitle":14916,"status":166,"phases":14917,"primaryCompletion":14918,"completion":75,"start":13505,"enrollment":210,"conditions":14919,"interventions":14921},"NCT02827435","Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft",[91],"2019-07-31",[11752,14920],"Transplantation",[14891],{"intervention":13107,"totalTrials":95,"cells":14923},{"EARLY_PHASE1":14924,"PHASE1":14926,"PHASE2":14932,"PHASE3":14934,"PHASE4":14936,"NA":14938},{"trials":14925,"activeCount":99},[],{"trials":14927,"activeCount":99},[14928],{"nctId":13100,"briefTitle":13101,"status":166,"phases":14929,"primaryCompletion":8022,"completion":8022,"start":13103,"enrollment":1795,"conditions":14930,"interventions":14931},[87],[13105],[13093,13107],{"trials":14933,"activeCount":99},[],{"trials":14935,"activeCount":99},[],{"trials":14937,"activeCount":99},[],{"trials":14939,"activeCount":99},[14940],{"nctId":14941,"briefTitle":14942,"status":166,"phases":14943,"primaryCompletion":14944,"completion":2672,"start":209,"enrollment":14945,"conditions":14946,"interventions":14947},"NCT05189704","The Effect of PCA on PONV After Microvascular Decompression",[91],"2023-02-15",94,[2491],[14948,13107],"NSAID",{"intervention":1694,"totalTrials":95,"cells":14950},{"EARLY_PHASE1":14951,"PHASE1":14953,"PHASE2":14955,"PHASE3":14957,"PHASE4":14959,"NA":14961},{"trials":14952,"activeCount":99},[],{"trials":14954,"activeCount":99},[],{"trials":14956,"activeCount":99},[],{"trials":14958,"activeCount":99},[],{"trials":14960,"activeCount":99},[],{"trials":14962,"activeCount":99},[14963,14967],{"nctId":1688,"briefTitle":1689,"status":154,"phases":14964,"primaryCompletion":1691,"completion":1691,"start":1652,"enrollment":569,"conditions":14965,"interventions":14966},[91],[1654],[1694,1657,51],{"nctId":1705,"briefTitle":1706,"status":154,"phases":14968,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1710,"conditions":14969,"interventions":14970},[91],[1712],[1694,51,1714,1715],{"intervention":13706,"totalTrials":95,"cells":14972},{"EARLY_PHASE1":14973,"PHASE1":14975,"PHASE2":14977,"PHASE3":14979,"PHASE4":14981,"NA":14987},{"trials":14974,"activeCount":99},[],{"trials":14976,"activeCount":99},[],{"trials":14978,"activeCount":99},[],{"trials":14980,"activeCount":99},[],{"trials":14982,"activeCount":99},[14983],{"nctId":13701,"briefTitle":13702,"status":166,"phases":14984,"primaryCompletion":821,"start":578,"enrollment":7638,"conditions":14985,"interventions":14986},[90],[7406,7407],[12391,13706],{"trials":14988,"activeCount":99},[14989],{"nctId":14990,"briefTitle":14991,"status":154,"phases":14992,"primaryCompletion":3649,"completion":3649,"start":673,"enrollment":850,"conditions":14993,"interventions":14994},"NCT02420392","Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell",[91],[705],[13706],{"intervention":14996,"totalTrials":95,"cells":14997},"Acetaminophen\u002FIbuprofen fixed-dose combination",{"EARLY_PHASE1":14998,"PHASE1":15000,"PHASE2":15002,"PHASE3":15004,"PHASE4":15006,"NA":15008},{"trials":14999,"activeCount":99},[],{"trials":15001,"activeCount":99},[],{"trials":15003,"activeCount":99},[],{"trials":15005,"activeCount":99},[],{"trials":15007,"activeCount":99},[],{"trials":15009,"activeCount":99},[15010,15019],{"nctId":15011,"briefTitle":15012,"status":154,"phases":15013,"primaryCompletion":15014,"completion":15015,"start":15016,"enrollment":14827,"conditions":15017,"interventions":15018},"NCT05685342","Preemptive and Preventive Acetaminophen\u002FIbuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy",[91],"2025-02-28","2025-07-30","2023-02-10",[466],[14996],{"nctId":588,"briefTitle":589,"status":154,"phases":15020,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":15021,"interventions":15022},[91],[466],[597,258],{"intervention":15024,"totalTrials":95,"cells":15025},"Atropine",{"EARLY_PHASE1":15026,"PHASE1":15028,"PHASE2":15030,"PHASE3":15032,"PHASE4":15034,"NA":15043},{"trials":15027,"activeCount":99},[],{"trials":15029,"activeCount":99},[],{"trials":15031,"activeCount":99},[],{"trials":15033,"activeCount":99},[],{"trials":15035,"activeCount":99},[15036],{"nctId":15037,"briefTitle":15038,"status":154,"phases":15039,"primaryCompletion":3670,"completion":3670,"start":6822,"enrollment":8024,"conditions":15040,"interventions":15042},"NCT00834470","Adjunctive Atropine During Ketamine Sedation",[90],[15041],"Conscious Sedation",[15024],{"trials":15044,"activeCount":99},[15045],{"nctId":15046,"briefTitle":15047,"status":166,"phases":15048,"primaryCompletion":673,"completion":2622,"start":2041,"enrollment":1273,"conditions":15049,"interventions":15050},"NCT02228473","Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort",[91],[1774,1775,27,1776],[15051,15024],"Glycopyrrolate",{"intervention":15053,"totalTrials":95,"cells":15054},"0.5% heavy bupivacaine",{"EARLY_PHASE1":15055,"PHASE1":15057,"PHASE2":15059,"PHASE3":15061,"PHASE4":15063,"NA":15065},{"trials":15056,"activeCount":99},[],{"trials":15058,"activeCount":99},[],{"trials":15060,"activeCount":99},[],{"trials":15062,"activeCount":99},[],{"trials":15064,"activeCount":99},[],{"trials":15066,"activeCount":99},[15067,15076],{"nctId":15068,"briefTitle":15069,"status":154,"phases":15070,"primaryCompletion":15071,"completion":15072,"start":2128,"enrollment":2053,"conditions":15073,"interventions":15075},"NCT03459105","Ultrasound-assisted Versus Conventional Landmark-guided Spinal Anesthesia in Patients With Abnormal Spinal Anatomy",[91],"2018-07-04","2018-07-05",[14067,15074,14366],"Ultrasonography",[15053],{"nctId":15077,"briefTitle":15078,"status":154,"phases":15079,"primaryCompletion":13321,"completion":13321,"start":14063,"enrollment":180,"conditions":15080,"interventions":15081},"NCT03316352","Ultrasound-assisted Versus Conventional Landmark-guided Paramedian Spinal Anesthesia in Elderly Patients",[91],[14067,15074],[15053],{"intervention":15083,"totalTrials":95,"cells":15084},"Zostavax",{"EARLY_PHASE1":15085,"PHASE1":15087,"PHASE2":15089,"PHASE3":15091,"PHASE4":15093,"NA":15095},{"trials":15086,"activeCount":99},[],{"trials":15088,"activeCount":99},[],{"trials":15090,"activeCount":99},[],{"trials":15092,"activeCount":99},[],{"trials":15094,"activeCount":99},[],{"trials":15096,"activeCount":99},[15097,15104],{"nctId":15098,"briefTitle":15099,"status":154,"phases":15100,"primaryCompletion":11639,"completion":11639,"start":1978,"enrollment":1795,"conditions":15101,"interventions":15103},"NCT02704572","Optimal Timing of Zoster Vaccine After Zoster Illness",[91],[15102],"Shingles",[15083],{"nctId":15105,"briefTitle":15106,"status":154,"phases":15107,"primaryCompletion":15108,"completion":15108,"start":4658,"enrollment":6266,"conditions":15109,"interventions":15111},"NCT03192319","Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation",[91],"2018-08-23",[15110],"Herpes Zoster",[15083],{"intervention":15113,"totalTrials":95,"cells":15114},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":15115,"PHASE1":15117,"PHASE2":15119,"PHASE3":15131,"PHASE4":15133,"NA":15135},{"trials":15116,"activeCount":99},[],{"trials":15118,"activeCount":99},[],{"trials":15120,"activeCount":99},[15121],{"nctId":15122,"briefTitle":15123,"status":154,"phases":15124,"primaryCompletion":15125,"completion":15125,"start":15126,"enrollment":12355,"conditions":15127,"interventions":15130},"NCT04027829","Pharmacokinetics-pharmacodynamics and Safety of Dexmedetomidine in Children",[88],"2019-11-14","2019-08-14",[15128,15129],"Intensive Care Unit","Postoperative Care",[15113],{"trials":15132,"activeCount":99},[],{"trials":15134,"activeCount":99},[],{"trials":15136,"activeCount":99},[15137],{"nctId":15138,"briefTitle":15139,"status":154,"phases":15140,"primaryCompletion":15141,"completion":15141,"start":15142,"enrollment":1795,"conditions":15143,"interventions":15144},"NCT03234660","Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia",[91],"2019-10-05","2017-09-01",[2083],[15113],{"intervention":15146,"totalTrials":95,"cells":15147},"Intranasal dexmedetomidine and ketamine",{"EARLY_PHASE1":15148,"PHASE1":15150,"PHASE2":15152,"PHASE3":15154,"PHASE4":15156,"NA":15158},{"trials":15149,"activeCount":99},[],{"trials":15151,"activeCount":99},[],{"trials":15153,"activeCount":99},[],{"trials":15155,"activeCount":99},[],{"trials":15157,"activeCount":99},[],{"trials":15159,"activeCount":99},[15160,15169],{"nctId":15161,"briefTitle":15162,"status":154,"phases":15163,"primaryCompletion":15164,"completion":15164,"start":15165,"enrollment":8882,"conditions":15166,"interventions":15167},"NCT04820205","Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children",[91],"2024-03-05","2021-10-29",[13843],[15146,15168],"Oral chloral hydrate",{"nctId":15170,"briefTitle":15171,"status":166,"phases":15172,"primaryCompletion":1000,"completion":1000,"start":15173,"enrollment":1444,"conditions":15174,"interventions":15175},"NCT04822064","Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation",[91],"2022-09-22",[13843],[15146,15168],{"intervention":15168,"totalTrials":95,"cells":15177},{"EARLY_PHASE1":15178,"PHASE1":15180,"PHASE2":15182,"PHASE3":15184,"PHASE4":15186,"NA":15188},{"trials":15179,"activeCount":99},[],{"trials":15181,"activeCount":99},[],{"trials":15183,"activeCount":99},[],{"trials":15185,"activeCount":99},[],{"trials":15187,"activeCount":99},[],{"trials":15189,"activeCount":99},[15190,15194],{"nctId":15161,"briefTitle":15162,"status":154,"phases":15191,"primaryCompletion":15164,"completion":15164,"start":15165,"enrollment":8882,"conditions":15192,"interventions":15193},[91],[13843],[15146,15168],{"nctId":15170,"briefTitle":15171,"status":166,"phases":15195,"primaryCompletion":1000,"completion":1000,"start":15173,"enrollment":1444,"conditions":15196,"interventions":15197},[91],[13843],[15146,15168],{"intervention":15199,"totalTrials":95,"cells":15200},"The intrathecal morphine",{"EARLY_PHASE1":15201,"PHASE1":15203,"PHASE2":15205,"PHASE3":15207,"PHASE4":15209,"NA":15211},{"trials":15202,"activeCount":99},[],{"trials":15204,"activeCount":99},[],{"trials":15206,"activeCount":99},[],{"trials":15208,"activeCount":99},[],{"trials":15210,"activeCount":99},[],{"trials":15212,"activeCount":99},[15213,15221],{"nctId":15214,"briefTitle":15215,"status":154,"phases":15216,"primaryCompletion":579,"completion":579,"start":2551,"enrollment":3557,"conditions":15217,"interventions":15218},"NCT01997788","The Intrathecal Morphine for Nephrectomy",[91],[1675],[15199,15219,15220],"The intravenous patient-controlled analgesia","Demerol on demand",{"nctId":15222,"briefTitle":15223,"status":154,"phases":15224,"primaryCompletion":2444,"completion":2444,"start":675,"enrollment":850,"conditions":15225,"interventions":15227},"NCT01991275","Intrathecal Morphine in Robot-assisted Prostatectomy",[91],[15226],"Prostatic Neoplasms",[15219,15199],{"intervention":15219,"totalTrials":95,"cells":15229},{"EARLY_PHASE1":15230,"PHASE1":15232,"PHASE2":15234,"PHASE3":15236,"PHASE4":15238,"NA":15240},{"trials":15231,"activeCount":99},[],{"trials":15233,"activeCount":99},[],{"trials":15235,"activeCount":99},[],{"trials":15237,"activeCount":99},[],{"trials":15239,"activeCount":99},[],{"trials":15241,"activeCount":99},[15242,15246],{"nctId":15214,"briefTitle":15215,"status":154,"phases":15243,"primaryCompletion":579,"completion":579,"start":2551,"enrollment":3557,"conditions":15244,"interventions":15245},[91],[1675],[15199,15219,15220],{"nctId":15222,"briefTitle":15223,"status":154,"phases":15247,"primaryCompletion":2444,"completion":2444,"start":675,"enrollment":850,"conditions":15248,"interventions":15249},[91],[15226],[15219,15199],{"intervention":15251,"totalTrials":95,"cells":15252},"Fimasartan",{"EARLY_PHASE1":15253,"PHASE1":15255,"PHASE2":15257,"PHASE3":15259,"PHASE4":15261,"NA":15270},{"trials":15254,"activeCount":99},[],{"trials":15256,"activeCount":99},[],{"trials":15258,"activeCount":99},[],{"trials":15260,"activeCount":99},[],{"trials":15262,"activeCount":99},[15263],{"nctId":15264,"briefTitle":15265,"status":166,"phases":15266,"primaryCompletion":3966,"completion":578,"start":1854,"enrollment":1743,"conditions":15267,"interventions":15269},"NCT01589380","A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)",[90],[15268],"Critical Stenosis of Aortic Valve",[15251],{"trials":15271,"activeCount":99},[15272],{"nctId":15273,"briefTitle":15274,"status":154,"phases":15275,"primaryCompletion":168,"completion":2171,"start":2622,"enrollment":3557,"conditions":15276,"interventions":15277},"NCT02312375","Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients",[91],[6623,7508],[15251,15278],"Amlodipine",{"intervention":15278,"totalTrials":95,"cells":15280},{"EARLY_PHASE1":15281,"PHASE1":15283,"PHASE2":15285,"PHASE3":15287,"PHASE4":15289,"NA":15298},{"trials":15282,"activeCount":99},[],{"trials":15284,"activeCount":99},[],{"trials":15286,"activeCount":99},[],{"trials":15288,"activeCount":99},[],{"trials":15290,"activeCount":99},[15291],{"nctId":15292,"briefTitle":15293,"status":154,"phases":15294,"primaryCompletion":578,"completion":578,"start":7680,"enrollment":15295,"conditions":15296,"interventions":15297},"NCT01120327","A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients",[90],211,[15],[15278],{"trials":15299,"activeCount":99},[15300],{"nctId":15273,"briefTitle":15274,"status":154,"phases":15301,"primaryCompletion":168,"completion":2171,"start":2622,"enrollment":3557,"conditions":15302,"interventions":15303},[91],[6623,7508],[15251,15278],{"intervention":2362,"totalTrials":95,"cells":15305},{"EARLY_PHASE1":15306,"PHASE1":15308,"PHASE2":15310,"PHASE3":15312,"PHASE4":15314,"NA":15316},{"trials":15307,"activeCount":99},[],{"trials":15309,"activeCount":99},[],{"trials":15311,"activeCount":99},[],{"trials":15313,"activeCount":99},[],{"trials":15315,"activeCount":99},[],{"trials":15317,"activeCount":99},[15318,15322],{"nctId":2770,"briefTitle":2771,"status":166,"phases":15319,"primaryCompletion":2773,"completion":2774,"start":2775,"enrollment":2307,"conditions":15320,"interventions":15321},[91],[2739,2777,2778],[136,2362],{"nctId":2353,"briefTitle":2354,"status":166,"phases":15323,"primaryCompletion":1010,"completion":1010,"start":2356,"enrollment":2357,"conditions":15324,"interventions":15325},[],[2359,1622,2360],[270,2362],{"intervention":7408,"totalTrials":95,"cells":15327},{"EARLY_PHASE1":15328,"PHASE1":15330,"PHASE2":15332,"PHASE3":15334,"PHASE4":15336,"NA":15342},{"trials":15329,"activeCount":99},[],{"trials":15331,"activeCount":99},[],{"trials":15333,"activeCount":99},[],{"trials":15335,"activeCount":99},[],{"trials":15337,"activeCount":99},[15338],{"nctId":7402,"briefTitle":7403,"status":166,"phases":15339,"primaryCompletion":821,"start":2041,"enrollment":1002,"conditions":15340,"interventions":15341},[90],[7406,7407,7408,7389],[7408,7389],{"trials":15343,"activeCount":99},[15344],{"nctId":15345,"briefTitle":15346,"status":154,"phases":15347,"primaryCompletion":2443,"completion":2443,"start":703,"enrollment":2470,"conditions":15348,"interventions":15349},"NCT02186080","Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia",[91],[3850],[7408],{"intervention":14040,"totalTrials":95,"cells":15351},{"EARLY_PHASE1":15352,"PHASE1":15354,"PHASE2":15356,"PHASE3":15358,"PHASE4":15360,"NA":15362},{"trials":15353,"activeCount":99},[],{"trials":15355,"activeCount":99},[],{"trials":15357,"activeCount":99},[],{"trials":15359,"activeCount":99},[],{"trials":15361,"activeCount":99},[],{"trials":15363,"activeCount":99},[15364,15370],{"nctId":15365,"briefTitle":15366,"status":154,"phases":15367,"primaryCompletion":5134,"completion":1010,"start":2218,"enrollment":19,"conditions":15368,"interventions":15369},"NCT04874246","Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy",[91],[2103],[14040],{"nctId":14031,"briefTitle":14032,"status":154,"phases":15371,"primaryCompletion":14034,"completion":14035,"start":14036,"enrollment":2232,"conditions":15372,"interventions":15373},[91],[14038],[2166,14021,14040],{"intervention":2318,"totalTrials":95,"cells":15375},{"EARLY_PHASE1":15376,"PHASE1":15378,"PHASE2":15380,"PHASE3":15382,"PHASE4":15384,"NA":15386},{"trials":15377,"activeCount":99},[],{"trials":15379,"activeCount":99},[],{"trials":15381,"activeCount":99},[],{"trials":15383,"activeCount":99},[],{"trials":15385,"activeCount":99},[],{"trials":15387,"activeCount":99},[15388,15392],{"nctId":2313,"briefTitle":2314,"status":154,"phases":15389,"primaryCompletion":702,"completion":702,"start":701,"enrollment":1889,"conditions":15390,"interventions":15391},[91],[2025],[2318,2319,2320,2321],{"nctId":14424,"briefTitle":14425,"status":154,"phases":15393,"primaryCompletion":702,"start":703,"enrollment":1374,"conditions":15394,"interventions":15395},[91],[14428,1858,14429,3207],[14431,14428,14397],{"intervention":7618,"totalTrials":95,"cells":15397},{"EARLY_PHASE1":15398,"PHASE1":15400,"PHASE2":15402,"PHASE3":15404,"PHASE4":15406,"NA":15412},{"trials":15399,"activeCount":99},[],{"trials":15401,"activeCount":99},[],{"trials":15403,"activeCount":99},[],{"trials":15405,"activeCount":99},[],{"trials":15407,"activeCount":99},[15408],{"nctId":7612,"briefTitle":7613,"status":154,"phases":15409,"primaryCompletion":2052,"completion":4066,"start":1771,"enrollment":7615,"conditions":15410,"interventions":15411},[90],[4940,3207],[7618,7599],{"trials":15413,"activeCount":99},[15414],{"nctId":15415,"briefTitle":15416,"status":166,"phases":15417,"primaryCompletion":10959,"completion":15418,"start":15419,"enrollment":1221,"conditions":15420,"interventions":15422},"NCT03977012","Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients",[],"2024-05-01","2019-06-11",[15421],"Complex Regional Pain Syndromes",[7618],{"intervention":14585,"totalTrials":121,"cells":15424},{"EARLY_PHASE1":15425,"PHASE1":15427,"PHASE2":15429,"PHASE3":15431,"PHASE4":15433,"NA":15435},{"trials":15426,"activeCount":99},[],{"trials":15428,"activeCount":99},[],{"trials":15430,"activeCount":99},[],{"trials":15432,"activeCount":99},[],{"trials":15434,"activeCount":99},[],{"trials":15436,"activeCount":99},[15437],{"nctId":14579,"briefTitle":14580,"status":154,"phases":15438,"primaryCompletion":1957,"completion":1957,"start":6265,"enrollment":22,"conditions":15439,"interventions":15440},[91],[14583],[14564,14585],{"intervention":15442,"totalTrials":121,"cells":15443},"iopromide",{"EARLY_PHASE1":15444,"PHASE1":15446,"PHASE2":15448,"PHASE3":15450,"PHASE4":15452,"NA":15454},{"trials":15445,"activeCount":99},[],{"trials":15447,"activeCount":99},[],{"trials":15449,"activeCount":99},[],{"trials":15451,"activeCount":99},[],{"trials":15453,"activeCount":99},[],{"trials":15455,"activeCount":99},[15456],{"nctId":15457,"briefTitle":15458,"status":166,"phases":15459,"primaryCompletion":821,"completion":15460,"start":7958,"enrollment":1878,"conditions":15461,"interventions":15464},"NCT01703650","Role of Perfusion CT in Pancreatic Cancer",[],"2021-09",[15462,15463],"Adenocarcinoma, Pancreas","Neuroendocrine Carcinoma of Pancreas",[15442],{"intervention":15466,"totalTrials":121,"cells":15467},"celecoxib medication",{"EARLY_PHASE1":15468,"PHASE1":15470,"PHASE2":15472,"PHASE3":15474,"PHASE4":15476,"NA":15478},{"trials":15469,"activeCount":99},[],{"trials":15471,"activeCount":99},[],{"trials":15473,"activeCount":99},[],{"trials":15475,"activeCount":99},[],{"trials":15477,"activeCount":99},[],{"trials":15479,"activeCount":99},[15480],{"nctId":15481,"briefTitle":15482,"status":154,"phases":15483,"primaryCompletion":15484,"completion":4240,"start":15485,"enrollment":2053,"conditions":15486,"interventions":15488},"NCT00526214","Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study",[91],"2009-05","2007-10",[15487],"Intracerebral Hemorrhage",[15466],{"intervention":15490,"totalTrials":121,"cells":15491},"triple therapy",{"EARLY_PHASE1":15492,"PHASE1":15494,"PHASE2":15496,"PHASE3":15498,"PHASE4":15500,"NA":15502},{"trials":15493,"activeCount":99},[],{"trials":15495,"activeCount":99},[],{"trials":15497,"activeCount":99},[],{"trials":15499,"activeCount":99},[],{"trials":15501,"activeCount":99},[],{"trials":15503,"activeCount":99},[15504],{"nctId":15505,"briefTitle":15506,"status":166,"phases":15507,"primaryCompletion":8706,"completion":8706,"start":15508,"enrollment":2153,"conditions":15509,"interventions":15512},"NCT04006340","Empirical vs Tailored Therapy for H. Pylori Infection",[91],"2019-01-04",[15510,15511],"Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation","Helicobacter Pylori Infection",[15490,15513],"quadruple therapy",{"intervention":15513,"totalTrials":121,"cells":15515},{"EARLY_PHASE1":15516,"PHASE1":15518,"PHASE2":15520,"PHASE3":15522,"PHASE4":15524,"NA":15526},{"trials":15517,"activeCount":99},[],{"trials":15519,"activeCount":99},[],{"trials":15521,"activeCount":99},[],{"trials":15523,"activeCount":99},[],{"trials":15525,"activeCount":99},[],{"trials":15527,"activeCount":99},[15528],{"nctId":15505,"briefTitle":15506,"status":166,"phases":15529,"primaryCompletion":8706,"completion":8706,"start":15508,"enrollment":2153,"conditions":15530,"interventions":15531},[91],[15510,15511],[15490,15513],{"intervention":15533,"totalTrials":121,"cells":15534},"Brilinta",{"EARLY_PHASE1":15535,"PHASE1":15537,"PHASE2":15539,"PHASE3":15541,"PHASE4":15543,"NA":15545},{"trials":15536,"activeCount":99},[],{"trials":15538,"activeCount":99},[],{"trials":15540,"activeCount":99},[],{"trials":15542,"activeCount":99},[],{"trials":15544,"activeCount":99},[],{"trials":15546,"activeCount":99},[15547],{"nctId":15548,"briefTitle":15549,"status":166,"phases":15550,"primaryCompletion":3753,"completion":3753,"start":2443,"enrollment":15551,"conditions":15552,"interventions":15553},"NCT02521038","Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry",[],2000,[7217],[15533],{"intervention":573,"totalTrials":121,"cells":15555},{"EARLY_PHASE1":15556,"PHASE1":15558,"PHASE2":15560,"PHASE3":15562,"PHASE4":15564,"NA":15566},{"trials":15557,"activeCount":99},[],{"trials":15559,"activeCount":99},[],{"trials":15561,"activeCount":99},[],{"trials":15563,"activeCount":99},[],{"trials":15565,"activeCount":99},[],{"trials":15567,"activeCount":99},[15568],{"nctId":564,"briefTitle":565,"status":154,"phases":15569,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":15570,"interventions":15571},[91],[571],[573,258],{"intervention":15573,"totalTrials":121,"cells":15574},"Adjuvant chemotherapy",{"EARLY_PHASE1":15575,"PHASE1":15577,"PHASE2":15579,"PHASE3":15581,"PHASE4":15583,"NA":15585},{"trials":15576,"activeCount":99},[],{"trials":15578,"activeCount":99},[],{"trials":15580,"activeCount":99},[],{"trials":15582,"activeCount":99},[],{"trials":15584,"activeCount":99},[],{"trials":15586,"activeCount":99},[15587],{"nctId":15588,"briefTitle":15589,"status":154,"phases":15590,"primaryCompletion":5134,"completion":15591,"start":15592,"enrollment":5403,"conditions":15593,"interventions":15596},"NCT06671431","Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma",[],"2024-10-01","2000-01-01",[15594,15595],"Distal Cholangiocarcinoma","Adjuvant Chemotherapy",[15573],{"intervention":15598,"totalTrials":121,"cells":15599},"Activated T lymphocyte",{"EARLY_PHASE1":15600,"PHASE1":15602,"PHASE2":15604,"PHASE3":15606,"PHASE4":15608,"NA":15610},{"trials":15601,"activeCount":99},[],{"trials":15603,"activeCount":99},[],{"trials":15605,"activeCount":99},[],{"trials":15607,"activeCount":99},[],{"trials":15609,"activeCount":99},[],{"trials":15611,"activeCount":99},[15612],{"nctId":15613,"briefTitle":15614,"status":154,"phases":15615,"primaryCompletion":179,"completion":15616,"start":1815,"enrollment":525,"conditions":15617,"interventions":15619},"NCT01802138","A Pilot Study of Activated T Cell Therapy for Refractory\u002FRelapsed Neuroblastoma",[91],"2018-10-31",[15618],"Neuroblastoma",[15598],{"intervention":14251,"totalTrials":121,"cells":15621},{"EARLY_PHASE1":15622,"PHASE1":15624,"PHASE2":15626,"PHASE3":15628,"PHASE4":15630,"NA":15632},{"trials":15623,"activeCount":99},[],{"trials":15625,"activeCount":99},[],{"trials":15627,"activeCount":99},[],{"trials":15629,"activeCount":99},[],{"trials":15631,"activeCount":99},[],{"trials":15633,"activeCount":99},[15634],{"nctId":14246,"briefTitle":14247,"status":658,"phases":15635,"primaryCompletion":168,"completion":168,"start":3555,"enrollment":99,"conditions":15636,"interventions":15637},[91],[18],[14251,1086],{"intervention":15639,"totalTrials":121,"cells":15640},"Rhinoebastel",{"EARLY_PHASE1":15641,"PHASE1":15643,"PHASE2":15645,"PHASE3":15647,"PHASE4":15649,"NA":15651},{"trials":15642,"activeCount":99},[],{"trials":15644,"activeCount":99},[],{"trials":15646,"activeCount":99},[],{"trials":15648,"activeCount":99},[],{"trials":15650,"activeCount":99},[],{"trials":15652,"activeCount":99},[15653],{"nctId":15654,"briefTitle":15655,"status":166,"phases":15656,"primaryCompletion":3510,"start":7680,"enrollment":6376,"conditions":15657,"interventions":15659},"NCT02065440","The Effect of Ebastine\u002FPseudoephedrine on Subacute Cough",[91],[15658],"Cough",[15639],{"intervention":15661,"totalTrials":121,"cells":15662},"plasmalyte solution",{"EARLY_PHASE1":15663,"PHASE1":15665,"PHASE2":15667,"PHASE3":15669,"PHASE4":15671,"NA":15673},{"trials":15664,"activeCount":99},[],{"trials":15666,"activeCount":99},[],{"trials":15668,"activeCount":99},[],{"trials":15670,"activeCount":99},[],{"trials":15672,"activeCount":99},[],{"trials":15674,"activeCount":99},[15675],{"nctId":15676,"briefTitle":15677,"status":154,"phases":15678,"primaryCompletion":6922,"completion":6922,"start":3621,"enrollment":1374,"conditions":15679,"interventions":15680},"NCT01713166","Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery",[91],[118],[15661,15681],"Hextend",{"intervention":15681,"totalTrials":121,"cells":15683},{"EARLY_PHASE1":15684,"PHASE1":15686,"PHASE2":15688,"PHASE3":15690,"PHASE4":15692,"NA":15694},{"trials":15685,"activeCount":99},[],{"trials":15687,"activeCount":99},[],{"trials":15689,"activeCount":99},[],{"trials":15691,"activeCount":99},[],{"trials":15693,"activeCount":99},[],{"trials":15695,"activeCount":99},[15696],{"nctId":15676,"briefTitle":15677,"status":154,"phases":15697,"primaryCompletion":6922,"completion":6922,"start":3621,"enrollment":1374,"conditions":15698,"interventions":15699},[91],[118],[15661,15681],{"intervention":15701,"totalTrials":121,"cells":15702},"COX-2 inhibitor",{"EARLY_PHASE1":15703,"PHASE1":15705,"PHASE2":15707,"PHASE3":15709,"PHASE4":15711,"NA":15713},{"trials":15704,"activeCount":99},[],{"trials":15706,"activeCount":99},[],{"trials":15708,"activeCount":99},[],{"trials":15710,"activeCount":99},[],{"trials":15712,"activeCount":99},[],{"trials":15714,"activeCount":99},[15715],{"nctId":15716,"briefTitle":15717,"status":166,"phases":15718,"primaryCompletion":4812,"completion":4812,"start":15719,"enrollment":1795,"conditions":15720,"interventions":15722},"NCT03391570","Comparing Postoperative Pain Following COX-2 and Prostanoids Expression",[91],"2017-10-17",[15721],"Female Genital Disease",[15701],{"intervention":15724,"totalTrials":121,"cells":15725},"Vitamin D",{"EARLY_PHASE1":15726,"PHASE1":15728,"PHASE2":15730,"PHASE3":15732,"PHASE4":15734,"NA":15736},{"trials":15727,"activeCount":99},[],{"trials":15729,"activeCount":99},[],{"trials":15731,"activeCount":99},[],{"trials":15733,"activeCount":99},[],{"trials":15735,"activeCount":99},[],{"trials":15737,"activeCount":99},[15738],{"nctId":15739,"briefTitle":15740,"status":154,"phases":15741,"primaryCompletion":15742,"completion":15742,"start":15743,"enrollment":33,"conditions":15744,"interventions":15746},"NCT05452512","Medication Adherence Monitoring Trial Using Smart Clinical Trial Application and Smart Watch",[91],"2022-12-16","2022-07-14",[15745],"Compliance, Medication",[15724],{"intervention":15748,"totalTrials":121,"cells":15749},"ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac",{"EARLY_PHASE1":15750,"PHASE1":15752,"PHASE2":15754,"PHASE3":15756,"PHASE4":15758,"NA":15760},{"trials":15751,"activeCount":99},[],{"trials":15753,"activeCount":99},[],{"trials":15755,"activeCount":99},[],{"trials":15757,"activeCount":99},[],{"trials":15759,"activeCount":99},[],{"trials":15761,"activeCount":99},[15762],{"nctId":15763,"briefTitle":15764,"status":154,"phases":15765,"primaryCompletion":178,"completion":8195,"start":4130,"enrollment":15766,"conditions":15767,"interventions":15769},"NCT02883569","Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back Pain",[91],1102,[15768],"Low Back Pain",[15748,15770],"codeine, oxycontine, IRcodone, Tramadol",{"intervention":15770,"totalTrials":121,"cells":15772},{"EARLY_PHASE1":15773,"PHASE1":15775,"PHASE2":15777,"PHASE3":15779,"PHASE4":15781,"NA":15783},{"trials":15774,"activeCount":99},[],{"trials":15776,"activeCount":99},[],{"trials":15778,"activeCount":99},[],{"trials":15780,"activeCount":99},[],{"trials":15782,"activeCount":99},[],{"trials":15784,"activeCount":99},[15785],{"nctId":15763,"briefTitle":15764,"status":154,"phases":15786,"primaryCompletion":178,"completion":8195,"start":4130,"enrollment":15766,"conditions":15787,"interventions":15788},[91],[15768],[15748,15770],{"intervention":15790,"totalTrials":121,"cells":15791},"COVID-19 vaccine",{"EARLY_PHASE1":15792,"PHASE1":15794,"PHASE2":15796,"PHASE3":15798,"PHASE4":15800,"NA":15802},{"trials":15793,"activeCount":99},[],{"trials":15795,"activeCount":99},[],{"trials":15797,"activeCount":99},[],{"trials":15799,"activeCount":99},[],{"trials":15801,"activeCount":99},[],{"trials":15803,"activeCount":99},[15804],{"nctId":15805,"briefTitle":15806,"status":154,"phases":15807,"primaryCompletion":10242,"completion":1010,"start":15808,"enrollment":6487,"conditions":15809,"interventions":15811},"NCT04910295","Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients",[],"2021-03-26",[4387,15810],"Covid19",[15790],{"intervention":15813,"totalTrials":121,"cells":15814},"Administering desflurane according to the patient's BIS value",{"EARLY_PHASE1":15815,"PHASE1":15817,"PHASE2":15819,"PHASE3":15821,"PHASE4":15823,"NA":15825},{"trials":15816,"activeCount":99},[],{"trials":15818,"activeCount":99},[],{"trials":15820,"activeCount":99},[],{"trials":15822,"activeCount":99},[],{"trials":15824,"activeCount":99},[],{"trials":15826,"activeCount":99},[15827],{"nctId":15828,"briefTitle":15829,"status":154,"phases":15830,"primaryCompletion":2622,"completion":2622,"start":2444,"enrollment":1878,"conditions":15831,"interventions":15833},"NCT02283866","Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil",[91],[15832],"Stabilizing Hypnotic Depth and Vital Sign During Balanced Anesthesia",[15813,15834],"Administering desflurane at 1 MAC",{"intervention":15834,"totalTrials":121,"cells":15836},{"EARLY_PHASE1":15837,"PHASE1":15839,"PHASE2":15841,"PHASE3":15843,"PHASE4":15845,"NA":15847},{"trials":15838,"activeCount":99},[],{"trials":15840,"activeCount":99},[],{"trials":15842,"activeCount":99},[],{"trials":15844,"activeCount":99},[],{"trials":15846,"activeCount":99},[],{"trials":15848,"activeCount":99},[15849],{"nctId":15828,"briefTitle":15829,"status":154,"phases":15850,"primaryCompletion":2622,"completion":2622,"start":2444,"enrollment":1878,"conditions":15851,"interventions":15852},[91],[15832],[15813,15834],{"intervention":15854,"totalTrials":121,"cells":15855},"gadoxetic acid",{"EARLY_PHASE1":15856,"PHASE1":15858,"PHASE2":15860,"PHASE3":15862,"PHASE4":15864,"NA":15866},{"trials":15857,"activeCount":99},[],{"trials":15859,"activeCount":99},[],{"trials":15861,"activeCount":99},[],{"trials":15863,"activeCount":99},[],{"trials":15865,"activeCount":99},[],{"trials":15867,"activeCount":99},[15868],{"nctId":15869,"briefTitle":15870,"status":154,"phases":15871,"primaryCompletion":2251,"completion":10195,"start":702,"enrollment":1795,"conditions":15872,"interventions":15873},"NCT02395991","Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI",[],[7837],[15854],{"intervention":14069,"totalTrials":121,"cells":15875},{"EARLY_PHASE1":15876,"PHASE1":15878,"PHASE2":15880,"PHASE3":15882,"PHASE4":15884,"NA":15886},{"trials":15877,"activeCount":99},[],{"trials":15879,"activeCount":99},[],{"trials":15881,"activeCount":99},[],{"trials":15883,"activeCount":99},[],{"trials":15885,"activeCount":99},[],{"trials":15887,"activeCount":99},[15888],{"nctId":14060,"briefTitle":14061,"status":154,"phases":15889,"primaryCompletion":14063,"completion":14064,"start":14065,"enrollment":7571,"conditions":15890,"interventions":15891},[91],[14067],[637,14069],{"intervention":15893,"totalTrials":121,"cells":15894},"COVID-19 vaccine, booster",{"EARLY_PHASE1":15895,"PHASE1":15897,"PHASE2":15899,"PHASE3":15901,"PHASE4":15903,"NA":15905},{"trials":15896,"activeCount":99},[],{"trials":15898,"activeCount":99},[],{"trials":15900,"activeCount":99},[],{"trials":15902,"activeCount":99},[],{"trials":15904,"activeCount":99},[],{"trials":15906,"activeCount":99},[15907],{"nctId":15908,"briefTitle":15909,"status":166,"phases":15910,"primaryCompletion":15911,"completion":15912,"start":15913,"enrollment":3249,"conditions":15914,"interventions":15916},"NCT05156086","Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients",[],"2022-08-01","2022-11-08","2021-11-16",[15915,5137],"COVID-19 Vaccination",[15893],{"intervention":15918,"totalTrials":121,"cells":15919},"Clozapine",{"EARLY_PHASE1":15920,"PHASE1":15922,"PHASE2":15924,"PHASE3":15926,"PHASE4":15928,"NA":15930},{"trials":15921,"activeCount":99},[],{"trials":15923,"activeCount":99},[],{"trials":15925,"activeCount":99},[],{"trials":15927,"activeCount":99},[],{"trials":15929,"activeCount":99},[],{"trials":15931,"activeCount":99},[15932],{"nctId":15933,"briefTitle":15934,"status":166,"phases":15935,"primaryCompletion":6620,"completion":4657,"start":15936,"enrollment":1743,"conditions":15937,"interventions":15938},"NCT03523741","Therapeutic Drug Monitoring for Individualized Clozapine Therapy",[],"2018-06-13",[32],[15918],{"intervention":15940,"totalTrials":121,"cells":15941},"combination therapy of terazosin and hydrochlorothiazide",{"EARLY_PHASE1":15942,"PHASE1":15944,"PHASE2":15946,"PHASE3":15948,"PHASE4":15950,"NA":15952},{"trials":15943,"activeCount":99},[],{"trials":15945,"activeCount":99},[],{"trials":15947,"activeCount":99},[],{"trials":15949,"activeCount":99},[],{"trials":15951,"activeCount":99},[],{"trials":15953,"activeCount":99},[15954],{"nctId":15955,"briefTitle":15956,"status":154,"phases":15957,"primaryCompletion":5929,"completion":5929,"start":9220,"enrollment":676,"conditions":15958,"interventions":15960},"NCT00700583","Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men",[91],[15959],"Nocturia",[15940],{"intervention":15962,"totalTrials":121,"cells":15963},"Lixisenatide",{"EARLY_PHASE1":15964,"PHASE1":15966,"PHASE2":15968,"PHASE3":15970,"PHASE4":15972,"NA":15974},{"trials":15965,"activeCount":99},[],{"trials":15967,"activeCount":99},[],{"trials":15969,"activeCount":99},[],{"trials":15971,"activeCount":99},[],{"trials":15973,"activeCount":99},[],{"trials":15975,"activeCount":99},[15976],{"nctId":15977,"briefTitle":15978,"status":154,"phases":15979,"primaryCompletion":168,"completion":168,"start":1977,"enrollment":850,"conditions":15980,"interventions":15981},"NCT02745470","Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain",[91],[6623],[15962],{"intervention":15983,"totalTrials":121,"cells":15984},"Sniffing emotional tears",{"EARLY_PHASE1":15985,"PHASE1":15987,"PHASE2":15989,"PHASE3":15991,"PHASE4":15993,"NA":15995},{"trials":15986,"activeCount":99},[],{"trials":15988,"activeCount":99},[],{"trials":15990,"activeCount":99},[],{"trials":15992,"activeCount":99},[],{"trials":15994,"activeCount":99},[],{"trials":15996,"activeCount":99},[15997],{"nctId":15998,"briefTitle":15999,"status":154,"phases":16000,"primaryCompletion":752,"completion":2385,"start":2394,"enrollment":7638,"conditions":16001,"interventions":16002},"NCT01389869","Appetite Regulation by Human Chemosignals From Tears and Plasma",[91],[12438],[15983,16003,16004,16005],"Sniffing trickled saline","Sniffing fasting plasma","Sniffing postprandial plasma",{"intervention":16003,"totalTrials":121,"cells":16007},{"EARLY_PHASE1":16008,"PHASE1":16010,"PHASE2":16012,"PHASE3":16014,"PHASE4":16016,"NA":16018},{"trials":16009,"activeCount":99},[],{"trials":16011,"activeCount":99},[],{"trials":16013,"activeCount":99},[],{"trials":16015,"activeCount":99},[],{"trials":16017,"activeCount":99},[],{"trials":16019,"activeCount":99},[16020],{"nctId":15998,"briefTitle":15999,"status":154,"phases":16021,"primaryCompletion":752,"completion":2385,"start":2394,"enrollment":7638,"conditions":16022,"interventions":16023},[91],[12438],[15983,16003,16004,16005],{"intervention":16004,"totalTrials":121,"cells":16025},{"EARLY_PHASE1":16026,"PHASE1":16028,"PHASE2":16030,"PHASE3":16032,"PHASE4":16034,"NA":16036},{"trials":16027,"activeCount":99},[],{"trials":16029,"activeCount":99},[],{"trials":16031,"activeCount":99},[],{"trials":16033,"activeCount":99},[],{"trials":16035,"activeCount":99},[],{"trials":16037,"activeCount":99},[16038],{"nctId":15998,"briefTitle":15999,"status":154,"phases":16039,"primaryCompletion":752,"completion":2385,"start":2394,"enrollment":7638,"conditions":16040,"interventions":16041},[91],[12438],[15983,16003,16004,16005],{"intervention":16005,"totalTrials":121,"cells":16043},{"EARLY_PHASE1":16044,"PHASE1":16046,"PHASE2":16048,"PHASE3":16050,"PHASE4":16052,"NA":16054},{"trials":16045,"activeCount":99},[],{"trials":16047,"activeCount":99},[],{"trials":16049,"activeCount":99},[],{"trials":16051,"activeCount":99},[],{"trials":16053,"activeCount":99},[],{"trials":16055,"activeCount":99},[16056],{"nctId":15998,"briefTitle":15999,"status":154,"phases":16057,"primaryCompletion":752,"completion":2385,"start":2394,"enrollment":7638,"conditions":16058,"interventions":16059},[91],[12438],[15983,16003,16004,16005],{"intervention":16061,"totalTrials":121,"cells":16062},"Regorafenib",{"EARLY_PHASE1":16063,"PHASE1":16065,"PHASE2":16067,"PHASE3":16069,"PHASE4":16071,"NA":16073},{"trials":16064,"activeCount":99},[],{"trials":16066,"activeCount":99},[],{"trials":16068,"activeCount":99},[],{"trials":16070,"activeCount":99},[],{"trials":16072,"activeCount":99},[],{"trials":16074,"activeCount":99},[16075],{"nctId":16076,"briefTitle":16077,"status":154,"phases":16078,"primaryCompletion":1979,"completion":2161,"start":579,"enrollment":16079,"conditions":16080,"interventions":16082},"NCT01996969","Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer",[91],117,[16081],"Metastatic Colorectal Cancer",[16061],{"intervention":16084,"totalTrials":121,"cells":16085},"neoadjuvant therapy",{"EARLY_PHASE1":16086,"PHASE1":16088,"PHASE2":16090,"PHASE3":16092,"PHASE4":16094,"NA":16096},{"trials":16087,"activeCount":99},[],{"trials":16089,"activeCount":99},[],{"trials":16091,"activeCount":99},[],{"trials":16093,"activeCount":99},[],{"trials":16095,"activeCount":99},[],{"trials":16097,"activeCount":99},[16098],{"nctId":16099,"briefTitle":16100,"status":154,"phases":16101,"primaryCompletion":1863,"completion":16102,"start":16103,"enrollment":3943,"conditions":16104,"interventions":16107},"NCT06630481","Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade",[],"2024-09-01","2009-01-01",[35,16105,16106],"Neoadjuvant Therapy","Pathological Complete Response",[16084],{"intervention":16109,"totalTrials":121,"cells":16110},"Low contrast dose CT",{"EARLY_PHASE1":16111,"PHASE1":16113,"PHASE2":16115,"PHASE3":16117,"PHASE4":16119,"NA":16121},{"trials":16112,"activeCount":99},[],{"trials":16114,"activeCount":99},[],{"trials":16116,"activeCount":99},[],{"trials":16118,"activeCount":99},[],{"trials":16120,"activeCount":99},[],{"trials":16122,"activeCount":99},[16123],{"nctId":16124,"briefTitle":16125,"status":154,"phases":16126,"primaryCompletion":4121,"completion":16127,"start":9244,"enrollment":2112,"conditions":16128,"interventions":16129},"NCT04722120","Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC",[91],"2021-01-01",[18],[16109,16130],"Conventional CT",{"intervention":16130,"totalTrials":121,"cells":16132},{"EARLY_PHASE1":16133,"PHASE1":16135,"PHASE2":16137,"PHASE3":16139,"PHASE4":16141,"NA":16143},{"trials":16134,"activeCount":99},[],{"trials":16136,"activeCount":99},[],{"trials":16138,"activeCount":99},[],{"trials":16140,"activeCount":99},[],{"trials":16142,"activeCount":99},[],{"trials":16144,"activeCount":99},[16145],{"nctId":16124,"briefTitle":16125,"status":154,"phases":16146,"primaryCompletion":4121,"completion":16127,"start":9244,"enrollment":2112,"conditions":16147,"interventions":16148},[91],[18],[16109,16130],{"intervention":16150,"totalTrials":121,"cells":16151},"Pangramin®",{"EARLY_PHASE1":16152,"PHASE1":16154,"PHASE2":16156,"PHASE3":16158,"PHASE4":16160,"NA":16162},{"trials":16153,"activeCount":99},[],{"trials":16155,"activeCount":99},[],{"trials":16157,"activeCount":99},[],{"trials":16159,"activeCount":99},[],{"trials":16161,"activeCount":99},[],{"trials":16163,"activeCount":99},[16164],{"nctId":16165,"briefTitle":16166,"status":154,"phases":16167,"primaryCompletion":2523,"completion":3671,"start":12634,"enrollment":8090,"conditions":16168,"interventions":16170},"NCT01247259","Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients",[91],[16169],"Allergic Rhinitis",[16150],{"intervention":16172,"totalTrials":121,"cells":16173},"Nefopam or saline",{"EARLY_PHASE1":16174,"PHASE1":16176,"PHASE2":16178,"PHASE3":16180,"PHASE4":16182,"NA":16184},{"trials":16175,"activeCount":99},[],{"trials":16177,"activeCount":99},[],{"trials":16179,"activeCount":99},[],{"trials":16181,"activeCount":99},[],{"trials":16183,"activeCount":99},[],{"trials":16185,"activeCount":99},[16186],{"nctId":16187,"briefTitle":16188,"status":154,"phases":16189,"primaryCompletion":4281,"completion":4281,"start":16190,"enrollment":2421,"conditions":16191,"interventions":16193},"NCT03130010","The Effect of Nefopam on Catheter-related Bladder Discomfort",[91],"2017-03-31",[554,16192],"Catheter-related Bladder Discomfort",[16172],{"intervention":16195,"totalTrials":121,"cells":16196},"AlloSeq cfDNA",{"EARLY_PHASE1":16197,"PHASE1":16199,"PHASE2":16201,"PHASE3":16203,"PHASE4":16205,"NA":16207},{"trials":16198,"activeCount":99},[],{"trials":16200,"activeCount":99},[],{"trials":16202,"activeCount":99},[],{"trials":16204,"activeCount":99},[],{"trials":16206,"activeCount":99},[],{"trials":16208,"activeCount":99},[16209],{"nctId":16210,"briefTitle":16211,"status":166,"phases":16212,"primaryCompletion":16213,"completion":16214,"start":16215,"enrollment":380,"conditions":16216,"interventions":16218},"NCT06013358","ddcfDNA in Kidney Transplant Recipients",[],"2024-11-30","2025-02-01","2022-12-26",[16217],"Kidney Transplant Rejection",[16195],{"intervention":16220,"totalTrials":121,"cells":16221},"Calcium Channel Blockers",{"EARLY_PHASE1":16222,"PHASE1":16224,"PHASE2":16226,"PHASE3":16228,"PHASE4":16230,"NA":16232},{"trials":16223,"activeCount":99},[],{"trials":16225,"activeCount":99},[],{"trials":16227,"activeCount":99},[],{"trials":16229,"activeCount":99},[],{"trials":16231,"activeCount":99},[],{"trials":16233,"activeCount":99},[16234],{"nctId":16235,"briefTitle":16236,"status":1813,"phases":16237,"primaryCompletion":11274,"completion":11274,"start":1771,"enrollment":5361,"conditions":16238,"interventions":16242},"NCT02642146","Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study",[],[16239,16240,16241],"Raynaud Disease","Systemic Sclerosis","Digital Ulcer",[16220,16243,16244,16245,16246],"Phosphodiesterase Inhibitors","Endothelin receptor blocker","Prostanoids","Other vasodilator",{"intervention":16243,"totalTrials":121,"cells":16248},{"EARLY_PHASE1":16249,"PHASE1":16251,"PHASE2":16253,"PHASE3":16255,"PHASE4":16257,"NA":16259},{"trials":16250,"activeCount":99},[],{"trials":16252,"activeCount":99},[],{"trials":16254,"activeCount":99},[],{"trials":16256,"activeCount":99},[],{"trials":16258,"activeCount":99},[],{"trials":16260,"activeCount":99},[16261],{"nctId":16235,"briefTitle":16236,"status":1813,"phases":16262,"primaryCompletion":11274,"completion":11274,"start":1771,"enrollment":5361,"conditions":16263,"interventions":16264},[],[16239,16240,16241],[16220,16243,16244,16245,16246],{"intervention":16244,"totalTrials":121,"cells":16266},{"EARLY_PHASE1":16267,"PHASE1":16269,"PHASE2":16271,"PHASE3":16273,"PHASE4":16275,"NA":16277},{"trials":16268,"activeCount":99},[],{"trials":16270,"activeCount":99},[],{"trials":16272,"activeCount":99},[],{"trials":16274,"activeCount":99},[],{"trials":16276,"activeCount":99},[],{"trials":16278,"activeCount":99},[16279],{"nctId":16235,"briefTitle":16236,"status":1813,"phases":16280,"primaryCompletion":11274,"completion":11274,"start":1771,"enrollment":5361,"conditions":16281,"interventions":16282},[],[16239,16240,16241],[16220,16243,16244,16245,16246],{"intervention":16245,"totalTrials":121,"cells":16284},{"EARLY_PHASE1":16285,"PHASE1":16287,"PHASE2":16289,"PHASE3":16291,"PHASE4":16293,"NA":16295},{"trials":16286,"activeCount":99},[],{"trials":16288,"activeCount":99},[],{"trials":16290,"activeCount":99},[],{"trials":16292,"activeCount":99},[],{"trials":16294,"activeCount":99},[],{"trials":16296,"activeCount":99},[16297],{"nctId":16235,"briefTitle":16236,"status":1813,"phases":16298,"primaryCompletion":11274,"completion":11274,"start":1771,"enrollment":5361,"conditions":16299,"interventions":16300},[],[16239,16240,16241],[16220,16243,16244,16245,16246],{"intervention":16246,"totalTrials":121,"cells":16302},{"EARLY_PHASE1":16303,"PHASE1":16305,"PHASE2":16307,"PHASE3":16309,"PHASE4":16311,"NA":16313},{"trials":16304,"activeCount":99},[],{"trials":16306,"activeCount":99},[],{"trials":16308,"activeCount":99},[],{"trials":16310,"activeCount":99},[],{"trials":16312,"activeCount":99},[],{"trials":16314,"activeCount":99},[16315],{"nctId":16235,"briefTitle":16236,"status":1813,"phases":16316,"primaryCompletion":11274,"completion":11274,"start":1771,"enrollment":5361,"conditions":16317,"interventions":16318},[],[16239,16240,16241],[16220,16243,16244,16245,16246],{"intervention":16320,"totalTrials":121,"cells":16321},"Capecitabine, oxaliplatin",{"EARLY_PHASE1":16322,"PHASE1":16324,"PHASE2":16326,"PHASE3":16328,"PHASE4":16330,"NA":16332},{"trials":16323,"activeCount":99},[],{"trials":16325,"activeCount":99},[],{"trials":16327,"activeCount":99},[],{"trials":16329,"activeCount":99},[],{"trials":16331,"activeCount":99},[],{"trials":16333,"activeCount":99},[16334],{"nctId":16335,"briefTitle":16336,"status":154,"phases":16337,"primaryCompletion":1977,"completion":9964,"start":791,"enrollment":16338,"conditions":16339,"interventions":16342},"NCT02298010","Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial",[],899,[16340,16341],"Stomach Neoplasms","Cancer of Lymph Node",[16320],{"intervention":16344,"totalTrials":121,"cells":16345},"0.25g\u002Fkgof 20% mannitol",{"EARLY_PHASE1":16346,"PHASE1":16348,"PHASE2":16350,"PHASE3":16352,"PHASE4":16354,"NA":16356},{"trials":16347,"activeCount":99},[],{"trials":16349,"activeCount":99},[],{"trials":16351,"activeCount":99},[],{"trials":16353,"activeCount":99},[],{"trials":16355,"activeCount":99},[],{"trials":16357,"activeCount":99},[16358],{"nctId":16359,"briefTitle":16360,"status":166,"phases":16361,"primaryCompletion":2161,"start":2444,"enrollment":5067,"conditions":16362,"interventions":16364},"NCT02168075","Mannitol Brain Relaxation Effect",[91],[16363],"Supratentorial Neoplasms",[16344,16365,16366,16367],"0.5g\u002Fkg of 20% mannitol","1.0g\u002Fkg of 20% mannitol","1.5g\u002Fkg of 20% mannitol",{"intervention":16365,"totalTrials":121,"cells":16369},{"EARLY_PHASE1":16370,"PHASE1":16372,"PHASE2":16374,"PHASE3":16376,"PHASE4":16378,"NA":16380},{"trials":16371,"activeCount":99},[],{"trials":16373,"activeCount":99},[],{"trials":16375,"activeCount":99},[],{"trials":16377,"activeCount":99},[],{"trials":16379,"activeCount":99},[],{"trials":16381,"activeCount":99},[16382],{"nctId":16359,"briefTitle":16360,"status":166,"phases":16383,"primaryCompletion":2161,"start":2444,"enrollment":5067,"conditions":16384,"interventions":16385},[91],[16363],[16344,16365,16366,16367],{"intervention":16366,"totalTrials":121,"cells":16387},{"EARLY_PHASE1":16388,"PHASE1":16390,"PHASE2":16392,"PHASE3":16394,"PHASE4":16396,"NA":16398},{"trials":16389,"activeCount":99},[],{"trials":16391,"activeCount":99},[],{"trials":16393,"activeCount":99},[],{"trials":16395,"activeCount":99},[],{"trials":16397,"activeCount":99},[],{"trials":16399,"activeCount":99},[16400],{"nctId":16359,"briefTitle":16360,"status":166,"phases":16401,"primaryCompletion":2161,"start":2444,"enrollment":5067,"conditions":16402,"interventions":16403},[91],[16363],[16344,16365,16366,16367],{"intervention":16367,"totalTrials":121,"cells":16405},{"EARLY_PHASE1":16406,"PHASE1":16408,"PHASE2":16410,"PHASE3":16412,"PHASE4":16414,"NA":16416},{"trials":16407,"activeCount":99},[],{"trials":16409,"activeCount":99},[],{"trials":16411,"activeCount":99},[],{"trials":16413,"activeCount":99},[],{"trials":16415,"activeCount":99},[],{"trials":16417,"activeCount":99},[16418],{"nctId":16359,"briefTitle":16360,"status":166,"phases":16419,"primaryCompletion":2161,"start":2444,"enrollment":5067,"conditions":16420,"interventions":16421},[91],[16363],[16344,16365,16366,16367],{"intervention":16423,"totalTrials":121,"cells":16424},"Neostigmine + Glycopyrrolate",{"EARLY_PHASE1":16425,"PHASE1":16427,"PHASE2":16429,"PHASE3":16431,"PHASE4":16433,"NA":16435},{"trials":16426,"activeCount":99},[],{"trials":16428,"activeCount":99},[],{"trials":16430,"activeCount":99},[],{"trials":16432,"activeCount":99},[],{"trials":16434,"activeCount":99},[],{"trials":16436,"activeCount":99},[16437],{"nctId":16438,"briefTitle":16439,"status":154,"phases":16440,"primaryCompletion":16441,"completion":16442,"start":45,"enrollment":229,"conditions":16443,"interventions":16445},"NCT06745492","Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery",[],"2023-08-20","2023-08-25",[16444],"Recovery Time",[16423],{"intervention":16447,"totalTrials":121,"cells":16448},"Topical application of 1.5% Butenyl ALA",{"EARLY_PHASE1":16449,"PHASE1":16451,"PHASE2":16453,"PHASE3":16455,"PHASE4":16457,"NA":16459},{"trials":16450,"activeCount":99},[],{"trials":16452,"activeCount":99},[],{"trials":16454,"activeCount":99},[],{"trials":16456,"activeCount":99},[],{"trials":16458,"activeCount":99},[],{"trials":16460,"activeCount":99},[16461],{"nctId":16462,"briefTitle":16463,"status":154,"phases":16464,"primaryCompletion":673,"completion":673,"start":732,"enrollment":2183,"conditions":16465,"interventions":16467},"NCT02313467","Topical PDT Cream Without Irradiation Source in the Acne Treatment",[91],[16466],"Acne, Photodynamic Therapy",[16447,16468],"Topical application of sham control",{"intervention":16468,"totalTrials":121,"cells":16470},{"EARLY_PHASE1":16471,"PHASE1":16473,"PHASE2":16475,"PHASE3":16477,"PHASE4":16479,"NA":16481},{"trials":16472,"activeCount":99},[],{"trials":16474,"activeCount":99},[],{"trials":16476,"activeCount":99},[],{"trials":16478,"activeCount":99},[],{"trials":16480,"activeCount":99},[],{"trials":16482,"activeCount":99},[16483],{"nctId":16462,"briefTitle":16463,"status":154,"phases":16484,"primaryCompletion":673,"completion":673,"start":732,"enrollment":2183,"conditions":16485,"interventions":16486},[91],[16466],[16447,16468],{"intervention":16488,"totalTrials":121,"cells":16489},"remimazolam-based TIVA",{"EARLY_PHASE1":16490,"PHASE1":16492,"PHASE2":16494,"PHASE3":16496,"PHASE4":16498,"NA":16500},{"trials":16491,"activeCount":99},[],{"trials":16493,"activeCount":99},[],{"trials":16495,"activeCount":99},[],{"trials":16497,"activeCount":99},[],{"trials":16499,"activeCount":99},[],{"trials":16501,"activeCount":99},[16502],{"nctId":16503,"briefTitle":16504,"status":154,"phases":16505,"primaryCompletion":16506,"completion":16507,"start":16508,"enrollment":265,"conditions":16509,"interventions":16511},"NCT05047939","Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol",[91],"2022-08-12","2022-09-11","2021-12-14",[16510],"Anesthesia, Intravenous",[16488,16512],"propofol-based TIVA",{"intervention":16512,"totalTrials":121,"cells":16514},{"EARLY_PHASE1":16515,"PHASE1":16517,"PHASE2":16519,"PHASE3":16521,"PHASE4":16523,"NA":16525},{"trials":16516,"activeCount":99},[],{"trials":16518,"activeCount":99},[],{"trials":16520,"activeCount":99},[],{"trials":16522,"activeCount":99},[],{"trials":16524,"activeCount":99},[],{"trials":16526,"activeCount":99},[16527],{"nctId":16503,"briefTitle":16504,"status":154,"phases":16528,"primaryCompletion":16506,"completion":16507,"start":16508,"enrollment":265,"conditions":16529,"interventions":16530},[91],[16510],[16488,16512],{"intervention":14948,"totalTrials":121,"cells":16532},{"EARLY_PHASE1":16533,"PHASE1":16535,"PHASE2":16537,"PHASE3":16539,"PHASE4":16541,"NA":16543},{"trials":16534,"activeCount":99},[],{"trials":16536,"activeCount":99},[],{"trials":16538,"activeCount":99},[],{"trials":16540,"activeCount":99},[],{"trials":16542,"activeCount":99},[],{"trials":16544,"activeCount":99},[16545],{"nctId":14941,"briefTitle":14942,"status":166,"phases":16546,"primaryCompletion":14944,"completion":2672,"start":209,"enrollment":14945,"conditions":16547,"interventions":16548},[91],[2491],[14948,13107],{"intervention":16550,"totalTrials":121,"cells":16551},"Different timing of influenza vaccination",{"EARLY_PHASE1":16552,"PHASE1":16554,"PHASE2":16556,"PHASE3":16558,"PHASE4":16560,"NA":16562},{"trials":16553,"activeCount":99},[],{"trials":16555,"activeCount":99},[],{"trials":16557,"activeCount":99},[],{"trials":16559,"activeCount":99},[],{"trials":16561,"activeCount":99},[],{"trials":16563,"activeCount":99},[16564],{"nctId":16565,"briefTitle":16566,"status":1813,"phases":16567,"primaryCompletion":673,"completion":1967,"start":2041,"enrollment":16568,"conditions":16569,"interventions":16570},"NCT02213432","Influenza Vaccination in Cancer Patients",[91],97,[4387],[16550],{"intervention":16572,"totalTrials":121,"cells":16573},"Crystalloid",{"EARLY_PHASE1":16574,"PHASE1":16576,"PHASE2":16578,"PHASE3":16580,"PHASE4":16582,"NA":16584},{"trials":16575,"activeCount":99},[],{"trials":16577,"activeCount":99},[],{"trials":16579,"activeCount":99},[],{"trials":16581,"activeCount":99},[],{"trials":16583,"activeCount":99},[],{"trials":16585,"activeCount":99},[16586],{"nctId":16587,"briefTitle":16588,"status":154,"phases":16589,"primaryCompletion":1977,"completion":1978,"start":674,"enrollment":380,"conditions":16590,"interventions":16591},"NCT02599155","The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery",[91],[133],[16572,16592],"Colloid",{"intervention":16592,"totalTrials":121,"cells":16594},{"EARLY_PHASE1":16595,"PHASE1":16597,"PHASE2":16599,"PHASE3":16601,"PHASE4":16603,"NA":16605},{"trials":16596,"activeCount":99},[],{"trials":16598,"activeCount":99},[],{"trials":16600,"activeCount":99},[],{"trials":16602,"activeCount":99},[],{"trials":16604,"activeCount":99},[],{"trials":16606,"activeCount":99},[16607],{"nctId":16587,"briefTitle":16588,"status":154,"phases":16608,"primaryCompletion":1977,"completion":1978,"start":674,"enrollment":380,"conditions":16609,"interventions":16610},[91],[133],[16572,16592],{"intervention":16612,"totalTrials":121,"cells":16613},"Vigabatrin 500 MG",{"EARLY_PHASE1":16614,"PHASE1":16616,"PHASE2":16618,"PHASE3":16620,"PHASE4":16622,"NA":16624},{"trials":16615,"activeCount":99},[],{"trials":16617,"activeCount":99},[],{"trials":16619,"activeCount":99},[],{"trials":16621,"activeCount":99},[],{"trials":16623,"activeCount":99},[],{"trials":16625,"activeCount":99},[16626],{"nctId":16627,"briefTitle":16628,"status":658,"phases":16629,"primaryCompletion":1763,"completion":1763,"start":538,"enrollment":99,"conditions":16630,"interventions":16632},"NCT03003143","Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients",[91],[16631],"Autoimmune Encephalopathy",[16612],{"intervention":16634,"totalTrials":121,"cells":16635},"FOLFIRINOX regimen",{"EARLY_PHASE1":16636,"PHASE1":16638,"PHASE2":16640,"PHASE3":16642,"PHASE4":16644,"NA":16646},{"trials":16637,"activeCount":99},[],{"trials":16639,"activeCount":99},[],{"trials":16641,"activeCount":99},[],{"trials":16643,"activeCount":99},[],{"trials":16645,"activeCount":99},[],{"trials":16647,"activeCount":99},[16648],{"nctId":16649,"briefTitle":16650,"status":166,"phases":16651,"primaryCompletion":13192,"completion":70,"start":2229,"enrollment":1795,"conditions":16652,"interventions":16655},"NCT05262452","Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer",[91],[16653,992,16654],"Pancreatic Cancer Non-resectable","Ultrasound Therapy",[16634],{"intervention":16657,"totalTrials":121,"cells":16658},"MgSO4",{"EARLY_PHASE1":16659,"PHASE1":16661,"PHASE2":16663,"PHASE3":16665,"PHASE4":16667,"NA":16669},{"trials":16660,"activeCount":99},[],{"trials":16662,"activeCount":99},[],{"trials":16664,"activeCount":99},[],{"trials":16666,"activeCount":99},[],{"trials":16668,"activeCount":99},[],{"trials":16670,"activeCount":99},[16671],{"nctId":16672,"briefTitle":16673,"status":154,"phases":16674,"primaryCompletion":16675,"start":16676,"enrollment":158,"conditions":16677,"interventions":16679},"NCT02538718","Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor",[91],"2016-11-29","2015-09-22",[16678],"Preterm Labor",[16657,16680],"YTP",{"intervention":16680,"totalTrials":121,"cells":16682},{"EARLY_PHASE1":16683,"PHASE1":16685,"PHASE2":16687,"PHASE3":16689,"PHASE4":16691,"NA":16693},{"trials":16684,"activeCount":99},[],{"trials":16686,"activeCount":99},[],{"trials":16688,"activeCount":99},[],{"trials":16690,"activeCount":99},[],{"trials":16692,"activeCount":99},[],{"trials":16694,"activeCount":99},[16695],{"nctId":16672,"briefTitle":16673,"status":154,"phases":16696,"primaryCompletion":16675,"start":16676,"enrollment":158,"conditions":16697,"interventions":16698},[91],[16678],[16657,16680],{"intervention":16700,"totalTrials":121,"cells":16701},"Cabergoline",{"EARLY_PHASE1":16702,"PHASE1":16704,"PHASE2":16706,"PHASE3":16708,"PHASE4":16710,"NA":16712},{"trials":16703,"activeCount":99},[],{"trials":16705,"activeCount":99},[],{"trials":16707,"activeCount":99},[],{"trials":16709,"activeCount":99},[],{"trials":16711,"activeCount":99},[],{"trials":16713,"activeCount":99},[16714],{"nctId":16715,"briefTitle":16716,"status":166,"phases":16717,"primaryCompletion":75,"completion":75,"start":16718,"enrollment":2112,"conditions":16719,"interventions":16724},"NCT03457389","Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma",[91],"2018-02-22",[16720,16721,16722,16723],"Pituitary Adenoma","Prolactinoma","Pituitary Tumor","Recurrence Tumor",[16700],{"intervention":2235,"totalTrials":121,"cells":16726},{"EARLY_PHASE1":16727,"PHASE1":16729,"PHASE2":16731,"PHASE3":16733,"PHASE4":16735,"NA":16737},{"trials":16728,"activeCount":99},[],{"trials":16730,"activeCount":99},[],{"trials":16732,"activeCount":99},[],{"trials":16734,"activeCount":99},[],{"trials":16736,"activeCount":99},[],{"trials":16738,"activeCount":99},[16739],{"nctId":2226,"briefTitle":2227,"status":154,"phases":16740,"primaryCompletion":2229,"completion":2230,"start":2231,"enrollment":2232,"conditions":16741,"interventions":16742},[91],[466],[2235,270],{"intervention":14468,"totalTrials":121,"cells":16744},{"EARLY_PHASE1":16745,"PHASE1":16747,"PHASE2":16749,"PHASE3":16751,"PHASE4":16753,"NA":16755},{"trials":16746,"activeCount":99},[],{"trials":16748,"activeCount":99},[],{"trials":16750,"activeCount":99},[],{"trials":16752,"activeCount":99},[],{"trials":16754,"activeCount":99},[],{"trials":16756,"activeCount":99},[16757],{"nctId":14463,"briefTitle":14464,"status":154,"phases":16758,"primaryCompletion":3565,"completion":3565,"start":6265,"enrollment":850,"conditions":16759,"interventions":16760},[91],[12343],[14468,14469],{"intervention":2246,"totalTrials":121,"cells":16762},{"EARLY_PHASE1":16763,"PHASE1":16765,"PHASE2":16767,"PHASE3":16769,"PHASE4":16771,"NA":16773},{"trials":16764,"activeCount":99},[],{"trials":16766,"activeCount":99},[],{"trials":16768,"activeCount":99},[],{"trials":16770,"activeCount":99},[],{"trials":16772,"activeCount":99},[],{"trials":16774,"activeCount":99},[16775],{"nctId":2237,"briefTitle":2238,"status":658,"phases":16776,"primaryCompletion":2240,"completion":2241,"start":2242,"enrollment":99,"conditions":16777,"interventions":16778},[91],[1004,2244],[2246,270],{"intervention":16780,"totalTrials":121,"cells":16781},"HBV booster vaccination 1dose",{"EARLY_PHASE1":16782,"PHASE1":16784,"PHASE2":16786,"PHASE3":16788,"PHASE4":16790,"NA":16792},{"trials":16783,"activeCount":99},[],{"trials":16785,"activeCount":99},[],{"trials":16787,"activeCount":99},[],{"trials":16789,"activeCount":99},[],{"trials":16791,"activeCount":99},[],{"trials":16793,"activeCount":99},[16794],{"nctId":16795,"briefTitle":16796,"status":1813,"phases":16797,"primaryCompletion":3741,"completion":3741,"start":16798,"enrollment":10394,"conditions":16799,"interventions":16801},"NCT02166671","Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years",[91],"2014-04-25",[16800],"Hepatitis B Vaccination",[16780],{"intervention":16803,"totalTrials":121,"cells":16804},"Epiduo once daily with detailed instruction for how to apply it",{"EARLY_PHASE1":16805,"PHASE1":16807,"PHASE2":16809,"PHASE3":16811,"PHASE4":16813,"NA":16815},{"trials":16806,"activeCount":99},[],{"trials":16808,"activeCount":99},[],{"trials":16810,"activeCount":99},[],{"trials":16812,"activeCount":99},[],{"trials":16814,"activeCount":99},[],{"trials":16816,"activeCount":99},[16817],{"nctId":16818,"briefTitle":16819,"status":154,"phases":16820,"primaryCompletion":673,"completion":673,"start":732,"enrollment":9,"conditions":16821,"interventions":16824},"NCT02192632","Dermatologists' Educational Demonstration for Epiduo Application",[91],[16822,16823],"Facial Acne","Local Adverse Effects",[16803,16825,16826],"Epiduo- once daily, simple instruction for application","BPO once daily",{"intervention":16825,"totalTrials":121,"cells":16828},{"EARLY_PHASE1":16829,"PHASE1":16831,"PHASE2":16833,"PHASE3":16835,"PHASE4":16837,"NA":16839},{"trials":16830,"activeCount":99},[],{"trials":16832,"activeCount":99},[],{"trials":16834,"activeCount":99},[],{"trials":16836,"activeCount":99},[],{"trials":16838,"activeCount":99},[],{"trials":16840,"activeCount":99},[16841],{"nctId":16818,"briefTitle":16819,"status":154,"phases":16842,"primaryCompletion":673,"completion":673,"start":732,"enrollment":9,"conditions":16843,"interventions":16844},[91],[16822,16823],[16803,16825,16826],{"intervention":16826,"totalTrials":121,"cells":16846},{"EARLY_PHASE1":16847,"PHASE1":16849,"PHASE2":16851,"PHASE3":16853,"PHASE4":16855,"NA":16857},{"trials":16848,"activeCount":99},[],{"trials":16850,"activeCount":99},[],{"trials":16852,"activeCount":99},[],{"trials":16854,"activeCount":99},[],{"trials":16856,"activeCount":99},[],{"trials":16858,"activeCount":99},[16859],{"nctId":16818,"briefTitle":16819,"status":154,"phases":16860,"primaryCompletion":673,"completion":673,"start":732,"enrollment":9,"conditions":16861,"interventions":16862},[91],[16822,16823],[16803,16825,16826],{"intervention":16864,"totalTrials":121,"cells":16865},"Amiodarone, diltiazem or esmolol",{"EARLY_PHASE1":16866,"PHASE1":16868,"PHASE2":16870,"PHASE3":16872,"PHASE4":16874,"NA":16876},{"trials":16867,"activeCount":99},[],{"trials":16869,"activeCount":99},[],{"trials":16871,"activeCount":99},[],{"trials":16873,"activeCount":99},[],{"trials":16875,"activeCount":99},[],{"trials":16877,"activeCount":99},[16878],{"nctId":16879,"briefTitle":16880,"status":1813,"phases":16881,"primaryCompletion":16882,"completion":16882,"start":16883,"enrollment":121,"conditions":16884,"interventions":16887},"NCT05950971","Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation",[91],"2022-01-21","2021-07-01",[16885,16886],"Atrial Fibrillation New Onset","Atrial Fibrillation Paroxysmal",[16864],{"intervention":14369,"totalTrials":121,"cells":16889},{"EARLY_PHASE1":16890,"PHASE1":16892,"PHASE2":16894,"PHASE3":16896,"PHASE4":16898,"NA":16900},{"trials":16891,"activeCount":99},[],{"trials":16893,"activeCount":99},[],{"trials":16895,"activeCount":99},[],{"trials":16897,"activeCount":99},[],{"trials":16899,"activeCount":99},[],{"trials":16901,"activeCount":99},[16902],{"nctId":14359,"briefTitle":14360,"status":166,"phases":16903,"primaryCompletion":14362,"completion":14363,"start":14364,"enrollment":463,"conditions":16904,"interventions":16905},[91],[14366],[14368,14369],{"intervention":16907,"totalTrials":121,"cells":16908},"10mg Dinoprostone vaginal insert",{"EARLY_PHASE1":16909,"PHASE1":16911,"PHASE2":16913,"PHASE3":16915,"PHASE4":16917,"NA":16919},{"trials":16910,"activeCount":99},[],{"trials":16912,"activeCount":99},[],{"trials":16914,"activeCount":99},[],{"trials":16916,"activeCount":99},[],{"trials":16918,"activeCount":99},[],{"trials":16920,"activeCount":99},[16921],{"nctId":16922,"briefTitle":16923,"status":154,"phases":16924,"primaryCompletion":10195,"completion":10195,"start":1815,"enrollment":16925,"conditions":16926,"interventions":16928},"NCT01792375","Concurrent Membrane Sweeping With Dinoprostone Versus Dinoprostone in Labor Induction of Nulliparas at Term With an Unfavorable Cervix",[91],192,[16927],"Nulliparous Women Who Scheduled for Labor Induction",[16907],{"intervention":16930,"totalTrials":121,"cells":16931},"Influenza vaccination",{"EARLY_PHASE1":16932,"PHASE1":16934,"PHASE2":16936,"PHASE3":16938,"PHASE4":16940,"NA":16942},{"trials":16933,"activeCount":99},[],{"trials":16935,"activeCount":99},[],{"trials":16937,"activeCount":99},[],{"trials":16939,"activeCount":99},[],{"trials":16941,"activeCount":99},[],{"trials":16943,"activeCount":99},[16944],{"nctId":16945,"briefTitle":16946,"status":154,"phases":16947,"primaryCompletion":16948,"completion":16949,"start":16950,"enrollment":16951,"conditions":16952,"interventions":16954},"NCT03590808","Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor",[91],"2018-12-21","2019-05-30","2018-09-01",143,[8224,16953],"Solid Carcinoma",[16930],{"intervention":1868,"totalTrials":121,"cells":16956},{"EARLY_PHASE1":16957,"PHASE1":16959,"PHASE2":16961,"PHASE3":16963,"PHASE4":16965,"NA":16967},{"trials":16958,"activeCount":99},[],{"trials":16960,"activeCount":99},[],{"trials":16962,"activeCount":99},[],{"trials":16964,"activeCount":99},[],{"trials":16966,"activeCount":99},[],{"trials":16968,"activeCount":99},[16969],{"nctId":1860,"briefTitle":1861,"status":658,"phases":16970,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":16971,"interventions":16972},[91],[1866],[1868,1858,1668,1727,1869,1870],{"intervention":1869,"totalTrials":121,"cells":16974},{"EARLY_PHASE1":16975,"PHASE1":16977,"PHASE2":16979,"PHASE3":16981,"PHASE4":16983,"NA":16985},{"trials":16976,"activeCount":99},[],{"trials":16978,"activeCount":99},[],{"trials":16980,"activeCount":99},[],{"trials":16982,"activeCount":99},[],{"trials":16984,"activeCount":99},[],{"trials":16986,"activeCount":99},[16987],{"nctId":1860,"briefTitle":1861,"status":658,"phases":16988,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":99,"conditions":16989,"interventions":16990},[91],[1866],[1868,1858,1668,1727,1869,1870],{"intervention":16992,"totalTrials":121,"cells":16993},"Dinoprostone 10mg",{"EARLY_PHASE1":16994,"PHASE1":16996,"PHASE2":16998,"PHASE3":17000,"PHASE4":17002,"NA":17004},{"trials":16995,"activeCount":99},[],{"trials":16997,"activeCount":99},[],{"trials":16999,"activeCount":99},[],{"trials":17001,"activeCount":99},[],{"trials":17003,"activeCount":99},[],{"trials":17005,"activeCount":99},[17006],{"nctId":17007,"briefTitle":17008,"status":154,"phases":17009,"primaryCompletion":2101,"completion":2101,"start":5092,"enrollment":14827,"conditions":17010,"interventions":17011},"NCT01596296","Foley Catheter Versus Dinoprostone Vaginal Insert for Induction of Labor in Parous Women at Term: A Randomized Trial",[91],[14829],[16992],{"intervention":17013,"totalTrials":121,"cells":17014},"Tulobuterol Hydrochloride",{"EARLY_PHASE1":17015,"PHASE1":17017,"PHASE2":17019,"PHASE3":17021,"PHASE4":17023,"NA":17025},{"trials":17016,"activeCount":99},[],{"trials":17018,"activeCount":99},[],{"trials":17020,"activeCount":99},[],{"trials":17022,"activeCount":99},[],{"trials":17024,"activeCount":99},[],{"trials":17026,"activeCount":99},[17027],{"nctId":17028,"briefTitle":17029,"status":154,"phases":17030,"primaryCompletion":10719,"completion":10719,"start":17031,"enrollment":9016,"conditions":17032,"interventions":17034},"NCT04057469","Tulobuterol Patch in Pediatric Patients Undergoing Tonsillectomy",[91],"2019-12-20",[17033],"Tonsillar Hypertrophy",[17013],{"intervention":2262,"totalTrials":121,"cells":17036},{"EARLY_PHASE1":17037,"PHASE1":17039,"PHASE2":17041,"PHASE3":17043,"PHASE4":17045,"NA":17047},{"trials":17038,"activeCount":99},[],{"trials":17040,"activeCount":99},[],{"trials":17042,"activeCount":99},[],{"trials":17044,"activeCount":99},[],{"trials":17046,"activeCount":99},[],{"trials":17048,"activeCount":99},[17049],{"nctId":2256,"briefTitle":2257,"status":658,"phases":17050,"primaryCompletion":1978,"completion":1978,"start":1957,"enrollment":99,"conditions":17051,"interventions":17052},[91],[2260],[270,2262],{"intervention":17054,"totalTrials":121,"cells":17055},"Beraprost sodium",{"EARLY_PHASE1":17056,"PHASE1":17058,"PHASE2":17060,"PHASE3":17062,"PHASE4":17064,"NA":17066},{"trials":17057,"activeCount":99},[],{"trials":17059,"activeCount":99},[],{"trials":17061,"activeCount":99},[],{"trials":17063,"activeCount":99},[],{"trials":17065,"activeCount":99},[],{"trials":17067,"activeCount":99},[17068],{"nctId":17069,"briefTitle":17070,"status":166,"phases":17071,"primaryCompletion":6922,"start":3621,"enrollment":2328,"conditions":17072,"interventions":17073},"NCT01796418","Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy",[91],[3615],[17054],{"intervention":17075,"totalTrials":121,"cells":17076},"Helicobacter Pylori eradication therapy",{"EARLY_PHASE1":17077,"PHASE1":17079,"PHASE2":17081,"PHASE3":17083,"PHASE4":17085,"NA":17087},{"trials":17078,"activeCount":99},[],{"trials":17080,"activeCount":99},[],{"trials":17082,"activeCount":99},[],{"trials":17084,"activeCount":99},[],{"trials":17086,"activeCount":99},[],{"trials":17088,"activeCount":99},[17089],{"nctId":17090,"briefTitle":17091,"status":166,"phases":17092,"primaryCompletion":8022,"completion":8022,"start":13831,"enrollment":1795,"conditions":17093,"interventions":17095},"NCT03837990","One Sequencing Find All for Helicobacter Pylori Infection",[],[15511,17094],"Resistant Infection",[17075],{"intervention":17097,"totalTrials":121,"cells":17098},"hENT1",{"EARLY_PHASE1":17099,"PHASE1":17101,"PHASE2":17103,"PHASE3":17105,"PHASE4":17107,"NA":17109},{"trials":17100,"activeCount":99},[],{"trials":17102,"activeCount":99},[],{"trials":17104,"activeCount":99},[],{"trials":17106,"activeCount":99},[],{"trials":17108,"activeCount":99},[],{"trials":17110,"activeCount":99},[17111],{"nctId":17112,"briefTitle":17113,"status":154,"phases":17114,"primaryCompletion":17115,"completion":17115,"start":1979,"enrollment":170,"conditions":17116,"interventions":17117},"NCT02486497","Adjuvant Gemcitabine Versus 5-FU\u002FLeucovorin Based on hENT1 Immunostaining",[91],"2017-05",[35],[17097],{"intervention":17119,"totalTrials":121,"cells":17120},"Amoxicillin Clavulanate",{"EARLY_PHASE1":17121,"PHASE1":17123,"PHASE2":17125,"PHASE3":17127,"PHASE4":17129,"NA":17131},{"trials":17122,"activeCount":99},[],{"trials":17124,"activeCount":99},[],{"trials":17126,"activeCount":99},[],{"trials":17128,"activeCount":99},[],{"trials":17130,"activeCount":99},[],{"trials":17132,"activeCount":99},[17133],{"nctId":17134,"briefTitle":17135,"status":166,"phases":17136,"primaryCompletion":8775,"completion":17137,"start":17138,"enrollment":1048,"conditions":17139,"interventions":17142},"NCT03295955","Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy",[91],"2018-12-03","2017-09-04",[17140,17141],"Surgical Wound Infection","Thyroid Nodule",[17119],{"intervention":2269,"totalTrials":121,"cells":17144},{"EARLY_PHASE1":17145,"PHASE1":17147,"PHASE2":17149,"PHASE3":17151,"PHASE4":17153,"NA":17155},{"trials":17146,"activeCount":99},[],{"trials":17148,"activeCount":99},[],{"trials":17150,"activeCount":99},[],{"trials":17152,"activeCount":99},[],{"trials":17154,"activeCount":99},[],{"trials":17156,"activeCount":99},[17157],{"nctId":2264,"briefTitle":2265,"status":154,"phases":17158,"primaryCompletion":742,"completion":1815,"start":2267,"enrollment":1743,"conditions":17159,"interventions":17160},[91],[30,2269],[2269,270],{"intervention":17162,"totalTrials":121,"cells":17163},"milrinone",{"EARLY_PHASE1":17164,"PHASE1":17166,"PHASE2":17168,"PHASE3":17170,"PHASE4":17172,"NA":17174},{"trials":17165,"activeCount":99},[],{"trials":17167,"activeCount":99},[],{"trials":17169,"activeCount":99},[],{"trials":17171,"activeCount":99},[],{"trials":17173,"activeCount":99},[],{"trials":17175,"activeCount":99},[17176],{"nctId":17177,"briefTitle":17178,"status":154,"phases":17179,"primaryCompletion":7381,"completion":7381,"start":7382,"enrollment":9411,"conditions":17180,"interventions":17182},"NCT00966745","Milrinone During Living Donor Hepatectomy",[91],[17181],"Hepatectomy",[17162],{"intervention":17184,"totalTrials":121,"cells":17185},"Lactitol Monohydrate",{"EARLY_PHASE1":17186,"PHASE1":17188,"PHASE2":17190,"PHASE3":17192,"PHASE4":17194,"NA":17196},{"trials":17187,"activeCount":99},[],{"trials":17189,"activeCount":99},[],{"trials":17191,"activeCount":99},[],{"trials":17193,"activeCount":99},[],{"trials":17195,"activeCount":99},[],{"trials":17197,"activeCount":99},[17198],{"nctId":17199,"briefTitle":17200,"status":154,"phases":17201,"primaryCompletion":17202,"completion":17202,"start":2208,"enrollment":17203,"conditions":17204,"interventions":17209},"NCT04579731","Development of Fecal Scoring for the Management of Fecal Impaction With Regards to Lower Urinary Tract Dysfunction",[],"2021-06-02",187,[17205,17206,17207,17208],"Fecal Impaction","Lower Urinary Tract Disorder","Bladder Dysfunction","Bowel Dysfunction",[17184],{"intervention":17211,"totalTrials":121,"cells":17212},"non-ionic monomer iodinated CT contrast media",{"EARLY_PHASE1":17213,"PHASE1":17215,"PHASE2":17217,"PHASE3":17219,"PHASE4":17221,"NA":17223},{"trials":17214,"activeCount":99},[],{"trials":17216,"activeCount":99},[],{"trials":17218,"activeCount":99},[],{"trials":17220,"activeCount":99},[],{"trials":17222,"activeCount":99},[],{"trials":17224,"activeCount":99},[17225],{"nctId":17226,"briefTitle":17227,"status":154,"phases":17228,"primaryCompletion":17229,"completion":17230,"start":17231,"enrollment":17232,"conditions":17233,"interventions":17235},"NCT02675920","A Study of HCC High Risk Group Using Two Surveillance Tools",[],"2019-01-11","2019-10-01","2014-11-28",139,[17234],"HCC",[17211],{"intervention":17237,"totalTrials":121,"cells":17238},"Antithrombin III, continuous",{"EARLY_PHASE1":17239,"PHASE1":17241,"PHASE2":17243,"PHASE3":17245,"PHASE4":17247,"NA":17249},{"trials":17240,"activeCount":99},[],{"trials":17242,"activeCount":99},[],{"trials":17244,"activeCount":99},[],{"trials":17246,"activeCount":99},[],{"trials":17248,"activeCount":99},[],{"trials":17250,"activeCount":99},[17251],{"nctId":17252,"briefTitle":17253,"status":154,"phases":17254,"primaryCompletion":17255,"completion":17256,"start":5884,"enrollment":6376,"conditions":17257,"interventions":17258},"NCT04219579","Antithrombin III Concentrate After Liver Transplantation",[91],"2022-06-28","2022-06-30",[1622],[17237,17259],"Antithrombin III, Intermittent",{"intervention":17259,"totalTrials":121,"cells":17261},{"EARLY_PHASE1":17262,"PHASE1":17264,"PHASE2":17266,"PHASE3":17268,"PHASE4":17270,"NA":17272},{"trials":17263,"activeCount":99},[],{"trials":17265,"activeCount":99},[],{"trials":17267,"activeCount":99},[],{"trials":17269,"activeCount":99},[],{"trials":17271,"activeCount":99},[],{"trials":17273,"activeCount":99},[17274],{"nctId":17252,"briefTitle":17253,"status":154,"phases":17275,"primaryCompletion":17255,"completion":17256,"start":5884,"enrollment":6376,"conditions":17276,"interventions":17277},[91],[1622],[17237,17259],{"intervention":17279,"totalTrials":121,"cells":17280},"Not used remifentanil",{"EARLY_PHASE1":17281,"PHASE1":17283,"PHASE2":17285,"PHASE3":17287,"PHASE4":17289,"NA":17291},{"trials":17282,"activeCount":99},[],{"trials":17284,"activeCount":99},[],{"trials":17286,"activeCount":99},[],{"trials":17288,"activeCount":99},[],{"trials":17290,"activeCount":99},[],{"trials":17292,"activeCount":99},[17293],{"nctId":17294,"briefTitle":17295,"status":154,"phases":17296,"primaryCompletion":17297,"completion":716,"start":17298,"enrollment":2112,"conditions":17299,"interventions":17300},"NCT04236323","The Effect of Remifentanil on Rebound Pain",[91],"2020-08-12","2020-02-14",[3207],[17279],{"intervention":2627,"totalTrials":121,"cells":17302},{"EARLY_PHASE1":17303,"PHASE1":17305,"PHASE2":17307,"PHASE3":17309,"PHASE4":17311,"NA":17313},{"trials":17304,"activeCount":99},[],{"trials":17306,"activeCount":99},[],{"trials":17308,"activeCount":99},[],{"trials":17310,"activeCount":99},[],{"trials":17312,"activeCount":99},[],{"trials":17314,"activeCount":99},[17315],{"nctId":2619,"briefTitle":2620,"status":166,"phases":17316,"primaryCompletion":673,"completion":2622,"start":2294,"enrollment":2623,"conditions":17317,"interventions":17318},[91],[2625],[2332,2627],{"intervention":17320,"totalTrials":121,"cells":17321},"Autologous Adipose Tissue Derived MSCs Transplantation",{"EARLY_PHASE1":17322,"PHASE1":17324,"PHASE2":17326,"PHASE3":17328,"PHASE4":17330,"NA":17332},{"trials":17323,"activeCount":99},[],{"trials":17325,"activeCount":99},[],{"trials":17327,"activeCount":99},[],{"trials":17329,"activeCount":99},[],{"trials":17331,"activeCount":99},[],{"trials":17333,"activeCount":99},[17334],{"nctId":17335,"briefTitle":17336,"status":154,"phases":17337,"primaryCompletion":538,"completion":17338,"start":17339,"enrollment":6744,"conditions":17340,"interventions":17341},"NCT02474342","Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease",[91],"2016-11-07","2015-07-07",[1493],[17320,17320,17320],{"intervention":17343,"totalTrials":121,"cells":17344},"Human fibrinogen concentrate",{"EARLY_PHASE1":17345,"PHASE1":17347,"PHASE2":17349,"PHASE3":17351,"PHASE4":17353,"NA":17355},{"trials":17346,"activeCount":99},[],{"trials":17348,"activeCount":99},[],{"trials":17350,"activeCount":99},[],{"trials":17352,"activeCount":99},[],{"trials":17354,"activeCount":99},[],{"trials":17356,"activeCount":99},[17357],{"nctId":17358,"briefTitle":17359,"status":154,"phases":17360,"primaryCompletion":15743,"completion":15743,"start":17361,"enrollment":8090,"conditions":17362,"interventions":17365},"NCT04602689","Fibrin Glue After ESD for High Risk Patients of Bleeding",[91],"2020-10-30",[17363,17364],"Early Gastric Cancer","Gastric Adenoma",[17343],{"intervention":14807,"totalTrials":121,"cells":17367},{"EARLY_PHASE1":17368,"PHASE1":17370,"PHASE2":17372,"PHASE3":17374,"PHASE4":17376,"NA":17378},{"trials":17369,"activeCount":99},[],{"trials":17371,"activeCount":99},[],{"trials":17373,"activeCount":99},[],{"trials":17375,"activeCount":99},[],{"trials":17377,"activeCount":99},[],{"trials":17379,"activeCount":99},[17380],{"nctId":14798,"briefTitle":14799,"status":166,"phases":17381,"primaryCompletion":1000,"completion":14801,"start":8195,"enrollment":14802,"conditions":17382,"interventions":17383},[91],[14804,14805],[14773,14807],{"intervention":17385,"totalTrials":121,"cells":17386},"Icariin",{"EARLY_PHASE1":17387,"PHASE1":17389,"PHASE2":17391,"PHASE3":17393,"PHASE4":17395,"NA":17397},{"trials":17388,"activeCount":99},[],{"trials":17390,"activeCount":99},[],{"trials":17392,"activeCount":99},[],{"trials":17394,"activeCount":99},[],{"trials":17396,"activeCount":99},[],{"trials":17398,"activeCount":99},[17399],{"nctId":17400,"briefTitle":17401,"status":154,"phases":17402,"primaryCompletion":1000,"completion":1000,"start":17403,"enrollment":22,"conditions":17404,"interventions":17405},"NCT07076784","Topical Icariin on Acne and Acne Scars",[91],"2023-03-21",[14583,3049],[17385,17406],"Vehicle Control",{"intervention":17406,"totalTrials":121,"cells":17408},{"EARLY_PHASE1":17409,"PHASE1":17411,"PHASE2":17413,"PHASE3":17415,"PHASE4":17417,"NA":17419},{"trials":17410,"activeCount":99},[],{"trials":17412,"activeCount":99},[],{"trials":17414,"activeCount":99},[],{"trials":17416,"activeCount":99},[],{"trials":17418,"activeCount":99},[],{"trials":17420,"activeCount":99},[17421],{"nctId":17400,"briefTitle":17401,"status":154,"phases":17422,"primaryCompletion":1000,"completion":1000,"start":17403,"enrollment":22,"conditions":17423,"interventions":17424},[91],[14583,3049],[17385,17406],{"intervention":17426,"totalTrials":121,"cells":17427},"recombinant hCG",{"EARLY_PHASE1":17428,"PHASE1":17430,"PHASE2":17432,"PHASE3":17434,"PHASE4":17436,"NA":17438},{"trials":17429,"activeCount":99},[],{"trials":17431,"activeCount":99},[],{"trials":17433,"activeCount":99},[],{"trials":17435,"activeCount":99},[],{"trials":17437,"activeCount":99},[],{"trials":17439,"activeCount":99},[17440],{"nctId":17441,"briefTitle":17442,"status":166,"phases":17443,"primaryCompletion":675,"completion":264,"start":7680,"enrollment":1444,"conditions":17444,"interventions":17447},"NCT01406600","Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles",[91],[17445,17446],"in Vitro Fertilization","Poor Responder",[17426],{"intervention":14151,"totalTrials":121,"cells":17449},{"EARLY_PHASE1":17450,"PHASE1":17452,"PHASE2":17454,"PHASE3":17456,"PHASE4":17458,"NA":17460},{"trials":17451,"activeCount":99},[],{"trials":17453,"activeCount":99},[],{"trials":17455,"activeCount":99},[],{"trials":17457,"activeCount":99},[],{"trials":17459,"activeCount":99},[],{"trials":17461,"activeCount":99},[17462],{"nctId":14143,"briefTitle":14144,"status":166,"phases":17463,"primaryCompletion":14146,"completion":14147,"start":14148,"enrollment":676,"conditions":17464,"interventions":17465},[91],[1891],[1686,14151],{"intervention":15051,"totalTrials":121,"cells":17467},{"EARLY_PHASE1":17468,"PHASE1":17470,"PHASE2":17472,"PHASE3":17474,"PHASE4":17476,"NA":17478},{"trials":17469,"activeCount":99},[],{"trials":17471,"activeCount":99},[],{"trials":17473,"activeCount":99},[],{"trials":17475,"activeCount":99},[],{"trials":17477,"activeCount":99},[],{"trials":17479,"activeCount":99},[17480],{"nctId":15046,"briefTitle":15047,"status":166,"phases":17481,"primaryCompletion":673,"completion":2622,"start":2041,"enrollment":1273,"conditions":17482,"interventions":17483},[91],[1774,1775,27,1776],[15051,15024],{"intervention":15220,"totalTrials":121,"cells":17485},{"EARLY_PHASE1":17486,"PHASE1":17488,"PHASE2":17490,"PHASE3":17492,"PHASE4":17494,"NA":17496},{"trials":17487,"activeCount":99},[],{"trials":17489,"activeCount":99},[],{"trials":17491,"activeCount":99},[],{"trials":17493,"activeCount":99},[],{"trials":17495,"activeCount":99},[],{"trials":17497,"activeCount":99},[17498],{"nctId":15214,"briefTitle":15215,"status":154,"phases":17499,"primaryCompletion":579,"completion":579,"start":2551,"enrollment":3557,"conditions":17500,"interventions":17501},[91],[1675],[15199,15219,15220],{"intervention":17503,"totalTrials":121,"cells":17504},"Gd-EOB-DTPA",{"EARLY_PHASE1":17505,"PHASE1":17507,"PHASE2":17509,"PHASE3":17511,"PHASE4":17513,"NA":17515},{"trials":17506,"activeCount":99},[],{"trials":17508,"activeCount":99},[],{"trials":17510,"activeCount":99},[],{"trials":17512,"activeCount":99},[],{"trials":17514,"activeCount":99},[],{"trials":17516,"activeCount":99},[17517],{"nctId":17518,"briefTitle":17519,"status":154,"phases":17520,"primaryCompletion":3510,"completion":168,"start":752,"enrollment":5361,"conditions":17521,"interventions":17522},"NCT01490203","Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection\u002FAblation of Hepatocellular Carcinoma",[],[9846,5615],[17503,17503],{"intervention":17524,"totalTrials":121,"cells":17525},"administration of propofol and rocuronium",{"EARLY_PHASE1":17526,"PHASE1":17528,"PHASE2":17530,"PHASE3":17532,"PHASE4":17534,"NA":17536},{"trials":17527,"activeCount":99},[],{"trials":17529,"activeCount":99},[],{"trials":17531,"activeCount":99},[],{"trials":17533,"activeCount":99},[],{"trials":17535,"activeCount":99},[],{"trials":17537,"activeCount":99},[17538],{"nctId":17539,"briefTitle":17540,"status":154,"phases":17541,"primaryCompletion":17542,"completion":17542,"start":17543,"enrollment":2295,"conditions":17544,"interventions":17545},"NCT03270696","Simultaneous Injection of Propofol and Rocuronium in Inducing General Anesthesia",[91],"2018-01-30","2017-08-23",[1746],[17524],{"intervention":17547,"totalTrials":121,"cells":17548},"group C",{"EARLY_PHASE1":17549,"PHASE1":17551,"PHASE2":17553,"PHASE3":17555,"PHASE4":17557,"NA":17559},{"trials":17550,"activeCount":99},[],{"trials":17552,"activeCount":99},[],{"trials":17554,"activeCount":99},[],{"trials":17556,"activeCount":99},[],{"trials":17558,"activeCount":99},[],{"trials":17560,"activeCount":99},[17561],{"nctId":17562,"briefTitle":17563,"status":166,"phases":17564,"primaryCompletion":2383,"completion":2383,"start":549,"enrollment":180,"conditions":17565,"interventions":17567},"NCT01737437","Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation",[91],[17566],"Neurosurgical Patients",[17547,17568,17569,17570],"group L","group V","group LV",{"intervention":17568,"totalTrials":121,"cells":17572},{"EARLY_PHASE1":17573,"PHASE1":17575,"PHASE2":17577,"PHASE3":17579,"PHASE4":17581,"NA":17583},{"trials":17574,"activeCount":99},[],{"trials":17576,"activeCount":99},[],{"trials":17578,"activeCount":99},[],{"trials":17580,"activeCount":99},[],{"trials":17582,"activeCount":99},[],{"trials":17584,"activeCount":99},[17585],{"nctId":17562,"briefTitle":17563,"status":166,"phases":17586,"primaryCompletion":2383,"completion":2383,"start":549,"enrollment":180,"conditions":17587,"interventions":17588},[91],[17566],[17547,17568,17569,17570],{"intervention":17569,"totalTrials":121,"cells":17590},{"EARLY_PHASE1":17591,"PHASE1":17593,"PHASE2":17595,"PHASE3":17597,"PHASE4":17599,"NA":17601},{"trials":17592,"activeCount":99},[],{"trials":17594,"activeCount":99},[],{"trials":17596,"activeCount":99},[],{"trials":17598,"activeCount":99},[],{"trials":17600,"activeCount":99},[],{"trials":17602,"activeCount":99},[17603],{"nctId":17562,"briefTitle":17563,"status":166,"phases":17604,"primaryCompletion":2383,"completion":2383,"start":549,"enrollment":180,"conditions":17605,"interventions":17606},[91],[17566],[17547,17568,17569,17570],{"intervention":17570,"totalTrials":121,"cells":17608},{"EARLY_PHASE1":17609,"PHASE1":17611,"PHASE2":17613,"PHASE3":17615,"PHASE4":17617,"NA":17619},{"trials":17610,"activeCount":99},[],{"trials":17612,"activeCount":99},[],{"trials":17614,"activeCount":99},[],{"trials":17616,"activeCount":99},[],{"trials":17618,"activeCount":99},[],{"trials":17620,"activeCount":99},[17621],{"nctId":17562,"briefTitle":17563,"status":166,"phases":17622,"primaryCompletion":2383,"completion":2383,"start":549,"enrollment":180,"conditions":17623,"interventions":17624},[91],[17566],[17547,17568,17569,17570],{"intervention":17626,"totalTrials":121,"cells":17627},"6 weeks of treatment with amisulpride",{"EARLY_PHASE1":17628,"PHASE1":17630,"PHASE2":17632,"PHASE3":17634,"PHASE4":17636,"NA":17638},{"trials":17629,"activeCount":99},[],{"trials":17631,"activeCount":99},[],{"trials":17633,"activeCount":99},[],{"trials":17635,"activeCount":99},[],{"trials":17637,"activeCount":99},[],{"trials":17639,"activeCount":99},[17640],{"nctId":17641,"briefTitle":17642,"status":166,"phases":17643,"primaryCompletion":3690,"completion":3690,"start":11402,"enrollment":2153,"conditions":17644,"interventions":17645},"NCT02880995","[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis",[91],[32],[17626],{"intervention":27,"totalTrials":121,"cells":17647},{"EARLY_PHASE1":17648,"PHASE1":17650,"PHASE2":17652,"PHASE3":17654,"PHASE4":17656,"NA":17658},{"trials":17649,"activeCount":99},[],{"trials":17651,"activeCount":99},[],{"trials":17653,"activeCount":99},[],{"trials":17655,"activeCount":99},[],{"trials":17657,"activeCount":99},[],{"trials":17659,"activeCount":99},[17660],{"nctId":17661,"briefTitle":17662,"status":166,"phases":17663,"primaryCompletion":16883,"completion":1010,"start":17664,"enrollment":6401,"conditions":17665,"interventions":17667},"NCT03597087","The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study",[91],"2018-07-19",[17666],"Bladder Cancer",[27],{"intervention":13835,"totalTrials":121,"cells":17669},{"EARLY_PHASE1":17670,"PHASE1":17672,"PHASE2":17674,"PHASE3":17676,"PHASE4":17678,"NA":17680},{"trials":17671,"activeCount":99},[],{"trials":17673,"activeCount":99},[],{"trials":17675,"activeCount":99},[],{"trials":17677,"activeCount":99},[],{"trials":17679,"activeCount":99},[],{"trials":17681,"activeCount":99},[17682],{"nctId":13827,"briefTitle":13828,"status":166,"phases":17683,"primaryCompletion":13830,"completion":13830,"start":13831,"enrollment":5319,"conditions":17684,"interventions":17685},[91],[13833],[13835,735],{"intervention":17687,"totalTrials":121,"cells":17688},"Rivastigmine",{"EARLY_PHASE1":17689,"PHASE1":17691,"PHASE2":17693,"PHASE3":17695,"PHASE4":17697,"NA":17699},{"trials":17690,"activeCount":99},[],{"trials":17692,"activeCount":99},[],{"trials":17694,"activeCount":99},[],{"trials":17696,"activeCount":99},[],{"trials":17698,"activeCount":99},[],{"trials":17700,"activeCount":99},[17701],{"nctId":17702,"briefTitle":17703,"status":166,"phases":17704,"primaryCompletion":2172,"completion":2172,"start":3510,"enrollment":1444,"conditions":17705,"interventions":17706},"NCT02063269","Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles",[91],[12223],[17687],{"intervention":17708,"totalTrials":121,"cells":17709},"Low-dose (10mg) rosuvastatin",{"EARLY_PHASE1":17710,"PHASE1":17712,"PHASE2":17714,"PHASE3":17716,"PHASE4":17718,"NA":17720},{"trials":17711,"activeCount":99},[],{"trials":17713,"activeCount":99},[],{"trials":17715,"activeCount":99},[],{"trials":17717,"activeCount":99},[],{"trials":17719,"activeCount":99},[],{"trials":17721,"activeCount":99},[17722],{"nctId":17723,"briefTitle":17724,"status":154,"phases":17725,"primaryCompletion":17726,"completion":17727,"start":17728,"enrollment":2623,"conditions":17729,"interventions":17730},"NCT03903029","Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC\u002FAHA Guideline",[],"2016-07-05","2019-12-05","2014-10-10",[5889],[17708],{"intervention":17732,"totalTrials":121,"cells":17733},"aspirin continuation",{"EARLY_PHASE1":17734,"PHASE1":17736,"PHASE2":17738,"PHASE3":17740,"PHASE4":17742,"NA":17744},{"trials":17735,"activeCount":99},[],{"trials":17737,"activeCount":99},[],{"trials":17739,"activeCount":99},[],{"trials":17741,"activeCount":99},[],{"trials":17743,"activeCount":99},[],{"trials":17745,"activeCount":99},[17746],{"nctId":17747,"briefTitle":17748,"status":154,"phases":17749,"primaryCompletion":169,"completion":169,"start":703,"enrollment":1878,"conditions":17750,"interventions":17751},"NCT02209909","Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery",[91],[15],[17732,17752],"aspirin discontinuation",{"intervention":17752,"totalTrials":121,"cells":17754},{"EARLY_PHASE1":17755,"PHASE1":17757,"PHASE2":17759,"PHASE3":17761,"PHASE4":17763,"NA":17765},{"trials":17756,"activeCount":99},[],{"trials":17758,"activeCount":99},[],{"trials":17760,"activeCount":99},[],{"trials":17762,"activeCount":99},[],{"trials":17764,"activeCount":99},[],{"trials":17766,"activeCount":99},[17767],{"nctId":17747,"briefTitle":17748,"status":154,"phases":17768,"primaryCompletion":169,"completion":169,"start":703,"enrollment":1878,"conditions":17769,"interventions":17770},[91],[15],[17732,17752],{"intervention":17772,"totalTrials":121,"cells":17773},"Low dose midazolam",{"EARLY_PHASE1":17774,"PHASE1":17776,"PHASE2":17778,"PHASE3":17780,"PHASE4":17782,"NA":17784},{"trials":17775,"activeCount":99},[],{"trials":17777,"activeCount":99},[],{"trials":17779,"activeCount":99},[],{"trials":17781,"activeCount":99},[],{"trials":17783,"activeCount":99},[],{"trials":17785,"activeCount":99},[17786],{"nctId":17787,"briefTitle":17788,"status":154,"phases":17789,"primaryCompletion":3671,"completion":753,"start":621,"conditions":17790,"interventions":17792},"NCT00783731","Low Dose of Midazolam is Superior to Conventional Dose for Rapid Sequence Intubation in Emergency Department (ED)",[91],[17791],"Intubation",[17772],{"intervention":17794,"totalTrials":121,"cells":17795},"total intravenous anesthesia with propofol",{"EARLY_PHASE1":17796,"PHASE1":17798,"PHASE2":17800,"PHASE3":17802,"PHASE4":17804,"NA":17806},{"trials":17797,"activeCount":99},[],{"trials":17799,"activeCount":99},[],{"trials":17801,"activeCount":99},[],{"trials":17803,"activeCount":99},[],{"trials":17805,"activeCount":99},[],{"trials":17807,"activeCount":99},[17808],{"nctId":17809,"briefTitle":17810,"status":154,"phases":17811,"primaryCompletion":17812,"completion":17813,"start":17814,"enrollment":1420,"conditions":17815,"interventions":17817},"NCT04447105","Comparison of Postoperative Recovery Between TIVA and Inhalation Agent",[91],"2021-07-05","2021-07-27","2020-06-28",[17816],"Enhanced Recovery After Surgery",[17794,17818],"inhalation anesthesia with desflurane",{"intervention":17818,"totalTrials":121,"cells":17820},{"EARLY_PHASE1":17821,"PHASE1":17823,"PHASE2":17825,"PHASE3":17827,"PHASE4":17829,"NA":17831},{"trials":17822,"activeCount":99},[],{"trials":17824,"activeCount":99},[],{"trials":17826,"activeCount":99},[],{"trials":17828,"activeCount":99},[],{"trials":17830,"activeCount":99},[],{"trials":17832,"activeCount":99},[17833],{"nctId":17809,"briefTitle":17810,"status":154,"phases":17834,"primaryCompletion":17812,"completion":17813,"start":17814,"enrollment":1420,"conditions":17835,"interventions":17836},[91],[17816],[17794,17818],{"intervention":14749,"totalTrials":121,"cells":17838},{"EARLY_PHASE1":17839,"PHASE1":17841,"PHASE2":17843,"PHASE3":17845,"PHASE4":17847,"NA":17849},{"trials":17840,"activeCount":99},[],{"trials":17842,"activeCount":99},[],{"trials":17844,"activeCount":99},[],{"trials":17846,"activeCount":99},[],{"trials":17848,"activeCount":99},[],{"trials":17850,"activeCount":99},[17851],{"nctId":14742,"briefTitle":14743,"status":154,"phases":17852,"primaryCompletion":3481,"completion":3481,"start":12221,"enrollment":14745,"conditions":17853,"interventions":17854},[91],[14747],[14718,14749],{"intervention":17856,"totalTrials":121,"cells":17857},"Conventional neuromuscular blockade",{"EARLY_PHASE1":17858,"PHASE1":17860,"PHASE2":17862,"PHASE3":17864,"PHASE4":17866,"NA":17868},{"trials":17859,"activeCount":99},[],{"trials":17861,"activeCount":99},[],{"trials":17863,"activeCount":99},[],{"trials":17865,"activeCount":99},[],{"trials":17867,"activeCount":99},[],{"trials":17869,"activeCount":99},[17870],{"nctId":17871,"briefTitle":17872,"status":154,"phases":17873,"primaryCompletion":2251,"completion":2251,"start":2041,"enrollment":17874,"conditions":17875,"interventions":17877},"NCT02249585","Effects of Neuromuscular Blockade Level and Intra-abdominal Pressure on Surgical Conditions and Cardiopulmonary Responses During Laparoscopic Colon Surgery With the Trendelenburg Position",[91],131,[17876],"Cardiac Index",[17856,17878],"Deep neuromuscular blockade",{"intervention":17878,"totalTrials":121,"cells":17880},{"EARLY_PHASE1":17881,"PHASE1":17883,"PHASE2":17885,"PHASE3":17887,"PHASE4":17889,"NA":17891},{"trials":17882,"activeCount":99},[],{"trials":17884,"activeCount":99},[],{"trials":17886,"activeCount":99},[],{"trials":17888,"activeCount":99},[],{"trials":17890,"activeCount":99},[],{"trials":17892,"activeCount":99},[17893],{"nctId":17871,"briefTitle":17872,"status":154,"phases":17894,"primaryCompletion":2251,"completion":2251,"start":2041,"enrollment":17874,"conditions":17895,"interventions":17896},[91],[17876],[17856,17878],{"intervention":17898,"totalTrials":121,"cells":17899},"Sugammadex 200 MG in 2 ML",{"EARLY_PHASE1":17900,"PHASE1":17902,"PHASE2":17904,"PHASE3":17906,"PHASE4":17908,"NA":17910},{"trials":17901,"activeCount":99},[],{"trials":17903,"activeCount":99},[],{"trials":17905,"activeCount":99},[],{"trials":17907,"activeCount":99},[],{"trials":17909,"activeCount":99},[],{"trials":17911,"activeCount":99},[17912],{"nctId":17913,"briefTitle":17914,"status":154,"phases":17915,"primaryCompletion":17916,"completion":17916,"start":17917,"enrollment":2328,"conditions":17918,"interventions":17920},"NCT03689413","Adequate Dosage of Sugammadex on Thyroid Surgery",[91],"2019-08-28","2018-10-01",[17919],"Thyroid Surgery",[17898],{"intervention":585,"totalTrials":121,"cells":17922},{"EARLY_PHASE1":17923,"PHASE1":17925,"PHASE2":17927,"PHASE3":17929,"PHASE4":17931,"NA":17933},{"trials":17924,"activeCount":99},[],{"trials":17926,"activeCount":99},[],{"trials":17928,"activeCount":99},[],{"trials":17930,"activeCount":99},[],{"trials":17932,"activeCount":99},[],{"trials":17934,"activeCount":99},[17935],{"nctId":575,"briefTitle":576,"status":154,"phases":17936,"primaryCompletion":578,"completion":578,"start":579,"enrollment":463,"conditions":17937,"interventions":17938},[91],[581,582,583],[585,586],{"intervention":17940,"totalTrials":121,"cells":17941},"Umbilicus Bupivacaine",{"EARLY_PHASE1":17942,"PHASE1":17944,"PHASE2":17946,"PHASE3":17948,"PHASE4":17950,"NA":17952},{"trials":17943,"activeCount":99},[],{"trials":17945,"activeCount":99},[],{"trials":17947,"activeCount":99},[],{"trials":17949,"activeCount":99},[],{"trials":17951,"activeCount":99},[],{"trials":17953,"activeCount":99},[17954],{"nctId":17955,"briefTitle":17956,"status":166,"phases":17957,"primaryCompletion":1967,"completion":1967,"start":2041,"enrollment":1795,"conditions":17958,"interventions":17961},"NCT02373410","Effect of the Height of the Operating Table During Spinal Anesthesia",[91],[17959,17960],"Anesthesia, Spinal [E03.155.086.331]","Operating Tables [E07.325.662]",[17940,17962,17963,17964],"Lowest rib margin Bupivacaine","Xiphoid Bupivacaine","Nipple Bupivacaine",{"intervention":17962,"totalTrials":121,"cells":17966},{"EARLY_PHASE1":17967,"PHASE1":17969,"PHASE2":17971,"PHASE3":17973,"PHASE4":17975,"NA":17977},{"trials":17968,"activeCount":99},[],{"trials":17970,"activeCount":99},[],{"trials":17972,"activeCount":99},[],{"trials":17974,"activeCount":99},[],{"trials":17976,"activeCount":99},[],{"trials":17978,"activeCount":99},[17979],{"nctId":17955,"briefTitle":17956,"status":166,"phases":17980,"primaryCompletion":1967,"completion":1967,"start":2041,"enrollment":1795,"conditions":17981,"interventions":17982},[91],[17959,17960],[17940,17962,17963,17964],{"intervention":17963,"totalTrials":121,"cells":17984},{"EARLY_PHASE1":17985,"PHASE1":17987,"PHASE2":17989,"PHASE3":17991,"PHASE4":17993,"NA":17995},{"trials":17986,"activeCount":99},[],{"trials":17988,"activeCount":99},[],{"trials":17990,"activeCount":99},[],{"trials":17992,"activeCount":99},[],{"trials":17994,"activeCount":99},[],{"trials":17996,"activeCount":99},[17997],{"nctId":17955,"briefTitle":17956,"status":166,"phases":17998,"primaryCompletion":1967,"completion":1967,"start":2041,"enrollment":1795,"conditions":17999,"interventions":18000},[91],[17959,17960],[17940,17962,17963,17964],{"intervention":17964,"totalTrials":121,"cells":18002},{"EARLY_PHASE1":18003,"PHASE1":18005,"PHASE2":18007,"PHASE3":18009,"PHASE4":18011,"NA":18013},{"trials":18004,"activeCount":99},[],{"trials":18006,"activeCount":99},[],{"trials":18008,"activeCount":99},[],{"trials":18010,"activeCount":99},[],{"trials":18012,"activeCount":99},[],{"trials":18014,"activeCount":99},[18015],{"nctId":17955,"briefTitle":17956,"status":166,"phases":18016,"primaryCompletion":1967,"completion":1967,"start":2041,"enrollment":1795,"conditions":18017,"interventions":18018},[91],[17959,17960],[17940,17962,17963,17964],{"intervention":18020,"totalTrials":121,"cells":18021},"Iron Isomaltoside 1000",{"EARLY_PHASE1":18022,"PHASE1":18024,"PHASE2":18026,"PHASE3":18028,"PHASE4":18030,"NA":18032},{"trials":18023,"activeCount":99},[],{"trials":18025,"activeCount":99},[],{"trials":18027,"activeCount":99},[],{"trials":18029,"activeCount":99},[],{"trials":18031,"activeCount":99},[],{"trials":18033,"activeCount":99},[18034],{"nctId":18035,"briefTitle":18036,"status":154,"phases":18037,"primaryCompletion":18038,"completion":18039,"start":2140,"enrollment":1743,"conditions":18040,"interventions":18043},"NCT03470649","Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients",[91],"2019-04-16","2019-04-17",[18041,18042],"Anemia","Knee Arthropathy",[18020],{"intervention":13985,"totalTrials":121,"cells":18045},{"EARLY_PHASE1":18046,"PHASE1":18048,"PHASE2":18050,"PHASE3":18052,"PHASE4":18054,"NA":18056},{"trials":18047,"activeCount":99},[],{"trials":18049,"activeCount":99},[],{"trials":18051,"activeCount":99},[],{"trials":18053,"activeCount":99},[],{"trials":18055,"activeCount":99},[],{"trials":18057,"activeCount":99},[18058],{"nctId":13979,"briefTitle":13980,"status":154,"phases":18059,"primaryCompletion":2294,"completion":2294,"start":6922,"enrollment":265,"conditions":18060,"interventions":18061},[91],[13983],[13985,6096],{"intervention":18063,"totalTrials":121,"cells":18064},"Determination of drug effects through amantadine cessation",{"EARLY_PHASE1":18065,"PHASE1":18067,"PHASE2":18069,"PHASE3":18071,"PHASE4":18073,"NA":18075},{"trials":18066,"activeCount":99},[],{"trials":18068,"activeCount":99},[],{"trials":18070,"activeCount":99},[],{"trials":18072,"activeCount":99},[],{"trials":18074,"activeCount":99},[],{"trials":18076,"activeCount":99},[18077],{"nctId":18078,"briefTitle":18079,"status":166,"phases":18080,"primaryCompletion":18081,"completion":18081,"start":9671,"enrollment":6325,"conditions":18082,"interventions":18083},"NCT04260581","Is Long-term Use of Amantadine Effective in PD?",[91],"2021-02-28",[3937],[18063],{"intervention":18085,"totalTrials":121,"cells":18086},"Rivastigmine patch",{"EARLY_PHASE1":18087,"PHASE1":18089,"PHASE2":18091,"PHASE3":18093,"PHASE4":18095,"NA":18097},{"trials":18088,"activeCount":99},[],{"trials":18090,"activeCount":99},[],{"trials":18092,"activeCount":99},[],{"trials":18094,"activeCount":99},[],{"trials":18096,"activeCount":99},[],{"trials":18098,"activeCount":99},[18099],{"nctId":18100,"briefTitle":18101,"status":154,"phases":18102,"primaryCompletion":2394,"completion":7724,"start":7013,"enrollment":18103,"conditions":18104,"interventions":18105},"NCT01312363","Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients",[],300,[12223],[18085],{"intervention":18107,"totalTrials":121,"cells":18108},"NEOVIST 370 INJ.",{"EARLY_PHASE1":18109,"PHASE1":18111,"PHASE2":18113,"PHASE3":18115,"PHASE4":18117,"NA":18119},{"trials":18110,"activeCount":99},[],{"trials":18112,"activeCount":99},[],{"trials":18114,"activeCount":99},[],{"trials":18116,"activeCount":99},[],{"trials":18118,"activeCount":99},[],{"trials":18120,"activeCount":99},[18121],{"nctId":18122,"briefTitle":18123,"status":154,"phases":18124,"primaryCompletion":7958,"completion":264,"start":2267,"enrollment":1752,"conditions":18125,"interventions":18127},"NCT01654354","Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT",[],[18126],"Abdominal CT",[18107,18128],"Ultravist 370 INJ.",{"intervention":18128,"totalTrials":121,"cells":18130},{"EARLY_PHASE1":18131,"PHASE1":18133,"PHASE2":18135,"PHASE3":18137,"PHASE4":18139,"NA":18141},{"trials":18132,"activeCount":99},[],{"trials":18134,"activeCount":99},[],{"trials":18136,"activeCount":99},[],{"trials":18138,"activeCount":99},[],{"trials":18140,"activeCount":99},[],{"trials":18142,"activeCount":99},[18143],{"nctId":18122,"briefTitle":18123,"status":154,"phases":18144,"primaryCompletion":7958,"completion":264,"start":2267,"enrollment":1752,"conditions":18145,"interventions":18146},[],[18126],[18107,18128],{"intervention":18148,"totalTrials":121,"cells":18149},"Ginkgo biloba",{"EARLY_PHASE1":18150,"PHASE1":18152,"PHASE2":18154,"PHASE3":18156,"PHASE4":18158,"NA":18160},{"trials":18151,"activeCount":99},[],{"trials":18153,"activeCount":99},[],{"trials":18155,"activeCount":99},[],{"trials":18157,"activeCount":99},[],{"trials":18159,"activeCount":99},[],{"trials":18161,"activeCount":99},[18162],{"nctId":18163,"briefTitle":18164,"status":658,"phases":18165,"primaryCompletion":4130,"completion":4130,"start":2041,"enrollment":99,"conditions":18166,"interventions":18168},"NCT01663467","Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy",[91],[18167],"Tinnitus",[18148],{"intervention":2319,"totalTrials":121,"cells":18170},{"EARLY_PHASE1":18171,"PHASE1":18173,"PHASE2":18175,"PHASE3":18177,"PHASE4":18179,"NA":18181},{"trials":18172,"activeCount":99},[],{"trials":18174,"activeCount":99},[],{"trials":18176,"activeCount":99},[],{"trials":18178,"activeCount":99},[],{"trials":18180,"activeCount":99},[],{"trials":18182,"activeCount":99},[18183],{"nctId":2313,"briefTitle":2314,"status":154,"phases":18184,"primaryCompletion":702,"completion":702,"start":701,"enrollment":1889,"conditions":18185,"interventions":18186},[91],[2025],[2318,2319,2320,2321],{"intervention":18188,"totalTrials":121,"cells":18189},"prolonged DAPT",{"EARLY_PHASE1":18190,"PHASE1":18192,"PHASE2":18194,"PHASE3":18196,"PHASE4":18198,"NA":18200},{"trials":18191,"activeCount":99},[],{"trials":18193,"activeCount":99},[],{"trials":18195,"activeCount":99},[],{"trials":18197,"activeCount":99},[],{"trials":18199,"activeCount":99},[],{"trials":18201,"activeCount":99},[18202],{"nctId":18203,"briefTitle":18204,"status":166,"phases":18205,"primaryCompletion":18206,"completion":15616,"start":8443,"enrollment":18207,"conditions":18208,"interventions":18211},"NCT03338335","Ethnic Differences and the Ischemia\u002FBleeding Risk of DAPT Duration",[],"2018-03-31",16000,[15,18209,18210],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy",[18188],{"intervention":18213,"totalTrials":121,"cells":18214},"Injection of neostigmine",{"EARLY_PHASE1":18215,"PHASE1":18217,"PHASE2":18219,"PHASE3":18221,"PHASE4":18223,"NA":18225},{"trials":18216,"activeCount":99},[],{"trials":18218,"activeCount":99},[],{"trials":18220,"activeCount":99},[],{"trials":18222,"activeCount":99},[],{"trials":18224,"activeCount":99},[],{"trials":18226,"activeCount":99},[18227],{"nctId":18228,"briefTitle":18229,"status":154,"phases":18230,"primaryCompletion":2444,"completion":2444,"start":157,"enrollment":6487,"conditions":18231,"interventions":18232},"NCT01885715","Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium",[91],[581],[18213],{"intervention":18234,"totalTrials":121,"cells":18235},"Ropivacaine 0.75% Injectable Solution",{"EARLY_PHASE1":18236,"PHASE1":18238,"PHASE2":18240,"PHASE3":18242,"PHASE4":18244,"NA":18246},{"trials":18237,"activeCount":99},[],{"trials":18239,"activeCount":99},[],{"trials":18241,"activeCount":99},[],{"trials":18243,"activeCount":99},[],{"trials":18245,"activeCount":99},[],{"trials":18247,"activeCount":99},[18248],{"nctId":18249,"briefTitle":18250,"status":154,"phases":18251,"primaryCompletion":1078,"completion":18252,"start":18253,"enrollment":6487,"conditions":18254,"interventions":18255},"NCT04138901","Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy",[91],"2020-06-07","2019-11-04",[466],[18234],{"intervention":14428,"totalTrials":121,"cells":18257},{"EARLY_PHASE1":18258,"PHASE1":18260,"PHASE2":18262,"PHASE3":18264,"PHASE4":18266,"NA":18268},{"trials":18259,"activeCount":99},[],{"trials":18261,"activeCount":99},[],{"trials":18263,"activeCount":99},[],{"trials":18265,"activeCount":99},[],{"trials":18267,"activeCount":99},[],{"trials":18269,"activeCount":99},[18270],{"nctId":14424,"briefTitle":14425,"status":154,"phases":18271,"primaryCompletion":702,"start":703,"enrollment":1374,"conditions":18272,"interventions":18273},[91],[14428,1858,14429,3207],[14431,14428,14397],{"intervention":1983,"totalTrials":121,"cells":18275},{"EARLY_PHASE1":18276,"PHASE1":18278,"PHASE2":18280,"PHASE3":18282,"PHASE4":18284,"NA":18286},{"trials":18277,"activeCount":99},[],{"trials":18279,"activeCount":99},[],{"trials":18281,"activeCount":99},[],{"trials":18283,"activeCount":99},[],{"trials":18285,"activeCount":99},[],{"trials":18287,"activeCount":99},[18288],{"nctId":1974,"briefTitle":1975,"status":154,"phases":18289,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":380,"conditions":18290,"interventions":18291},[91],[1981],[1983,1668],{"intervention":18293,"totalTrials":121,"cells":18294},"cultivated oral mucosal epithelial sheet transplantation",{"EARLY_PHASE1":18295,"PHASE1":18297,"PHASE2":18299,"PHASE3":18301,"PHASE4":18303,"NA":18305},{"trials":18296,"activeCount":99},[],{"trials":18298,"activeCount":99},[],{"trials":18300,"activeCount":99},[],{"trials":18302,"activeCount":99},[],{"trials":18304,"activeCount":99},[],{"trials":18306,"activeCount":99},[18307],{"nctId":18308,"briefTitle":18309,"status":18310,"phases":18311,"primaryCompletion":168,"completion":168,"start":1957,"conditions":18312,"interventions":18317},"NCT02149732","Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation","AVAILABLE",[],[18313,18314,18315,18316],"Limbal Stem Cell Deficiency","Stevens-johnson Syndrome","Ocular Cicatricial Pemphigoid","Chemical Burn",[18293],{"intervention":18319,"totalTrials":121,"cells":18320},"Vitamin C",{"EARLY_PHASE1":18321,"PHASE1":18323,"PHASE2":18325,"PHASE3":18327,"PHASE4":18329,"NA":18331},{"trials":18322,"activeCount":99},[],{"trials":18324,"activeCount":99},[],{"trials":18326,"activeCount":99},[],{"trials":18328,"activeCount":99},[],{"trials":18330,"activeCount":99},[],{"trials":18332,"activeCount":99},[18333],{"nctId":18334,"briefTitle":18335,"status":154,"phases":18336,"primaryCompletion":1957,"completion":1957,"start":1815,"enrollment":6487,"conditions":18337,"interventions":18339},"NCT02127060","The Effectiveness of Vitamin C in Postoperative Pain Management of Single-level Posterior Lumbar Interbody Fusion (PLIF)",[91],[18338],"Fusion of Spine (Disease)",[18319],{"intervention":18341,"totalTrials":121,"cells":18342},"Genexl PM",{"EARLY_PHASE1":18343,"PHASE1":18345,"PHASE2":18347,"PHASE3":18349,"PHASE4":18351,"NA":18353},{"trials":18344,"activeCount":99},[],{"trials":18346,"activeCount":99},[],{"trials":18348,"activeCount":99},[],{"trials":18350,"activeCount":99},[],{"trials":18352,"activeCount":99},[],{"trials":18354,"activeCount":99},[18355],{"nctId":18356,"briefTitle":18357,"status":154,"phases":18358,"primaryCompletion":10242,"completion":1010,"start":18359,"enrollment":18360,"conditions":18361,"interventions":18362},"NCT05300828","Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer",[],"2015-10-19",600,[2116],[18341],{"intervention":18364,"totalTrials":121,"cells":18365},"anticholinergic",{"EARLY_PHASE1":18366,"PHASE1":18368,"PHASE2":18370,"PHASE3":18372,"PHASE4":18374,"NA":18376},{"trials":18367,"activeCount":99},[],{"trials":18369,"activeCount":99},[],{"trials":18371,"activeCount":99},[],{"trials":18373,"activeCount":99},[],{"trials":18375,"activeCount":99},[],{"trials":18377,"activeCount":99},[18378],{"nctId":18379,"briefTitle":18380,"status":154,"phases":18381,"primaryCompletion":2443,"completion":2443,"start":10099,"enrollment":18382,"conditions":18383,"interventions":18385},"NCT02845648","Ability to Awaken in Nonmonosymptomatic Enuresis",[],119,[18384],"Enuresis, Nocturnal, 2 (Disorder)",[18364],{"intervention":18387,"totalTrials":121,"cells":18388},"De-escalation Treatment Strategy of dual antiplatelet therapy",{"EARLY_PHASE1":18389,"PHASE1":18391,"PHASE2":18393,"PHASE3":18395,"PHASE4":18397,"NA":18399},{"trials":18390,"activeCount":99},[],{"trials":18392,"activeCount":99},[],{"trials":18394,"activeCount":99},[],{"trials":18396,"activeCount":99},[],{"trials":18398,"activeCount":99},[],{"trials":18400,"activeCount":99},[18401],{"nctId":18402,"briefTitle":18403,"status":166,"phases":18404,"primaryCompletion":15460,"completion":8195,"start":3704,"enrollment":18405,"conditions":18406,"interventions":18407},"NCT04848766","IPD Meta-analysis of De-escalation Treatment Strategy After PCI in ACS",[],9000,[7217,15],[18387],{"intervention":18409,"totalTrials":121,"cells":18410},"HLA-B*5801 test",{"EARLY_PHASE1":18411,"PHASE1":18413,"PHASE2":18415,"PHASE3":18417,"PHASE4":18419,"NA":18421},{"trials":18412,"activeCount":99},[],{"trials":18414,"activeCount":99},[],{"trials":18416,"activeCount":99},[],{"trials":18418,"activeCount":99},[],{"trials":18420,"activeCount":99},[],{"trials":18422,"activeCount":99},[18423],{"nctId":18424,"briefTitle":18425,"status":166,"phases":18426,"primaryCompletion":18427,"completion":18427,"start":18428,"enrollment":18360,"conditions":18429,"interventions":18432},"NCT03046914","HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction",[91],"2017-11-30","2016-02-24",[18430,18431],"Stevens-Johnson Syndrome","Kidney Failure, Chronic",[18409],{"intervention":18434,"totalTrials":121,"cells":18435},"Oral anti-diabetic drugs",{"EARLY_PHASE1":18436,"PHASE1":18438,"PHASE2":18440,"PHASE3":18442,"PHASE4":18444,"NA":18446},{"trials":18437,"activeCount":99},[],{"trials":18439,"activeCount":99},[],{"trials":18441,"activeCount":99},[],{"trials":18443,"activeCount":99},[],{"trials":18445,"activeCount":99},[],{"trials":18447,"activeCount":99},[18448],{"nctId":18449,"briefTitle":18450,"status":166,"phases":18451,"primaryCompletion":9964,"completion":9964,"start":9220,"enrollment":1125,"conditions":18452,"interventions":18454},"NCT01922492","Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.",[91],[18453],"Partial Pancreatectomy Due to Benign Pancreatic Neoplasm",[18434],{"intervention":18456,"totalTrials":121,"cells":18457},"Volume loading",{"EARLY_PHASE1":18458,"PHASE1":18460,"PHASE2":18462,"PHASE3":18464,"PHASE4":18466,"NA":18468},{"trials":18459,"activeCount":99},[],{"trials":18461,"activeCount":99},[],{"trials":18463,"activeCount":99},[],{"trials":18465,"activeCount":99},[],{"trials":18467,"activeCount":99},[],{"trials":18469,"activeCount":99},[18470],{"nctId":18471,"briefTitle":18472,"status":166,"phases":18473,"primaryCompletion":168,"start":703,"enrollment":2500,"conditions":18474,"interventions":18475},"NCT02208570","Predictability of the Pulse Pressure Variation (PPV) During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia",[91],[518],[18456],{"intervention":18477,"totalTrials":121,"cells":18478},"high dose CRRT",{"EARLY_PHASE1":18479,"PHASE1":18481,"PHASE2":18483,"PHASE3":18485,"PHASE4":18487,"NA":18489},{"trials":18480,"activeCount":99},[],{"trials":18482,"activeCount":99},[],{"trials":18484,"activeCount":99},[],{"trials":18486,"activeCount":99},[],{"trials":18488,"activeCount":99},[],{"trials":18490,"activeCount":99},[18491],{"nctId":18492,"briefTitle":18493,"status":154,"phases":18494,"primaryCompletion":2443,"completion":2443,"start":753,"enrollment":2568,"conditions":18495,"interventions":18499},"NCT01191905","Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury",[91],[18496,18497,18498],"Sepsis","Kidney Failure, Acute","Renal Replacement Therapy",[18477,18500],"Conventional dose CRRT",{"intervention":18500,"totalTrials":121,"cells":18502},{"EARLY_PHASE1":18503,"PHASE1":18505,"PHASE2":18507,"PHASE3":18509,"PHASE4":18511,"NA":18513},{"trials":18504,"activeCount":99},[],{"trials":18506,"activeCount":99},[],{"trials":18508,"activeCount":99},[],{"trials":18510,"activeCount":99},[],{"trials":18512,"activeCount":99},[],{"trials":18514,"activeCount":99},[18515],{"nctId":18492,"briefTitle":18493,"status":154,"phases":18516,"primaryCompletion":2443,"completion":2443,"start":753,"enrollment":2568,"conditions":18517,"interventions":18518},[91],[18496,18497,18498],[18477,18500],{"intervention":18520,"totalTrials":121,"cells":18521},"Neoadjuvant atezolizumab",{"EARLY_PHASE1":18522,"PHASE1":18524,"PHASE2":18526,"PHASE3":18528,"PHASE4":18530,"NA":18532},{"trials":18523,"activeCount":99},[],{"trials":18525,"activeCount":99},[],{"trials":18527,"activeCount":99},[],{"trials":18529,"activeCount":99},[],{"trials":18531,"activeCount":99},[],{"trials":18533,"activeCount":99},[18534],{"nctId":18535,"briefTitle":18536,"status":166,"phases":18537,"primaryCompletion":2181,"completion":18538,"start":10602,"enrollment":1221,"conditions":18539,"interventions":18540},"NCT03577132","The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer",[91],"2022-05-31",[9526],[18520],{"intervention":18542,"totalTrials":121,"cells":18543},"Neoadjuvant treatment",{"EARLY_PHASE1":18544,"PHASE1":18546,"PHASE2":18548,"PHASE3":18550,"PHASE4":18552,"NA":18554},{"trials":18545,"activeCount":99},[],{"trials":18547,"activeCount":99},[],{"trials":18549,"activeCount":99},[],{"trials":18551,"activeCount":99},[],{"trials":18553,"activeCount":99},[],{"trials":18555,"activeCount":99},[18556],{"nctId":18557,"briefTitle":18558,"status":154,"phases":18559,"primaryCompletion":8195,"completion":8195,"start":18560,"enrollment":18561,"conditions":18562,"interventions":18564},"NCT06129812","An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer",[],"2007-01",1132,[35,18563],"Neoadjuvant",[18542],{"intervention":18566,"totalTrials":121,"cells":18567},"Multi-strain probiotics",{"EARLY_PHASE1":18568,"PHASE1":18570,"PHASE2":18572,"PHASE3":18574,"PHASE4":18576,"NA":18578},{"trials":18569,"activeCount":99},[],{"trials":18571,"activeCount":99},[],{"trials":18573,"activeCount":99},[],{"trials":18575,"activeCount":99},[],{"trials":18577,"activeCount":99},[],{"trials":18579,"activeCount":99},[18580],{"nctId":18581,"briefTitle":18582,"status":166,"phases":18583,"primaryCompletion":3555,"completion":3555,"start":2267,"enrollment":1444,"conditions":18584,"interventions":18586},"NCT01637714","The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome",[91],[18585],"Diarrhea Predominant Irritable Bowel Syndrome",[18566],{"intervention":18588,"totalTrials":121,"cells":18589},"Silymarin",{"EARLY_PHASE1":18590,"PHASE1":18592,"PHASE2":18594,"PHASE3":18596,"PHASE4":18598,"NA":18600},{"trials":18591,"activeCount":99},[],{"trials":18593,"activeCount":99},[],{"trials":18595,"activeCount":99},[],{"trials":18597,"activeCount":99},[],{"trials":18599,"activeCount":99},[],{"trials":18601,"activeCount":99},[18602],{"nctId":18603,"briefTitle":18604,"status":166,"phases":18605,"primaryCompletion":579,"completion":264,"start":7680,"enrollment":18360,"conditions":18606,"interventions":18607},"NCT01436929","Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs",[91],[755],[18588]]